FN Thomson Reuters Web of Knowledge
VR 1.0
PT J
AU Zheng, Y
   Jin, Y
   Zhu, HB
   Xu, ST
   Xia, YX
   Huang, Y
AF Zheng, Yan
   Jin, Yue
   Zhu, Hai-Bin
   Xu, Shao-Ting
   Xia, Ya-Xian
   Huang, Yue
TI EFFECTS OF A CHINESE MEDICINAL PLANT RADIX ASTRAGALI ON THE
   OVARIECTOMIZED FEMALE RATS
SO AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES
LA English
DT Article
DE Perimenopausal syndrome; Radix Astragali; ovariectomized rats
ID HORMONE REPLACEMENT THERAPY; MENOPAUSAL SYMPTOMS; POSTMENOPAUSAL WOMEN;
   ALTERNATIVE MEDICINE; COMPLEMENTARY; CYTOKINES; ESTROGEN
AB Perimenopausal syndrome occurs during the transition to menopause. Complementary and alternative medicine, especially Chinese medicinal plants, has manifested significant effects in alleviating perimenopausal symptoms. However, little research has been focused on the effects of Chinese medicinal plant on the immune function of the perimenopausal women. The present study aimed to explore the effects of Radix Astragali (RA) on the sex hormone levels and the interleukins of the ovariectomized female rats. 24 female Sprague-Dawley (SD) rats were randomly divided into model control group (MOD group), sham-operation group (SHAM group), RA group and estrogen group (EST group). After all the treatment ended, the serum levels of estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), interleukin-2 (IL-2), and interleukin-8 (IL-8) were measured using enzyme-linked immune-sorbent assay (ELISA) and the uterus was removed and weighed after blood exsanguinations immediately. In the MOD group, the serum levels of E2 were significantly lower, and the serum levels of FSH and LH were markedly higher than those of the RA group, EST group and SHAM group (P<0.05). In the RA group, the serum levels of E2 were significantly lower, and the serum levels of FSH were markedly higher than those of the SHAM group and EST group, respectively. In the MOD group, the serum levels of IL-2 and IL-8 were significantly lower than those of the RA group, EST group and SHAM group (P<0.05), and no marked differences existed among RA group, EST group and SHAM group in the serum levels of IL-2 and IL-8 (P>0.05). The uterine weight of the rats in the RA group, EST group and SHAM group were significantly higher than those of the rats in MOD group (P<0.05). There were no marked differences among the rats from RA group, EST group and SHAM group on the uterine weight (P>0.05). It is concluded that RA can significantly improve the immune functions of the ovariectomized female rats, although it cannot change the sex hormones levels as significantly as estrogen.
C1 [Zheng, Yan; Jin, Yue; Zhu, Hai-Bin; Xu, Shao-Ting; Xia, Ya-Xian] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Gynaecol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Huang, Yue] Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Dept Orthopaed Surg, Hangzhou 310016, Zhejiang, Peoples R China.
RP Zheng, Y (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Gynaecol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM drhuangyue@126.com
FU grants for young scientists of TCM, Zhejiang Province [2006Y004];
   Science Technology Department of Zhejiang Province [2012C37005]
FX The present research was funded by the grants for young scientists of
   TCM, Zhejiang Province (No.2006Y004) and Analysis and testing grants
   from Science Technology Department of Zhejiang Province (No.2012C37005)
CR Borrelli F, 2010, MATURITAS, V66, P333, DOI 10.1016/j.maturitas.2010.05.010
   Carneiro ALB, 2012, MENOPAUSE, V19, P830, DOI 10.1097/gme.0b013e31824a74ce
   Cioffi M, 2002, MATURITAS, V41, P187, DOI 10.1016/S0378-5122(01)00286-9
   Dieli-Conwright CM, 2009, J APPL PHYSIOL, V107, P853, DOI 10.1152/japplphysiol.00404.2009
   Duijts Saskia F A, 2009, BMC Womens Health, V9, P15
   El-Bakri NK, 2004, J CELL MOL MED, V8, P537, DOI 10.1111/j.1582-4934.2004.tb00478.x
   Kamada M, 2001, GYNECOL OBSTET INVES, V52, P82, DOI 10.1159/000052948
   Kessel B, 2004, ENDOCRIN METAB CLIN, V33, P717, DOI 10.1016/j.ecl.2004.07.004
   Kronenberg F, 2002, ANN INTERN MED, V137, P805
   Lloyd KB, 2009, NUTR CLIN PRACT, V24, P589, DOI 10.1177/0884533609343001
   Martin K, 2006, MEDIAT INFLAMM, DOI 10.1155/MI/2006/65237
   Mazaro-Costa R, 2010, J SEX MED, V7, P3695, DOI 10.1111/j.1743-6109.2010.01987.x
   Miquel J, 2006, ARCH GERONTOL GERIAT, V42, P289, DOI 10.1016/j.archger.2005.08.005
   Noguchi M, 2009, J ETHNOPHARMACOL, V126, P96, DOI 10.1016/j.jep.2009.08.005
   Roberts H, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e815
   Saucedo R, 2002, GYNECOL OBSTET INVES, V53, P114, DOI 10.1159/000053005
   Seidl MM, 1998, CAN FAM PHYSICIAN, V44, P1299
   Shou C, 2011, CHIN J INTEGR MED, V17, P883, DOI 10.1007/s11655-011-0932-7
   Stopinska-Gluszak U, 2006, J REPROD IMMUNOL, V69, P65, DOI 10.1016/j.iri.2005.07.006
   Voytko ML, 2009, AM J PRIMATOL, V71, P794, DOI 10.1002/ajp.20705
   Xia X, 2009, J REPROD IMMUNOL, V81, P89, DOI 10.1016/j.jri.2009.02.008
   Yeh S.C., 2012, J ALTERN COMPLEMENT
NR 22
TC 0
Z9 0
PU AFRICAN NETWORKS ETHNOMEDICINES
PI ILE-IFE
PA OBAFEMI AWOLOWO UNIV,CLEMENT O ADEWUNMI, DRUG RES PROD UNIT, FAC
   PHARMACY, ILE-IFE, 00000, NIGERIA
SN 0189-6016
J9 AFR J TRADIT COMPLEM
JI Afr. J. Tradit. Complement. Alt. M.
PY 2013
VL 10
IS 1
BP 9
EP 14
DI 10.4314/ajtcam.v10i1.2
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 016GW
UT WOS:000309506800002
ER

PT J
AU Liu, CH
   Lin, YW
   Tang, NY
   Liu, HJ
   Huang, CY
   Hsieh, CL
AF Liu, Chung-Hsiang
   Lin, Yi-Wen
   Tang, Nou-Ying
   Liu, Hsu-Jan
   Huang, Chih-Yang
   Hsieh, Ching-Liang
TI EFFECT OF ORAL ADMINISTRATION OF PHERETIMA ASPERGILLUM (EARTHWORM) IN
   RATS WITH CEREBRAL INFARCTION INDUCED BY MIDDLE-CEREBRAL ARTERY
   OCCLUSION.
SO AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES
LA English
DT Article
DE Cerebral infarction; Middle cerebral occlusion; Neuroprotective effect;
   Pheretima aspergillum
ID FIBRILLARY ACIDIC PROTEIN; PLASMA S100B LEVEL; INTRACEREBRAL HEMORRHAGE;
   NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA;
   EISENIA-FOETIDA; GROWTH-FACTOR; ACUTE STROKE; NEURONS
AB We investigated the curative effect of Pheretima aspergillum (earthworm, PA) on rats with middle cerebral artery occlusion (MCAo). The MCAo-induced cerebral infarction was established and its underlying mechanisms by counting the infarction areas and evaluating the rats' neurological status. Immunostaining was used to test the expression of NeuN, and glial fibrillary acidic (GFAP), S100B, and brain-derived neurotrophic factor (BDNF) proteins. Our results showed that oral administration of PA for two weeks to rats with MCAo successfully reduced cerebral infarction areas in the cortex and striatum, and also reduced scores of neurological deficit. The PA-treated MCAo rats showed greatly decreased neuronal death, glial proliferation, and S100B proteins in the penumbra area of the cortex and in the ischemic core area of the cortex, but BDNF did not changed. These results demonstrated novel and detailed cellular mechanisms underlying the neuroprotective effects of PA in MCAo rats
C1 [Liu, Chung-Hsiang] China Med Univ Hosp, Dept Neurol, Taichung 40402, Taiwan.
   [Lin, Yi-Wen; Liu, Hsu-Jan; Hsieh, Ching-Liang] China Med Univ, Coll Chinese Med, Grad Inst Acupuncture Sci, Taichung 40402, Taiwan.
   [Lin, Yi-Wen; Liu, Hsu-Jan; Hsieh, Ching-Liang] China Med Univ, Acupuncture Res Ctr, Taichung 40402, Taiwan.
   [Tang, Nou-Ying] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung 40402, Taiwan.
   [Huang, Chih-Yang] China Med Univ, Grad Inst Basic Med Sci, Coll Med, Taichung 40402, Taiwan.
   [Hsieh, Ching-Liang] China Med Univ Hosp, Dept Chinese Med, Taichung 40402, Taiwan.
RP Liu, CH (reprint author), China Med Univ Hosp, Dept Neurol, Taichung 40402, Taiwan.
EM clhsieh@mail.cmuh.org.tw
FU China Medical University [CMU99-EW-02]; Taiwanese Department of Health,
   Clinical Trials and Research Center of Excellence [DOH101-TD-B-111-004]
FX This study was supported by a grant from China Medical University
   (CMU99-EW-02). It was also supported in part by the Taiwanese Department
   of Health, Clinical Trials and Research Center of Excellence
   (DOH101-TD-B-111-004).
CR Al Sabti H, 2007, J CARDIOTHORAC SURG, V2, DOI 10.1186/1749-8090-2-49
   BARGER SW, 1992, J BIOL CHEM, V267, P9689
   Chang Y. M., 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep079
   Chang Y. M., 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep216
   CHANG YM, 2009, EVID-BASED COMPL ALT, DOI DOI 10.1093/ECAM/NEP131
   Chen CT, 2010, AM J CHINESE MED, V38, P547, DOI 10.1142/S0192415X10008044
   Datta A, 2011, J PROTEOME RES, V10, P5199, DOI 10.1021/pr200673y
   Delgado P, 2006, STROKE, V37, P2837, DOI 10.1161/01.STR.0000245085.58807.ad
   Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0
   Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823
   Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676
   Grdisa M, 2001, COMP BIOCHEM PHYS A, V128, P821, DOI 10.1016/S1095-6433(00)00323-8
   Hrzenjak T, 1998, COMP BIOCHEM PHYS B, V119, P825, DOI 10.1016/S0305-0491(98)00060-1
   Hu YY, 2010, SHOCK, V33, P134, DOI 10.1097/SHK.0b013e3181ad5c88
   HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0
   Ichikawa H, 1997, BRAIN RES, V748, P253, DOI 10.1016/S0006-8993(96)01364-9
   Kordower JH, 1999, ANN NEUROL, V46, P419, DOI 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q
   Krakovsky M, 2011, NEUROL RES, V33, P983, DOI 10.1179/1743132811Y.0000000018
   LEVIMONTALCINI R, 1951, J EXP ZOOL, V116, P321, DOI 10.1002/jez.1401160206
   Lin YW, 2010, J INTEGR NEUROSCI, V9, P269, DOI 10.1142/S0219635210002433
   Lin YW, 2011, J ETHNOPHARMACOL, V135, P313, DOI 10.1016/j.jep.2011.03.018
   Liu CH, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/194790
   Missler U, 1999, CLIN CHEM, V45, P138
   Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2
   Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366
   Pasti L, 1997, J NEUROSCI, V17, P7817
   Patil C. G., WORLD NEURO IN PRESS
   RICKMANN M, 1995, NEUROSCIENCE, V67, P977, DOI 10.1016/0306-4522(94)00615-C
   Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239
   Wei SY, 2009, J ETHNOPHARMACOL, V123, P51, DOI 10.1016/j.jep.2009.02.030
   Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005
NR 31
TC 0
Z9 0
PU AFRICAN NETWORKS ETHNOMEDICINES
PI ILE-IFE
PA OBAFEMI AWOLOWO UNIV,CLEMENT O ADEWUNMI, DRUG RES PROD UNIT, FAC
   PHARMACY, ILE-IFE, 00000, NIGERIA
SN 0189-6016
J9 AFR J TRADIT COMPLEM
JI Afr. J. Tradit. Complement. Alt. M.
PY 2013
VL 10
IS 1
BP 66
EP 82
DI 10.4314/ajtcam.v10i1.11
PG 17
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 016GW
UT WOS:000309506800011
ER

PT J
AU Zhang, DQ
   Zhu, JH
   Chen, WC
AF Zhang, De-Qing
   Zhu, Jian-Hong
   Chen, Wei-Chang
TI ACARBOSE: A NEW OPTION IN THE TREATMENT OF ULCERATIVE COLITIS BY
   INCREASING HYDROGEN PRODUCTION
SO AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES
LA English
DT Article
DE acarbose; ulcerative colitis; hydrogen
ID INFLAMMATORY-BOWEL-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; OXIDATIVE
   STRESS; INJURY; ANTIOXIDANTS; INHALATION; ALPHA; MODEL; RISK
AB Acarbose, which is clinically widely used to treat Type 2 Diabetes, is thought to act at the small intestine by competitively inhibiting enzymes that delay the release of glucose from complex carbohydrates, thereby specifically reducing post prandial glucose excursion. The major side-effect of treatment with acarbose, flatulence, occurs when undigested carbohydrates are fermented by colonic bacteria, resulting in considerable amount of hydrogen. We propose that enteric benefits of acarbose is partly attributable to be their ability to neutralise oxidative stress via increased production of H-2 in the gastrointestinal tract. Therefore, symptoms of ulcerative colitis in human beings can be ameliorated by acarbose.
C1 [Zhang, De-Qing; Zhu, Jian-Hong; Chen, Wei-Chang] Soochow Univ, Affiliated Hosp 1, Dept Digest Internal Med, Suzhou 215006, Peoples R China.
RP Zhang, DQ (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Digest Internal Med, Suzhou 215006, Peoples R China.
EM chenweichang2012@163.com
CR Carty E, 2003, BRIT J CLIN PHARMACO, V56, P351, DOI 10.1046/j.1365-2125.2003.01965.x
   Chen H, 2010, BIOCHEM BIOPH RES CO, V393, P308, DOI 10.1016/j.bbrc.2010.02.005
   Chen XA, 2011, MED HYPOTHESES, V76, P325, DOI 10.1016/j.mehy.2010.09.026
   Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486
   Fries W, 2011, CURR DRUG TARGETS, V12, P1373
   Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088
   Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011
   GRISHAM MB, 1988, DIGEST DIS SCI, V33, pS6, DOI 10.1007/BF01538126
   Hanefeld M, 2004, EUR HEART J, V25, P10, DOI 10.1016/S0195-668X(03)00468-8
   Hawthorne B., 2008, ALIMENT PHARM THER, V27, P1157
   Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165
   Kajiya M, 2009, BIOCHEM BIOPH RES CO, V386, P11, DOI 10.1016/j.bbrc.2009.05.117
   Kajiyama S, 2008, NUTR RES, V28, P137, DOI 10.1016/j.nutres.2008.01.008
   Karp SM, 2006, DM-DIS MON, V52, P199, DOI 10.1016/j.disamonth.2006.05.005
   Kawai D, 2012, HEPATOLOGY, V56, P912, DOI 10.1002/hep.25782
   LADAS SD, 1992, GUT, V33, P1246, DOI 10.1136/gut.33.9.1246
   Li G, 2012, J SURG RES
   McClave Stephen A., 2012, J PARENTERAL ENTERAL, V36, P24
   Michael D, 1969, NEW ENGL J MED, V281, P122
   Moe KT, 2006, J CELL MOL MED, V10, P231, DOI 10.1111/j.1582-4934.2006.tb00304.x
   Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577
   Ohta S, 2011, BIOCHIM BIOPHYS ACTA, DOI [10.1016/j.physletb.2003.10.071, DOI 10.1016/J.PHYSLETB.2003.10.071]
   Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007
   ROESSNER A, 2008, RES PRACTICE, V204, P511, DOI DOI 10.1016/J.PRP.2008.04.011
   Solberg IC, 2008, SCAND J GASTROENTERO, V27, P1157
   Suzuki Y, 2009, FEBS LETT, V583, P2157, DOI 10.1016/j.febslet.2009.05.052
   Yoshida A, 2012, CARDIOVASC DRUG THER, V26, P217, DOI 10.1007/s10557-012-6381-5
NR 27
TC 0
Z9 0
PU AFRICAN NETWORKS ETHNOMEDICINES
PI ILE-IFE
PA OBAFEMI AWOLOWO UNIV,CLEMENT O ADEWUNMI, DRUG RES PROD UNIT, FAC
   PHARMACY, ILE-IFE, 00000, NIGERIA
SN 0189-6016
J9 AFR J TRADIT COMPLEM
JI Afr. J. Tradit. Complement. Alt. M.
PY 2013
VL 10
IS 1
BP 166
EP 169
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 016GW
UT WOS:000309506800022
ER

PT J
AU Tang, JJ
   Lai, LX
   Han, YB
AF Tang, Jiangjing
   Lai, Liangxue
   Han, Yibing
TI Dynamic expression pattern of PP1 gamma and its interacting protein
   Tctex5 during spermatogenesis
SO ASIA LIFE SCIENCES
LA English
DT Article
DE male germ cells; male infertility; PP1 gamma; Tctex5; spermatogenic stem
   cells
ID INTRACYTOPLASMIC SPERM INJECTION; PHOSPHATASE-1 INHIBITOR-3;
   IDENTIFICATION; GENE; MICE
AB Gene abnormality during spermatogenesis stages before mature spermatozoa can cause their inability to fertilize eggs. In order to solve this problem of male infertility, studying gene function and its regulation mechanism during spermatogenesis becomes more and more important. Tctex5 is a novel sperm motility-related gene discovered in mouse testis recently and encodes Tctex5 interacting with PP1 gamma, which is predominantly expressed in the testis. In this study, we have compared expression of Tctex5 in male germ cell lines representing different spermatogenic stages (spermatogenic stem cells, differentiating spermatogonia and differentiated spermatocytes, respectively) and the Sertoli cell line in mouse. Restricted to the nuclei, expression of Tctex5 decreases from highest in the spermatogenic stem cell stage to lowest in the differentiated spermatocyte stage. The estimated interacting protein of Tctex5, PP1 gamma, is co-expressed in the nuclei. PP1 gamma expression showed a similar pattern with that of Tctex5. When Tctex5 is knocked down by siRNA, expression of the interacting protein PP1 gamma is also reduced. Tctex5 expression is reduced when germ cell enters into meiosis indicating that Tctex5 may act as a regulating factor to prepare cell entering into meiosis. Its down expression caused PP1 gamma expression to be reduced. This may change the phosphorylation level of many proteins in germ cells which may further regulate meiosis, apoptosis or other cell events.
C1 [Tang, Jiangjing; Lai, Liangxue] Chinese Acad Sci, Guangzhou Inst Biomed, Guangzhou, Guangdong, Peoples R China.
   [Tang, Jiangjing; Han, Yibing] Tongji Univ, Shanghai Matern & Infants Hlth Hosp 1, Shanghai 200092, Peoples R China.
   [Han, Yibing] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China.
   [Tang, Jiangjing; Lai, Liangxue] Chinese Acad Sci, Guangzhou Inst Hlth, Guangzhou, Guangdong, Peoples R China.
RP Lai, LX (reprint author), Chinese Acad Sci, Guangzhou Inst Biomed, Guangzhou, Guangdong, Peoples R China.
EM tang_jj85@163.com; lai_liangxue@gibh.ac.cn; ybhan@yahoo.com
FU Hong Kong RGC [464809]
FX This study was supported by Hong Kong RGC grant (464809) to Prof. Yibing
   Han.
CR Alphonse G., 2003, BIOCHIMIE, V85, P721
   Bart L., 2007, BIOCHEMISTRY-US, V46, P8909
   Fourest L. A., 2006, MOL BIOL CELL, V1, P1041
   Gary D. S., 1996, BIOL REPROD, V54, P719
   Giffon T, 1996, IMMUNOGENETICS, V44, P331, DOI 10.1007/BF02602777
   HA H, 1991, DEV GENET, V12, P318, DOI 10.1002/dvg.1020120409
   Han Y. B., 1991, MOL REPROD DEV, V74, P1132
   Henderson H., 2010, INT J ANDROL, V34, P339
   Hofmann MC, 2005, STEM CELLS, V23, P200, DOI 10.1634/stemcells.2003-0036
   Huang HS, 2008, J BIOL CHEM, V283, P18135, DOI 10.1074/jbc.M709735200
   Huang HS, 2005, ARCH BIOCHEM BIOPHYS, V443, P33, DOI 10.1016/j.abb.2005.08.021
   Huang ZH, 2004, BIOL REPROD, V70, P439, DOI 10.1095/biolreprod.103.020024
   Hugo C., 2004, PHYSIOL REV, V84, P1
   Liesbeth V., 2010, REPRODUCTION, V139, P303
   Lina C., 2009, PLOS ONE, V4, P4861
   NAGY ZP, 1995, HUM REPROD, V10, P1123
   Nicole F. A., 2010, REPRODUCTION, P1470
   Oppedisano L, 2002, HUM REPROD, V17, P710, DOI 10.1093/humrep/17.3.710
   Poongothai J, 2009, SINGAP MED J, V50, P336
   Richard M. S. D., 2004, BRIT MED J, V328, P447
   Rumela C., 2007, BIOL REPROD, V76, P992
   Ryan I. S., 2010, J ASSIST REPROD GEN, V27, P3
   Shalender B., 2007, J CLIN ENDOCRINOLOGY, V92, P1995
   Sherman J. S., 2002, HUMAN REPROD UPDATE, V8, P217
   Simpson JL, 2001, SEMIN REPROD MED, V19, P239, DOI 10.1055/s-2001-18043
   Srinivasan V., 1996, BIOL REPROD, V54, P709
   Susannah V, 1999, DEV BIOL, V205, P98
   Ulrich S., 2004, MOL BIOL CELL, V15, P1031
   VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055
   Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g
   Zhang LF, 2008, BIOCHEM BIOPH RES CO, V377, P710, DOI 10.1016/j.bbrc.2008.10.062
NR 31
TC 0
Z9 0
PU ASIA LIFE SCIENCES
PI LOS BANOS, COLLEGE
PA C/O DR. WILLIAM SM. GRUEZO, CHAIRMAN, UNIVERSITY OF THE PHILIPPINES,
   D-206 BIOLOGICAL SCIENCES BUIL, LOS BANOS, COLLEGE, LAGUNA, 4031,
   PHILIPPINES
SN 0117-3375
J9 ASIA LIFE SCI
JI Asia Life Sci.
PD JAN-JUN
PY 2013
VL 22
IS 1
BP 141
EP 153
PG 13
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 015HJ
UT WOS:000309436700010
ER

PT J
AU Yang, XJ
   Zhang, YS
AF Yang, Xiao Juan
   Zhang, Yong Sen
TI Molecular Iodine: A Powerful Catalyst for the Knoevenagel Condensation
   of Isatins with Malononitrile
SO JOURNAL OF CHEMISTRY
LA English
DT Article
ID ONE-POT SYNTHESIS; VERSATILE CATALYST; 2-OXINDOLE DERIVATIVES; EFFICIENT
   CATALYST; INHIBITORS
AB Molecular iodine has been used as an efficient catalyst for an improved and rapid condensation of isatins with malononitrile in excellent yields. The significant features of the iodine-catalyzed Knoevenagel condensation are operational simplicity, inexpensive reagents, high yield of products, and the use of nontoxic reagents.
C1 [Yang, Xiao Juan] Xinxiang Univ, Coll Chem & Chem Engn, Henan 453003, Xinxiang, Peoples R China.
   [Zhang, Yong Sen] Xinxiang Med Univ, Affiliated Hosp 3, Henan 45300, Xinxiang, Peoples R China.
RP Yang, XJ (reprint author), Xinxiang Univ, Coll Chem & Chem Engn, Henan 453003, Xinxiang, Peoples R China.
EM yangxiaojuan2005@126.com
FU Xinxiang University
FX The authors are pleased to acknowledge the financial support from
   Xinxiang University.
CR Abdelhamid IA, 2009, SYNLETT, P625, DOI 10.1055/s-0028-1087558
   Abdelhamid IA, 2009, TETRAHEDRON, V65, P10069, DOI 10.1016/j.tet.2009.09.081
   Bal TR, 2005, BIOORG MED CHEM LETT, V15, P4451, DOI 10.1016/j.bmcl.2005.07.046
   Dandia A., 1999, SYNTHETIC COMMUN, V29, P2323
   Dandia A, 2003, HETEROCYCL COMMUN, V9, P415
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2109, DOI 10.1016/j.bmcl.2006.01.066
   Kayukov YS, 2011, RUSS J ORG CHEM+, V47, P392, DOI 10.1134/S1070428011030110
   Kidwai M, 2007, J MOL CATAL A-CHEM, V266, P43, DOI 10.1016/j.molcata.2006.10.037
   Kidwai M, 2007, J MOL CATAL A-CHEM, V265, P177, DOI 10.1016/j.molcata.2006.10.009
   Kidwai M, 2006, TETRAHEDRON LETT, V47, P5029, DOI 10.1016/j.tetlet.2006.05.097
   Ko S, 2005, TETRAHEDRON LETT, V46, P5771, DOI 10.1016/j.tetlet.2005.05.148
   Redkin RG, 2007, TETRAHEDRON, V63, P11444, DOI 10.1016/j.tet.2007.08.050
   Tripathy R, 2006, BIOORG MED CHEM LETT, V16, P2158, DOI 10.1016/j.bmcl.2006.01.063
   Verma Manjusha, 2004, Acta Pharmaceutica (Zagreb), V54, P49
   Wang X, 2011, E-J CHEM, V8, P1000
   Wu LQ, 2009, B KOREAN CHEM SOC, V30, P2777
NR 16
TC 0
Z9 0
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 2090-9063
J9 J CHEM-NY
JI J. Chem.
PY 2013
AR 543219
DI 10.1155/2013/543219
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA 005ML
UT WOS:000308754400001
ER

PT J
AU Ren, H
   Chen, MW
   Yue, P
   Tao, H
   Owonikoko, TK
   Ramalingam, SS
   Khuri, FR
   Sun, SY
AF Ren, Hui
   Chen, Mingwei
   Yue, Ping
   Tao, Hui
   Owonikoko, Taofeek K.
   Ramalingam, Suresh S.
   Khuri, Fadlo R.
   Sun, Shi-Yong
TI The combination of RAD001 and NVP-BKM120 synergistically inhibits the
   growth of lung cancer in vitro and in vivo
SO CANCER LETTERS
LA English
DT Review
DE RAD001; BKM120; PI3 kinase; mTOR; Lung cancer
ID SYNTHETIC RETINOID CD437; MAMMALIAN TARGET; CARCINOMA CELLS; APOPTOSIS;
   ACTIVATION; PATHWAY; AKT; THERAPY; EVEROLIMUS; MUTATIONS
AB This study focuses on determining whether the combination of NYP-BKM120 (BKM120) and RA0001 exerts enhanced therapeutic effect against lung cancer. The combination of BKM120 and RAD001 exerted synergistic inhibitory effects on the growth of lung cancer cells both in culture and in mouse xenograft model. This combination abrogated RAD001-induced Akt phosphorylation and exerted enhanced suppressive effect on 4EBP1 phosphorylation. Collectively, we suggest that the combination of RAD001 and BKM120 may be an effective regimen for treatment of lung cancer, hence warranting further evaluation of the combination in the clinic. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Ren, Hui; Chen, Mingwei; Yue, Ping; Tao, Hui; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Khuri, Fadlo R.; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
   [Ren, Hui; Chen, Mingwei] Xi An Jiao Tong Univ, Dept Respirat, Affiliated Hosp 1, Coll Med, Xian, Shaanxi, Peoples R China.
RP Chen, MW (reprint author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, 1365-C Clifton Rd NE,Suite C3088, Atlanta, GA 30322 USA.
EM chenmingwei@mail.xjtu.edu.cn; ssun@emory.edu
FU Georgia Cancer Coalition Distinguished Cancer Scholar award; NIH [R01
   CA118450, R01 CA160522, P01 CA116676]
FX We thank Dr. A. Hammond in our department for editing the manuscript.
   This study is supported by the Georgia Cancer Coalition Distinguished
   Cancer Scholar award and NIH R01 CA118450 (S.-Y. Sun), R01 CA160522
   (S.-Y. Sun) and P01 CA116676 (Project 1 to F.R. Khuri and S.-Y. Sun). TK
   Owonikoko, SS Ramalingam, F.R. Khuri and S.-Y. Sun are Georgia Cancer
   Coalition Distinguished Cancer Scholars.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abraham RT, 2007, CLIN CANCER RES, V13, P3109, DOI 10.1158/1078-0432.CCR-06-2798
   Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360
   Chen Yulong L, 2005, Curr Med Chem Anticancer Agents, V5, P575, DOI 10.2174/156801105774574649
   Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001
   Elrod HA, 2007, MOL CANCER THER, V6, P2029, DOI 10.1158/1535-7163.MCT-07-0004
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Koul D, 2012, CLIN CANCER RES, V18, P184, DOI 10.1158/1078-0432.CCR-11-1558
   Liu XG, 2004, J NATL CANCER I, V96, P1769, DOI 10.1093/jnci/djh322
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5
   Sanders HR, 2010, CANCER GENET CYTOGEN, V203, P7, DOI 10.1016/j.cancergencyto.2010.07.134
   Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917
   Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543
   Sun SY, 1997, CANCER RES, V57, P4931
   Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8
   Sun SY, 2004, CANCER BIOL THER, V3, P1092
   Wang X., 2007, MOL CELL BIOL
   Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522
   Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07
   Wang XR, 2008, CANCER BIOL THER, V7, P1952, DOI 10.4161/cbt.7.12.6944
   Wang XR, 2009, EXPERT OPIN THER TAR, V13, P1193, DOI 10.1517/14728220903225008
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Zheng Y., 2011, J MOL MED BERL
NR 27
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2012
VL 325
IS 2
BP 139
EP 146
DI 10.1016/j.canlet.2012.06.018
PG 8
WC Oncology
SC Oncology
GA 007QZ
UT WOS:000308904500004
ER

PT J
AU Hu, QD
   Chen, W
   Yan, TL
   Ma, T
   Chen, CL
   Liang, C
   Zhang, Q
   Xia, XF
   Liu, H
   Zhi, X
   Zheng, XX
   Bai, XL
   Yu, XZ
   Liang, TB
AF Hu, Qi-Da
   Chen, Wei
   Yan, Tian-Lian
   Ma, Tao
   Chen, Cong-Lin
   Liang, Chao
   Zhang, Qi
   Xia, Xue-Feng
   Liu, Hao
   Zhi, Xiao
   Zheng, Xiao-Xiao
   Bai, Xue-Li
   Yu, Xia-Zhen
   Liang, Ting-Bo
TI NSC 74859 enhances doxorubicin cytotoxicity via inhibition of
   epithelial-mesenchyrnal transition in hepatocellular carcinoma cells
SO CANCER LETTERS
LA English
DT Article
DE Hepatocellular carcinoma; Signal transducer and activator of
   transcription 3; Epithelial-mesenchymal transition; Doxorubicin; NSC
   74859
ID BREAST-CANCER CELLS; ANTITUMOR-ACTIVITY; SYSTEMIC THERAPY; GENE-THERAPY;
   STAT3; CHEMOTHERAPY; ACTIVATION; LIVER; TRANSCRIPTION; HEPATOMA
AB Doxorubicin-based therapy is not effective for the treatment of hepatocellular carcinomas (HCCs). which often undergo epithelial-mesenchymal transition (EMT) during tumor progression. Activation of signal transducer and activator of transcription 3 (STAT3) is associated with chemosensitivity and may contribute to EMT during HCC chemotherapy. Low doses of NSC 78459 (a novel STAT3 inhibitor) have little effect on HCC cell proliferation, but efficiently inhibit STAT3.
   HuH-7, Hep3B, and HepG2 cells, with epithelial phenotypes, show significantly enhanced doxorubicin cytotoxicity following co-treatment with NSC 74859, whereas mesenchymal SNU-449 cells show no such enhancement. NSC 74859 inhibits STAT3 activity and suppressed doxorubicin-induced EMT in epithelial HCC cells. siRNA-mediated STAT3 knockdown resulted in EMT inhibition, which led to attenuation of NSC 74859-mediated chemosensitivity. Our data indicate NSC 74859 co-administration enhances doxorubicin cytotoxicity by inhibiting STAT3 in epithelial HCC cells. STAT3 deactivation and associated EMT attenuation contribute to the synergistic anti-tumor effects of combined NSC 74859/doxorubicin therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Hu, Qi-Da; Chen, Wei; Ma, Tao; Chen, Cong-Lin; Liang, Chao; Zhang, Qi; Xia, Xue-Feng; Liu, Hao; Zhi, Xiao; Zheng, Xiao-Xiao; Bai, Xue-Li; Yu, Xia-Zhen; Liang, Ting-Bo] Zhejiang Univ, Sch Med, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Yan, Tian-Lian] Zhejiang Univ, Sch Med, Dept Gastroenterol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
RP Liang, TB (reprint author), Zhejiang Univ, Sch Med, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 2, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM liangtingbo@zju.edu.cn
FU National Natural Science Funds for Distinguished Young Scholar
   [30925033]; National Natural Science Funds of China [81101841,
   81171884]; Innovation and High-Level Talent Training Program of
   Department of Health of Zhejiang
FX This work was supported by grants from the National Natural Science
   Funds for Distinguished Young Scholar (No. 30925033), the National
   Natural Science Funds of China (Nos. 81101841 and 81171884), and the
   Innovation and High-Level Talent Training Program of Department of
   Health of Zhejiang.
CR Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672
   Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Chen W, 2012, LIVER INT, V32, P70, DOI 10.1111/j.1478-3231.2011.02631.x
   Chen XL, 2011, J HEPATOL, V55, P838
   Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200
   Choi SS, 2009, HEPATOLOGY, V50, P2007, DOI 10.1002/hep.23196
   Ding W, 2010, HEPATOLOGY, V52, P945, DOI 10.1002/hep.23748
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683
   Fan H, 2012, BIOMATERIALS, V33, P1428, DOI 10.1016/j.biomaterials.2011.10.043
   Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460
   Jiang RQ, 2011, HEPATOLOGY, V54, P900, DOI 10.1002/hep.24486
   Jou J, 2010, J CLIN INVEST, V120, P1031, DOI 10.1172/JCI42615
   Lau CK, 2007, CANCER BIOL THER, V6, P1900
   Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092
   Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372
   Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103
   Li YH, 2001, CANCER RES, V61, P6428
   Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468
   Lin L, 2009, ONCOGENE, V28, P961, DOI 10.1038/onc.2008.448
   Liu FJ, 2008, CANCER SCI, V99, P2055, DOI 10.1111/j.1349-7006.2008.00905.x
   Lopez CA, 2004, MOL CANCER THER, V3, P1167
   Masuda M, 2001, CLIN CANCER RES, V7, P4220
   Park SH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-3
   Pokorny H, 2005, AM J TRANSPLANT, V5, P788, DOI 10.1111/j.1600-6143.2005.00780.x
   Schwartz JD, 2002, LANCET ONCOL, V3, P593, DOI 10.1016/S1470-2045(02)00873-2
   Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104
   Tai WT, 2011, J HEPATOL, V55, P1041, DOI 10.1016/j.jhep.2011.06.005
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thomas MB, 2008, ANN SURG ONCOL, V15, P1008, DOI 10.1245/s10434-007-9705-0
   WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yau T, 2010, CANCER-AM CANCER SOC, V116, P5022, DOI 10.1002/cncr.25372
   Yeo W, 2005, J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315
   Yin XY, 2005, WORLD J GASTROENTERO, V11, P2526
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Yu XT, 2007, J CANCER RES CLIN, V133, P145, DOI 10.1007/s00432-006-0139-z
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhou J, 2010, BIOCHEM PHARMACOL, V79, P1242, DOI 10.1016/j.bcp.2009.12.014
   Zhu AX, 2006, ONCOLOGIST, V11, P790, DOI 10.1634/theoncologist.11-7-790
NR 40
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2012
VL 325
IS 2
BP 207
EP 213
DI 10.1016/j.canlet.2012.07.003
PG 7
WC Oncology
SC Oncology
GA 007QZ
UT WOS:000308904500011
ER

PT J
AU Wang, SH
   Chen, CC
   Meng, YC
   Hu, S
   Zheng, L
   Song, JJ
   Zhang, DP
   Li, BH
   Guo, YJ
AF Wang, Shuhui
   Chen, Changchun
   Meng, Yanchun
   Hu, Shi
   Zheng, Lei
   Song, Jinjing
   Zhang, Dapeng
   Li, Bohua
   Guo, Yajun
TI Effective suppression of breast tumor growth by an anti-EGFR/ErbB2
   bispecific antibody
SO CANCER LETTERS
LA English
DT Article
DE ErbB2; EGFR; Breast cancer; Bispecific; Monoclonal antibody
ID FACTOR RECEPTOR; TRASTUZUMAB RESISTANCE; MONOCLONAL-ANTIBODIES;
   CANCER-THERAPY; MECHANISM; COMPLEX; EFFICACY
AB Despite the effectiveness of the anti-ErbB2 humanized antibody trastuzumab, less than 35% of patients with ErbB2-overexpressing breast cancer respond to the treatment. Here we engineered an anti-EGFR/ErbB2 bispecific antibody (TC-BsAb) using trastuzumab and cetuximab, an anti-EGFR chimeric antibody. TC-BsAb treatment led to internalization of both EGFR and ErbB2, whereas trastuzumab and cetuximab, either alone or in combination, failed to induce ErbB2 internalization. Both in vitro and in vivo experiments indicated that TC-BsAb was significantly more potent in inhibiting the growth of breast cancer cell lines than trastuzumab, cetuximab, and trastuzumab plus cetuximab, suggesting its potential use for treating breast cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Meng, Yanchun; Hu, Shi; Zheng, Lei; Song, Jinjing; Zhang, Dapeng; Li, Bohua; Guo, Yajun] Mil Med Coll 2, Int Joint Canc Inst, Shanghai 200433, Peoples R China.
   [Wang, Shuhui; Chen, Changchun; Guo, Yajun] Shanghai Jiao Tong Univ, Sch Pharm, Ctr Antibody Med, Minist Educ, Shanghai 200240, Peoples R China.
   [Zhang, Dapeng; Li, Bohua; Guo, Yajun] Natl Engn Res Ctr Antibody Med, Shanghai 201203, Peoples R China.
   [Zhang, Dapeng; Li, Bohua; Guo, Yajun] Shanghai Key Lab Cell Engn & Antibody, Shanghai 201203, Peoples R China.
   [Li, Bohua; Guo, Yajun] Peoples Liberat Army Gen Hosp, PLA Postgrad Sch Med, Ctr Canc, Beijing 100853, Peoples R China.
RP Li, BH (reprint author), Mil Med Coll 2, Int Joint Canc Inst, Shanghai 200433, Peoples R China.
EM bohuali@gmail.com; yjguo@smmu.edu.cn
FU National Natural Science Foundation of China. Ministry of Science &
   Technology of China (973 & 863 program projects); National Key project
   for New Drug Development and Manufacture; Shanghai Commission of Science
   Technology; Ministry of Education of China; Shanghai Commission of
   Education for excellent research team in Oncology and Shanghai Key
   Project in Oncology
FX This research was partly funded by National Natural Science Foundation
   of China. Ministry of Science & Technology of China (973 & 863 program
   projects), National Key project for New Drug Development and
   Manufacture, and Shanghai Commission of Science & Technology as well as
   special grants from Ministry of Education of China and Shanghai
   Commission of Education for excellent research team in Oncology and
   Shanghai Key Project in Oncology.
CR Carnahan J, 2003, CLIN CANCER RES, V9, p3982S
   CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285
   Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392
   Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2
   Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226
   Glennie MJ, 2007, MOL IMMUNOL, V44, P3823, DOI 10.1016/j.molimm.2007.06.151
   Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020
   KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3
   Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380
   Li BH, 2010, J BIOL CHEM, V285, P3865, DOI 10.1074/jbc.M109.076547
   Li BH, 2008, CANCER RES, V68, P2400, DOI 10.1158/0008-5472.CAN-07-6663
   Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Qu ZX, 2008, BLOOD, V111, P2211, DOI 10.1182/blood-2007-08-110072
   SHIH LB, 1994, INT J CANCER, V56, P538, DOI 10.1002/ijc.2910560413
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507
   Valabrega G, 2007, ANN ONCOL, V18, P977, DOI 10.1093/annonc/mdl475
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   Wu CB, 2007, NAT BIOTECHNOL, V25, P1290, DOI 10.1038/nbt1345
   Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972
NR 23
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2012
VL 325
IS 2
BP 214
EP 219
DI 10.1016/j.canlet.2012.07.007
PG 6
WC Oncology
SC Oncology
GA 007QZ
UT WOS:000308904500012
ER

PT J
AU Zhang, SC
   Cai, WS
   Zhang, Y
   Jiang, KL
   Zhang, KR
   Wang, WL
AF Zhang, Shu-Cheng
   Cai, Wei-Song
   Zhang, Yao
   Jiang, Kai-Lei
   Zhang, Ke-Ren
   Wang, Wei-Lin
TI Engineered measles virus Edmonston strain used as a novel oncolytic
   viral system against human neuroblastoma through a CD46 and nectin
   4-independent pathway
SO CANCER LETTERS
LA English
DT Article
DE Neuroblastoma; Oncolytic; Measles virus Edmonston strain; CD46; Nectin 4
ID SODIUM-IODIDE SYMPORTER; IN-VIVO; NEURONAL CELLS; IMMUNE-RESPONSE;
   VACCINE STRAIN; TUMOR-CELLS; KAPPA-B; THERAPY; CANCER; RECEPTOR
AB Neuroblastoma (NB) is the most common extracranial solid tumor in children. In this study, we investigated the potential antitumor capability of the engineered Edmonston strain of the carcinoembryonic antigen-expressing measles virus (MV-CEA) against human NB. The infection of a variety of NB cell lines, including SK-N-SH. SMS-KCNR, and primary NB cells, resulted in significant cytopathic effects. None of the NB cell lines showed an overexpression of the measles virus receptor CD46 and nectin 4, but the cell lines did support robust viral replication. The efficacy of this approach was examined in murine SK-N-SH xenograft models. Flow cytometry and TUNEL assays indicated an apoptotic mechanism of cell death. In summary, MV-CEA has potent therapeutic efficacy against NB mediated by a CD46- and nectin 4-independent pathway. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Shu-Cheng; Jiang, Kai-Lei; Zhang, Ke-Ren; Wang, Wei-Lin] China Med Univ, Dept Pediat Surg, Major Lab,Shengjing Hosp, Chinese Hlth Minist Congenital Malformat, Shenyang 110004, Peoples R China.
   [Cai, Wei-Song] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Zhang, Yao] China Med Univ, Dept Ultrasound, Shengjing Hosp, Shenyang 110004, Peoples R China.
RP Wang, WL (reprint author), China Med Univ, Dept Pediat Surg, Major Lab,Shengjing Hosp, Chinese Hlth Minist Congenital Malformat, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM zhangshucheng2009@163.com
FU National Natural Science Foundation of China [30700917]
FX All work was performed at the Shengjing Hospital of China Medical
   University, Shenyang, PR China. The study was supported by the National
   Natural Science Foundation of China (No. 30700917), and the paper has
   not been presented at any meetings.
CR Anderson BD, 2004, CANCER RES, V64, P4919, DOI 10.1158/0008-5472.CAN-04-0884
   Blechacz B, 2006, HEPATOLOGY, V44, P1465, DOI 10.1002/hep.21437
   Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332
   Dhib-Jalbut S, 1999, J IMMUNOL, V162, P4024
   Dhiman N, 2004, REV MED VIROL, V14, P217, DOI 10.1002/rmv.430
   Dingli D, 2004, BLOOD, V103, P1641, DOI 10.1182/blood-2003-07-2233
   Dingli D, 2003, J CELL BIOCHEM, V90, P1079, DOI 10.1002/jcb.10714
   Duprex WP, 2000, J VIROL, V74, P7972, DOI 10.1128/JVI.74.17.7972-7979.2000
   Elankumaran S, 2006, J VIROL, V80, P7522, DOI 10.1128/JVI.00241-06
   ESOLEN LM, 1995, J VIROL, V69, P3955
   Faivre J, 2004, CANCER RES, V64, P8045, DOI 10.1158/0008-5472.CAN-04-0893
   Fang YY, 2001, J NEUROVIROL, V7, P25
   Garcia-Castro J, 2010, CANCER GENE THER, V17, P476, DOI 10.1038/cgt.2010.4
   Gauvrit A, 2008, CANCER RES, V68, P4882, DOI 10.1158/0008-5472.CAN-07-6265
   Griffin D.E., 2007, MEASLES VIRUS FIELDS
   Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746
   Haralambieva I, 2007, MOL THER, V15, P588, DOI 10.1038/sj.mt.6300076
   Heinzerling L, 2005, BLOOD, V106, P2287, DOI 10.1182/blood-2004-11-4558
   Higuchi H, 2000, CANCER RES, V60, P6396
   Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009
   Lacroix J, 2010, INT J CANCER, V127, P1230, DOI 10.1002/ijc.25168
   Lawrence DMP, 2000, J VIROL, V74, P1908, DOI 10.1128/JVI.74.4.1908-1918.2000
   Li H, 2007, CLIN CANCER RES, V13, P316, DOI 10.1158/1078-0432.CCR-06-1625
   Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736
   MARIS JM, 2007, J GERONTOL B-PSYCHOL, V369, P2106
   Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577
   Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601
   McDonald CJ, 2006, BREAST CANCER RES TR, V99, P177, DOI 10.1007/s10549-006-9200-5
   McQuaid S, 1998, J VIROL, V72, P5245
   Meng X, 2010, MOL THER, V18, P544, DOI 10.1038/mt.2009.296
   Modak S, 2010, CANCER TREAT REV, V36, P307, DOI 10.1016/j.ctrv.2010.02.006
   Muhlebach MD, 2011, NATURE, V480, P530, DOI 10.1038/nature10639
   National cancer institute, SURV EP END RES DAT
   Nemunaitis J, 2000, CANCER RES, V60, P6359
   Noyce RS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002240
   Parikh NS, 2005, PEDIATR BLOOD CANCER, V44, P469, DOI 10.1002/pbc.20268
   Parks CL, 2001, J VIROL, V75, P910, DOI 10.1128/JVI.75.2.910-920.2001
   Peng KW, 2001, BLOOD, V98, P2002, DOI 10.1182/blood.V98.7.2002
   Peng KW, 2002, NAT MED, V8, P527, DOI 10.1038/nm0502-527
   Peng KW, 2003, HUM GENE THER, V14, P1565, DOI 10.1089/104303403322495070
   Peng KW, 2002, CANCER RES, V62, P4656
   Peng WP, 2005, J VIROL, V79, P6162, DOI 10.1128/JVI.79.10.6162-6171.2005
   Pesonen Sari, 2010, Acta Oncol, V49, P117
   Phuong LK, 2003, CANCER RES, V63, P2462
   RADECKE F, 1995, EMBO J, V14, P5773
   Ramirez Manuel, 2010, Discov Med, V10, P387
   Russell S, 2004, TISSUE ANTIGENS, V64, P111, DOI 10.1111/j.1399-0039-.2004.00277.x
   Sato Hiroki, 2012, Front Microbiol, V3, P75
   Servet-Delprat C, 2000, J VIROL, V74, P4387, DOI 10.1128/JVI.74.9.4387-4393.2000
   Soto BL, 2011, CANCER IMMUNOL IMMUN, V60, P731, DOI 10.1007/s00262-011-0971-0
   Tatsuo H, 2000, NATURE, V406, P893
   Terao-Muto Y, 2008, ANTIVIR RES, V80, P370, DOI 10.1016/j.antiviral.2008.08.006
   Toth AM, 2009, J VIROL, V83, P961, DOI 10.1128/JVI.01669-08
   Toyoda H, 2007, CANCER RES, V67, P2857, DOI 10.1158/0008-5472.CAN-06-3713
   Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524
   Watanabe A, 2010, J VIROL, V84, P4183, DOI 10.1128/JVI.02168-09
   WOLMAN SR, 1988, J CELL BIOCHEM, V36, P147, DOI 10.1002/jcb.240360206
NR 57
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2012
VL 325
IS 2
BP 227
EP 237
DI 10.1016/j.canlet.2012.07.008
PG 11
WC Oncology
SC Oncology
GA 007QZ
UT WOS:000308904500014
ER

PT J
AU Chan, APC
   Yi, W
   Wong, DP
   Yam, MCH
   Chan, DWM
AF Chan, Albert P. C.
   Yi, Wen
   Wong, Del P.
   Yam, Michael C. H.
   Chan, Daniel W. M.
TI Determining an optimal recovery time for construction rebar workers
   after working to exhaustion in a hot and humid environment
SO BUILDING AND ENVIRONMENT
LA English
DT Article
DE Heat stress; Physiological strain index (PSI); Heat tolerance time;
   Field studies; Rebar workers; Rest time
ID UNCOMPENSABLE HEAT-STRESS; PHYSIOLOGICAL STRAIN INDEX; RESPIRATORY
   EXCHANGE RATIO; AEROBIC FITNESS; EXERCISE INTENSITY; PERCEIVED EXERTION;
   REST SCHEDULES; TOLERANCE; HYDRATION; RELIABILITY
AB This paper is an extension to a paper previously published in the journal Building and Environment. Having determined an optimal recovery time in a controlled climatic environment, this paper aims to investigate the real impact on construction rebar workers by replicating the clinical experimentation to a series of field studies. Field studies were conducted during the summer time in Hong Kong. Nineteen rebar workers performed tasks of fixing and bending steel reinforcement bars on two building construction sites until voluntary exhaustion and were allowed to recover on site until their physiological conditions returned to the pre-work level or lower. Physiological Strain Index (PSI) was used as a yardstick to determine the rate of recovery. A total of 411 sets of meteorological and physiological data collected over fourteen working days between July and August of 2011 were collated to derive the optimal recovery time. It was found that on average a rebar worker could achieve 94% recovery in 40 min; 93% in 35 min; 92% in 30 min; 88% in 25 min; 84% in 20 min; 78% in 15 min; 68% in 10 min; and 58% in 5 min. Curve estimation results showed that recovery time is a significant variable to predict the rate of recovery (R-2 = 0.99, P < 0.05). Additional rest times should be introduced between works in extreme hot weather to enable workers to recover from heat stress. Frequency and duration of each rest time should be agreed among different stakeholders based on the cumulative recovery curve. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Chan, Albert P. C.; Yi, Wen; Yam, Michael C. H.; Chan, Daniel W. M.] Hong Kong Polytech Univ, Dept Bldg & Real Estate, Kowloon, Hong Kong, Peoples R China.
   [Wong, Del P.] Technol & Higher Educ Inst Hong Kong, Fac Management & Hospitality, Hong Kong, Hong Kong, Peoples R China.
RP Yi, W (reprint author), Hong Kong Polytech Univ, Dept Bldg & Real Estate, Kowloon, Hong Kong, Peoples R China.
EM yiwen96@163.com
FU Research Grants Council of the Hong Kong Special Administrative Region,
   China (RGC Project) [PolyU510409]
FX This project is funded by a grant from the Research Grants Council of
   the Hong Kong Special Administrative Region, China (RGC Project No.
   PolyU510409). The research team is indebted to the technical support
   from technicians of the Hong Kong Polytechnic University and the Hong
   Kong Institute of Education. In particular, the participation of
   volunteers in this experimental study is gratefully acknowledged. This
   paper forms part of the research project titled "Experimental research
   on health and safety measures for working in hot weather", from which
   other deliverables will be produced with different objectives/scopes but
   sharing common background and methodology. The authors also wish to
   acknowledge the contributions of other team members including Prof
   Francis Wong, Prof Joanne Chung, Prof Esmond Mok, Dr Geoffrey Shea, Dr
   Min Wu, Dr Herbert Biggs, Dr Donald Dingsdag, and Miss Alice Guan.
CR Anderson GS, 1999, INT J BIOMETEOROL, V43, P99, DOI 10.1007/s004840050123
   BERNARD TE, 1994, AM IND HYG ASSOC J, V55, P505, DOI 10.1202/0002-8894(1994)055<0505:RFAPMF>2.0.CO;2
   Birkett WA, 1998, CLIN REHABIL, V12, P319, DOI 10.1191/026921598676065152
   Borg G, 1976, REPORTS I APPL PSYCH, P75
   BORG G, 1990, SCAND J WORK ENV HEA, V16, P55
   Brezinski C, 1991, EXTRAPOLATION METHOD
   Carnahan BJ, 2000, ERGONOMICS, V43, P543, DOI 10.1080/001401300184404
   Chan APC, 2012, BUILD ENVIRON, V56, P28, DOI 10.1016/j.buildenv.2012.02.013
   Chan PC, 2012, J FACIL MANAG, V10, P59
   Cheung SS, 2000, SPORTS MED, V29, P329, DOI 10.2165/00007256-200029050-00004
   Cheung SS, 1998, J APPL PHYSIOL, V84, P1731
   Choudhry RM, 2008, SAFETY SCI, V46, P566, DOI 10.1016/j.ssci.2007.06.027
   Christensen EH, 2000, INT J IND ERGONOM, V25, P367
   Construction Industry Council, 2008, VERS 1 GUID SIT SAF, V2
   Coquart JBJ, 2009, PSYCHOPHYSIOLOGY, V46, P209, DOI 10.1111/j.1469-8986.2008.00717.x
   Cuthbert D., 1999, FITTING EQUATIONS DA
   Department of Health HKSAR Government, 2010, PREV MEAS HEAT STROK
   DUNBAR CC, 1992, MED SCI SPORT EXER, V24, P94
   Flouris AD, 2005, BRIT J SPORT MED, V39, P166, DOI 10.1136/bjsm.2004.012500
   Foster C, 2001, J STRENGTH COND RES, V15, P109, DOI 10.1519/00124278-200102000-00019
   Frakes Michael A, 2008, Air Med J, V27, P37, DOI 10.1016/j.amj.2007.05.010
   FRANKENHAEUSER M, 1991, Annals of Behavioral Medicine, V13, P197
   Frisancho AR, 1981, HUMAN ADAPTATION FUN
   Frone MR, 1999, ALCOHOL RES HEALTH, V23, P284
   Garcin M, 2004, INT J SPORTS MED, V25, P270, DOI 10.1055/s-2004-819939
   Gotshall RW, 2004, J EXERC PHYSL, V3, P22
   Hancher DE, 1998, COST ENG, V40, P32
   Helander MG, 1991, INT J IND ERGONOM, V8, P205, DOI 10.1016/0169-8141(91)90033-I
   Hirata A, 2003, IEEE T ELECTROMAGN C, V45, P109, DOI 10.1109/TEMC.2002.808045
   Hong Kong Observatory The Government of the Hong Kong Special Administrative Region, 2011, COLD VER HOT WEATH W
   Hoonakker P, 2005, APPL ERGON, V36, P461, DOI 10.1016/j.apergo.2004.07.006
   Ingle L, 2008, INT J CARDIOL, V127, P88, DOI 10.1016/j.ijcard.2007.04.075
   KAHKONEN E, 1992, APPL ERGON, V23, P95, DOI 10.1016/0003-6870(92)90080-F
   KING AC, 1994, J GERONTOL, V49, pM239
   Kloner RA, 2007, CIRCULATION, V116, P1306, DOI 10.1161/CIRCULATIONAHA.106.678375
   KOPARDEKAR P, 1994, ERGONOMICS, V37, P1697, DOI 10.1080/00140139408964946
   Labour Department, 2008, PREV HEAT STROK WORK
   Lai JY, 2000, PSYCHOSOM MED, V62, P648
   Lawson L, 2007, AM J CRIT CARE, V16, P485
   Leon LR, 2006, J THERM BIOL, V31, P67, DOI 10.1016/j.jtherbio.2005.11.023
   Linden W, 1997, J PSYCHOSOM RES, V42, P117, DOI 10.1016/S0022-3999(96)00240-1
   Lu SL, 2007, BUILD ENVIRON, V42, P4016, DOI 10.1016/j.buildenv.2006.06.029
   Lumingu HMM, 2009, J THERM BIOL, V34, P299, DOI 10.1016/j.jtherbio.2009.04.001
   Macsween A, 2001, J SPORT MED PHYS FIT, V41, P312
   Maiti Rina, 2008, Appl Ergon, V39, P754, DOI 10.1016/j.apergo.2007.11.010
   Maxwell NS, 2008, J SCI MED SPORT, V11, P491, DOI 10.1016/j.jsams.2007.05.008
   Mezzani A, 2003, AM HEART J, V145, P1102, DOI 10.1016/S0002-8703(03)00100-5
   MONTAIN SJ, 1994, J APPL PHYSIOL, V77, P216
   Moran DS, 1999, AM J PHYSIOL-REG I, V276, pR1798
   Moran DS, 1998, AM J PHYSIOL-REG I, V275, pR854
   Moran DS, 1999, T9910 US ARM RES I E, P1
   National Academy of Sciences, 2008, CONSTR RES NIOSH REV
   National institute on alcohol abuse and alcoholism, 1996, 32PH363 NAT I ALC AB
   Norusis MJ, 2008, SPSS 16 0 STAT PROC
   Pierzga JM, 2002, AM J PHYSL, P282
   SAWKA MN, 1992, J APPL PHYSIOL, V73, P368
   Selkirk GA, 2001, J APPL PHYSIOL, V91, P2055
   Spaak J, 2008, AM J PHYSIOL-HEART C, V294, pH605, DOI 10.1152/ajpheart.01162.2007
   Stewart T, 1980, VISUAL DISPLAY TERMI
   Tam WY, 2011, SAFETY SCI, V49, P208
   Tian Z, 2011, BUILD ENVIRON, V46, P2033, DOI 10.1016/j.buildenv.2011.04.027
   Tiwari PS, 2006, INT J IND ERGONOM, V36, P203, DOI 10.1016/j.ergon.2005.11.001
   WAERSTED M, 1991, ERGONOMICS, V34, P265
   World of Sports Science, 2012, WORLD SPORTS SCI EXH
   Yia J, 2012, ACCIDENT ANAL PREV, V48, P185
   Zeni AI, 1996, ARCH PHYS MED REHAB, V77, P237, DOI 10.1016/S0003-9993(96)90104-5
   Zhao J, 2009, BUILD ENVIRON, V44, P2202, DOI 10.1016/j.buildenv.2009.01.003
   [Anonymous], 2007, APPLE DAILY     0724
   [Anonymous], 2010, APPLE DAILY     0919
   [Anonymous], 2009, APPLE DAILY     0705
NR 70
TC 0
Z9 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-1323
J9 BUILD ENVIRON
JI Build. Environ.
PD DEC
PY 2012
VL 58
BP 163
EP 171
DI 10.1016/j.buildenv.2012.07.006
PG 9
WC Construction & Building Technology; Engineering, Environmental;
   Engineering, Civil
SC Construction & Building Technology; Engineering
GA 013VA
UT WOS:000309332800015
ER

PT J
AU Chen, MB
   Wu, XY
   Tao, GQ
   Liu, CY
   Chen, J
   Wang, LQ
   Lu, PH
AF Chen, Min-Bin
   Wu, Xiao-Yang
   Tao, Guo-Qing
   Liu, Chao-Ying
   Chen, Jian
   Wang, Li-Qiang
   Lu, Pei-Hua
TI Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by
   targeting multiple signaling pathways both in vivo and in vitro
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE perifosine; curcumin; colorectal cancer; apoptosis; signal transduction
ID NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; COLON-CANCER;
   ANTITUMOR-ACTIVITY; LEUKEMIA-CELLS; ALKYL-LYSOPHOSPHOLIPIDS; INHIBITION;
   APOPTOSIS; AKT; EXPRESSION
AB Our study shows that coadministration of curcumin and an orally bioactive alkylphospholipid perifosine results in a significant increase in colorectal cancer cell apoptosis and a marked inhibition of cell growth both in vitro and in vivo. This novel combinatorial regimen leads to changes of multiple cell signaling pathways including inactivation of Akt and nuclear factor-?B as well as activation of c-Jun N-terminal kinases and endoplasmic reticulum stress. Further, perifosine and curcumin synergistically increase intracellular level of reactive oxygen species and ceramide, and downregulate the expression of cyclin D1 and Bcl-2 in colorectal cancer cells. These changes at molecular level together account for the cancer cell apoptosis and growth inhibition. We conclude that perifosine sensitizes colorectal cancer cells to curcumin by modulating multiple signaling pathways. Adding perifosine with curcumin may represent an effective therapy regimen against colorectal cancers, and possible other aggressive tumors.
C1 [Tao, Guo-Qing; Lu, Pei-Hua] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Gen Surg, Ctr Oncol, Wuxi 214023, Jiangsu, Peoples R China.
   [Chen, Min-Bin; Wang, Li-Qiang] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Med Oncol, Kunshan, Jiangsu, Peoples R China.
   [Wu, Xiao-Yang; Chen, Jian] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Gen Surg, Kunshan, Jiangsu, Peoples R China.
   [Liu, Chao-Ying] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Med Oncol, Ctr Oncol, Wuxi 214023, Jiangsu, Peoples R China.
RP Lu, PH (reprint author), Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Gen Surg, Ctr Oncol, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.
EM lphty1_1@yahoo.com.cn
FU National Natural Science Foundation [81101801, 81101676]; Natural
   Science Foundation of Jiangsu Province [BK2010160, BK2011374];
   Foundation of Wuxi Health Bureau [ZD1008]
FX Grant sponsor: The National Natural Science Foundation; Grant numbers:
   81101801, 81101676; Grant sponsor: Natural Science Foundation of Jiangsu
   Province; Grant numbers: BK2010160, BK2011374; Grant sponsor: The
   Foundation of Wuxi Health Bureau; Grant number: ZD1008
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Bakhshi J, 2008, APOPTOSIS, V13, P904, DOI 10.1007/s10495-008-0221-x
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Campbell Frederick C, 2005, Future Oncol, V1, P405, DOI 10.1517/14796694.1.3.405
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Chen MB, 2011, J CELL PHYSIOL, V226, P1915, DOI 10.1002/jcp.22522
   Chen MB, 2011, CELL BIOCHEM BIOPHYS, V60, P311, DOI 10.1007/s12013-011-9153-0
   Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941
   Chiarini F, 2008, LEUKEMIA, V22, P1106, DOI 10.1038/leu.2008.79
   Cirstea D, 2010, MOL CANCER THER, V9, P963, DOI 10.1158/1535-7163.MCT-09-0763
   Du BY, 2006, CHEMOTHERAPY, V52, P23, DOI 10.1159/000090238
   Fu L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-315
   Garcea G, 2004, BRIT J CANCER, V90, P1011, DOI 10.1038/sj.bjc.6601623
   Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3
   Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653
   HARIGAYA K, 1993, PHYS REV B, V47, P16563, DOI 10.1103/PhysRevB.47.16563
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434
   Hilgard P, 1997, EUR J CANCER, V33, P442, DOI 10.1016/S0959-8049(96)00466-2
   Howells LM, 2007, INT J CANCER, V121, P175, DOI 10.1002/ijc.22645
   Jin S, 2007, APOPTOSIS, V12, P1317, DOI 10.1007/s10495-007-0062-z
   Kondapaka SB, 2003, MOL CANCER THER, V2, P1093
   Li X, 2006, ONCOGENE, V25, P525
   Lin YG, 2007, CLIN CANCER RES, V13, P3423, DOI 10.1158/1078-0432.CCR-06-3072
   Majumdar APN, 2009, NUTR CANCER, V61, P544, DOI 10.1080/01635580902752262
   MERRILL AH, 1993, J BIOL CHEM, V268, P27299
   Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405
   Mohandas K M, 1999, Indian J Gastroenterol, V18, P118
   Moragoda L, 2001, ANTICANCER RES, V21, P873
   Moussavi M, 2006, CARCINOGENESIS, V27, P1636, DOI 10.1093/carcin/bgi371
   Ozes ON, 1999, NATURE, V401, P82
   Pae HO, 2007, BIOCHEM BIOPH RES CO, V353, P1040, DOI 10.1016/j.bbrc.2006.12.133
   Patel BB, 2010, ANTICANCER RES, V30, P319
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Patel BB, 2009, NUTR CANCER, V61, P842, DOI 10.1080/01635580903285106
   Patel V, 2002, CANCER RES, V62, P1401
   Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440
   Rajasekaran Sigrid A, 2011, World J Gastrointest Pathophysiol, V2, P1, DOI 10.4291/wjgp.v2.i1.1
   Romashkova JA, 1999, NATURE, V401, P86
   Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/01.cad.0000054974.31252.f7
   Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0
   Salminen A, 2009, CELLULAR SIGNALLING, V22, P573
   Sun H, 2011, CANCER LETT, V310, P118, DOI 10.1016/j.canlet.2011.06.010
   Taylor Rebecca A, 2011, Altern Med Rev, V16, P152
   Thangapazham RL, 2006, AAPS J, V8, pE443, DOI 10.1208/aapsj080352
   van Lummel M, 2011, FASEB J, V25, P280, DOI 10.1096/fj.10-163709
   Yu T, 2010, CANCER CHEMOTH PHARM, V66, P999, DOI 10.1007/s00280-010-1374-1
   Yu YJ, 2009, TRANSL ONCOL, V2, P321, DOI 10.1593/tlo.09193
NR 47
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2012
VL 131
IS 11
BP 2487
EP 2498
DI 10.1002/ijc.27548
PG 12
WC Oncology
SC Oncology
GA 011SN
UT WOS:000309185400003
ER

PT J
AU Yuasa, Y
   Nagasaki, H
   Oze, I
   Akiyama, Y
   Yoshida, S
   Shitara, K
   Ito, S
   Hosono, S
   Watanabe, M
   Ito, H
   Tanaka, H
   Kang, D
   Pan, KF
   You, WC
   Matsuo, K
AF Yuasa, Yasuhito
   Nagasaki, Hiromi
   Oze, Isao
   Akiyama, Yoshimitsu
   Yoshida, Shunsuke
   Shitara, Kouhei
   Ito, Seiji
   Hosono, Satoyo
   Watanabe, Miki
   Ito, Hidemi
   Tanaka, Hideo
   Kang, Daehee
   Pan, Kai-feng
   You, Wei-cheng
   Matsuo, Keitaro
TI Insulin-like growth factor 2 hypomethylation of blood leukocyte DNA is
   associated with gastric cancer risk
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; gastric cancer; IGF2; blood leukocyte; lifestyle
ID DIETARY FACTORS; METHYLATION STATUS; COLORECTAL-CANCER; FACTOR-II; GENE;
   IGF2; CARCINOGENESIS; EPIGENETICS; CARCINOMA; EVENTS
AB To determine whether or not the methylation status of blood leukocyte DNA can be used as a surrogate marker of the risk for cancer, we quantitatively determined the methylation levels of insulin-like growth factor 2 (IGF2) and TUSC3 in 299 gastric cancer cases, and 299 age- and gender-matched controls. The IGF2 methylation levels in blood leukocyte DNA of the cases were lower than those of the healthy controls and there was a significant trend of increasing gastric cancer risk with decreasing methylation level of IGF2. Patients with hypermethylated IGF2 in blood leukocyte DNA showed a significantly better survival rate than those with hypomethylated IGF2, indicating that the IGF2 methylation level in blood leukocyte DNA can be a possible marker not only of the risk for but also of the prognosis of gastric cancer. In contrast, the TUSC3 methylation level in blood leukocyte DNA was higher in the cases than in the healthy controls, but the difference was not significant. The past lifestyle and clinicopathological characteristics of the participants were analyzed for any relationship with the methylation level. With aging and smoking, methylation of IGF2 and TUSC3 decreased and increased in blood leukocyte DNA, respectively. These results indicate that the methylation level of IGF2 in blood leukocyte DNA may be used as an important surrogate marker of the risk for gastric cancer.
C1 [Yuasa, Yasuhito; Nagasaki, Hiromi; Akiyama, Yoshimitsu; Yoshida, Shunsuke] Tokyo Med & Dent Univ, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan.
   [Kang, Daehee] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.
   [Pan, Kai-feng; You, Wei-cheng] Peking Univ, Canc Hosp & Inst, Dept Canc Epidemiol, Beijing 100871, Peoples R China.
RP Yuasa, Y (reprint author), Tokyo Med & Dent Univ, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM yuasa.monc@tmd.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [17015013]; Japan Society for the Promotion of Science [20390169,
   AA005]; Ministry of Health, Labor, and Welfare of Japan [00001]
FX Grant sponsor: Ministry of Education, Culture, Sports, Science and
   Technology of Japan; Grant number: 17015013 (Grant-in-Aid for Scientific
   Research on Priority Areas-Cancer); Grant sponsor: Japan Society for the
   Promotion of Science; Grant number: 20390169 (Grant-in-Aid for
   Scientific Research B); Grant sponsor: Japan Society for the Promotion
   of Science; Grant number: AA005 (A3 Foresight Program); Grant sponsor:
   Ministry of Health, Labor, and Welfare of Japan; Grant number: 00001
   (Grant-in-Aid for Cancer Research)
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Arasaradnam RP, 2008, EPIGENETICS-US, V3, P193
   Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050
   Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Esteller M, 2001, CANCER RES, V61, P3225
   Hamajima N, 2001, ASIAN PAC J CANCER P, V2, P99
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/ge1068
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaaks R, 2009, CANCER RES, V69, P5400, DOI 10.1158/0008-5472.CAN-08-3020
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Nicolucci A, 2010, ACTA DIABETOL, V47, P87, DOI 10.1007/s00592-010-0187-3
   Pils D, 2005, CANCER, V104, P2417, DOI 10.1002/cncr.21538
   Tajima K, 2000, ASIAN PAC J CANCER P, V1, P35
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Tokudome Shinkan, 2004, Asian Pac J Cancer Prev, V5, P40
   Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135
   Toyota M, 1999, CANCER RES, V59, P5438
   Tsugane S, 2007, GASTRIC CANCER, V10, P75, DOI 10.1007/s10120-007-0420-0
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   Wanajo A, 2008, GASTROENTEROLOGY, V135, P580, DOI 10.1053/j.gastro.2008.05.041
   Watabe H, 2005, GUT, V54, P764, DOI 10.1136/gut.2004.055400
   Watanabe Y, 1997, DIGEST DIS SCI, V42, P1383, DOI 10.1023/A:1018833819860
   Willett W, 1998, NUTR EPIDEMIOLOGY, P273
   Wu MS, 1997, CANCER LETT, V120, P9, DOI 10.1016/S0304-3835(97)00279-6
   Yuasa Y, 2010, ADV GENET, V71, P211, DOI 10.1016/S0065-2660(10)71008-7
   Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141
   Yuasa Y, 2009, INT J CANCER, V124, P2677, DOI 10.1002/ijc.24231
   Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304
   Zhao RH, 2005, CANCER EPIDEM BIOMAR, V14, P1819, DOI 10.1158/1055-9965.EPI-04-0803
   Zuo QS, 2011, MOL CARCINOGEN, V50, P390, DOI 10.1002/mc.20731
NR 38
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2012
VL 131
IS 11
BP 2596
EP 2603
DI 10.1002/ijc.27554
PG 8
WC Oncology
SC Oncology
GA 011SN
UT WOS:000309185400014
ER

PT J
AU Zhang, CP
   Tong, JL
   Sun, XG
   Liu, JJ
   Wang, YT
   Huang, G
AF Zhang, Chenpeng
   Tong, Jinlu
   Sun, Xiaoguang
   Liu, Jianjun
   Wang, Yuting
   Huang, Gang
TI 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in
   patients with locally advanced rectal cancer: A meta-analysis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE meta-analysis; rectal cancer; positron-emission tomography; predicting
   response
ID POSITRON-EMISSION-TOMOGRAPHY; PREOPERATIVE CHEMORADIATION THERAPY;
   FDG-PET; TUMOR RESPONSE; F-18-FDG PET; COLORECTAL-CANCER; NONOPERATIVE
   TREATMENT; COMPUTED-TOMOGRAPHY; METABOLIC-RESPONSE; RADICAL SURGERY
AB The purpose of this meta-analysis was to evaluate the utility of positron emission tomography (PET) using fluor-18-deoxyglucose (FDG) to predict the response of rectal cancer to neo-adjuvant therapy. All previously published studies on the role of FDG-PET in predicting the response of rectal cancer to neo-adjuvant therapy were collected. Pooled sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated using statistical software. A total of 28 studies, comprising 1,204 patients with rectal cancer, were included in the meta-analysis. Pooled sensitivity, specificity, PPV and NPV for FDG-PET predicting the response to therapy was 78% [95% confidence interval (CI): 7582%], 66% (95% CI: 6269%), 70% (95% CI; 6673%) and 75% (95% CI: 710.79%), respectively. The included studies were of a relatively high methodological quality according to the QUADAS (quality assessment of studies of diagnostic accuracy included in systematic reviews) criteria. Based on the subgroup analyses, there was no significant difference between the response index, the standardized uptake value and the visual response score in predicting the therapy response. However, the accuracy of the group that underwent PET scanning during therapy showed significantly higher values (sensitivity 86% and specificity 80%) than the group that was scanned after completion of the therapy. Therefore, FDG-PET is valuable for predicting the response of rectal carcinoma to neo-adjuvant therapy, and early evaluation of response during the therapy may be more promising. However, additional studies using prospective clinical trials will be required to assess the clinical benefit of this strategy.
C1 [Zhang, Chenpeng; Sun, Xiaoguang; Liu, Jianjun; Wang, Yuting; Huang, Gang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.
   [Tong, Jinlu] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Gastroenterol,Shanghai Inst Gastrointestinal, Shanghai 200030, Peoples R China.
   [Huang, Gang] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Shanghai 200030, Peoples R China.
   [Huang, Gang] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
RP Huang, G (reprint author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Nucl Med, Shanghai 200030, Peoples R China.
EM huang2802@163.com
FU National Natural Science Foundation of China [30830038, 30970842,
   81071180, 81000929]; "973" Project [2012CB932604]; New Drug Discovery
   Project [2012ZX09506-001-005]; Science and Technology Commission of
   Shanghai Municipality [10JC1410000]; Shanghai Leading Academic
   Discipline Project [S30203]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 30830038, 30970842, 81071180, 81000929; Grant sponsor: "973"
   Project; Grant number: 2012CB932604; Grant sponsor: New Drug Discovery
   Project; Grant number: 2012ZX09506-001-005; Grant sponsor: Key Project
   of Science and Technology Commission of Shanghai Municipality; Grant
   number: 10JC1410000; Grant sponsor: Shanghai Leading Academic Discipline
   Project; Grant number: S30203
CR Amthauer H, 2004, EUR J NUCL MED MOL I, V31, P811, DOI 10.1007/s00259-003-1453-1
   Brierley JD, 2006, CANCER, V106, P2526, DOI 10.1002/cncr.21887
   Calvo FA, 2010, RADIOTHER ONCOL, V97, P212, DOI 10.1016/j.radonc.2010.09.021
   Capirci C, 2004, BIOMED PHARMACOTHER, V58, P451, DOI 10.1016/j.biopha.2004.08.005
   Capirci C, 2009, INT J RADIAT ONCOL, V74, P1461, DOI 10.1016/j.ijrobp.2008.10.064
   Cascini GL, 2006, J NUCL MED, V47, P1241
   Chennupati SK, 2011, AM J CLIN ONCOL
   Cho YB, 2009, WORLD J SURG, V33, P2688, DOI 10.1007/s00268-009-0248-3
   Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979
   de Geus-Oei LF, 2009, J NUCL MED, V50, p43S, DOI 10.2967/jnumed.108.057224
   Denecke T, 2005, EUR RADIOL, V15, P1658, DOI 10.1007/s00330-005-2658-4
   ENGENHART R, 1990, STRAHLENTHER ONKOL, V166, P95
   Everaert H, 2011, INT J RADIAT ONCOL, V80, P91, DOI 10.1016/j.ijrobp.2010.01.021
   Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629
   Guerra L, 2009, ABDOM IMAGING, V36, P38
   Guillem JG, 2004, J AM COLL SURGEONS, V199, P1, DOI 10.1016/j.jamcollsurg.2004.02.024
   Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32
   Huh JW, 2011, AM J CLIN ONCOL
   Hur H, 2011, J SURG ONCOL, V103, P17, DOI 10.1002/jso.21736
   Janssen MHM, 2010, RADIOTHER ONCOL, V95, P203, DOI 10.1016/j.radonc.2010.01.021
   Janssen MHM, 2012, INT J RADIAT ONCOL, V82, P871, DOI 10.1016/j.ijrobp.2010.11.038
   Kalff V, 2008, INT J RAD ONCOL BIOL
   Kristiansen C, 2008, DIS COLON RECTUM, V51, P21, DOI 10.1007/s10350-007-9095-1
   Kwee RM, 2010, RADIOLOGY, V254, P707, DOI 10.1148/radiol.09091324
   Lambrecht M, 2011, ACTA ONCOL, V49, P956
   Leibold T, 2011, ANN SURG ONCOL
   Martoni AA, 2011, ANN ONCOL, V22, P650, DOI 10.1093/annonc/mdq433
   Melton GB, 2007, J GASTROINTEST SURG, V11, P961, DOI 10.1007/s11605-007-0170-7
   Oku S, 2002, ANN NUCL MED, V16, P409, DOI 10.1007/BF02990079
   O'Neill BDP, 2007, LANCET ONCOL, V8, P625, DOI 10.1016/S1470-2045(07)70202-4
   Palma P, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-119
   Rosenberg R, 2009, INT J COLORECTAL DIS, V24, P191, DOI 10.1007/s00384-008-0616-8
   Siegel R, 2008, ONKOLOGIE, V31, P166, DOI 10.1159/000118037
   Song I, 2011, BR J RADIOL
   Vliegen RFA, 2008, STRAHLENTHER ONKOL, V184, P457, DOI 10.1007/s00066-008-1858-7
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   Yeung JMC, 2011, DIS COLON RECTUM, V54, P518, DOI 10.1007/DCR.0b013e31820b36f0
   Yoon MS, 2011, RADIOTHER ONCOL, V98, P134, DOI 10.1016/j.radonc.2010.10.012
   Zhang CP, 2009, INT J CANCER, V124, P167, DOI 10.1002/ijc.23926
NR 39
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2012
VL 131
IS 11
BP 2604
EP 2611
DI 10.1002/ijc.27557
PG 8
WC Oncology
SC Oncology
GA 011SN
UT WOS:000309185400015
ER

PT J
AU Zheng, S
   Bai, JQ
   Li, J
   Fan, JH
   Pang, Y
   Song, QK
   Huang, R
   Yang, HJ
   Xu, F
   Lu, N
   Qiao, YL
AF Zheng, Shan
   Bai, Jing-Qiao
   Li, Jing
   Fan, Jin-Hu
   Pang, Yi
   Song, Qing-Kun
   Huang, Rong
   Yang, Hong-Jian
   Xu, Feng
   Lu, Ning
   Qiao, You-Lin
TI The pathologic characteristics of breast cancer in China and its shift
   during 1999-2008: A national-wide multicenter cross-sectional image over
   10 years
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast carcinoma; pathologic characteristics; ethnic populations
ID MIDDLE-INCOME COUNTRIES; LIMITED-RESOURCE COUNTRIES; GUIDELINE
   IMPLEMENTATION; HEALTH-CARE; CLINICAL-PRACTICE; ASIAN WOMEN; SURVIVAL;
   ALLOCATION; DIAGNOSIS; UPDATE
AB In China, breast cancer is currently the most common malignancy and the sixth leading cause of cancer death in women. But, the characteristics of breast cancer in the whole population are not determined. The aim of this study was to perform a detailed study on pathologic characteristics of breast cancer representing the whole population in China during 19992008 and to compare the difference in invasive breast cancer between the Western and Chinese. We randomly collected 4,211 inpatient at seven hospitals in representative geographical regions of China during 19992008. All the hospitals had the ability of comprehensive cancer treatment. The pathologic characters including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status were surveyed. The shift of pathologic characters was evaluated and the data from China were also compared with those of the Western, both using Chi-square test. We found as follow. (i) The median age of the patients was 48 years and showed the similar characters of Asia. (ii) Breast cancer in China showed more invasive ductal carcinoma with larger tumor size, later stage, lower ER and PR expression and higher HER2 overexpression than those in the Western (p < 0.001). (iii) Both tumor size and stage at diagnosis decreased year by year (p < 0.001). Breast cancer in China showed more aggressive behavior than those in western countries, although tumor size and stage at diagnosis decreased by year during 19992008. We addressed the urgent needs for employ race-specific breast cancer screen, diagnosis methods, and therapeutic models in China.
C1 [Lu, Ning] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China.
   [Zheng, Shan; Bai, Jing-Qiao; Li, Jing; Fan, Jin-Hu; Pang, Yi; Song, Qing-Kun; Huang, Rong; Lu, Ning; Qiao, You-Lin] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Bai, Jing-Qiao] Chinese Acad Med Sci, Canc Inst & Hosp, State Key Lab Mol Oncol, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China.
   [Li, Jing; Fan, Jin-Hu; Pang, Yi; Song, Qing-Kun; Huang, Rong; Qiao, You-Lin] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Canc Epidemiol, Beijing 100021, Peoples R China.
   [Pang, Yi; Huang, Rong] Sichuan Univ, W China Sch Publ Hlth, Dept Epidemiol, Chengdu 610041, Sichuan, Peoples R China.
   [Yang, Hong-Jian] Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou 310022, Zhejiang, Peoples R China.
   [Xu, Feng] Cent S Univ, Xiangya Hosp 2, Dept Breast Thyroid Surg, Changsha 410011, Hunan, Peoples R China.
RP Lu, N (reprint author), Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, POB 2258, Beijing 100021, Peoples R China.
EM nlu03@126.com; qiaoy@cicams.ac.cn
FU Pfizer
FX The authors thank Cancer Foundation of China originating this
   retrospective clinical epidemiological study of breast cancer. They
   thank the local investigators from Beijing, Liaoning (Shenyang), Hunan
   (Changsha), Guangdong (Guangzhou), Zhejiang (Hangzhou), Shanxi (Xian)
   and Sichuan (Chengdu) for data collection and assisting us complete the
   project successfully. The authors also thank Pfizer for funding in the
   form of donations to Cancer Foundation of China.
CR American Joint Committee on Cancer, 1997, AJCC CANC STAG MAN, P171
   American Joint Committee on Cancer, 2002, AJCC CANC STAGING MA, P223
   Anderson BO, 2006, BREAST J, V12, pS54, DOI 10.1111/j.1075-122X.2006.00203.x
   Anderson Benjamin O, 2003, Breast J, V9 Suppl 2, pS51, DOI 10.1046/j.1524-4741.9.s2.4.x
   Anderson Benjamin O, 2003, Breast J, V9 Suppl 2, pS42, DOI 10.1046/j.1524-4741.9.s2.3.x
   Bast RC, 2001, J CLIN ONCOL, V19, P1865
   Bates T, 2009, BRIT J CANCER, V101, P395, DOI 10.1038/sj.bjc.6605155
   Blamey RW, 2010, EUR J CANCER, V46, P56, DOI 10.1016/j.ejca.2009.09.009
   Bordoni A, 2009, BRIT J CANCER, V101, P1925, DOI 10.1038/sj.bjc.6605378
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chen XD, 2010, COMPREHENSIVE EVALUATION OF ECONOMY AND SOCIETY WITH STATISTICAL SCIENCE, P26
   Chuwa EWL, 2009, BREAST J, V15, P133, DOI 10.1111/j.1524-4741.2009.00687.x
   Ding SL, 2010, CLIN CANCER RES, V16, P3473, DOI 10.1158/1078-0432.CCR-09-3092
   Eniu A, 2008, CANCER-AM CANCER SOC, V113, P2269, DOI 10.1002/cncr.23843
   Fan L, 2009, BREAST CANCER RES TR, V117, P409, DOI 10.1007/s10549-008-0303-z
   Harirchi I, 2010, EUR J CANCER PREV, V19, P126, DOI 10.1097/CEJ.0b013e328333d0b3
   Hausauer AK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1839
   Hopp TA, 2004, CLIN CANCER RES, V10, P2751, DOI 10.1158/1078-0432.CCR-03-0141
   Kakarala M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-191
   Ko SS, 2008, J SURG ONCOL, V98, P318, DOI 10.1002/jso.21110
   Kuo WH, 2009, BRIT J CANCER, V100, P563, DOI 10.1038/sj.bjc.6604898
   Kuraparthy Sambasivaiah, 2007, World J Surg Oncol, V5, P56, DOI 10.1186/1477-7819-5-56
   Kwong A, 2008, WORLD J SURG, V32, P2554, DOI 10.1007/s00268-008-9589-6
   Li J, 2011, BMC CANCER, V11, P364
   Lim SE, 2007, WORLD J SURG, V31, P1387, DOI 10.1007/s00268-007-9086-3
   Linos E, 2008, J NATL CANCER I, V100, P1352, DOI 10.1093/jnci/djn305
   Lokuhetty MDS, 2009, WORLD J SURG, V33, P455, DOI 10.1007/s00268-008-9860-x
   Majid Runnak A, 2009, BMC Womens Health, V9, P33
   Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074
   Masood S, 2008, CANCER-AM CANCER SOC, V113, P2297, DOI 10.1002/cncr.23833
   Murff HJ, 2011, INT J CANCER, V128, P1434, DOI 10.1002/ijc.25703
   National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health, 2010, NAT SURV CANC MORT C, P10
   National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health, 2010, NAT SURV CANC MORT C, P120
   National Office for Cancer Prevention and Control (NOCPC) of the Chinese Ministry of Health, 2007, NAT SURV CANC INC MO, P302
   Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159
   Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200
   Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
   Porter PL, 2009, SALUD PUBLICA MEXICO, V51, pS141
   Rezaianzadeh A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-168
   Shyyan R, 2006, BREAST J, V12, pS27, DOI 10.1111/j.1075-122X.2006.00201.x
   Shyyan R, 2008, CANCER-AM CANCER SOC, V113, P2257, DOI 10.1002/cncr.23840
   Statistical information Team Cancer Research UK, 2009, BREAST CANC
   Stewart BW, 2003, WORLD CANC REPORT
   Tavassoli FA, 2003, PATHOLOGY GENETICS T, P221
   Veronesi U, 2002, NEW ENGL J MED, V347, P1227, DOI 10.1056/NEJMoa020989
   WHO, 1981, HIST TYP BREAST TUM, P15
   Yin WJ, 2009, BREAST CANCER RES TR, V115, P325, DOI 10.1007/s10549-008-0096-0
   Zarbo RJ, 2003, ARCH PATHOL LAB MED, V127, P549
   Zhang M, 2009, INT J CANCER, V124, P1404, DOI 10.1002/ijc.24047
NR 50
TC 1
Z9 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 1
PY 2012
VL 131
IS 11
BP 2622
EP 2631
DI 10.1002/ijc.27513
PG 10
WC Oncology
SC Oncology
GA 011SN
UT WOS:000309185400017
ER

PT J
AU Liu, Y
   Cheng, HD
   Huang, JH
   Zhang, YT
   Tang, XL
   Tian, JW
   Wang, Y
AF Liu, Yan
   Cheng, H. D.
   Huang, J. H.
   Zhang, Y. T.
   Tang, X. L.
   Tian, J. W.
   Wang, Y.
TI Computer Aided Diagnosis System for Breast Cancer Based on Color Doppler
   Flow Imaging
SO JOURNAL OF MEDICAL SYSTEMS
LA English
DT Article
DE Color Doppler flow imaging; Feature extraction; Color coherence vector;
   Computer-aided diagnosis system
ID ULTRASOUND; CLASSIFICATION; BENIGN; TUMORS
AB Color Doppler flow imaging takes a great value in diagnosing and classifying benign and malignant breast lesions. However, scanning of color Doppler sonography is operator-dependent and ineffective. In this paper, a novel breast classification system based on B-Mode ultrasound and color Doppler flow imaging is proposed. First, different feature extraction methods were used to obtain the texture and geometric features from B-Mode ultrasound images. In color Doppler feature extraction stage, several spectrum features are extracted by applying blood flow velocity analysis to Doppler signals. Moreover, a velocity coherent vector method is proposed based on color coherence vector, which is helpful for designing to the optimize detection of flow indices from different blood flow velocity fields automatically. Finally, a support vector machine classifier with selected feature vectors is used to classify breast tumors into benign and malignant. The experimental results demonstrate that the proposed computer-aided diagnosis system is useful for reducing the unnecessary biopsy and death rate.
C1 [Liu, Yan] Harbin Inst Technol, Coll Sci, Harbin 150001, Peoples R China.
   [Liu, Yan; Cheng, H. D.; Huang, J. H.; Zhang, Y. T.; Tang, X. L.] Harbin Inst Technol, Sch Comp Sci & Technol, Harbin 150001, Peoples R China.
   [Cheng, H. D.] Utah State Univ, Dept Comp Sci, Logan, UT 84322 USA.
   [Tian, J. W.; Wang, Y.] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China.
RP Liu, Y (reprint author), Harbin Inst Technol, Coll Sci, 92 Xidazhi St, Harbin 150001, Peoples R China.
EM snacly@163.com
FU National Nature Science Foundation of China (NSFC) [81071216, 61100097,
   81101103]
FX Financial support from the National Nature Science Foundation of China
   (NSFC) greatly appreciated; Grant numbers: 81071216, 61100097, and
   81101103.
CR Bastos CAC, 1999, IEEE T ULTRASON FERR, V46, P1201, DOI 10.1109/58.796126
   Chang RF, 2005, BREAST CANCER RES TR, V89, P179, DOI 10.1007/s10549-004-2043-z
   Chao TC, 1999, BREAST CANCER RES TR, V57, P193, DOI 10.1023/A:1006277617884
   Cheng HD, 2010, PATTERN RECOGN, V43, P299, DOI 10.1016/j.patcog.2009.05.012
   Choi H. Y., 2000, CLIN IMAG, V23, P284
   Diao XF, 2011, J MED SYST, V35, P801, DOI 10.1007/s10916-010-9461-8
   Drukker K, 2004, ACAD RADIOL, V11, P526, DOI 10.1016/S1076-6332(03)00723-2
   GORDON R, 1984, APPL OPTICS, V23, P560
   Hsiao YH, 2009, EUR J RADIOL, V71, P89, DOI 10.1016/j.ejrad.2008.03.024
   Huang YL, 2005, CLIN IMAG, V29, P179, DOI 10.1016/j.clinimag.2004.08.002
   Ikeda O, 2004, ACTA RADIOL, V45, P446, DOI 10.1080/02841850410005372
   Jessee E., 2008, VISUAL PERCEPTION HS, P7
   Kang K. H., 2007, P 7 WSEAS INT C MULT, P15
   Li JB, 2012, J MED SYST, V36, P2235, DOI 10.1007/s10916-011-9691-4
   Li JB, 2012, J MED SYST, V36, P2779, DOI 10.1007/s10916-011-9754-6
   Liu B., 2010, PATTERN RECOGNITION, V43
   Liu Y, 2012, J DIGIT IMAGING, V25, P580, DOI 10.1007/s10278-011-9450-6
   Madjar H., 2000, CLIN SCI, V1, P123
   Madjar H., 2001, EUR RADIOL, V11, P41
   Manglem Singh Kh, 2011, J INFORM HIDING MULT, V2, P108
   MITCHELL DG, 1990, RADIOLOGY, V177, P1
   Sergey T., 2008, STUDIES COMPUTATIONA, V90, P361
   Wu CH, 1998, CANCER-AM CANCER SOC, V83, P1189, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1189::AID-CNCR19>3.3.CO;2-1
   Zhu W., 2010, SENSITIVITY SPECIFIC
NR 24
TC 0
Z9 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0148-5598
J9 J MED SYST
JI J. Med. Syst.
PD DEC
PY 2012
VL 36
IS 6
BP 3975
EP 3982
DI 10.1007/s10916-012-9869-4
PG 8
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA 014AU
UT WOS:000309348200053
ER

PT J
AU Tu, B
   Du, L
   Fan, QM
   Tang, Z
   Tang, TT
AF Tu, Bing
   Du, Lin
   Fan, Qi-Ming
   Tang, Ze
   Tang, Ting-Ting
TI STAT3 activation by IL-6 from mesenchymal stem cells promotes the
   proliferation and metastasis of osteosarcoma
SO CANCER LETTERS
LA English
DT Article
DE STAT3; Interleukin-6; Osteosarcoma; Mesenchymal stem cells
ID SIGNAL TRANSDUCER; TUMOR MICROENVIRONMENT; PULMONARY METASTASIS;
   INTERLEUKIN-6 IL-6; DRUG-RESISTANCE; GENE-EXPRESSION; PROSTATE-CANCER;
   APOPTOSIS; PATHWAY; SURVIVAL
AB We previously demonstrated that human mesenchymal stem cells (MSCs) promote the growth of osteosarcoma in the bone microenvironment. The aim of the present study was to further determine the effect of IL-6/STAT3 signaling on the progression of osteosarcoma. First, conditioned medium from MSCs was used to stimulate the growth of osteosarcoma cells (Saos-2) in vitro. We found that STAT3 was activated and that the activation could be blocked by an IL-6-neutralizing antibody. The inhibition of STAT3 in Saos-2 cells by siRNA or AG490 decreased cell proliferation, migration and invasion, down-regulated the mRNA expression of Cyclin 0, Bcl-xL and Survivin and enhanced the apoptotic response. Furthermore, a nude mouse osteosarcoma model was established by injecting luciferase-labeled Saos-2 cells into the tibia, and the effect of STAT3 on tumor growth was determined by treating the mice with AG490. In vivo bioluminescence images showed that tumor growth was dramatically reduced in the AG490 group. In addition, STAT3 inhibition decreased the lung metastasis rate and prolonged the survival of these mice. After treatment with AG490, the protein levels of IL-6, p-STAT3 and PCNA were decreased, and the level of apoptosis in the tumor was increased. Altogether, these data indicate that MSCs in the bone microenvironment might promote the progression of osteosarcoma and protect tumor cells from drug-induced apoptosis through IL-6/STAT3 signaling. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Tu, Bing; Du, Lin; Fan, Qi-Ming; Tang, Ze; Tang, Ting-Ting] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implant, Dept Orthoped Surg,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.
RP Tang, TT (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implant, Dept Orthoped Surg,Shanghai Peoples Hosp 9, Zhizaoju Rd 639, Shanghai 200011, Peoples R China.
EM tingtingtang@hotmail.com
FU National Natural Science Foundation of China [81172549]; Shanghai
   Science and Technology Development Fund [10410711100, 11XD1403300];
   Shanghai Municipal Education Commission [J50206]; Shanghai Jiaotong
   University School of Medicine [BXJ201126]
FX This work was supported by a Grant from the National Natural Science
   Foundation of China (81172549) and Grants from the Shanghai Science and
   Technology Development Fund (10410711100, 11XD1403300), the key
   disciplines program of the Shanghai Municipal Education Commission
   (J50206), the program for innovative research team of the Shanghai
   Municipal Education Commission (phase I) and a Grant from Ph.D.
   Innovation Fund of Shanghai Jiaotong University School of Medicine
   (BXJ201126).
CR Barre B, 2007, TRENDS MOL MED, V13, P4, DOI 10.1016/j.molmed.2006.11.001
   Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7
   Bian ZY, 2009, ARCH MED RES, V40, P163, DOI 10.1016/j.arcmed.2009.01.002
   Bian ZY, 2010, CANCER SCI, V101, P2554, DOI 10.1111/j.1349-7006.2010.01731.x
   Chauhan D, 1997, BLOOD, V89, P227
   Chen CL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-111
   Chung TDK, 2000, PROSTATE, V42, P1
   Deng JX, 2007, CURR CANCER DRUG TAR, V7, P91, DOI 10.2174/156800907780006922
   Gorlick R, 2010, J BONE MINER RES, V25, P683, DOI 10.1002/jbmr.77
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005
   HARDIN J, 1994, BLOOD, V84, P3063
   Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943
   He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048
   Heikkila K, 2008, EUR J CANCER, V44, P937, DOI 10.1016/j.ejca.2008.02.047
   Heinrich PC, 1998, BIOCHEM J, V334, P297
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20020407
   Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313
   Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031
   Jourdan M, 2009, BRIT J HAEMATOL, V145, P45, DOI 10.1111/j.1365-2141.2008.07562.x
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3
   Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3
   Kuhn NZ, 2010, J CELL PHYSIOL, V222, P268, DOI 10.1002/jcp.21940
   Lin L., 2011, CANC RES
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031-3955(05)70540-X
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814
   Musselman DL, 2001, AM J PSYCHIAT, V158, P1252, DOI 10.1176/appi.ajp.158.8.1252
   Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007
   Onimoe GI, 2012, INVEST NEW DRUG, V30, P916, DOI 10.1007/s10637-011-9645-1
   Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088
   Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-78
   Tan ML, 2009, CANCER BIOL THER, V8, P106
   Tang TT, 2002, MAT SCI ENG C-BIO S, V20, P57, DOI 10.1016/S0928-4931(02)00013-9
   Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674
   Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323
   Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078-0432.CCR-07-1992
NR 48
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2012
VL 325
IS 1
BP 80
EP 88
DI 10.1016/j.canlet.2012.06.006
PG 9
WC Oncology
SC Oncology
GA 005WU
UT WOS:000308781600010
ER

PT J
AU Chen, H
   Ko, JMY
   Wong, VCL
   Hyytiainen, M
   Keski-Oja, J
   Chua, D
   Nicholls, JM
   Cheung, FMF
   Lee, AWM
   Kwong, DLW
   Chiu, PM
   Zabarovsky, ER
   Tsao, SW
   Tao, Q
   Kan, R
   Chan, SHK
   Stanbridge, EJ
   Lung, ML
AF Chen, Han
   Ko, Josephine Mun Yee
   Wong, Victor Chun Lam
   Hyytiainen, Marko
   Keski-Oja, Jorma
   Chua, Daniel
   Nicholls, John M.
   Cheung, Florence Man Fung
   Lee, Anne Wing Mui
   Kwong, Dora Lai-Wan
   Chiu, Pui Man
   Zabarovsky, Eugene R.
   Tsao, Sai Wah
   Tao, Qian
   Kan, Rebecca
   Chan, Stephen Ho Kin
   Stanbridge, Eric J.
   Lung, Maria Li
TI LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth
   factor permissive microenvironment in nasopharyngeal carcinoma
SO CANCER LETTERS
LA English
DT Article
DE Latent transforming growth factor beta binding protein 2 (LTBP-2);
   Nasopharyngeal carcinoma (NPC); Anti-angiogenesis; Tumor suppression;
   Tumor cell dormancy; Metastatic growth
ID EPSTEIN-BARR-VIRUS; CELL-LINES; EXTRACELLULAR-MATRIX; TUMOR-FORMATION;
   PROTEIN LTBP-2; MELANOMA-CELLS; BREAST-CANCER; BINDING; EXPRESSION; GENE
AB This study identified LTBP-2 as a pleiotropic tumor suppressor in nasopharyngeal carcinoma, which safeguards against critical malignant behaviors of tumor cells. LTBP-2 expression was significantly decreased or lost in up to 100% of NPC cell lines (7/7) and 80% of biopsies (24/30). Promoter hypermethylation was found to be involved in LTBP-2 silencing. Using a tetracycline-regulated inducible expression system, we unveiled functional roles of LTBP-2 in suppressing colony formation, anchorage-independent growth, cell migration, angiogenesis, VEGF secretion, and tumorigenicity. Three-dimensional culture studies suggested the involvement of LTBP-2 in maintenance of tumor cell dormancy in a growth factor favorable microenvironment. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Ko, Josephine Mun Yee; Wong, Victor Chun Lam; Chua, Daniel; Kwong, Dora Lai-Wan; Chiu, Pui Man; Kan, Rebecca; Chan, Stephen Ho Kin; Lung, Maria Li] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China.
   [Chen, Han] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Hyytiainen, Marko; Keski-Oja, Jorma] Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland.
   [Hyytiainen, Marko; Keski-Oja, Jorma] Univ Helsinki, Helsinki Univ Hosp, FIN-00014 Helsinki, Finland.
   [Chua, Daniel; Nicholls, John M.; Cheung, Florence Man Fung; Lee, Anne Wing Mui; Kwong, Dora Lai-Wan; Chiu, Pui Man; Tsao, Sai Wah; Lung, Maria Li] Univ Hong Kong, Ctr Nasopharyngeal Carcinoma Res, Pokfulam, Hong Kong, Peoples R China.
   [Chua, Daniel] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China.
   [Nicholls, John M.] Univ Hong Kong, Dept Pathol, Pokfulam, Hong Kong, Peoples R China.
   [Cheung, Florence Man Fung] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Lee, Anne Wing Mui] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Kwong, Dora Lai-Wan; Tsao, Sai Wah; Lung, Maria Li] Univ Hong Kong, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China.
   [Zabarovsky, Eugene R.] Karolinska Inst, Soder Sjukhuset, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden.
   [Zabarovsky, Eugene R.] Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Struct & Funct Genom, Moscow 119991, Russia.
   [Zabarovsky, Eugene R.] Linkoping Univ, Div Cell Biol, Dept Clin & Expt Med, SE-58185 Linkoping, Sweden.
   [Tsao, Sai Wah] Univ Hong Kong, Dept Anat, Pokfulam, Hong Kong, Peoples R China.
   [Tao, Qian] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China.
   [Stanbridge, Eric J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.
RP Lung, ML (reprint author), Univ Hong Kong, Dept Clin Oncol, Room L2-23,2-F,Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM mlilung@hku.hk
FU University Grants Council [AoE/M-06/08]; Finnish Cancer Foundation;
   Swedish Cancer Society; Swedish Research Council; Swedish Institute;
   Karolinska Institute
FX We acknowledge the University Grants Council AoE/M-06/08 for grant
   support to MLL, the Finnish Cancer Foundation to JK-O, and the Swedish
   Cancer Society, the Swedish Research Council, the Swedish Institute, and
   Karolinska Institute to ERZ. We acknowledge the Area of Excellence Hong
   Kong NPC Research Tissue Bank for NPC specimens.
CR Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027
   Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Chan SHK, 2011, INT J CANCER, V129, P565, DOI 10.1002/ijc.25698
   Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F
   Demicheli R, 2001, BRIT J CANCER, V85, P490, DOI 10.1054/bjoc.2001.1969
   GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524
   Goldberg SF, 1999, CLIN EXP METASTAS, V17, P601, DOI 10.1023/A:1006718800891
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Hirani R, 2007, MATRIX BIOL, V26, P213, DOI 10.1016/j.matbio.2006.12.006
   HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202
   Hyytiainen M, 2003, J CELL BIOL, V163, P1363, DOI 10.1083/jcb.200309105
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Ko JMY, 2008, MOL CANCER RES, V6, P592, DOI 10.1158/1541-7786.MCR-07-0154
   Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738
   Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo KW, 2000, CANCER RES, V60, P3348
   Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510
   Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812
   Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528
   Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590
   Lv X., 2010, HEAD NECK-J SCI SPEC, V33, P780
   Mauel S, 2007, APMIS, V115, P687, DOI 10.1111/j.1600-0463.2007.apm_453.x
   Naumov GN, 2002, CANCER RES, V62, P2162
   Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   PANTEL K, 1993, J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419
   Parsi MK, 2010, MATRIX BIOL, V29, P393, DOI 10.1016/j.matbio.2010.03.005
   Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283
   Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Teng ZP, 1996, VIRUS GENES, V13, P53, DOI 10.1007/BF00576978
   Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2
   Vehvilainen P, 2003, J BIOL CHEM, V278, P24705, DOI 10.1074/jbc.M212953200
   Wong VCL, 2012, INT J CANCER, V130, P83, DOI 10.1002/ijc.25970
   Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.02.182
NR 39
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2012
VL 325
IS 1
BP 89
EP 98
DI 10.1016/j.canlet.2012.06.005
PG 10
WC Oncology
SC Oncology
GA 005WU
UT WOS:000308781600011
ER

PT J
AU Zheng, MJ
   Wang, J
   Chen, YW
   Xu, L
   Xue, DD
   Fu, W
   Zhang, YF
   Du, Q
   Zhao, Y
   Ling, LJ
   Ding, Q
   Liu, XA
   Zha, XM
   Zheng, W
   Xia, TS
   Wang, S
AF Zheng, Ming-Jie
   Wang, Jue
   Chen, Yuan-Wen
   Xu, Lu
   Xue, Dan-Dan
   Fu, Wei
   Zhang, Yi-Fen
   Du, Qing
   Zhao, Yi
   Ling, Li-Jun
   Ding, Qiang
   Liu, Xiao-An
   Zha, Xiao-Ming
   Zheng, Wei
   Xia, Tian-Song
   Wang, Shui
TI A novel mouse model of gastric cancer with human gastric
   microenvironment
SO CANCER LETTERS
LA English
DT Article
DE Gastric cancer; Mouse model; Microenvironment; Metastasis
ID BREAST-CANCER; ORTHOTOPIC IMPLANTATION; GENE-EXPRESSION; STOMACH-CANCER;
   TUMOR-STROMA; NUDE-MICE; METASTASIS; CELLS; BIOLOGY; BONE
AB Mouse models play an irreplaceable role in the in vivo research of human gastric cancer. In this study, we developed a novel human Gastric tissue-derived Orthotopic and Metastatic (GOM) mouse model of human gastric cancer, in which the human normal gastric tissues were implanted subcutaneously into immunodeficient mice to create a human gastric microenvironment. Then, human gastric cancer cells were injected into the implants. GOM model could mimic the interactions between human gastric microenvironment and human gastric cancer cells, which help exhibit the real characteristics of tumor cells, and finally mimic the clinical-like tumor proliferation and metastases of human beings. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Zheng, Ming-Jie; Wang, Jue; Chen, Yuan-Wen; Xu, Lu; Xue, Dan-Dan; Zhao, Yi; Ling, Li-Jun; Ding, Qiang; Liu, Xiao-An; Zha, Xiao-Ming; Zheng, Wei; Xia, Tian-Song; Wang, Shui] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.
   [Fu, Wei] Nantong Univ, Affiliated Wujiang Hosp, Wujiang Peoples Hosp 1, Dept Gen Surg, Suzhou, Jiangsu, Peoples R China.
   [Zhang, Yi-Fen] Nanjing Univ, Sch Med, Nanjing Drum Tower Hosp, Dept Pathol, Nanjing, Jiangsu, Peoples R China.
   [Du, Qing] Nanjing Med Univ, Affiliated Hosp 1, Lab Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.
RP Wang, S (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM ws0801@hotmail.com
FU National Natural Science Foundation of China [81071753, 81172502]; Six
   Kinds of Outstanding Talent Foundation of Jiangsu Province
   [2010-ws-079]; First Affiliated Hospital of NJMU [IRT-008]; Natural
   Science Foundation of Jiangsu Province [BK2011853, BK2011855]
FX This research was supported in part by National Natural Science
   Foundation of China (81071753, 81172502), Six Kinds of Outstanding
   Talent Foundation of Jiangsu Province (2010-ws-079 to Wei He and 2009 to
   Qiang Ding), Program for Development of Innovative Research Team in the
   First Affiliated Hospital of NJMU (IRT-008), and Natural Science
   Foundation of Jiangsu Province (BK2011853 and BK2011855).
CR Al-Batran S.E., 2011, ANN ONCOL
   Bhargava S, 2009, INT J COLORECTAL DIS, V24, P31, DOI 10.1007/s00384-008-0584-z
   Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Brenner Hermann, 2009, V472, P467
   FIDLER IJ, 1990, CANCER RES, V50, P6130
   FIDLER IJ, 1986, CANCER METAST REV, V5, P29, DOI 10.1007/BF00049529
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   FURUKAWA T, 1993, CANCER RES, V53, P1204
   Gonda TA, 2009, CELL CYCLE, V8, P2005, DOI 10.4161/cc.8.13.8985
   Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   KYRIAZIS AP, 1978, CANCER RES, V38, P3186
   Li X, 2005, WORLD J GASTROENTERO, V11, P61
   Li Y, 2011, WORLD J GASTROENTERO, V17, P1442, DOI 10.3748/wjg.v17.i11.1442
   LIN CH, 1984, CHINESE MED J-PEKING, V97, P831
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Macchiarini Francesca, 2005, J Exp Med, V202, P1307, DOI 10.1084/jem.20051547
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Onn A, 2003, CLIN CANCER RES, V9, P5532
   Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142
   Roberts TG, 2004, JAMA-J AM MED ASSOC, V292, P2130, DOI 10.1001/jama.292.17.2130
   Takahashi T, 2004, CANCER SCI, V95, P514, DOI 10.1111/j.1349-7006.2004.tb03242.x
   Wang J, 2010, BREAST CANCER RES TR, V120, P337, DOI 10.1007/s10549-009-0391-4
   Xia TS, 2010, ONCOL REP, V24, P203, DOI 10.3892/or_00000847
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
NR 29
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2012
VL 325
IS 1
BP 108
EP 115
DI 10.1016/j.canlet.2012.06.011
PG 8
WC Oncology
SC Oncology
GA 005WU
UT WOS:000308781600013
ER

PT J
AU Wang, JP
   Gui, ZF
   Deng, LY
   Sun, MC
   Guo, RH
   Zhang, WM
   Shen, LZ
AF Wang, Jianping
   Gui, Zhifu
   Deng, Longying
   Sun, Maocai
   Guo, Renhua
   Zhang, Weiming
   Shen, Lizong
TI c-Met upregulates aquaporin 3 expression in human gastric carcinoma
   cells via the ERK signalling pathway (vol 319, pg 109, 2012)
SO CANCER LETTERS
LA English
DT Correction
C1 [Wang, Jianping; Gui, Zhifu; Deng, Longying; Sun, Maocai; Shen, Lizong] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Jianping] Yangzhong Peoples Hosp, Dept Surg, Zhenjiang, Jiangsu, Peoples R China.
   [Guo, Renhua] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Weiming] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China.
RP Shen, LZ (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM shenlz@163.com
CR Wang JP, 2012, CANCER LETT, V319, P109, DOI 10.1016/j.canlet.2011.12.040
NR 1
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2012
VL 325
IS 1
BP 116
EP 116
DI 10.1016/j.canlet.2012.07.019
PG 1
WC Oncology
SC Oncology
GA 005WU
UT WOS:000308781600014
ER

PT J
AU Guo, Q
   Luo, P
   Luo, Y
   Du, F
   Lu, W
   Liu, SY
   Huang, J
   Yu, JH
AF Guo, Qian
   Luo, Ping
   Luo, Yu
   Du, Fang
   Lu, Wei
   Liu, Shiyuan
   Huang, Jin
   Yu, Jiahui
TI Fabrication of biodegradable micelles with sheddable poly(ethylene
   glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Micelle; SN-38; Reduction-triggered drug release; Stability; Solubility;
   Cytotoxicity
ID ANTITUMOR-ACTIVITY; CAMPTOTHECIN; NANOPARTICLES; FORMULATION; SN-38;
   STABILITY; DELIVERY; SERUM; DRUG
AB Biodegradable micelles with sheddable poly(ethylene glycol) shells were fabricated based on poly(ethylene glycol)-block-poly(gamma-benzyl L-glutamate) (mPEG-SS-PBLG)diblock copolymer and applied as the carrier of 7-ethyl-10-hydroxy-camptothecin (SN-38) in order to enhance its solubility and stability in aqueous media. The diblock polymer was designed to have the hydrophilic PEG moiety and hydrophobic PBLG moiety linked by biodegradable disulfide bond, so in reducing environment the PEG shells can be detached. The polymer was able to form the micelles of nano-scale in aqueous media, suggesting their passive targeting potential to tumor tissue. Water-insoluble antitumor drug, SN-38, was easily encapsulated into mPEG-SS-PBLG nanomicelles by lyophilization method. When setting theoretical drug loading content at 10 wt%, the drug encapsulation efficiency (EE) was assayed as 73.5%. Owing to the disulfide bond in mPEG-SS-PBLG, intense release of SN-38 occurred in the presence of dithiothreitol (DTT) at the concentration of simulating the intracellular condition, however, micelles showed gradual release of SN-38 in the absence of DTT. Also, the mPEG-SS-PBLG micelles effectively protected the active lactone ring of SN-38 from hydrolysis under physiological condition. Compared with free SN-38, SN-38-loaded nanomicelles showed essentially decreased cytotoxicity against L929 cell line in 24 h, bare mPEG-SS-PBLG nanomicelles showed almost non-toxicity. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Guo, Qian; Luo, Ping; Du, Fang; Lu, Wei; Yu, Jiahui] E China Normal Univ, Inst Adv Interdisciplinary Res, Inst Drug Discovery & Dev, Shanghai 200062, Peoples R China.
   [Luo, Yu] E China Normal Univ, Dept Chem, Shanghai 200062, Peoples R China.
   [Liu, Shiyuan] Changzheng Hosp, Dept Diagnost Imaging, Shanghai 200003, Peoples R China.
   [Huang, Jin] Wuhan Univ Technol, Coll Chem Engn, Wuhan 430070, Peoples R China.
RP Yu, JH (reprint author), E China Normal Univ, Inst Adv Interdisciplinary Res, Inst Drug Discovery & Dev, Shanghai 200062, Peoples R China.
EM jhyu@sist.ecnu.edu.cn
FU National Natural Science Foundation of China [81171333]; Shanghai
   Municipality Commission for Special Project of Nanometer Science and
   Technology [11nm0506000]; Scientific Research Foundation for the
   Returned Overseas Chinese Scholars, State Education Ministry [01103197]
FX The research work was supported by the National Natural Science
   Foundation of China (81171333), the Shanghai Municipality Commission for
   Special Project of Nanometer Science and Technology (11nm0506000), and
   the Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry (01103197).
CR Carbonero R., 2002, CLIN CANCER RES, V8, P641
   Chang YC, 2008, EUR POLYM J, V44, P3922, DOI 10.1016/j.eurpolymj.2008.09.021
   Cho CS, 1999, POLYMER, V40, P6769, DOI 10.1016/S0032-3861(99)00007-5
   Duan KR, 2010, COLLOID SURFACE B, V76, P475, DOI 10.1016/j.colsurfb.2009.12.007
   Fan HL, 2010, POLYMER, V51, P5107, DOI 10.1016/j.polymer.2010.09.004
   Ganta S, 2008, J CONTROL RELEASE, V126, P187, DOI 10.1016/j.jconrel.2007.12.017
   GILBERT HF, 1995, METHOD ENZYMOL, V251, P8
   Go Young-Mi, 2008, Biochim Biophys Acta, V1780, P1273, DOI 10.1016/j.bbagen.2008.01.011
   Goldberg DS, 2011, J CONTROL RELEASE, V150, P318, DOI 10.1016/j.jconrel.2010.11.022
   Gu FX, 2007, NANO TODAY, V2, P14, DOI 10.1016/S1748-0132(07)70083-X
   Karnik F., 2006, CANCER RES, V66, P10048
   Kuppusamy P, 2002, CANCER RES, V62, P307
   Kuppusamy P., 1998, CANCER RES, V581, P562
   Meng FH, 2009, BIOMATERIALS, V30, P2180, DOI 10.1016/j.biomaterials.2009.01.026
   MeriskoLiversidge E, 1996, PHARMACEUT RES, V13, P272
   Opanasopit P, 2005, J CONTROL RELEASE, V104, P313, DOI 10.1016/j.jcornel.2005.02.014
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Peikov V, 2005, INT J PHARM, V299, P92, DOI 10.1016/j.ijpharm.2005.04.028
   Poche DS, 1999, SYNTHETIC COMMUN, V29, P843, DOI 10.1080/00397919908086042
   Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179
   RIVORY LP, 1994, CANCER RES, V54, P6330
   Robert T.C., 1992, J MED CHEM, V35, P4160
   Sun HL, 2009, BIOMATERIALS, V30, P6358, DOI 10.1016/j.biomaterials.2009.07.051
   Tang LY, 2009, BIOCONJUGATE CHEM, V20, P1095, DOI 10.1021/bc900144m
   WANI MC, 1987, J MED CHEM, V30, P1774, DOI 10.1021/jm00393a016
   Watanabe M, 2008, J CONTROL RELEASE, V127, P231, DOI 10.1016/j.jconrel.2008.02.005
   Wu GY, 2004, J NUTR, V134, P489
   Xuan T, 2006, J PHARMACEUT BIOMED, V41, P582, DOI 10.1016/j.jpba.2005.10.051
NR 28
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD DEC 1
PY 2012
VL 100
BP 138
EP 145
DI 10.1016/j.colsurfb.2012.04.041
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 991EI
UT WOS:000307683900020
ER

PT J
AU Zhang, XZ
   Du, F
   Huang, J
   Lu, W
   Liu, SY
   Yu, JH
AF Zhang, Xuzhu
   Du, Fang
   Huang, Jin
   Lu, Wei
   Liu, Shiyuan
   Yu, Jiahui
TI Fabrication of biodegradable micelles with reduction-triggered release
   of 6-mercaptopurine profile based on disulfide-linked graft copolymer
   conjugate
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Micelle; 6-Mercaptopurine; Reduction-triggered drug release;
   Thoil-disulfide exchange; Cytotoxicity
ID DRUG-DELIVERY; POLY(ASPARTIC ACID); GLUTATHIONE; GENE; PH; THIOPURINES;
   POLYESTERS; STABILITY; DISEASE; COMPLEX
AB This research is aimed to develop a biodegradable micelle delivery system with sheddable poly (ethylene glycol) shell to achieve the reduction-triggered intracellular sustained release of 6-mercaptopurine (6-MP) and decreased toxicity. Firstly, the amino-disulfide linked poly (ethylene glycol) monomethyl ether (mPEG-SS-NH2) was synthesized by the amidation reaction between cystamine and active ester of mPEG and p-nitrophenyl chloroformate (p-NPC) (mPEG-NPC). And then, the five-member rings in poly (L-succinimide) (PSI) were successively opened by mPEG-SS-NH2 and 2-(pyridyldithio)-ethylamine (PDA) to produce the graft copolymer of mPEG-SS-NH-graft-PAsp-PDA. To avoid the drug initial burst, 6-MP was covalently conjugated with mPEG-SS-NH-graft-PAsp-PDA by thoil-disulfide exchange reaction to give the resultant product mPEG-SS-NH-graft-PAsp-MP. The product was found to form spherical micelles in aqueous media because of its amphiphilic nature with average particle size of 160 nm measured by dynamic light scattering (DLS). It was found that the mPEG-SS-NH-graft-PAsp-MP micelles, though stable in phosphate buffer solution (PBS), were prone to aggregation in the presence of dithiothreitol (DTT). The in vitro drug release studies revealed the release of 6-MP were distinct from the conventional micelles whose drugs loaded by physical encapsulation. Sustained release profile of 6-MP over 85 h was found in the presence of DTT (40 mM) simulating the intracellular condition while minimal drug release was observed within 24 h at the level of DTT corresponding to extracellular environment. Remarkably, the cell viability results showed there was essential decrease of cytotoxicity to HL-60 cell line compared to free 6-MP. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Xuzhu; Du, Fang; Huang, Jin; Lu, Wei; Yu, Jiahui] E China Normal Univ, Inst Drug Discovery & Dev, Inst Adv Interdisciplinary Res, Shanghai 200062, Peoples R China.
   [Huang, Jin] Wuhan Univ Technol, Coll Chem Engn, Wuhan 430070, Peoples R China.
   [Liu, Shiyuan] Changzheng Hosp, Dept Diagnost Imaging, Shanghai 200003, Peoples R China.
RP Yu, JH (reprint author), E China Normal Univ, Inst Drug Discovery & Dev, Inst Adv Interdisciplinary Res, Shanghai 200062, Peoples R China.
EM jhyu@sist.ecnu.edu.cn
FU Shanghai Municipality Commission for Special Project of Nanometer
   Science and Technology [11nm0506000]; Scientific Research Foundation for
   the Returned Overseas Chinese Scholars, State Education Ministry
   [01103197]; National Natural Science Foundation of China [81171333]
FX The research work was supported by the Shanghai Municipality Commission
   for Special Project of Nanometer Science and Technology (11nm0506000),
   the Scientific Research Foundation for the Returned Overseas Chinese
   Scholars, State Education Ministry (01103197), and the National Natural
   Science Foundation of China (81171333).
CR Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x
   Carroll William L, 2003, Hematology Am Soc Hematol Educ Program, P102, DOI 10.1182/asheducation-2003.1.102
   Chen W, 2006, COLLOID SURFACE A, V278, P60, DOI 10.1016/j.colsurfa.2005.11.084
   Cheng R, 2011, J CONTROL RELEASE, V152, P2, DOI 10.1016/j.jconrel.2011.01.030
   Chong SF, 2009, SMALL, V5, P2601, DOI 10.1002/smll.200900906
   Coulthard S, 2005, INVEST NEW DRUG, V23, P523, DOI 10.1007/s10637-005-4020-8
   CUENCA AG, 2006, AM CANC SOC, V107, P459, DOI DOI 10.1002/CNCR.22035
   Dubinsky MC, 2004, CLIN GASTROENTEROL H, V2, P731, DOI 10.1053/S1542-3565(04)00344-1
   EBRIGHT YW, 1992, BIOCHEMISTRY-US, V31, P10664, DOI 10.1021/bi00159a004
   Gertrude B.E., 1952, J AM CHEM SOC, V74, P411
   GILBERT HF, 1995, METHOD ENZYMOL, V251, P8
   Glen S.K., 1996, ADV DRUG DELIVERY RE, V21, P107
   Go Young-Mi, 2008, Biochim Biophys Acta, V1780, P1273, DOI 10.1016/j.bbagen.2008.01.011
   Gregg C., 1997, J APPL POLYM SCI, V66, P911
   Ikada Y, 2000, MACROMOL RAPID COMM, V21, P117, DOI 10.1002/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.3.CO;2-O
   Jiang TY, 2006, J APPL POLYM SCI, V99, P2702, DOI 10.1002/app.22818
   Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0
   Karran P, 2006, BRIT MED BULL, V79-80, P153, DOI 10.1093/bmb/ldl020
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Kuppusamy P, 2002, CANCER RES, V62, P307
   LE M, 1995, ANAL BIOCHEM, V229, P264, DOI 10.1006/abio.1995.1411
   Meng FH, 2009, BIOMATERIALS, V30, P2180, DOI 10.1016/j.biomaterials.2009.01.026
   Opanasopit P, 2005, J CONTROL RELEASE, V104, P313, DOI 10.1016/j.jcornel.2005.02.014
   Qiu LY, 2006, PHARM RES, V23, P1, DOI 10.1007/s11095-005-9046-2
   Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179
   Ren TB, 2011, SOFT MATTER, V7, P2329, DOI 10.1039/c1sm05020f
   Rosler A, 2001, ADV DRUG DELIVER REV, V53, P95, DOI 10.1016/S0169-409X(01)00222-8
   Saltzman W.M., 1997, ADV DRUG DELIV REV, V26, P209
   Soppimath KS, 2005, ADV MATER, V17, P318, DOI 10.1002/adma.200401057
   Sourkohi BK, 2011, BIOMACROMOLECULES, V12, P3819, DOI 10.1021/bm2011032
   Sun HL, 2009, BIOMATERIALS, V30, P6358, DOI 10.1016/j.biomaterials.2009.07.051
   Sun HL, 2010, BIOMACROMOLECULES, V11, P848, DOI 10.1021/bm1001069
   Teramura Y, 2007, BIOMATERIALS, V28, P4818, DOI 10.1016/j.biomaterials.2007.07.050
   Torchilin VP, 2007, PHARM RES, V24, P1, DOI 10.1007/s11095-006-9132-0
   Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00013-X
   VERT M, 1992, J MATER SCI-MATER M, V3, P432, DOI 10.1007/BF00701240
   Watters JW, 2003, BBA-REV CANCER, V1603, P99, DOI 10.1016/S0304-419X(03)00003-9
   Wen HY, 2011, CHEM COMMUN, V47, P3550, DOI 10.1039/c0cc04983b
   West KR, 2005, ORG LETT, V7, P2615, DOI 10.1021/ol0507524
   Wu GY, 2004, J NUTR, V134, P489
   Zacchigna M, 2007, BIOORG MED CHEM LETT, V17, P6607, DOI 10.1016/j.bmcl.2007.09.064
   Zhao Y, 2005, POLYMER, V46, P5368, DOI 10.1016/j.polymer.2005.04.015
NR 42
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD DEC 1
PY 2012
VL 100
BP 155
EP 162
DI 10.1016/j.colsurfb.2012.04.043
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 991EI
UT WOS:000307683900022
ER

PT J
AU Qiu, YQ
   Hu, AB
   Wei, HY
   Liao, HY
   Li, SY
   Chen, CY
   Zhong, WH
   Huang, D
   Cai, JY
   Jiang, LF
   Zeng, GC
   Chen, ZW
AF Qiu, Yueqin
   Hu, An-Bin
   Wei, Huiyong
   Liao, Hongying
   Li, Shaoyuan
   Chen, Crystal Y.
   Zhong, Weihua
   Huang, Dan
   Cai, Jiye
   Jiang, Lifang
   Zeng, Gucheng
   Chen, Zheng W.
TI An atomic-force basis for the bacteriolytic effects of granulysin
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE AFM; Granulysin; Perforin; Bacteria; Listeria monocytogenes
ID CD8(+) T-CELLS; POISSON STATISTICAL-ANALYSIS;
   MYCOBACTERIUM-TUBERCULOSIS; NK-LYSIN; MICROSCOPY; PERFORIN; MECHANISM;
   LYMPHOCYTES; ACTIVATION; EXPRESSION
AB While granulysin has been suggested to play an important role in adaptive immune responses against bacterial infections by killing pathogens, and molecular force for protein-protein interaction or protein-bacteria interaction may designate the specific functions of a protein, the molecular-force basis underlying the bacteriolytic effects of granulysin at single-molecule level remains unknown. Here, we produced and purified bactericidal domain of macaque granulysin (GNL). Our bacterial lysis assays suggested that GNL could efficiently kill bacteria such as Listeria monocytogenes. Furthermore, we found that the interaction force between GNL and L monocytogenes measured by an atomic force microscopy (AFM) was about 22.5 pN. Importantly, our AFM-based single molecular analysis suggested that granulysin might lyse the bacteria not only through electrostatic interactions but also by hydrogen bonding and van der Waals interaction. Thus, this work provides a previous unknown mechanism for bacteriolytic effects of granulysin. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Qiu, Yueqin; Li, Shaoyuan; Jiang, Lifang; Zeng, Gucheng] Sun Yat Sen Univ, Dept Microbiol, Minist Educ, Zhongshan Sch Med,Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China.
   [Qiu, Yueqin; Cai, Jiye] Jinan Univ, Coll Life Sci & Technol, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
   [Hu, An-Bin] Sun Yat Sen Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Wei, Huiyong; Chen, Crystal Y.; Zhong, Weihua; Huang, Dan; Chen, Zheng W.] Univ Illinois, Coll Med, Dept Immunol & Microbiol, Chicago, IL 60612 USA.
   [Wei, Huiyong; Chen, Crystal Y.; Zhong, Weihua; Huang, Dan; Chen, Zheng W.] Univ Illinois, Coll Med, Ctr Nonhuman Primate Biomed Res, Chicago, IL 60612 USA.
   [Liao, Hongying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Thorac Surg, Guangzhou 510630, Guangdong, Peoples R China.
RP Zeng, GC (reprint author), Sun Yat Sen Univ, Dept Microbiol, Minist Educ, Zhongshan Sch Med,Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China.
EM zenggch@mail.sysu.edu.cn
FU National Natural Science Foundation of China (NSFC) [31170847]; Overseas
   Cooperation Project of NSFC [31129002]; National 973 Project
   [2010CB833603]; Fundamental Research Funds for the Central Universities
   of China
FX This work was supported by National Natural Science Foundation of China
   (NSFC) (31170847 to G.Z.), Overseas Cooperation Project of NSFC
   (31129002 to Z.W.C.) and National 973 Project (2010CB833603 to J.C.).
   G.Z. is also supported by the Fundamental Research Funds for the Central
   Universities of China. We should thank Dr. Y. Dufrene for very useful
   discussion of bacterial immobilization for AFM measurements.
CR Abu-Lail NI, 2006, LANGMUIR, V22, P7296, DOI 10.1021/la0533415
   Anderson DH, 2003, J MOL BIOL, V325, P355, DOI 10.1016/S0022-2836(02)01234-2
   Andersson J, 2007, INFECT IMMUN, V75, P5210, DOI 10.1128/IAI.00624-07
   Andreu D, 1999, BIOCHEM J, V344, P845, DOI 10.1042/0264-6021:3440845
   Barman H, 2006, J MEMBRANE BIOL, V212, P29, DOI 10.1007/s00232-006-0040-3
   Canaday DH, 2001, J IMMUNOL, V167, P2734
   Chen Y, 2004, MOL IMMUNOL, V41, P1247, DOI 10.1016/j.molimm.2004.05.012
   Chen Y, 2005, ULTRAMICROSCOPY, V103, P173, DOI 10.1016/j.ultramic.2004.11.019
   Chen Y, 2011, BIOCHEM BIOPH RES CO, V407, P301, DOI 10.1016/j.bbrc.2011.03.006
   Clayberger C, 2003, CURR OPIN IMMUNOL, V15, P560, DOI 10.1016/S0952-7915(03)00097-9
   Dieli F, 2001, J INFECT DIS, V184, P1082, DOI 10.1086/323600
   Dufrene YF, 2004, NAT REV MICROBIOL, V2, P451, DOI 10.1038/nrmicro905
   Dupres V, 2005, NAT METHODS, V2, P515, DOI 10.1038/NMETH769
   Ernst WA, 2000, J IMMUNOL, V165, P7102
   Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2
   Huang D, 2007, J INFECT DIS, V195, P55, DOI 10.1086/509895
   Jiang YX, 2003, ANAL CHEM, V75, P2112, DOI 10.1021/ac026182s
   Krensky AM, 2000, BIOCHEM PHARMACOL, V59, P317, DOI 10.1016/S0006-2952(99)00177-X
   Kuznetsov VY, 2004, PROTEOMICS, V4, P2390, DOI 10.1002/pmic.200300751
   LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0
   Linde CMA, 2005, INFECT IMMUN, V73, P6332, DOI 10.1128/IAI.73.10.6332-6339.2005
   Lo YS, 1999, LANGMUIR, V15, P1373, DOI 10.1021/la981003g
   Lo YS, 1999, LANGMUIR, V15, P6522, DOI 10.1021/la990371x
   Pelling AE, 2004, SCIENCE, V305, P1147, DOI 10.1126/science.1097640
   Pena S V, 1997, Semin Immunol, V9, P117, DOI 10.1006/smim.1997.0061
   Pena SV, 1997, J IMMUNOL, V158, P2680
   Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819
   Stegelmann F, 2005, J IMMUNOL, V175, P7474
   Stenger S, 1999, IMMUNOL TODAY, V20, P390, DOI 10.1016/S0167-5699(99)01449-8
   Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121
   Stevens F, 1999, LANGMUIR, V15, P207, DOI 10.1021/la980683k
   Walch M, 2005, J IMMUNOL, V174, P4220
   Wallis R S, 2001, Curr Opin Pulm Med, V7, P124, DOI 10.1097/00063198-200105000-00003
   Wang Z, 2000, J IMMUNOL, V165, P1486
   Wei HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006905
   Zeng GC, 2005, PROTEOMICS, V5, P4347, DOI 10.1002/pmic.200500017
   Zeng GC, 2009, PROTEOMICS, V9, P1538, DOI 10.1002/pmic.200800528
   Zheng CF, 2007, BLOOD, V109, P2049, DOI 10.1182/blood-2006-03-009720
NR 38
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD DEC 1
PY 2012
VL 100
BP 163
EP 168
DI 10.1016/j.colsurfb.2012.05.011
PG 6
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 991EI
UT WOS:000307683900023
ER

PT J
AU Nie, L
   Chen, D
   Suo, JP
   Zou, P
   Feng, SB
   Yang, Q
   Yang, SH
   Ye, SN
AF Nie, Lei
   Chen, Dong
   Suo, Jinping
   Zou, Peng
   Feng, Shuibin
   Yang, Qi
   Yang, Shuhua
   Ye, Shunan
TI Physicochemical characterization and biocompatibility in vitro of
   biphasic calcium phosphate/polyvinyl alcohol scaffolds prepared by
   freeze-drying method for bone tissue engineering applications
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Porous scaffold; Biphasic calcium phosphate; PVA; Cell culture
ID MESENCHYMAL STEM-CELLS; MECHANICAL-PROPERTIES; HYDROXYAPATITE
   COMPOSITES; GENE-EXPRESSION; PVA HYDROGEL; NANOCOMPOSITE; RABBIT;
   MATRIX; REPAIR; DEFECT
AB In this study, a well developed porous biphasic calcium phosphate (BCP)/polyvinyl alcohol (PVA) scaffold was prepared by emulsion foam freeze-drying method possessed moderate inter-connected pores and porosity. The SEM analysis showed that BCP nano-particles could disperse uniformly in the scaffolds, and the pore size, porosity, and compressive strength could be controlled by the weight ratio of BCP/PVA. The in vitro degradation and cytocompatibility of scaffolds were examined in this study. The degradation analysis showed the prepared scaffolds have a low variation of pH values (approximately 7.18-7.36) in SBF solution, and have the biodegradation rate of BCP/PVA scaffolds decreased with the increase of PVA concentration. Moreover, MTT assay indicated that the BCP/PVA porous scaffold has no negative effects on cells growth and proliferation, and the hBMSCs possessed a favorable spreading morphology on the BCP/PVA scaffold surface. The inter-connected pore structure, mechanical strength, biodegradation rate and cytocompatibility of the prepared BCP/PVA scaffold can meet essential requirements for blame bearing bone tissue engineering and regeneration. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Nie, Lei; Suo, Jinping; Zou, Peng; Feng, Shuibin; Yang, Qi] Huazhong Univ Sci & Technol, Coll Mat Sci & Engn, State Key Lab Mould Technol, Wuhan 430074, Peoples R China.
   [Chen, Dong; Yang, Shuhua; Ye, Shunan] Huazhong Univ Sci & Technol, Union Hosp, Dept Orthoped, Tongji Med Coll, Wuhan 430022, Peoples R China.
RP Suo, JP (reprint author), Huazhong Univ Sci & Technol, Coll Mat Sci & Engn, State Key Lab Mould Technol, Wuhan 430074, Peoples R China.
EM jinpingsuo@mail.hust.edu.cn
FU Fundamental Research Funds for the Central Universities [HUST:
   2010JC029/2011JC042]; National Natural Sciences Foundation of China
   [30973027]
FX The authors acknowledge the Fundamental Research Funds for the Central
   Universities, HUST: 2010JC029/2011JC042, and the National Natural
   Sciences Foundation of China (No. 30973027). Technical assistance from
   the Analytical and Testing Center of HUST was gratefully acknowledged.
CR Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927
   Arts JJC, 2006, BIOMATERIALS, V27, P1110, DOI 10.1016/j.biomaterials.2005.07.024
   Asran AS, 2010, POLYMER, V51, P868, DOI 10.1016/j.polymer.2009.12.046
   Balcik C, 2007, ACTA BIOMATER, V3, P985, DOI 10.1016/j.actbio.2007.04.004
   Bandyopadhyay-Ghosh S., 2008, TRENDS BIOMATER ARTI, V22, P116
   Binulal N.S., 2009, TISSUE ENG PART A, V16, P393
   Bogun M, 2009, J APPL POLYM SCI, V114, P3452, DOI 10.1002/app.30728
   Dorozhkin SV, 2012, ACTA BIOMATER, V8, P963, DOI 10.1016/j.actbio.2011.09.003
   Ficai M, 2010, COLLOID SURFACE B, V81, P614, DOI 10.1016/j.colsurfb.2010.08.009
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Jin HH, 2010, POLYM DEGRAD STABIL, V95, P1856, DOI 10.1016/j.polymdegradstab.2010.04.025
   Kim G.M., 2008, BIOINSPIR BIOMIM, V3, P1
   Kim HW, 2005, BIOMATERIALS, V26, P5221, DOI 10.1016/j.biomaterials.2005.01.047
   Kim HW, 2005, J MATER SCI-MATER M, V16, P189, DOI 10.1007/s10856-005-6679-y
   Kim K.W., 2005, ADV FUNCT MATER, V15, P1988
   Kobayashi M, 2003, BIOMATERIALS, V24, P639, DOI 10.1016/S0142-9612(02)00378-2
   Kobayashi H, 2004, MAT SCI ENG C-BIO S, V24, P729, DOI 10.1016/j.msec.2004.08.038
   Kwok S, 2009, J CELL BIOCHEM, V106, P161, DOI 10.1002/jcb.21991
   Lin PL, 2007, MATER LETT, V61, P3009, DOI 10.1016/j.matlet.2006.10.064
   Linhart W, 2004, UNFALLCHIRURG, V107, P154, DOI 10.1007/s00113-003-0707-5
   Manjubala I, 2006, ACTA BIOMATER, V2, P75, DOI 10.1016/j.actbio.2005.09.007
   Mikolajczyk T, 2011, J APPL POLYM SCI, V120, P1234, DOI 10.1002/app.33233
   Mollazadeh S, 2007, CERAM INT, V33, P1579, DOI 10.1016/j.ceramint.2006.06.006
   Mostafa AA, 2009, CHEM ENG J, V153, P187, DOI 10.1016/j.cej.2009.05.039
   Mu YH, 2006, MATER SCI FORUM, V510-511, P878
   Murugan R, 2004, BIOMATERIALS, V25, P3829, DOI 10.1016/j.biomaterials.2003.10.016
   Pan YS, 2009, WEAR, V266, P699, DOI 10.1016/j.wear.2008.08.012
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pon-On W, 2008, MATER CHEM PHYS, V112, P453, DOI 10.1016/j.matchemphys.2008.05.082
   Poursamar SA, 2011, COLLOID SURFACE B, V84, P310, DOI 10.1016/j.colsurfb.2011.01.015
   Qu D, 2011, J BIOMED MATER RES B, V96B, P9, DOI 10.1002/jbm.b.31697
   Rezwan K., 2006, BIOMATERIALS, V27, P1465
   Roohani-Esfahani SI, 2011, ACTA BIOMATER, V7, P1307, DOI 10.1016/j.actbio.2010.10.015
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Shalumon KT, 2009, CARBOHYD POLYM, V77, P863, DOI 10.1016/j.carbpol.2009.03.009
   Sinha A, 2009, MAT SCI ENG C-BIO S, V29, P1330, DOI 10.1016/j.msec.2008.10.024
   Spiller KL, 2008, ACTA BIOMATER, V4, P17, DOI 10.1016/j.actbio.2007.09.001
   Stammen JA, 2001, BIOMATERIALS, V22, P799, DOI 10.1016/S0142-9612(00)00242-8
   Stevens MM, 2004, BIOMATERIALS, V25, P887, DOI 10.1016/j.biomaterials.2003.07.002
   Suetsugu Y, 2009, J MATER SCI, V44, P5806, DOI 10.1007/s10853-009-3815-y
   Tajitsu Y, 2008, MACROMOL SYMP, V268, P14, DOI 10.1002/masy.200850803
   Tang YF, 2009, J BIOMED MATER RES A, V91A, P953, DOI 10.1002/jbm.a.32240
   Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3
   Wahl DA, 2006, EUR CELLS MATER, V11, P43
   Wahl DA, 2007, J MATER SCI-MATER M, V18, P201, DOI 10.1007/s10856-006-0682-9
   Wang MB, 2008, J BIOMED MATER RES A, V85A, P418, DOI 10.1002/jbm.a.31585
   Wei G., 2004, BIOMATERIALS, V25, P47
   Yang DZ, 2008, J APPL POLYM SCI, V110, P3328, DOI 10.1002/app.28829
   Yang DZ, 2011, CARBOHYD POLYM, V84, P990, DOI 10.1016/j.carbpol.2010.12.057
   Zhang DK, 2010, J BIONIC ENG, V7, P235, DOI 10.1016/S1672-6529(10)60246-6
   Zuo KH, 2010, MAT SCI ENG C-MATER, V30, P283, DOI 10.1016/j.msec.2009.11.003
NR 51
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7765
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD DEC 1
PY 2012
VL 100
BP 169
EP 176
DI 10.1016/j.colsurfb.2012.04.046
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
SC Biophysics; Chemistry; Materials Science
GA 991EI
UT WOS:000307683900024
ER

PT J
AU Chow, M
   Herold, DK
   Choo, TM
   Chan, K
AF Chow, Meyrick
   Herold, David Kurt
   Choo, Tat-Ming
   Chan, Kitty
TI Extending the technology acceptance model to explore the intention to
   use Second Life for enhancing healthcare education
SO COMPUTERS & EDUCATION
LA English
DT Article
DE Technology acceptance model; 3D learning environment; Second Life;
   Virtual ward; lntubation; Airway management
ID STUDENTS BEHAVIORAL INTENTION; E-LEARNING ACCEPTANCE;
   INFORMATION-TECHNOLOGY; REPORTING SYSTEM; PROFESSIONALS; COURSES; ERROR;
   VIEW; FLOW
AB Learners need to have good reasons to engage and accept e-learning. They need to understand that unless they do, the outcomes will be less favourable. The technology acceptance model (TAM) is the most widely recognized model addressing why users accept or reject technology. This study describes the development and evaluation of a virtual environment, the online 3D world Second Life (SL), for learning rapid sequence intubation (RSI). RSI is an increasingly frequently used method of acute airway management in healthcare settings. The intention of learners to use the system was explored based on the TAM, with the computer self-efficacy construct as an external variable. Two hundred and six nursing students participated in this study. The findings suggest that the system was perceived as useful, and that the students felt confident working with computers and intended to review RSI in SL as often as needed. However, they remained neutral regarding the ease of use of the system. Strategies were suggested for boosting the students' self-confidence in using the system. Overall use of the TAM in this context was successful, indicating the robustness of the model. The limitations of the study were discussed and further areas of research on the TAM were proposed. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Chow, Meyrick; Chan, Kitty] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
   [Herold, David Kurt] Hong Kong Polytech Univ, Dept Appl Social Sci, Kowloon, Hong Kong, Peoples R China.
   [Choo, Tat-Ming] Queen Mary Hosp, Adult Intens Care Unit, Pok Fu Lam, Hong Kong, Peoples R China.
RP Chow, M (reprint author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
EM hsmchow@polyu.edu.hk; ssherold@polyu.edu.hk; chootm@ha.org.hk;
   hskittyc@polyu.edu.hk
CR ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411
   Ash JS, 2003, J AM MED INFORM ASSN, V10, P188, DOI 10.1197/jamia.M770
   Atkinson T., 2008, TECH TRENDS, V52, P18
   Austin David, 2006, Aust Fam Physician, V35, P365
   Bagozzi R.P., 1988, J ACADEMY MARKETING, V16, P74, DOI [10.1007/BF02723327, DOI 10.1007/BF02723327]
   Bandura A, 1986, SOCIAL FDN THOUGHT A
   Benger J., 2008, EMERGENCY AIRWAY MAN
   Boulos MNK, 2007, HEALTH INFO LIBR J, V24, P233, DOI 10.1111/J.1471-1842.2007.00733.x
   Celuch K., 2004, J INSURANCE ISSUES, V27, P22
   Chen L. D., 2004, EUROPEAN MANAGEMENT, V22, P74, DOI 10.1016/j.emj.2003.11.014
   COMPEAU DR, 1995, MIS QUART, V19, P189, DOI 10.2307/249688
   Crown L. A., 2004, AM J CLIN MED, V1, P12
   DAVIS FD, 1989, MIS QUART, V13, P319, DOI 10.2307/249008
   Davis F. D., 1986, THESIS MIT
   DeLone WH, 2003, J MANAGE INFORM SYST, V19, P9
   Elbeltagi I, 2005, J GLOB INF MANAG, V13, P42, DOI 10.4018/jgim.2005040103
   Evans T., 2001, AM J NURSING S, V101, P16
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Gefen D., 2000, COMMUNICATIONS ASS I, V4, P1
   Grassian E., 2007, Reference Services Review, V35, DOI 10.1108/00907320710729382
   Hair J. T., 1992, MULTIVARIATE DATA AN
   Herald D. K., 2009, J VIRTUAL WORLDS RES, V2
   Herold DK, 2010, COMPUT EDUC, V54, P791, DOI 10.1016/j.compedu.2009.10.019
   Holden RJ, 2010, J BIOMED INFORM, V43, P159, DOI 10.1016/j.jbi.2009.07.002
   Holsapple C.W., 2007, Data Base for Advances in Information Systems, V38
   Jennings N., 2007, INT J SOCIAL SCI, V2, P180
   Karsh BT, 2006, APPL ERGON, V37, P283, DOI 10.1016/j.apergo.2005.07.003
   Kerlinger F. N., 2000, FDN BEHAV RES
   Kilmon Carol A, 2010, Nurs Educ Perspect, V31, P314
   King WR, 2006, INFORM MANAGE-AMSTER, V43, P740, DOI 10.1016/j.im.2006.05.003
   Lee A., 2011, KNOWLEDGE MANAGEMENT, V3, P17
   Lee MKO, 2005, INFORM MANAGE-AMSTER, V42, P1095, DOI 10.1016/j.im.2003.10.007
   Legris P, 2003, INFORM MANAGE-AMSTER, V40, P191, DOI 10.1016/S0378-7206(01)00143-4
   Liu SH, 2009, COMPUT EDUC, V52, P599, DOI 10.1016/j.compedu.2008.11.002
   Lu YB, 2009, COMPUT HUM BEHAV, V25, P29, DOI 10.1016/j.chb.2008.06.002
   Nunnally J. C., 1994, PSYCHOMETRIC THEORY
   Ong CS, 2006, COMPUT HUM BEHAV, V22, P816, DOI 10.1016/j.chb.2004.03.006
   Ong CS, 2004, INFORM MANAGE-AMSTER, V41, P795, DOI 10.1016/j.im.2003.08.012
   Park SY, 2009, EDUC TECHNOL SOC, V12, P150
   Phillips Beth, 2010, Creat Nurs, V16, P132
   Pituch KA, 2006, COMPUT EDUC, V47, P222, DOI 10.1016/j.compedu.2004.10.007
   Rogers L., 2009, P SAM PLAC DIFF SPAC
   Sanchez-Franco MJ, 2010, COMPUT EDUC, V54, P37, DOI 10.1016/j.compedu.2009.07.005
   Schmidt B, 2010, NURS EDUC, V35, P74, DOI 10.1097/NNE.0b013e3181ced999
   Simon S.J., 2007, Journal of Organizational and End User Computing, V19, DOI 10.4018/joeuc.2007010102
   Skiba Diane J, 2007, Nurs Educ Perspect, V28, P156
   Skiba Diane J, 2009, Nurs Educ Perspect, V30, P129
   Skiba DJ, 2008, NURS OUTLOOK, V56, P225, DOI 10.1016/j.outlook.2008.06.012
   Stewart S, 2010, CIN-COMPUT INFORM NU, V28, P253, DOI 10.1097/01.NCN.0000388348.29174.9f
   Teo T, 2010, INTERNET HIGH EDUC, V13, P148, DOI 10.1016/j.iheduc.2010.02.001
   Tung FC, 2008, INT J NURS STUD, V45, P1299, DOI 10.1016/j.ijnurstu.2007.09.011
   Venkatesh V, 2003, MIS QUART, V27, P425
   Venkatesh V, 2000, MANAGE SCI, V46, P186, DOI 10.1287/mnsc.46.2.186.11926
   Wu JH, 2008, INT J QUAL HEALTH C, V20, P123, DOI 10.1093/intqhc/mzm074
   Yarbrough AK, 2007, MED CARE RES REV, V64, P650, DOI 10.1177/1077558707305942
   Yi MY, 2006, INFORM MANAGE-AMSTER, V43, P350, DOI 10.1016/j.im.2005.08.006
NR 56
TC 0
Z9 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-1315
J9 COMPUT EDUC
JI Comput. Educ.
PD DEC
PY 2012
VL 59
IS 4
BP 1136
EP 1144
DI 10.1016/j.compedu.2012.05.011
PG 9
WC Computer Science, Interdisciplinary Applications; Education &
   Educational Research
SC Computer Science; Education & Educational Research
GA 013LQ
UT WOS:000309307300006
ER

PT J
AU Hu, C
   Xiang, YT
   Wang, G
   Ungvari, GS
   Dickerson, FB
   Kilbourne, AM
   Lai, KYC
   Si, TM
   Fang, YR
   Lu, Z
   Yang, HC
   Hu, J
   Chen, ZY
   Huang, Y
   Sun, J
   Wang, XP
   Li, HC
   Zhang, JB
   Chiu, HFK
AF Hu, Chen
   Xiang, Yu-Tao
   Wang, Gang
   Ungvari, Gabor S.
   Dickerson, Faith B.
   Kilbourne, Amy M.
   Lai, Kelly Y. C.
   Si, Tian-Mei
   Fang, Yi-Ru
   Lu, Zheng
   Yang, Hai-Chen
   Hu, Jian
   Chen, Zhi-Yu
   Huang, Yi
   Sun, Jing
   Wang, Xiao-Ping
   Li, Hui-Chun
   Zhang, Jin-Bei
   Chiu, Helen F. K.
TI Screening for bipolar disorder with the Mood Disorders Questionnaire in
   patients diagnosed as major depressive disorder - The experience in
   China
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar disorder; Major depressive disorder; Screening; Diagnostic
   criteria
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; SPECTRUM DISORDER; DSM-IV;
   VALIDATION; VERSION; INSTRUMENT; UNIPOLAR; LIFETIME; MINI; MDQ
AB Background: Bipolar disorder (BD) is often misdiagnosed as a major depressive disorder (MDD). This study aimed to test the usefulness of the screening tool, the Mood Disorders Questionnaire (MDQ), to identify BD patients misdiagnosed as MDD in Chinese clinical settings.
   Methods: A total of 1487 patients treated for MDD were consecutively examined in 13 mental health centers in China. The patients' socio-demographic and clinical characteristics were recorded using a standardized protocol and data collection procedure. The MDQ was completed by patients to identify symptoms characteristic of BD. DSM-IV diagnoses were established using the Mini International Neuropsychiatric Interview (MINI).
   Results: Three hundred-nine of the 1487 patients (20.8%) satisfied DSM-IV criteria for BD; 118 (7.9%) for BD-I and 191 (12.8%) for BD-II on the MINI. The optimal cut-off point on the MDQ to differentiate BD from MDD was 3, while cut-off points of 5 and 3 differentiated BD-I and BD-II from MDD, respectively. The maximum sensitivity was 0.31, 0.45 and 0.22 for differentiating BD. BD-I and BD-II from MDD, respectively.
   Conclusions: The optimal cutoff points of the MDQ for screening BD in Chinese patients originally diagnosed as MDD were considerably lower than those in earlier studies. The routine clinical use of the MDQ as a screening scale for BD in Chinese patients treated for MDD does not seem to be justified. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Xiang, Yu-Tao; Lai, Kelly Y. C.; Chiu, Helen F. K.] Chinese Univ Hong Kong, Dept Psychiat, Tai Po, Hong Kong, Peoples R China.
   [Hu, Chen; Wang, Gang] Capital Med Univ, Beijing Anding Hosp, Mood Disorders Ctr, Beijing, Peoples R China.
   [Ungvari, Gabor S.] Univ Western Australia, Dept Psychiat &Clin Neurosci, Perth, WA 6009, Australia.
   [Dickerson, Faith B.] Sheppard Pratt, Stanley Res Program, Baltimore, MD USA.
   [Kilbourne, Amy M.] Vet Adm Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA.
   [Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
   [Si, Tian-Mei] Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China.
   [Fang, Yi-Ru] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Div Mood Disorders, Shanghai 200030, Peoples R China.
   [Lu, Zheng] Tongji Univ, Sch Med, Shanghai Tongji Hosp, Shanghai 200092, Peoples R China.
   [Yang, Hai-Chen] Shenzhen Mental Hlth Ctr, Div Mood Disorders, Shenzhen, Guangdong, Peoples R China.
   [Hu, Jian] Harbin Med Univ, Hosp 1, Harbin, Heilongjiang Pr, Peoples R China.
   [Chen, Zhi-Yu] Hangzhou Seventh Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Huang, Yi] Sichuan Univ, W China Hosp, Chengdu, Sichuan Provinc, Peoples R China.
   [Sun, Jing] Nanjing Med Univ, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.
   [Wang, Xiao-Ping] Cent S Univ, Xiangya Hosp 2, Mental Hlth Inst, Changsha, Hunan, Peoples R China.
   [Li, Hui-Chun] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Jin-Bei] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
RP Xiang, YT (reprint author), Chinese Univ Hong Kong, Multictr, Tai Po Hosp, Dept Psychiat, Ground Floor, Tai Po, Hong Kong, Peoples R China.
EM xyutly@gmail.com; gangwangdoc@gmail.com
FU National Key Scientific and Technological Projects for the 11th
   Five-Year from the Ministry of Science and Technology of China (Project
   Title: Early Diagnostic Assessment and Standardized Treatment Approach
   for Depression [2007BAI17B05]; AstraZeneca China
FX This study was funded by the National Key Scientific and Technological
   Projects for the 11th Five-Year from the Ministry of Science and
   Technology of China (Project Title: Early Diagnostic Assessment and
   Standardized Treatment Approach for Depression; No.2007BAI17B05).The
   study was initiated by the Chinese Society of Psychiatry (CSP) with
   support from AstraZeneca China. AstraZeneca China had no role in the
   study design, generating or interpreting the results. The authors are
   grateful to all clinicians who helped to organize the study in each
   study site.
CR Akiskal HS, 2005, J AFFECT DISORDERS, V84, P209, DOI 10.1016/j.jad.2004.05.004
   Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1
   Angst J, 2003, EUR NEUROPSYCHOPHARM, V13, pS43, DOI 10.1016/S0924-977X(03)00077-4
   Bowden CL, 2001, PSYCHIATR SERV, V52, P51, DOI 10.1176/appi.ps.52.1.51
   Chung KF, 2008, PSYCHIAT CLIN NEUROS, V62, P464, DOI 10.1111/j.1440-1819.2008.01827.x
   Goodwin F.K., 2007, MANIC DEPRESSIVE ILL
   Hirschfeld RMA, 2003, J CLIN PSYCHIAT, V64, P161
   Hirschfeld RMA, 2004, J CLIN PSYCHIAT, V65, P5
   Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI 10.1176/appi.ajp.157.11.1873
   Kemp DE, 2008, J PSYCHIATR RES, V42, P778, DOI 10.1016/j.jpsychires.2007.08.001
   LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879
   Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
   Meyer TD, 2011, J AFFECT DISORDERS, V128, P291, DOI 10.1016/j.jad.2010.07.003
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22
   [司天梅 SI Tian-Mei], 2009, [中国心理卫生杂志, Chinese Mental Health Journal], V23, P493
   Smith DJ, 2011, BRIT J PSYCHIAT, V199, P49, DOI 10.1192/bjp.bp.110.083840
   Solomon DA, 2006, J CLIN PSYCHIAT, V67, P434
   Vieta E, 2007, J AFFECT DISORDERS, V101, P43, DOI 10.1016/j.jad.2006.09.040
   Yang HC, 2011, PSYCHIAT RES, V189, P446, DOI 10.1016/j.psychres.2011.02.007
   Zimmerman M, 2004, J CLIN PSYCHIAT, V65, P605
   Zimmerman M, 2011, HARVARD REV PSYCHIAT, V19, P219, DOI 10.3109/10673229.2011.614101
   Zimmerman M., 2004, J CLIN PSYCHIAT, V65, P721
NR 22
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD DEC 1
PY 2012
VL 141
IS 1
BP 40
EP 46
DI 10.1016/j.jad.2012.02.035
PG 7
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 011EV
UT WOS:000309148500005
ER

PT J
AU Zhang, YP
   Zhang, W
   Wang, SQ
   Wang, CX
   Xie, JJ
   Chen, XY
   Xu, YL
   Mao, P
AF Zhang, Yuping
   Zhang, Wei
   Wang, Shunqing
   Wang, Caixia
   Xie, Jianjin
   Chen, Xiaoyan
   Xu, Yanli
   Mao, Ping
TI Detection of human erythrocytes influenced by iron deficiency anemia and
   thalassemia using atomic force microscopy
SO MICRON
LA English
DT Review
DE AFM; Iron deficiency anemia; Thalassemia; Erythrocytes
ID RED-BLOOD-CELLS; MEMBRANE SKELETON; BETA-THALASSEMIA; SPECTROSCOPY;
   BINDING
AB Purpose: Iron deficiency anemia (IDA) and thalassemia (THAL) are two types of microcytic anemia, and both of these conditions disturb the morphology and function of erythrocytes at the molecular level. The ability to distinguish between thalassemic and iron deficiency anemia microcytosis has important clinical implications. The purpose of this study was to show that pathophysiological changes to erythrocytes could be detected at the nanometer scale, which is important for the early diagnosis of anemia and for distinguishing between IDA and THAL.
   Methods: Blood samples were taken from six healthy volunteers and six patients with either iron deficiency anemia or thalassemia. Changes in the morphological of erythrocytes were studied at the nanometer level using atomic force microscopy (AFM).
   Results: There were dramatic overall shape and surface membrane deformations of the erythrocytes associated with iron deficiency anemia and thalassemia compared to healthy erythrocytes. Healthy and pathological erythrocytes of iron deficiency anemia and thalassemia could be distinguished by the morphologic parameters of width, length, the ratio of length to width, valley, peak, valley-to-peak, standard deviations, and surface fluctuation. These AFM parameters of erythrocyte morphology differed greatly between iron deficiency anemia and thalassemia.
   Conclusion: AFM was found to be an extremely useful tool for detecting and distinguishing between iron deficiency anemia and thalassemia. Erythrocyte morphology is an important determinant for diagnosing and distinguishing IDA and THAL. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yuping; Wang, Shunqing; Wang, Caixia; Xie, Jianjin; Chen, Xiaoyan; Xu, Yanli; Mao, Ping] Guangzhou Med Coll, Guangzhou Municipal Peoples Hosp 1, Dept Hematol, Guangzhou 510180, Guangdong, Peoples R China.
   [Zhang, Wei] Guangzhou Med Coll, Guangzhou Municipal Peoples Hosp 1, Dept Ophthalmol, Guangzhou 510180, Guangdong, Peoples R China.
RP Zhang, YP (reprint author), Guangzhou Med Coll, Guangzhou Municipal Peoples Hosp 1, Dept Hematol, Guangzhou 510180, Guangdong, Peoples R China.
EM jnzhangyuping@163.com; maoping0620@hotmail.com
FU Key Programs of Health Bureau of Guangzhou City [201102A212025]
FX This work was supported by Key Programs of Health Bureau of Guangzhou
   City (Project No. 201102A212025).
CR Chen Y, 2011, BIOCHEM BIOPH RES CO, V407, P301, DOI 10.1016/j.bbrc.2011.03.006
   Di Bucchianico S., 2011, J NANOBIOTECHNOL, V28, P9
   Dulinska I, 2006, J BIOCHEM BIOPH METH, V66, P1, DOI 10.1016/j.jbbm.2005.11.003
   El-Shoura Samir, 1993, Applied Parasitology, V34, P173
   Engel A, 2011, METHODS MOL BIOL, V736, P153, DOI 10.1007/978-1-61779-105-5_11
   Girasole M, 2007, BBA-BIOMEMBRANES, V1768, P1268, DOI 10.1016/j.bbamem.2007.01.014
   Grant CC, 2007, J PAEDIATR CHILD H, V43, P513, DOI 10.1111/j.1440-1754.2007.01128.x
   Heus HA, 2011, ANAL BIOCHEM, V414, P1, DOI 10.1016/j.ab.2011.03.012
   Hoshi O, 2011, METHODS MOL BIOL, V736, P109, DOI 10.1007/978-1-61779-105-5_8
   Jin H, 2010, BIOCHEM BIOPH RES CO, V391, P1698, DOI 10.1016/j.bbrc.2009.12.133
   Lesoil C, 2010, BIOCHEM BIOPH RES CO, V391, P1312, DOI 10.1016/j.bbrc.2009.12.023
   Lower SK, 2011, ADV EXP MED BIOL, V715, P285, DOI 10.1007/978-94-007-0940-9_18
   Maciaszek JL, 2011, J BIOMECH, V44, P657, DOI 10.1016/j.jbiomech.2010.11.008
   Miklaszewska Monika, 2004, Przegl Lek, V61, P126
   Moreno-Herrero F, 2001, BIOCHEM BIOPH RES CO, V280, P151, DOI 10.1006/bbrc.2000.4074
   Odorico M, 2007, ULTRAMICROSCOPY, V107, P887, DOI 10.1016/j.ultramic.2007.04.019
   O'Reilly M, 2001, ULTRAMICROSCOPY, V86, P107, DOI 10.1016/S0304-3991(00)00081-4
   Ricci D, 2011, METHODS MOL BIOL, V736, P243, DOI 10.1007/978-1-61779-105-5_16
   Schrier SL, 2002, CURR OPIN HEMATOL, V9, P123, DOI 10.1097/00062752-200203000-00007
   SHINAR E, 1987, BLOOD, V70, P158
   Sinniah K, 2002, CURR EYE RES, V25, P61, DOI 10.1076/ceyr.25.1.61.9963
   Testa U, 2004, LEUKEMIA, V18, P1176, DOI 10.1038/sj.leu.2403383
   Tsilimbaris MK, 2000, INVEST OPHTH VIS SCI, V41, P680
   Urrechaga E, 2011, J CLIN LAB ANAL, V25, P223, DOI 10.1002/jcla.20462
   WINICHAGOON P, 1993, BRIT J HAEMATOL, V83, P633, DOI 10.1111/j.1365-2141.1993.tb04702.x
   Xing XB, 2011, MICRON, V42, P42, DOI 10.1016/j.micron.2010.08.004
   YUAN J, 1995, BLOOD, V86, P3945
NR 27
TC 0
Z9 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-4328
J9 MICRON
JI Micron
PD DEC
PY 2012
VL 43
IS 12
SI SI
BP 1287
EP 1292
DI 10.1016/j.micron.2011.10.018
PG 6
WC Microscopy
SC Microscopy
GA 004KP
UT WOS:000308680900011
ER

PT J
AU Du, XL
   Xie, YL
   Xian, CJ
   Chen, L
AF Du, Xiaolan
   Xie, Yangli
   Xian, Cory J.
   Chen, Lin
TI Role of FGFs/FGFRs in skeletal development and bone regeneration
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
ID FIBROBLAST-GROWTH-FACTOR; FAMILIAL TUMORAL CALCINOSIS; TEMPORAL
   GENE-EXPRESSION; FACTOR RECEPTOR-3 FGFR3; PROTEIN-KINASE-C; FRACTURE
   REPAIR; NATRIURETIC PEPTIDE; ACANTHOSIS NIGRICANS; TRANSGENIC MICE;
   APERT-SYNDROME
AB Fibroblast growth factor (FGF)/FGF (FGFR) signaling is an important pathway involved in skeletal development. Missense mutations in FGFs and FGFRs were found clinically to cause multiple congenital skeleton diseases including chondrodysplasia, craniosynostosis, syndromes with dysregulated phosphate metabolism. FGFs/FGFRs also have crucial roles in bone fracture repair and bone regeneration. Understanding the molecular mechanisms for the role of FGFs/FGFRs in the regulation of skeletal development, genetic skeletal diseases, and fracture healing will ultimately lead to better treatment of skeleton diseases caused by mutations of FGFs/FGFRs and fracture. This review summarizes the major findings on the role of FGF signaling in skeletal development, genetic skeletal diseases and bone healing, and discusses issues that remain to be resolved in applying FGF signaling-related measures to promote bone healing. This review has also provided a perspective view on future work for exploring the roles and action mechanisms of FGF signaling in skeletal development, genetic skeletal diseases, and fracture healing. J. Cell. Physiol. 227: 37313743, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Du, Xiaolan; Xie, Yangli; Chen, Lin] Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Ctr Bone Metab & Repair, Inst Surg Res,Daping Hosp, Chongqing 400042, Peoples R China.
   [Xian, Cory J.] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia.
RP Chen, L (reprint author), Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Ctr Bone Metab & Repair, Inst Surg Res,Daping Hosp, Chongqing 400042, Peoples R China.
EM linchen70@tmmu.edu.cn
RI Xian, Cory/D-2646-2009
FU Special Funds for Major State Basic Research Program of China (973
   program) [2011CB964701, 2012CB518106]; National Natural Science
   Foundation of China [81030036, 81170809, 30901527, 30971607]
FX The work in Lin Chen's laboratory was supported by the Special Funds for
   Major State Basic Research Program of China (973 program) (No.
   2011CB964701, No. 2012CB518106), and grants from National Natural
   Science Foundation of China (No. 81030036, No. 81170809, No. 30901527,
   No. 30971607).
CR Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849-07
   Araya K, 2005, J CLIN ENDOCR METAB, V90, P5523, DOI 10.1210/jc.2005-0301
   Arnaud-Lopez L, 2007, CLIN GENET, V72, P405, DOI 10.1111/j.1399-0004.2007.00884.x
   Behr B, 2010, P NATL ACAD SCI USA, V107, P11853, DOI 10.1073/pnas.1003317107
   Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034
   Bland YS, 1995, ACTA ORTHOP SCAND, V66, P543, DOI 10.3109/17453679509002313
   Bocciardi R, 2007, HUM MUTAT, V28, P724, DOI 10.1002/humu.20511
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   BOURQUE WT, 1993, INT J DEV BIOL, V37, P573
   Chen L, 2003, BONE, V33, P169, DOI 10.1016/S8756-3282(02)00222-9
   Chen L, 2001, HUM MOL GENET, V10, P457, DOI 10.1093/hmg/10.5.457
   Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690
   Chen L, 2005, FRONT BIOSCI, V10, P1961, DOI 10.2741/1671
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774-004-0487-6
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chi LJ, 2004, DEVELOPMENT, V131, P3345, DOI 10.1242/dev.01200
   COFFIN JD, 1995, MOL BIOL CELL, V6, P1861
   Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390
   Consortium A, 2000, NAT GENET, V26, P345
   Coumoul X, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni100
   Cuevas P, 1997, SURG NEUROL, V47, P242, DOI 10.1016/S0090-3019(96)00438-7
   Cunningham ML, 2007, ORTHOD CRANIOFAC RES, V10, P67, DOI 10.1111/j.1601-6343.2007.00389.x
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   de Frutos CA, 2007, DEV CELL, V13, P872, DOI 10.1016/j.devcel.2007.09.016
   Delezoide AL, 1998, MECH DEVELOP, V77, P19, DOI 10.1016/S0925-4773(98)00133-6
   Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122
   Fakhry A, 2005, BONE, V36, P254, DOI 10.1016/j.bone.2004.10.003
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Franceschi RT, 2005, J DENT RES, V84, P1093
   Fu XB, 1998, LANCET, V352, P1661, DOI 10.1016/S0140-6736(98)01260-4
   Fukumoto S, 2007, BONE, V40, P1190, DOI 10.1016/j.bone.2006.12.062
   Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750
   Furthauer M, 2001, DEVELOPMENT, V128, P2175
   Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867
   Haque T, 2007, HISTOL HISTOPATHOL, V22, P119
   Harada M, 2009, NAT GENET, V41, P289, DOI 10.1038/ng.316
   Hong KS, 2010, J BIOMED MATER RES A, V94A, P1187, DOI 10.1002/jbm.a.32799
   Hung IH, 2007, DEV BIOL, V307, P300, DOI 10.1016/j.ydbio.2007.04.048
   Hurley MM, 2006, BIOCHEM BIOPH RES CO, V341, P989, DOI 10.1016/j.bbrc.2006.01.044
   Ignelzi MA, 2003, J BONE MINER RES, V18, P751, DOI 10.1359/jbmr.2003.18.4.751
   Iseki S, 1999, DEVELOPMENT, V126, P5611
   Iwaniec UT, 2002, ENDOCRINOLOGY, V143, P2515, DOI 10.1210/en.143.7.2515
   Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603
   Jacob AL, 2006, DEV BIOL, V296, P315, DOI 10.1016/j.ydbio.2006.05.031
   Javed A, 2010, ORAL MAXIL SURG CLIN, V22, P283, DOI 10.1016/j.coms.2010.05.001
   Jeong I, 2010, J MATER SCI-MATER M, V21, P1335, DOI 10.1007/s10856-009-3971-2
   Jilka RL, 2008, BONE, V44, P275
   JINGUSHI S, 1990, J ORTHOPAED RES, V8, P364, DOI 10.1002/jor.1100080308
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawaguchi H, 2007, J ORTHOP RES, V25, P480, DOI 10.1002/jor.20315
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   Kawaguchi Hiroshi, 2009, Clin Calcium, V19, P653
   Kawaguchi H, 2010, J BONE MINER RES, V25, P2459, DOI 10.1002/jbmr.146
   Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   Kimoto T, 1998, J DENT RES, V77, P1965
   Kodama N, 2009, BONE, V44, P699, DOI 10.1016/j.bone.2008.12.017
   Komaki H, 2006, BIOMATERIALS, V27, P5118, DOI 10.1016/j.biomaterials.2006.05.031
   Krejci P, 2005, J CELL SCI, V118, P5089, DOI 10.1242/jcs.02618
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kuroda S, 1999, BONE, V25, P431, DOI 10.1016/S8756-3282(99)00193-3
   Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004-2238
   Lazarus JE, 2007, BONE, V40, P577, DOI 10.1016/j.bone.2006.10.013
   Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9
   Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35
   Li MQ, 2010, J ELECTRON MICROSC, V59, P227, DOI 10.1093/jmicro/dfq002
   Lisignoli G, 2001, BIOMATERIALS, V22, P2095, DOI 10.1016/S0142-9612(00)00398-7
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Lomri A, 1998, J CLIN INVEST, V101, P1310
   Lomri A, 2001, J BONE MINER RES, V16, P705, DOI 10.1359/jbmr.2001.16.4.705
   Longaker MT, 2011, TISSUE ENG PART A, V17, P2061
   Lu XM, 2009, BIOCHEM BIOPH RES CO, V390, P494, DOI 10.1016/j.bbrc.2009.09.123
   Maehara H, 2010, J ORTHOP RES, V28, P677, DOI 10.1002/jor.21032
   Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Mariani FV, 2008, NATURE, V453, P401, DOI 10.1038/nature06876
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0
   Martinez-Frias ML, 2010, AM J MED GENET A, V152A, P245, DOI 10.1002/ajmg.a.33188
   MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583
   MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462
   Milunsky JM, 2006, CLIN GENET, V69, P349, DOI 10.1111/j.1399-0004.2006.00597.x
   Minina E, 2002, DEV CELL, V3, P439, DOI 10.1016/S1534-5807(02)00261-7
   Minowada G, 1999, DEVELOPMENT, V126, P4465
   Moncla A, 2007, HUM MUTAT, V28, P1183, DOI 10.1002/humu.20611
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   Moon AM, 2000, NAT GENET, V26, P455
   Moore EE, 2005, OSTEOARTHR CARTILAGE, V13, P623, DOI 10.1016/j.joca.2005.03.003
   Moore R, 2002, DEV BIOL, V243, P99, DOI 10.1006/dbio.2001.0533
   Muenke M, 1997, AM J HUM GENET, V60, P555
   Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104
   Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113
   Nakajima A, 2001, BONE, V29, P458, DOI 10.1016/S8756-3282(01)00604-4
   Nakajima A, 2003, ENDOCRINOLOGY, V144, P4659, DOI 10.1210/en.2003-0158
   Nakajima F, 2007, CALCIFIED TISSUE INT, V81, P132, DOI 10.1007/s00223-007-9048-7
   Nakajima F, 2001, J ORTHOPAED RES, V19, P935, DOI 10.1016/S0736-0266(01)00024-9
   NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276
   Nakamura Y, 2005, BONE, V36, P399, DOI 10.1016/j.bone.2004.11.010
   Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Olney RC, 2006, J CLIN ENDOCR METAB, V91, P1229, DOI 10.1210/jc.2005-1949
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003
   Ornitz DM, 2001, GENOME BIOL, V2
   Ozasa A, 2005, BONE, V36, P1056, DOI 10.1016/j.bone.2005.03.006
   Pacicca DM, 2003, BONE, V33, P889, DOI 10.1016/j.bone.2003.06.002
   Podkowa M, 2010, DEV CELL, V19, P1, DOI 10.1016/j.devcel.2010.07.004
   Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068
   Pun S, 2000, BONE, V27, P197, DOI 10.1016/S8756-3282(00)00312-4
   Radomsky ML, 1999, J ORTHOPAED RES, V17, P607, DOI 10.1002/jor.1100170422
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Rohmann E, 2006, NAT GENET, V38, P414, DOI 10.1038/ng1757
   Roscioli T, 2000, AM J MED GENET, V93, P22, DOI 10.1002/1096-8628(20000703)93:1<22::AID-AJMG5>3.0.CO;2-U
   Rundle CH, 2002, CLIN ORTHOP RELAT R, P253, DOI 10.1097/01.blo.0000022174.66847.09
   Sakano S, 2002, BIOCHEM BIOPH RES CO, V293, P680, DOI 10.1016/S0006-291X(02)00273-5
   Sasaki Atsuo, 2003, Cell Cycle, V2, P281
   Schmid GJ, 2009, DEV DYNAM, V238, P766, DOI 10.1002/dvdy.21882
   Shapiro F, 2008, EUR CELLS MATER, V15, P53
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Simons M, 2002, CIRCULATION, V105, P788, DOI 10.1161/hc0802.104407
   Sobue T, 2005, J CELL BIOCHEM, V95, P83, DOI 10.1002/jcb.20389
   Song SJ, 2006, GENE, V379, P92, DOI 10.1016/j.gene.2006.04.029
   Su N, 2010, HUM MOL GENET, V19, P1199, DOI 10.1093/hmg/ddp590
   Su N, 2008, FRONT BIOSCI-LANDMRK, V13, P2842, DOI 10.2741/2890
   Su Nan, 2008, Biochem Biophys Res Commun, V376, P454, DOI 10.1016/j.bbrc.2008.08.165
   Takechi M, 2008, J MATER SCI-MATER M, V19, P2949, DOI 10.1007/s10856-008-3416-3
   TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321
   Terkeltaub RA, 1998, J BONE MINER RES, V13, P931, DOI 10.1359/jbmr.1998.13.6.931
   Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019
   Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159
   Toydemir RM, 2006, AM J HUM GENET, V79, P935, DOI 10.1086/508433
   Tsang M., 2004, SCI STKE, P17
   Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749
   Ueda K, 2007, BONE, V41, P13, DOI 10.1016/j.bone.2007.02.028
   Valverde-Franco G, 2004, HUM MOL GENET, V13, P271, DOI 10.1093/hmg/ddh034
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7
   Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914
   White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956
   Wilkes D, 1996, J MED GENET, V33, P744, DOI 10.1136/jmg.33.9.744
   Wu XL, 2009, AM J HUM GENET, V85, P53, DOI 10.1016/j.ajhg.2009.06.007
   Xiao LP, 2004, J BIOL CHEM, V279, P27743, DOI 10.1074/jbc.M314323200
   Xiong SQ, 2003, J BIOL CHEM, V278, P50273, DOI 10.1074/jbc.M306936200
   Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264
   Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971
   Yasoda A, 2010, ENDOCR J, V57, P659
   Yin L, 2008, BONE, V42, P631, DOI 10.1016/j.bone.2007.11.019
   Yoshiko Y, 2007, BONE, V40, P1565, DOI 10.1016/j.bone.2007.01.017
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
   Yu XJ, 2005, CYTOKINE GROWTH F R, V16, P221, DOI 10.1016/j.cytogfr.2005.01.002
   Zellin G, 2000, BONE, V26, P161, DOI 10.1016/S8756-3282(99)00252-5
   Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001
NR 164
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2012
VL 227
IS 12
BP 3731
EP 3743
DI 10.1002/jcp.24083
PG 13
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 994TA
UT WOS:000307953600003
ER

PT J
AU Zhou, CJ
   Pan, WL
   Wang, XP
   Chen, TS
AF Zhou, Chenjuan
   Pan, Wenliang
   Wang, Xiao Ping
   Chen, Tong Sheng
TI Artesunate induces apoptosis via a Bak-mediated caspase-independent
   intrinsic pathway in human lung adenocarcinoma cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BCL-X-L; CANCER-CELLS; MITOCHONDRIAL APOPTOSIS; DEATH PATHWAY; IN-VIVO;
   TRANSLOCATION; ACTIVATION; SENSITIZES; LINES; PUMA
AB This report is designed to explore the exact molecular mechanism by which artesunate (ART), a semisynthetic derivative of the herbal antimalaria drug artemisinin, induces apoptosis in human lung adenocarcinoma (ASTC-a-1 and A549) cell lines. ART treatment induced ROS-mediated apoptosis in a concentration- and time-dependent fashion accompanying the loss of mitochondrial potential and subsequent release of Smac and AIF indicative of intrinsic apoptosis pathway. Blockage of casapse-8 and -9 did not show any inhibitory effect on the ART-induced apoptosis, but which was remarkably prevented by silencing AIF. Of the utmost importance, ART treatment induced the activation of Bak but not Bax, and silencing Bak but not Bax remarkably inhibited ART-induced apoptosis and AIF release. Furthermore, although ART treatment did not induced a significant down-regulation of voltage-dependent anion channel 2 (VDAC2) expression and up-regulation of Bim expression, silencing VDAC2 potently enhanced the ART-induced Bak activation and apoptosis which were significantly prevented by silencing Bim. Collectively, our data firstly demonstrate that ART induces Bak-mediated caspase-independent intrinsic apoptosis in which Bim and VDAC2 as well as AIF play important roles in both ASTC-a-1 and A549 cell lines, indicating a potential therapeutic effect of ART for lung cancer. J. Cell. Physiol. 227: 37783786, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Zhou, Chenjuan; Pan, Wenliang; Chen, Tong Sheng] S China Normal Univ, Inst Laser Life Sci, Coll Biophoton, Guangzhou 510631, Guangdong, Peoples R China.
   [Zhou, Chenjuan; Pan, Wenliang; Chen, Tong Sheng] S China Normal Univ, MOE Key Lab Laser Life Sci, Coll Biophoton, Guangzhou 510631, Guangdong, Peoples R China.
   [Wang, Xiao Ping] Jinan Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China.
RP Chen, TS (reprint author), S China Normal Univ, Inst Laser Life Sci, Coll Biophoton, Guangzhou 510631, Guangdong, Peoples R China.
EM chentsh@scnu.edu.cn
FU National Natural Science Foundation of China [31071218, 61178078,
   81071491]; Key Project of the Department of Education and Finance of
   Guangdong Province [cxzd115]
FX Contract grant sponsor: National Natural Science Foundation of
   China;Contract grant numbers: 31071218, 61178078, 81071491.Contract
   grant sponsor: Key Project of the Department of Education and Finance of
   Guangdong Province (cxzd115).
CR Autret A, 2009, MOL CELL, V36, P355, DOI 10.1016/j.molcel.2009.10.011
   Bachmeier B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020550
   Chen T, 2009, J CELL MOL MED, V13, P1358, DOI 10.1111/j.1582-4934.2008.00360.x
   Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995
   Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   Choudhury S, 2011, BASIC RES CARDIOL, V106, P397, DOI 10.1007/s00395-011-0164-1
   Du JH, 2010, CANCER CHEMOTH PHARM, V65, P895, DOI 10.1007/s00280-009-1095-5
   Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034
   Efferth T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000693
   Efferth T, 2001, INT J ONCOL, V18, P767
   Efferth T, 2003, INT J ONCOL, V23, P1231
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382
   Fandy TE, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-60
   Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835
   Gelinas Celine, 2005, Genes & Development, V19, P1263, DOI 10.1101/gad.1326205
   Germain M, 2008, J BIOL CHEM, V283, P6384, DOI 10.1074/jbc.M707762200
   Hamacher-Brady A, 2011, J BIOL CHEM, V286, P6587, DOI 10.1074/jbc.M110.210047
   Handrick R, 2010, MOL CANCER THER, V9, P2497, DOI 10.1158/1535-7163.MCT-10-0051
   Hangen E, 2010, TRENDS BIOCHEM SCI, V35, P278, DOI 10.1016/j.tibs.2009.12.008
   Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648
   Karlberg M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.20
   Kim JS, 2008, INT J CANCER, V122, P672, DOI 10.1002/ijc.23158
   Lazarou M, 2010, J BIOL CHEM, V285, P36876, DOI 10.1074/jbc.M110.159301
   Lee DH, 2008, BIOCHEM PHARMACOL, V75, P2020, DOI 10.1016/j.bcp.2008.02.023
   Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1
   Li PCH, 2008, CANCER RES, V68, P4347, DOI 10.1158/0008-5472.CAN-07-2970
   Li SP, 2012, J CELL PHYSIOL, V227, P1639, DOI 10.1002/jcp.22881
   Liptay S, 2002, BRIT J PHARMACOL, V137, P608, DOI 10.1038/sj.bjp.0704870
   Lorenzo HK, 2007, DRUG RESIST UPDATE, V10, P235, DOI 10.1016/j.drup.2007.11.001
   Lu YY, 2010, FEBS LETT, V584, P4019, DOI 10.1016/j.febslet.2010.08.014
   Mercer AE, 2007, J BIOL CHEM, V282, P9372, DOI 10.1074/jbc.M610375200
   Michaelis M, 2010, BIOCHEM PHARMACOL, V79, P130, DOI 10.1016/j.bcp.2009.08.013
   Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195
   Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330
   Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773
   Norberg E, 2010, EMBO J, V29, P3869, DOI 10.1038/emboj.2010.253
   Rajalingam K, 2007, APOPTOSIS, V12, P1503, DOI 10.1007/s10495-007-0067-7
   Rasheed SAK, 2010, INT J CANCER, V127, P1475, DOI 10.1002/ijc.25315
   Ren DC, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000274
   REN DC, 2010, AIDS RES HUM RETRO S, V330, P1390, DOI DOI 10.1126/SCIENCE.1190217
   Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005
   Sertel S, 2010, MOLECULES, V15, P2886, DOI 10.3390/molecules15042886
   Sharma G, 2012, J CELL PHYSIOL, V227, P1923, DOI 10.1002/jcp.22920
   Takikawa Y, 2001, GASTROENTEROLOGY, V120, P1810, DOI 10.1053/gast.2001.24835
   Thayyullathil F, 2008, FREE RADICAL BIO MED, V45, P1403, DOI 10.1016/j.freeradbiomed.2008.08.014
   Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200
   Wang Y, 2011, INT J NANOMED, V6, P1185, DOI 10.2147/IJN.S19723
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580
   Westphal D, 2011, BBA-MOL CELL RES, V1813, P521, DOI 10.1016/j.bbamcr.2010.12.019
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
   Zhang YJ, 2009, MOL BIOL CELL, V20, P3077, DOI 10.1091/mbc.E08-11-1109
   Zhao YY, 2011, INT IMMUNOPHARMACOL, V11, P2039, DOI 10.1016/j.intimp.2011.08.017
NR 55
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2012
VL 227
IS 12
BP 3778
EP 3786
DI 10.1002/jcp.24086
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 994TA
UT WOS:000307953600008
ER

PT J
AU Lin, M
   Huo, HF
   Li, YN
AF Lin, Mei
   Huo, Hai-Feng
   Li, Yu-Ning
TI A competitive model in a chemostat with nutrient recycling and
   antibiotic treatment
SO NONLINEAR ANALYSIS-REAL WORLD APPLICATIONS
LA English
DT Article
DE Chemostat; Antibiotic; Competition; Nutrient recycling; Uniform
   persistence
ID PLASMID-BEARING; HOSPITALS; DYNAMICS; POPULATIONS; RESISTANCE;
   INHIBITOR; STABILITY; STRAINS; AGENTS
AB A model for competition between antibiotic-sensitive and antibiotic-resistant bacteria with nutrient recycling and antibiotic treatment in a chemostat is considered. The sufficient and necessary conditions for boundedness of the solution and existence of non-negative equilibria are derived. The extinction and uniform persistence of antibiotic-sensitive and antibiotic-resistant bacteria are also carried out. Numerical simulations are then given to illustrate our main results. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lin, Mei; Huo, Hai-Feng] Lanzhou Univ Technol, Inst Appl Math, Lanzhou 730050, Gansu, Peoples R China.
   [Li, Yu-Ning] Lanzhou Univ, Hosp 1, Dept Pediat, Lanzhou 730000, Gansu, Peoples R China.
RP Huo, HF (reprint author), Lanzhou Univ Technol, Inst Appl Math, Lanzhou 730050, Gansu, Peoples R China.
EM hfhuo@lut.cn
FU NNSF of China [10961018]; NSF of Gansu Province of China [1107RJZA088];
   NSF for Distinguished Young Scholars of Gansu Province of China
   [1111RJDA003]; Special Fund for the Basic Requirements in the Research
   of University of Gansu Province of China; Lanzhou University of
   Technology
FX This work was partially supported by the NNSF of China (10961018), the
   NSF of Gansu Province of China (1107RJZA088), the NSF for Distinguished
   Young Scholars of Gansu Province of China (1111RJDA003), the Special
   Fund for the Basic Requirements in the Research of University of Gansu
   Province of China and the Development Program for HongLiu Distinguished
   Young Scholars in Lanzhou University of Technology.
CR Austin DJ, 1998, J THEOR BIOL, V194, P313, DOI 10.1006/jtbi.1997.0438
   BERETTA E, 1990, J MATH BIOL, V28, P99
   Cogan NG, 2006, J THEOR BIOL, V238, P694, DOI 10.1016/j.jtbi.2005.06.017
   Corvaisier S, 1998, ANTIMICROB AGENTS CH, V42, P1731
   D'Agata EMC, 2007, J THEOR BIOL, V249, P487, DOI 10.1016/j.jtbi.2007.08.011
   ELmojtaba IM, 2010, NONLINEAR ANAL-REAL, V11, P2175, DOI 10.1016/j.nonrwa.2009.01.011
   FREEDMAN HI, 1993, J MATH BIOL, V31, P513
   Imran M., 2006, COMPUT MATH METHOD M, V7, P229
   Leenheer P., 2010, J MATH BIOL, V61, P475, DOI DOI 10.1007/S00285-009-0302-7
   Lu ZQ, 1998, MATH BIOSCI, V148, P147, DOI 10.1016/S0025-5564(97)10010-4
   Meng X, 2010, J MATH CHEM, V47, P123, DOI 10.1007/s10910-009-9536-2
   Nie H, 2009, J MATH ANAL APPL, V355, P231, DOI 10.1016/j.jmaa.2009.01.045
   Nie H, 2010, NONLINEAR ANAL-REAL, V11, P3639, DOI 10.1016/j.nonrwa.2010.01.010
   Nikolaou M, 2006, J MATH BIOL, V52, P154, DOI 10.1007/s00285-005-0350-6
   Regoes RR, 2004, ANTIMICROB AGENTS CH, V48, P3670, DOI 10.1128/AAC.48.10.3670-3676.2004
   Ruan SG, 1998, SIAM J APPL MATH, V58, P170, DOI 10.1137/S0036139996299248
   Smith HL, 2012, J MATH BIOL, V64, P951, DOI 10.1007/s00285-011-0434-4
   Smith H. L., 1995, THEORY CHEMOSTAT
   Smith HL, 2011, MATH BIOSCI, V229, P149, DOI 10.1016/j.mbs.2010.12.001
   Sun HR, 2010, MATH BIOSCI, V227, P56, DOI 10.1016/j.mbs.2010.06.002
   Tagashira O, 2009, NONLINEAR ANAL-REAL, V10, P1443, DOI 10.1016/j.nonrwa.2008.01.015
   Wang LM, 2010, NONLINEAR ANAL-REAL, V11, P1374, DOI 10.1016/j.nonrwa.2009.02.027
   Webb GF, 2005, P NATL ACAD SCI USA, V102, P13343, DOI 10.1073/pnas.0504053102
   Webb Glenn F., 2010, Journal of Biological Dynamics, V4, P115, DOI 10.1080/17513750903026411
   Wiuff C, 2005, ANTIMICROB AGENTS CH, V49, P1483, DOI 10.1128/AAC.49.4.1483-1494.2005
   Yuan SL, 2006, MATH BIOSCI, V202, P1, DOI 10.1016/j.mbs.2006.04.003
   Yuan SL, 2009, NONLINEAR ANAL-REAL, V10, P1305, DOI 10.1016/j.nonrwa.2008.01.009
   Zhang H, 2009, APPL MATH MECH-ENGL, V30, P933, DOI 10.1007/s10483-009-0712-x
   Zou L, 2011, NONLINEAR ANAL-REAL, V12, P658, DOI 10.1016/j.nonrwa.2010.07.008
NR 29
TC 0
Z9 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1468-1218
J9 NONLINEAR ANAL-REAL
JI Nonlinear Anal.-Real World Appl.
PD DEC
PY 2012
VL 13
IS 6
BP 2540
EP 2555
DI 10.1016/j.nonrwa.2012.02.016
PG 16
WC Mathematics, Applied
SC Mathematics
GA 972AI
UT WOS:000306248500007
ER

PT J
AU Wang, Z
   Fang, Q
   Dang, BQ
   Shen, XM
   Shu, Z
   Zuo, G
   He, WC
   Chen, G
AF Wang, Zhong
   Fang, Qi
   Dang, Bao-Qi
   Shen, Xu-Ming
   Shu, Zhang
   Zuo, Gang
   He, Wei-Chun
   Chen, Gang
TI Potential Contribution of Matrix Metalloproteinase-9 (MMP-9) to Cerebral
   Vasospasm After Experimental Subarachnoid Hemorrhage in Rats
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE MMP-9; Subarachnoid hemorrhage; Vasospasm
ID BLOOD-BRAIN-BARRIER; RABBITS; INJURY
AB This study investigated the possible involvement of matrix metalloproteinase 9 (MMP-9) in cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rats. The CVS model was established by injection of fresh autologous nonheparinized arterial blood into the cisterna magna. Experiment 1 aimed to investigate the timecourse of the MMP-9 expression in the basilar artery after SAH. In Experiment 2, we chose the maximum time point of vasospasm (Day 3) and assessed the effect of SB-3CT (a selective MMP-9 inhibitor) on the regulation of cerebral vasospasm. The cross-sectional area of basilar artery was measured by H&E staining and the MMP-9 expression was assessed by immunohistochemistry analysis. The elevated expression of MMP-9 was detected in the basilar artery after SAH and peaked on day 3. After intracisternal administration of SB-3CT, the vasospasm was markedly attenuated after blood injection on day 3. Our results suggest that MMP-9 is increasingly expressed in a parallel time course to the development of cerebral vasospasm in this rat experimental model of SAH and that the administration of the specific MMP-9 inhibitor could prevent or reduce cerebral vasospasm caused by SAH.
C1 [Wang, Zhong; Fang, Qi; Dang, Bao-Qi; Zuo, Gang; Chen, Gang] Suzhou Univ, Affiliated Hosp 1, Dept Neurol & Neurosurg, Suzhou 215006, Peoples R China.
   [Dang, Bao-Qi; He, Wei-Chun] Zhangjiagang Hosp Tradit Chinese Med, Dept Neurosurg, Suzhou 215600, Peoples R China.
   [Shen, Xu-Ming; Shu, Zhang; Zuo, Gang] Taicang City First Peoples Hosp, Dept Neurosurg, Suzhou 215400, Peoples R China.
RP Chen, G (reprint author), Suzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Peoples R China.
EM nju_neurosurgery@163.com
FU National Natural Science Foundation of China [81171105, 81100872];
   Jiangsu Province's Outstanding Medical Academic Leader program
   [LJ201139]; special grant from the China Postdoctoral Science Foundation
   [201104540]; Education Department of Jiangsu Province [11KJB320011];
   Suzhou Government [SYS201109]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81171105 and 81100872), Jiangsu Province's
   Outstanding Medical Academic Leader program (NO. LJ201139), a special
   grant from the China Postdoctoral Science Foundation (No. 201104540),
   and grants from Education Department of Jiangsu Province (No.
   11KJB320011) and Suzhou Government (No. SYS201109).
CR Fang Q, 2009, MEDIAT INFLAMM, DOI 10.1155/2009/426346
   Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P81, DOI 10.1007/978-3-7091-0353-1_15
   Guo ZD, 2010, NEUROL SCI, V31, P143, DOI 10.1007/s10072-009-0192-x
   Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207
   McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1227/01.NEU.0000031751.23324.38
   Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203
   Rosenberg GA, 2004, E SCHERING RES FDN W, V47, P1
   Rothoerl RD, 2006, CEREBROVASC DIS, V22, P143, DOI 10.1159/000093243
   Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001
   Yin YH, 2009, AM J MED SCI, V337, P123
   Zhang BP, 2001, STROKE, V32, P2198, DOI 10.1161/hs0901.095382
   Zhou ML, 2007, J CEREBR BLOOD F MET, V27, P1583, DOI 10.1038/sj.jcbfm.9600456
   Zhou YL, 2011, ACTA NEUROCHIR SUPPL, V110, P15, DOI 10.1007/978-3-7091-0353-1_3
NR 13
TC 0
Z9 0
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD WIN
PY 2012
VL 42
IS 1
BP 14
EP 20
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 980SR
UT WOS:000306913900003
ER

PT J
AU Yu, ZQ
   Zha, JH
AF Yu, Zheng-Quan
   Zha, Ji-Hui
TI Genetic Ablation of Toll-Like Receptor 2 Reduces Secondary Brain Injury
   Caused by Cortical Contusion in Mice
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE Traumatic brain injury; Cerebral inflammation; Toll-like receptor 2
ID RAT MODEL; ACTIVATION; PROGESTERONE; INFLAMMATION; HEMORRHAGE;
   EXPRESSION; CYTOKINES
AB Previous studies have shown that Toll-like receptor 2 (TLR2) was up-regulated after traumatic brain injury (TBI), but the potential contribution of TLR2 to TBI still remains unclear. The present study investigated the role of TLR2 in modulating TBI-induced secondary brain injury in mice. Wild-type TLR2(+/+) and TLR2(-/-)-deficient mice were subjected to a moderately severe weight-drop impact head injury. Brain samples were extracted at 24 hours after trauma. We measured TLR2 by western blot; motor function by Grip test; brain edema by wet/dry method; cortical apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method; and IL-1 beta, TNF-alpha and IL-6 by enzyme-linked immunosorbent assay (ELISA). We found the absence of TLR2 function in mice resulted in ameliorating brain injury as shown by the reduced severity of neurological deficit, apoptosis, and brain edema at 24 hours after TBI, which was associated with the decreased expression of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6), compared with their wild-type counterparts after TBI. In combination, these results suggest that TLR2 might play an important aggravating role in the pathogenesis of TBI-induced secondary brain injury, possibly by regulating inflammatory cytokines in the cortex.
C1 [Yu, Zheng-Quan] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Jiangsu, Peoples R China.
   [Zha, Ji-Hui] Xuzhou Med Coll, Dept Neurosurg, Xuzhou 221002, Jiangsu, Peoples R China.
RP Yu, ZQ (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Jiangsu, Peoples R China.
EM yuzhengquan1964@gmail.com
CR Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279
   Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x
   Chen G, 2008, ANN CLIN LAB SCI, V38, P65
   Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022
   Chen G, 2009, CYTOKINE, V45, P162, DOI 10.1016/j.cyto.2008.11.015
   HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882
   Hang CH, 2005, NEUROL INDIA, V53, P312
   Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036
   Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42
   Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20
   Johnson Pauline, 2009, Crit Rev Immunol, V29, P347
   Kenny EF, 2008, CYTOKINE, V43, P342, DOI 10.1016/j.cyto.2008.07.010
   Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269
   Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181
   Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005
   Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039
   Mallard C, 2009, CLIN PERINATOL, V36, P763, DOI 10.1016/j.clp.2009.07.009
   Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3
   Palsson-McDermott EM, 2007, IRISH J MED SCI, V176, P253, DOI 10.1007/s11845-007-0103-1
   Park C, 2008, NEUROSCI LETT, V431, P123, DOI 10.1016/j.neulet.2007.11.057
   RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497
   Sen O, 2011, TURK NEUROSURG, V21, P203, DOI 10.5137/1019-5149.JTN.3646-10.1
   Yuan TM, 2010, J NEUROIMMUNOL, V229, P16, DOI 10.1016/j.jneuroim.2010.08.008
NR 23
TC 1
Z9 1
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD WIN
PY 2012
VL 42
IS 1
BP 26
EP 33
PG 8
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 980SR
UT WOS:000306913900005
ER

PT J
AU Zhang, X
   Zhao, XD
   Shi, JX
   Yin, HX
AF Zhang, Xing
   Zhao, Xu Dong
   Shi, Ji Xin
   Yin, Hong Xia
TI Inhibition of the p38 Mitogen-Activated Protein Kinase (MAPK) Pathway
   Attenuates Cerebral Vasospasm Following Experimental Subarachnoid
   Hemorrhage in Rabbits (vol 41, pg 244, 2011)
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Correction
C1 [Zhang, Xing; Shi, Ji Xin; Yin, Hong Xia] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.
   [Zhao, Xu Dong] Nanjing Med Univ, Wuxi Hosp Affiliated 2, Dept Neurosurg, Wuxi 214002, Jiangsu, Peoples R China.
RP Zhang, X (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
CR XING Z, 2011, ANN CLIN LAB SCI, V41, P244
NR 1
TC 0
Z9 0
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD WIN
PY 2012
VL 42
IS 1
BP 102
EP 102
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 980SR
UT WOS:000306913900016
ER

PT J
AU Shrestha, B
AF Shrestha, Balkrishna
TI Late Onset of Psychotic Symptoms in a Patient With Cavum Septum
   Pellucidum and Cavum Vergae
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Letter
ID SCHIZOPHRENIA
C1 Sichuan Univ, Dept Neurosurg, W China Hosp, W China Sch Med, Chengdu, Sichuan, Peoples R China.
RP Shrestha, B (reprint author), Sichuan Univ, Dept Neurosurg, W China Hosp, W China Sch Med, Chengdu, Sichuan, Peoples R China.
EM shresthabal2003@gmail.com
CR Flashman LA, 2007, PSYCHIAT RES-NEUROIM, V154, P147, DOI 10.1016/j.pscychresns.2006.09.001
   Kwon JS, 1998, AM J PSYCHIAT, V155, P509
   LEWIS SW, 1985, PSYCHOL MED, V15, P43
   Miyamori T, 1995, SURG NEUROL, V44, P471, DOI 10.1016/0090-3019(95)00339-8
   SARWAR M, 1989, AM J NEURORADIOL, V10, P989
NR 5
TC 0
Z9 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD WIN
PY 2012
VL 24
IS 1
BP E43
EP E44
PG 2
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 925AD
UT WOS:000302731500026
ER

PT J
AU Pang, MYC
   Yang, FZH
   Lau, RWK
   Cheng, AQ
   Li, LSW
   Zhang, M
AF Pang, Marco Y. C.
   Yang, Feigo Z. H.
   Lau, Ricky W. K.
   Cheng, Ada Q.
   Li, Leonard S. W.
   Zhang, Ming
TI Changes in Bone Density and Geometry of the Upper Extremities after
   Stroke: A Case Report
SO PHYSIOTHERAPY CANADA
LA English
DT Article
DE bone and bones; osteoporosis; muscles; rehabilitation; stroke
ID QUANTITATIVE COMPUTED-TOMOGRAPHY; MINERAL DENSITY; FRACTURE RISK;
   EXERCISE PROGRAM; STRENGTH INDEXES; MUSCLE STRENGTH; OSTEOPOROSIS;
   RADIUS; PQCT; ARM
AB Purpose: The purpose of this study was to examine changes in bone density and geometry of the forearm region and motor function of the paretic upper extremity in a person with subacute stroke. Client Description: The participant was a 48-year-old man with right hemiparesis. Intervention: Not applicable. Measures and Outcomes: The assessment of upper-extremity (UE) function and bone imaging took place at 3 months and 12 months after stroke. The participant had moderate motor impairment and severe disuse of the paretic UE 3 months after stroke. During the follow-up period, no substantial change in paretic UE function was observed. At the 12 month follow-up, the areal bone mineral density (aBMD) of the ultradistal and mid-regions of the paretic forearm, as measured by dual-energy X-ray absorptiometry, sustained a significant reduction of 7.9% and 5.9%, respectively. The non-paretic side, in contrast, had a significant 4.0% increase in aBMD of the mid-forearm and a 2.8% increase in aBMD of the total forearm. Significant findings from peripheral quantitative computed tomography were a reduction in total volumetric bone mineral density (-12.1%) and bone strength index (-20.6%) in the radius distal epiphysis on the paretic side and an increase in cortical bone mineral content (2.0%) and bone strength index (7.6%) in the radius diaphysis on the non-paretic side. Implications: After a stroke that resulted in moderate to severe UE impairment, a significant decline in bone mineral density was identified in various skeletal sites in the forearm region as the participant entered the subacute and chronic stages of recovery. The results point to the potential importance of early rehabilitative intervention in preventing unfavourable bone changes in the paretic upper limb among individuals with stroke.
C1 [Pang, Marco Y. C.; Yang, Feigo Z. H.; Lau, Ricky W. K.; Cheng, Ada Q.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.
   [Li, Leonard S. W.] Tung Wah Hosp, Div Rehabil Med, Hong Kong, Hong Kong, Peoples R China.
   [Zhang, Ming] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Hong Kong, Hong Kong, Peoples R China.
RP Pang, MYC (reprint author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.
EM marco.pang@inet.polyu.edu.hk
RI Zhang, Ming/F-8331-2011
FU Research Grants Council, Hong Kong [525607, 526708]; Hang Seng Bank;
   Hong Kong Polytechnic University
FX The study was supported by the General Research Funds provided by the
   Research Grants Council, Hong Kong (nos. 525607 and 526708). Ricky W.K.
   Lau was supported by the Hang Seng Bank Golden Jubilee Research
   Endowment Fund. Feigo Z.H. Yang and Ada Q. Cheng were supported by
   full-time MPhil Studentships provided by the Hong Kong Polytechnic
   University.
CR Ashe M. C., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P226
   Bohannon RW, 1997, J NEUROL REHABIL, V11, P115
   BOHANNON RW, 1987, PHYS THER, V67, P206
   Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621
   Di Monaco M, 2003, AM J PHYS MED REHABI, V82, P157, DOI 10.1097/00002060-200302000-00010
   Di Monaco M, 2003, AM J PHYS MED REHABI, V82, P149, DOI 10.1097/00002060-200302000-00010
   Di Monaco M, 2003, AM J PHYS MED REHAB, V82, P143, DOI 10.1097/01.PHM.0000046623.61944.94
   Eng JJ, 2008, J REHABIL RES DEV, V45, P297, DOI 10.1682/JRRD.2007.01.0014
   Frank AW, 2010, J MUSCULOSKEL NEURON, V10, P136
   Frost HM, 2003, J BONE MINER METAB, V21, P255, DOI 10.1007/s00774-003-0418-6
   Hangartner TN, 1996, J BONE MINER RES, V11, P1518
   Hayes W, 1997, BIOMECHANICS CORTICA
   Jorgensen L, 2001, CALCIFIED TISSUE INT, V68, P11, DOI 10.1007/BF02684997
   Kanis J, 2001, STROKE, V32, P702
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198-004-1811-2
   Kontulainen S, 2002, J BONE MINER RES, V17, P2281, DOI 10.1359/jbmr.2002.17.12.2281
   Kontulainen S. A., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P401
   Lazoura O, 2008, J CLIN DENSITOM, V11, P511, DOI 10.1016/j.jocd.2008.05.097
   Leonard M. B., 2003, PRIMER METABOLIC BON, P173
   Liu MG, 1999, ARCH PHYS MED REHAB, V80, P1219, DOI 10.1016/S0003-9993(99)90019-9
   Lochmuller EM, 2002, J BONE MINER RES, V17, P1629, DOI 10.1359/jbmr.2002.17.9.1629
   MacDonald H, 2006, BONE, V39, P598, DOI 10.1016/j.bone.2006.02.057
   Melton LJ, 2001, CALCIFIED TISSUE INT, V69, P179, DOI 10.1007/s00223-001-1043-9
   Pang MYC, 2006, OSTEOPOROSIS INT, V17, P1615, DOI 10.1007/s00198-006-0168-0
   Pang MYC, 2008, J BONE MINER RES, V23, P1023, DOI 10.1359/JBMR.080224
   Pang MYC, 2010, NEUROREHAB NEURAL RE, V24, P368, DOI 10.1177/1545968309353326
   Pang MYC, 2005, J AM GERIATR SOC, V53, P1667, DOI 10.1111/j.1532-5415.2005.53521.x
   Pang MYC, 2007, OSTEOPOROSIS INT, V18, P1243, DOI 10.1007/s00198-007-0372-6
   Pang MYC, 2005, BONE, V37, P103, DOI 10.1016/j.bone.2005.03.009
   Poole KES, 2002, STROKE, V33, P1432, DOI 10.1161/01.STR.0000014510.48897.7D
   Ramnemark A, 1999, OSTEOPOROSIS INT, V9, P269, DOI 10.1007/s001980050147
   Ramnemark A, 2000, STROKE, V31, P1572
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Ramnemark A, 1999, STROKE, V30, P755
   SANFORD J, 1993, PHYS THER, V73, P447
   Stevenson MD, 2006, WOMENS HLTH MED, V3, P149, DOI 10.1383/wohm.2006.3.4.149
   Stratec Medizintechnik Gmb H, 2004, XCT 3000 MAN SOFTW V
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K
   van der Lee JH, 2004, STROKE, V35, P1410, DOI 10.1161/01.STR.0000126900.24964.7e
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140-6736(00)02217-0
   Whitson HE, 2006, J AM GERIATR SOC, V54, P1082, DOI 10.1111/j.1532-5415.2006.00769.x
   Wilhelm G, 1999, MUSCULOSKELETAL INTE, V11, P105
   Yavuzer G, 2002, INT J REHABIL RES, V25, P235, DOI 10.1097/00004356-200209000-00010
NR 43
TC 0
Z9 0
PU UNIV TORONTO PRESS INC
PI TORONTO
PA JOURNALS DIVISION, 5201 DUFFERIN ST, DOWNSVIEW, TORONTO, ON M3H 5T8,
   CANADA
SN 0300-0508
J9 PHYSIOTHER CAN
JI Physiother. Can.
PD WIN
PY 2012
VL 64
IS 1
BP 88
EP 97
DI 10.3138/ptc.2010-34
PG 10
WC Rehabilitation
SC Rehabilitation
GA 903EF
UT WOS:000301098200013
ER

PT J
AU Wang, HY
   Shih, TTF
   Wang, JS
   Shiau, YY
   Chen, YJ
AF Wang, Huey-Yuan
   Shih, Tiffany Ting-Fang
   Wang, Juo-Song
   Shiau, Yuh-Yuan
   Chen, Yunn-Jy
TI Temporomandibular Joint Structural Derangement and General Joint
   Hypermobility
SO JOURNAL OF OROFACIAL PAIN
LA English
DT Article
DE Beighton score; general joint hypermobility; internal derangement;
   temporomandibular joint
ID ASYMPTOMATIC VOLUNTEERS; INTERNAL DERANGEMENTS; DISK DISPLACEMENT;
   DISORDERS; MOBILITY; RELIABILITY; OSTEOARTHROSIS; LAXITY
AB Aim: To explore the relationship between general joint hypermobility (GIN) and displacement of the temporomandibular joint (TMJ) disc as evident from magnetic resonance imaging (MRI). Methods: Fifth finger extension, thumb apposition, elbow extension, knee extension, trunk flexion, and ankle dorsiflexion were measured in 66 young female patients with MRI-evident TMJ internal derangement (ID) and in 30 age-matched female controls. The Beighton score of each subject was measured quantitatively. The possible association between TMJ ID and mobility of a single joint or index of GIN, ie, the Beighton score, were assessed with one-way ANOVA with post-hoc Bonferroni and chi-square test, respectively. Correlations of the mobility of every measured joint were also explored. Results: Very few of the TMJ ID patients and control subjects were diagnosed with GJH according to the Beighton score. The Beighton score did not differentiate between subjects with and without TMJ ID. Subjects with TMJ ID, especially patients with MRI-evident disc displacement without reduction, seemed to have a stiffer trunk than controls, but this may not be of clinical relevance. The mobilities of paired joints were significantly correlated; however; the mobilities of different anatomical joints seemed to be independent. Conclusion: Based on the Beighton score, GJH does not seem to be a reliable indicator of the presence of TMJ ID. J OROFAC PAIN 2012;26:33-38
C1 [Chen, Yunn-Jy] Natl Taiwan Univ, Sch Dent, Med Coll & Hosp, Natl Taiwan Univ Hosp, Taipei 100, Taiwan.
   [Wang, Huey-Yuan] Mackay Mem Hosp, Dept Dent, Taipei, Taiwan.
   [Wang, Huey-Yuan] Mackay Med Nursing & Management Coll, Taipei, Taiwan.
   [Shih, Tiffany Ting-Fang] Natl Taiwan Univ, Dept Radiol & Med Image, Med Coll & Hosp, Taipei 100, Taiwan.
   [Shiau, Yuh-Yuan] China Med Univ, Sch Dent, Taichung, Taiwan.
RP Chen, YJ (reprint author), Natl Taiwan Univ, Sch Dent, Med Coll & Hosp, Natl Taiwan Univ Hosp, 1 Chang Te St, Taipei 100, Taiwan.
EM chenyj@ntu.edu.tw
CR Artero EG, 2010, SCAND J MED SCI SPOR, V20, P418, DOI 10.1111/j.1600-0838.2009.00959.x
   BATES RE, 1984, J AM DENT ASSOC, V109, P446
   Bauss O, 2004, ORAL SURG ORAL MED O, V97, P592, DOI 10.1016/j.tripleo.2003.10.024
   BEIGHTON P, 1973, ANN RHEUM DIS, V32, P413, DOI 10.1136/ard.32.5.413
   Conti PCR, 2000, CRANIO, V18, P192
   De Coster PJ, 2005, J OROFAC PAIN, V19, P47
   DIJKSTRA PU, 1994, CRANIO, V12, P52
   DIJKSTRA PU, 1992, CRANIO, V10, P221
   DIJKSTRA PU, 1994, CRANIO, V12, P149
   DIJKSTRA PU, 1993, CRANIO, V11, P268
   Dijkstra PU, 2002, J DENT RES, V81, P158
   Emshoff R, 2002, J ORAL MAXIL SURG, V60, P36, DOI 10.1053/joms.2002.29071
   Grahame R, 2000, J RHEUMATOL, V27, P1777
   Katzberg RW, 1993, DIAGNOSIS TEMPOROMAN, P3
   Katzberg RW, 2005, J ORAL MAXIL SURG, V63, P1155, DOI 10.1016/j.joms.2005.04.012
   KIRCOS LT, 1987, J ORAL MAXIL SURG, V45, P852, DOI 10.1016/0278-2391(87)90235-7
   Okeson JP, 1996, OROFACIAL PAIN GUIDE, P244
   Perrini Frederico, 1997, Journal of Orofacial Pain, V11, P215
   Pinkert R, 1999, Mund Kiefer Gesichtschir, V3, P213, DOI 10.1007/s100060050133
   Ribeiro Rejane F., 1997, Journal of Orofacial Pain, V11, P37
   Scapino RP, 1997, SCI PRACTICE OCCLUSI, P220
   Saez-Yuguero MD, 2009, ORAL SURG ORAL MED O, V107, pE54, DOI 10.1016/j.tripleo.2009.02.021
   Slater JJRH, 2004, J OROFAC PAIN, V18, P138
   TALLENTS RH, 1993, J PROSTHET DENT, V69, P298, DOI 10.1016/0022-3913(93)90110-A
   Wang HY, 2007, J OROFAC PAIN, V21, P143
   WATKINS MA, 1991, PHYS THER, V71, P90
   WESTESSON PL, 1989, ORAL SURG ORAL MED O, V68, P551, DOI 10.1016/0030-4220(89)90236-3
   WESTLING L, 1989, ACTA ODONTOL SCAND, V47, P293, DOI 10.3109/00016358909007715
   Zhang Juan, 2009, Zhonghua Kou Qiang Yi Xue Za Zhi, V44, P598
NR 29
TC 0
Z9 0
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 1064-6655
J9 J OROFAC PAIN
JI J. Orofac. Pain
PD WIN
PY 2012
VL 26
IS 1
BP 33
EP 38
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 893CW
UT WOS:000300334200005
ER

PT J
AU Wang, YY
   Lehuede, C
   Laurent, V
   Dirat, B
   Dauvillier, S
   Bochet, L
   Le Gonidec, S
   Escourrou, G
   Valet, P
   Muller, C
AF Wang, Yuan-Yuan
   Lehuede, Camille
   Laurent, Victor
   Dirat, Beatrice
   Dauvillier, Stephanie
   Bochet, Ludivine
   Le Gonidec, Sophie
   Escourrou, Ghislaine
   Valet, Philippe
   Muller, Catherine
TI Adipose tissue and breast epithelial cells: A dangerous dynamic duo in
   breast cancer
SO CANCER LETTERS
LA English
DT Review
DE Adipose tissue; Breast cancer; Microenvironment; Obesity; Inflammation
ID MURINE MAMMARY-CARCINOMA; MESENCHYMAL STEM-CELLS; OF-THE-LITERATURE;
   IN-VIVO; TUMOR STROMA; FAT PADS; ADIPOCYTE DIFFERENTIATION; AROMATASE
   EXPRESSION; GENE-EXPRESSION; GLAND GROWTH
AB Among the many different cell types surrounding breast cancer cells, the most abundant are those that compose mammary adipose tissue, mainly mature adipocytes and progenitors. New accumulating recent evidences bring the tumor-surrounding adipose tissue into the light as a key component of breast cancer progression. The purpose of this review is to emphasize the role that adipose tissue might play by locally affecting breast cancer cell behavior and subsequent clinical consequences arising from this dialog. Two particular clinical aspects are addressed: obesity that was identified as an independent negative prognostic factor in breast cancer and the oncological safety of autologous fat transfer used in reconstructive surgery for breast cancer patients. This is preceded by the overall description of adipose tissue composition and function with special emphasis on the specificity of adipose depots and the species differences, key experimental aspects that need to be taken in account when cancer is considered. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Wang, Yuan-Yuan; Lehuede, Camille; Laurent, Victor; Dirat, Beatrice; Dauvillier, Stephanie; Bochet, Ludivine] CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France.
   [Wang, Yuan-Yuan; Lehuede, Camille; Laurent, Victor; Dirat, Beatrice; Dauvillier, Stephanie; Bochet, Ludivine; Le Gonidec, Sophie; Valet, Philippe; Muller, Catherine] Univ Toulouse, UPS, IPBS, F-31077 Toulouse, France.
   [Wang, Yuan-Yuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China.
   [Lehuede, Camille; Dirat, Beatrice; Bochet, Ludivine; Le Gonidec, Sophie; Valet, Philippe] INSERM, U1048, Inst Natl Sante & Rech Med, F-31432 Toulouse, France.
   [Escourrou, Ghislaine] Hop Rangueil, Serv Anatomo Pathol, F-31403 Toulouse, France.
RP Muller, C (reprint author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne,BP 64182, F-31077 Toulouse, France.
EM catherine.muller@ipbs.fr
RI Serrano, Luis/B-5905-2008
FU French National Cancer Institute [INCA PL 2006-035, PL 2010-214]; Ligue
   Regionale contre le Cancer; Fondation de France; University of Toulouse;
   Ligue Nationale contre le Cancer
FX Studies performed in our laboratories were supported by the French
   National Cancer Institute (INCA PL 2006-035 to GE, PV and CM and INCA PL
   2010-214 to PV and CM), the 'Ligue Regionale contre le Cancer' (Comite
   du Lot et Haute-Garonne to CM), the Fondation de France (to PV and CM)
   and the University of Toulouse (AO CS 2009 to CM). CL is a recipient of
   a PhD fellowship from the "Ligue Nationale contre le Cancer". The
   authors would like to thank Dr Max Lafontan and Pr Jean-Yves Petit for
   critical reading of the manuscript.
CR Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923
   Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05.1231
   Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254
   Behan JW, 2009, CANCER RES, V69, P7867, DOI 10.1158/0008-5472.CAN-09-0800
   Berstein LM, 2007, INT J CANCER, V121, P514, DOI 10.1002/ijc.22552
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328
   Bochet L, 2011, BIOCHEM BIOPH RES CO, V411, P102, DOI 10.1016/j.bbrc.2011.06.101
   Boucher J, 2005, ENDOCRINOLOGY, V146, P1764, DOI 10.1210/en.2004-1427
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200
   Chan CW, 2008, J PLAST RECONSTR AES, V61, P1438, DOI 10.1016/j.bjps.2008.08.006
   Chandler EM, 2011, PHYS BIOL, V8, DOI 10.1088/1478-3975/8/1/015008
   Coleman SR, 2001, CLIN PLAST SURG, V28, P111
   Couldrey C, 2002, DEV DYNAM, V223, P459, DOI 10.1002/dvdy.10065
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Dalmas E, 2011, TRENDS IMMUNOL, V32, P307, DOI 10.1016/j.it.2011.04.008
   Devarajan E., 2011, INT J CANC
   Dirat B, 2010, ENDOCRIN DEV, V19, P45
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323
   Dogan S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1840
   Donnenberg VS, 2010, TISSUE ENG PART B-RE, V16, P567, DOI 10.1089/ten.teb.2010.0352
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   El-Haibi CP, 2010, J MAMMARY GLAND BIOL, V15, P399, DOI 10.1007/s10911-010-9196-7
   ELLIOTT BE, 1992, INT J CANCER, V51, P416, DOI 10.1002/ijc.2910510314
   Ewertz M, 2011, J CLIN ONCOL, V29, P25, DOI 10.1200/JCO.2010.29.7614
   Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634
   Finley DS, 2009, J UROLOGY, V182, P1621, DOI 10.1016/j.juro.2009.06.015
   Fischbach C, 2004, EXP CELL RES, V300, P54, DOI 10.1016/j.yexcr.2004.05.036
   Fleming JM, 2010, J CELL PHYSIOL, V224, P795, DOI 10.1002/jcp.22190
   Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316
   Gehmert S, 2010, BIOCHEM BIOPH RES CO, V398, P601, DOI 10.1016/j.bbrc.2010.06.132
   Gerlach JC, 2012, TISSUE ENG PART C-ME, V18, P54, DOI 10.1089/ten.tec.2011.0216
   Gesta S, 2003, HORM METAB RES, V35, P158, DOI 10.1055/s-2003-39070
   GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119
   Griggs JJ, 2008, J CLIN ONCOL, V26, P4060, DOI 10.1200/JCO.2008.17.4250
   Hovey RC, 2010, J MAMMARY GLAND BIOL, V15, P279, DOI 10.1007/s10911-010-9187-8
   Hovey RC, 1999, J MAMMARY GLAND BIOL, V4, P53, DOI 10.1023/A:1018704603426
   Irigaray P, 2007, BIOMED PHARMACOTHER, V61, P665, DOI 10.1016/j.biopha.2007.10.008
   Iyengar P, 2005, J CLIN INVEST, V115, P1163, DOI 10.1172/JCI200523424
   Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737
   Jarde T, 2011, EUR J CANCER, V47, P33, DOI 10.1016/j.ejca.2010.09.005
   Jotzu C, 2011, CELL ONCOL, V34, P55, DOI 10.1007/s13402-011-0012-1
   Kaneko A, 2010, INT J UROL, V17, P369, DOI 10.1111/j.1442-2042.2010.02472.x
   Kim EJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2927
   Kim JH, 2008, CANCER LETT, V261, P253, DOI 10.1016/j.canlet.2007.11.020
   Kim KY, 2009, ONCOL REP, V22, P1497, DOI 10.3892/or_00000593
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Lafontan M, 2009, PROG LIPID RES, V48, P275, DOI 10.1016/j.plipres.2009.05.001
   Lafontan M, 1998, Adv Pharmacol, V42, P496
   Lafontan M, 2012, AM J PHYSIOL-CELL PH, V302, pC327, DOI 10.1152/ajpcell.00168.2011
   Ligibel J, 2011, ONCOLOGY-NY, V25, P994
   Lohsiriwat Visnu, 2011, Breast, V20, P351
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430
   Mandrup S, 1997, P NATL ACAD SCI USA, V94, P4300, DOI 10.1073/pnas.94.9.4300
   Mantovani A, 2007, BREAST, V16, pS27, DOI 10.1016/j.breast.2007.07.013
   Martin-Padura I, 2012, CANCER RES, V72, P325, DOI 10.1158/0008-5472.CAN-11-1739
   Meng L, 2001, CANCER RES, V61, P2250
   Meulle A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003345
   Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110
   Muehlberg FL, 2009, CARCINOGENESIS, V30, P589, DOI 10.1093/carcin/bgp036
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Olumi AF, 1999, CANCER RES, V59, P5002
   Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921
   Park J, 2011, ENDOCR REV, V32, P550, DOI 10.1210/er.2010-0030
   Petit JY, 2012, ANN ONCOL, V23, P582, DOI 10.1093/annonc/mdr158
   Pinilla S, 2009, CANCER LETT, V284, P80, DOI 10.1016/j.canlet.2009.04.013
   Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912
   Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244
   Proia DA, 2006, NAT PROTOC, V1, P206, DOI 10.1038/nprot.2006.31
   Rose DP, 2010, MATURITAS, V66, P33, DOI 10.1016/j.maturitas.2010.01.019
   Saint-Cyr M, 2012, J RECONSTR MICROSURG, V28, P99, DOI 10.1055/s-0031-1287675
   Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381
   Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887
   Sun XZ, 2012, BREAST CANCER RES TR, V131, P1003, DOI 10.1007/s10549-011-1789-3
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068
   Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130
   Welte G., 2011, MOL CARCINOG
   Yamaguchi J, 2008, AM J CLIN PATHOL, V130, P382, DOI 10.1309/MX6KKA1UNJ1YG8VN
   Yu JM, 2008, STEM CELLS DEV, V17, P463, DOI 10.1089/scd.2007.0181
   Zhao M, 2010, MOL CARCINOGEN, V49, P923, DOI 10.1002/mc.20675
NR 83
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2012
VL 324
IS 2
BP 142
EP 151
DI 10.1016/j.canlet.2012.05.019
PG 10
WC Oncology
SC Oncology
GA 992RI
UT WOS:000307797000004
ER

PT J
AU Ni, XL
   Yang, JX
   Li, M
AF Ni, Xiaoling
   Yang, Jingxuan
   Li, Min
TI Imaging-guided curative surgical resection of pancreatic cancer in a
   xenograft mouse model
SO CANCER LETTERS
LA English
DT Article
DE Pancreatic cancer; Distal pancreatectomy; Mouse model; Combinational
   therapy; Surgical resection; Imaging
ID TUMOR-INITIATING CELLS; RECTAL-CANCER; DUCTAL ADENOCARCINOMA;
   RANDOMIZED-TRIAL; COOPERATE; MICE; CHEMORADIOTHERAPY; RADIOTHERAPY;
   RECURRENCE; EXPRESSION
AB Pancreatic cancer is the fourth leading cause of cancer related deaths in North America. The poor survival statistics are due to the fact that there are no reliable tests for early diagnosis and no effective therapies once metastasis has occurred. Surgical resection is the only curative treatment for pancreatic cancer; however, only less than 15% of the patients are eligible for surgery at diagnosis. New therapies are urgently needed for this malignant disease. And combinational therapy including surgery, chemotherapy and molecular targeted therapy may further improve the efficacy of individual therapies. However, a reliable mouse model which mimics the human disease and can be used for testing the surgical treatment and surgery-based combinational therapy is not available. In this study, we have established a mouse model for curative surgical resection of pancreatic cancer. Human pancreatic cancer cells were used to create orthotopic xenografts in nude mice, distal pancreatectomy was performed using imaging-guided technology to remove the pancreatic tumors, and sham surgery was performed in the control group. All mice survived the operation and no complication was observed. Surgical resection at early stage improved the survival rate and quality of life of the mice compared with the sham surgery and surgical resection at the late stage. If combined with other therapies such as chemotherapy and molecular targeted therapy, it could further improve the outcome of pancreatic cancer. This mouse model is a useful tool to study the surgical therapy and the tumor recurrence of pancreatic cancer, and could potentially impact the therapeutic choices for this deadly disease. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Ni, Xiaoling; Yang, Jingxuan; Li, Min] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
   [Ni, Xiaoling] Fudan Univ, Shanghai Med Coll, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China.
RP Li, M (reprint author), Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, 6431 Fannin St,MSE R266, Houston, TX 77030 USA.
EM Minli@uth.tmc.edu
FU National Institutes of Health (NIH) [R01CA138701, R21CA133604];
   MacDonald Research Fund; William and Ella Owens Medical Research
   Foundation
FX This work was supported in part by the National Institutes of Health
   (NIH) Grants R01CA138701, R21CA133604, the MacDonald Research Fund, and
   the William and Ella Owens Medical Research Foundation (Li M.).
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Bujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506
   CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531
   Eibl G, 2005, PANCREAS, V31, P258, DOI 10.1097/01.mpa.0000175176.40045.0f
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017
   Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816
   Kim JS, 2009, ANN SURG ONCOL, V16, P1266, DOI 10.1245/s10434-009-0338-3
   Li M, 2007, P NATL ACAD SCI USA, V104, P18636, DOI 10.1073/pnas.0709307104
   Li M, 2009, CLIN CANCER RES, V15, P5993, DOI 10.1158/1078-0432.CCR-09-0557
   Liu SH, 2011, CANCER-AM CANCER SOC, V117, P723, DOI 10.1002/cncr.25629
   Liu SH, 2008, PANCREAS, V37, P210
   Long J, 2011, EXPERT OPIN THER TAR, V15, P817, DOI 10.1517/14728222.2011.566216
   Ni XL, 2012, J CELL MOL MED, V16, P988, DOI 10.1111/j.1582-4934.2011.01478.x
   Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467
   Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0
   Shi S, 2012, CANCER LETT, V317, P127, DOI 10.1016/j.canlet.2011.11.029
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   TAN MH, 1985, TUMOUR BIOL, V6, P89
   TAN MH, 1981, J NATL CANCER I, V67, P563
   Torgenson MJ, 2008, J SURG RES, V149, P57, DOI 10.1016/j.jss.2007.08.024
   Wong RKS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002102.pub2
   Yu XJ, 2010, BBA-REV CANCER, V1805, P97, DOI 10.1016/j.bbcan.2009.10.001
   Zhang YQ, 2010, CLIN CANCER RES, V16, P1423, DOI 10.1158/1078-0432.CCR-09-2405
   Zhang YQ, 2010, CANCER BIOL THER, V9, P235
NR 26
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2012
VL 324
IS 2
BP 179
EP 185
DI 10.1016/j.canlet.2012.05.013
PG 7
WC Oncology
SC Oncology
GA 992RI
UT WOS:000307797000008
ER

PT J
AU Long, MJ
   Wu, FX
   Li, P
   Liu, M
   Li, X
   Tang, H
AF Long, Mei-Jing
   Wu, Fu-Xia
   Li, Pu
   Liu, Min
   Li, Xin
   Tang, Hua
TI MicroRNA-10a targets CHL1 and promotes cell growth, migration and
   invasion in human cervical cancer cells
SO CANCER LETTERS
LA English
DT Article
DE MicroRNA-10a; CHL1; Cervical cancer; Migration; Invasion
ID ADHESION MOLECULES; BREAST-CANCER; TUMOR-GROWTH; IN-VITRO; METASTASIS;
   EXPRESSION; FAMILY; TUMORIGENESIS; PROGRESSION; MECHANISM
AB MicroRNAs (miRNAs) play an important role in cancer initiation, progression and metastasis by regulating their target genes. Here, we found microRNA-10a (miR-10a) is upregulated in human cervical cancer and promotes the colony formation activity, migration and invasion of HeLa and C33A cells. Subsequently. CHL1 is confirmed as a target of miR-10a and is negatively regulated by miR-10a at mRNA and protein levels. Furthermore, knockdown of CHL1 expression results in increased colony formation activity, migration and invasion. Finally, overexpression of CHL1 lacked the 3'UTR abolished the effects of miR-10a. Our results may provide a strategy for blocking tumor metastasis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Long, Mei-Jing; Wu, Fu-Xia; Liu, Min; Li, Xin; Tang, Hua] Tianjin Med Univ, Tianjin Life Sci Res Ctr, Tianjin, Peoples R China.
   [Long, Mei-Jing; Wu, Fu-Xia; Liu, Min; Li, Xin; Tang, Hua] Tianjin Med Univ, Basic Med Sch, Tianjin, Peoples R China.
   [Li, Pu] Tianjin Cent Hosp Gynecol Obstet, Tianjin, Peoples R China.
RP Tang, H (reprint author), Tianjin Med Univ, Tianjin Life Sci Res Ctr, Tianjin, Peoples R China.
EM htang2002@yahoo.com
FU National Foundation of China [30873017, 31071191, 91029714]
FX We thank the Cancer Center of Sun Yat-sen University of Medical Sciences
   for providing the cervical cancer tissues. We also thank the College of
   Public Health of Tianjin Medical University for the technical assistance
   in fluorescence detection. This work was supported by the National
   Foundation of China (Nos. 30873017, 31071191, 91029714).
CR Albulescu R, 2011, EXPERT REV MOL DIAGN, V11, P101, DOI 10.1586/ERM.10.106
   Ango F, 2008, PLOS BIOL, V6, P739, DOI 10.1371/journal.pbio.0060103
   Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bueno MJ, 2008, CELL CYCLE, V7, P3143, DOI 10.4161/cc.7.20.6833
   Cho WCS, 2010, BBA-REV CANCER, V1805, P209, DOI 10.1016/j.bbcan.2009.11.003
   Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014
   Demyanenko GP, 2010, NEUROSCIENCE, V165, P107, DOI 10.1016/j.neuroscience.2009.09.077
   Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4
   Gandellini P, 2011, EXPERT OPIN THER TAR, V15, P265, DOI 10.1517/14728222.2011.550878
   Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869
   Gavert N., 2010, MOL CANCER RES, V9, P14
   Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027
   Greenberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018936
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Huang X, 2011, MOL CELL NEUROSCI, V46, P296, DOI 10.1016/j.mcn.2010.09.013
   Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233
   Jung J, 2011, ONCOL REP, V25, P945, DOI 10.3892/or.2011.1181
   Kang HW, 2012, FEBS LETT, V586, P897, DOI 10.1016/j.febslet.2012.02.020
   Li YP, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-34
   Li Z., 2012, CANC LETT
   Liu HL, 2011, J BIOL CHEM, V286, P797, DOI 10.1074/jbc.M110.180281
   Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003
   Lynam-Lennon N, 2009, BIOL REV, V84, P55, DOI 10.1111/j.1469-185X.2008.00061.x
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Peng RQ, 2012, J BIOL CHEM, V287, P14301, DOI 10.1074/jbc.M111.337642
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Qiang R, 2011, INT J BIOCHEM CELL B, V43, P632, DOI 10.1016/j.biocel.2011.01.002
   Raveh S, 2009, CANCER LETT, V282, P137, DOI 10.1016/j.canlet.2008.12.021
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010
   Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274
   Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006
   Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612
   Shi M, 2010, CANCER METAST REV, V29, P785, DOI 10.1007/s10555-010-9265-9
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Tam GWC, 2010, BIOCHEM SOC T, V38, P445, DOI 10.1042/BST0380445
   Tian RQ, 2011, J BIOL CHEM, V286, P25556, DOI 10.1074/jbc.M111.221564
   Tischler V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-127
   Tsutsumi S, 2011, J SURG ONCOL, V103, P669, DOI 10.1002/jso.21880
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang FF, 2011, AM J PATHOL, V179, P2580, DOI 10.1016/j.ajpath.2011.07.037
   Wei MH, 1998, HUM GENET, V103, P355, DOI 10.1007/s004390050829
   Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065
   Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724
   Wilmott JS, 2011, PATHOLOGY, V43, P657, DOI 10.1097/PAT.0b013e32834a7358
   Xu J., 2012, ONCOGENE
   Xu X. M., 2012, CANC LETT
   Yang Weining, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P140
   Yang ZZ, 2009, IUBMB LIFE, V61, P1075, DOI 10.1002/iub.252
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 55
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2012
VL 324
IS 2
BP 186
EP 196
DI 10.1016/j.canlet.2012.05.022
PG 11
WC Oncology
SC Oncology
GA 992RI
UT WOS:000307797000009
ER

PT J
AU Yuan, QY
   Cai, SX
   Zhang, XN
   Liu, ZW
   Li, ZM
   Luo, XL
   Xiong, CM
   Wang, JP
   Hu, JB
   Ruan, J
AF Yuan, Qianying
   Cai, Shaoxin
   Zhang, Xuenong
   Liu, Ziwei
   Li, Zhaoming
   Luo, Xuelai
   Xiong, Chaomei
   Wang, Jianping
   Hu, Junbo
   Ruan, Jinlan
TI A new protoapigenone analog RY10-4 induces apoptosis and suppresses
   invasion through the PI3K/Akt pathway in human breast cancer
SO CANCER LETTERS
LA English
DT Article
DE RY10-4; Breast cancer; Anti-tumor; PI3K/Akt
ID PHOSPHOINOSITIDE 3-KINASE PATHWAY; NF-KAPPA-B; SIGNALING PATHWAYS;
   PROSTATE-CANCER; G(2)/M ARREST; CELLS; AKT; GROWTH; PTEN; GENE
AB RY10-4, a novel protoapigenone analog, shows potent cytotoxicity against a broad spectrum of human cancer cells. Here we investigate its anti-tumor activity on breast cancer. The results indicated that RY10-4 suppressed proliferation, arrested cell cycle, induced apoptosis and inhibited invasion in MDA-MB-231, MCF-7 and SKBR3 breast cancer cells. Western blot analysis showed that RY10-4 down-regulated the PI3K/Akt signaling pathway and inhibited doxorubicin-induced p-Akt. Moreover, it effectively suppressed tumor growth in mice without major side effects. Therefore. RY10-4 had potential anti-tumor activity, and could be used as a lead to design more potent derivatives. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Yuan, Qianying; Zhang, Xuenong; Liu, Ziwei; Xiong, Chaomei; Wang, Jianping; Ruan, Jinlan] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Key Lab Nat Med Chem & Resources Evaluat Hubei Pr, Wuhan 430030, Peoples R China.
   [Cai, Shaoxin; Li, Zhaoming; Luo, Xuelai; Hu, Junbo] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Mol Med Ctr, Wuhan 430030, Peoples R China.
RP Hu, JB (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Key Lab Nat Med Chem & Resources Evaluat Hubei Pr, Wuhan 430030, Peoples R China.
EM jbhu@tjh.tjmu.edu.cn; jinlan8152@163.com
FU National Nature Science Foundation of China [81173093]; Nature Science
   Foundation of Hubei Province [2009CDA067]
FX This research was supported by a Grant (No. 81173093) from the National
   Nature Science Foundation of China and a Grant (No. 2009CDA067) from the
   Nature Science Foundation of Hubei Province. Besides, the authors would
   like to thank professor Yung-Chi Cheng of Yale University for providing
   us with a good environment and facilities to finally complete this
   project. Also, we would like to take this opportunity to thank Elizabeth
   Gullen, Lam Wing, Amanda Wong Hui Chyn and Longbo Zhang for their
   valuable comments on this paper.
CR Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100
   BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412
   Brognard J, 2001, CANCER RES, V61, P3986
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chang HL, 2008, CANCER LETT, V267, P85, DOI 10.1016/j.canlet.2008.03.007
   Chen B, 2009, BIOCHEM PHARMACOL, V77, P1787, DOI 10.1016/j.bcp.2009.03.015
   Chen H.M., FREE RADIC BIOL MED, V50, P1151
   Chiu CC, 2009, DNA CELL BIOL, V28, P501, DOI 10.1089/dna.2009.0852
   Clark AS, 2002, MOL CANCER THER, V1, P707
   Dan S, 2009, BIOCHEM BIOPH RES CO, V379, P104, DOI 10.1016/j.bbrc.2008.12.015
   De Laurentiis A, 2011, CELL SIGNAL, V23, P529, DOI 10.1016/j.cellsig.2010.10.021
   Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Huang CY, 2009, BIOCHEM PHARMACOL, V77, P794, DOI 10.1016/j.bcp.2008.11.014
   Huang XH, 2010, PHYTOMEDICINE, V17, P930, DOI 10.1016/j.phymed.2010.03.006
   Jakubikova J, 2005, BIOCHEM PHARMACOL, V69, P1543, DOI 10.1016/j.bcp.2005.03.015
   Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008
   Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com
   Krystal GW, 2002, MOL CANCER THER, V1, P913
   Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304
   Li G, 2002, DEVELOPMENT, V129, P4159
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lin AS, 2005, PLANTA MED, V71, P867, DOI 10.1055/s-2005-871292
   Lin AS, 2007, J MED CHEM, V50, P3921, DOI 10.1021/jm070363a
   Liu HB, 2011, EUR J PHARMACOL, V654, P209, DOI 10.1016/j.ejphar.2010.12.036
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044
   Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019
   Moon DO, 2008, CANCER LETT, V264, P181, DOI 10.1016/j.canlet.2008.01.032
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Sousa LP, 2009, BIOCHEM PHARMACOL, V78, P396, DOI 10.1016/j.bcp.2009.04.030
   STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Suzuki H, 1998, CANCER RES, V58, P204
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839
   Wang J, 2009, CANCER LETT, V283, P193, DOI 10.1016/j.canlet.2009.03.039
   Yamamoto S, 2004, CLIN CANCER RES, V10, P2846, DOI 10.1158/1078-0432.CCR-02-1441
   Yeo EJ, 2003, J NATL CANCER I, V95, P516
   Yuan QY, 2011, BIOORG MED CHEM LETT, V21, P3427, DOI 10.1016/j.bmcl.2011.03.108
NR 45
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2012
VL 324
IS 2
BP 210
EP 220
DI 10.1016/j.canlet.2012.05.025
PG 11
WC Oncology
SC Oncology
GA 992RI
UT WOS:000307797000011
ER

PT J
AU Guo, H
   Li, MH
   Chen, P
   Blake, DJ
   Kong, XN
   Hao, XS
   Niu, RF
   Zhang, N
AF Guo, Hua
   Li, Menghui
   Chen, Peng
   Blake, David J.
   Kong, Xiaoni
   Hao, Xishan
   Niu, Ruifang
   Zhang, Ning
TI 4-Methyl-3-nitro-benzoic acid, a migration inhibitor, prevents breast
   cancer metastasis in SCID mice (vol 305, pg 69, 2011)
SO CANCER LETTERS
LA English
DT Correction
C1 [Guo, Hua; Li, Menghui; Chen, Peng; Blake, David J.; Kong, Xiaoni; Hao, Xishan; Niu, Ruifang; Zhang, Ning] Tianjin Med Univ, Canc Inst & Hosp, Res Ctr Basic Med Sci, Tianjin 300060, Peoples R China.
RP Zhang, N (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Res Ctr Basic Med Sci, Tianjin 300060, Peoples R China.
EM nzhangchina@yahoo.com
CR HUA G, 2011, CANCER LETT, V305, P69, DOI DOI 10.1016/J.CANLET.2011.02.028
NR 1
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD NOV 28
PY 2012
VL 324
IS 2
BP 232
EP 232
DI 10.1016/j.canlet.2011.08.005
PG 1
WC Oncology
SC Oncology
GA 992RI
UT WOS:000307797000014
ER

PT J
AU Dou, JF
   Xu, WY
   Ye, B
   Zhang, Y
   Mao, WL
AF Dou, JiuFeng
   Xu, WeiYi
   Ye, Bo
   Zhang, Yi
   Mao, WeiLin
TI Serum vitamin B12 levels as indicators of disease severity and mortality
   of patients with acute-on-chronic liver failure
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Vitamin B12; Acute-on-chronic liver failure (AoCLF); Mortality
ID HEPATOCELLULAR-CARCINOMA; COBALAMIN VITAMIN-B12; HEPATITIS-B;
   FOLIC-ACID; ASSOCIATION; SYSTEM; BLOOD
AB Background: The study was designed to investigate the association between vitamin B12 levels and patients with acute-on-chronic liver failure (AoCLF). In addition, we analyzed whether B12 is associated with mortality in the AoCLF patients.
   Methods: One hundred five patients with AoCLF and 44 healthy controls (HCs) were prospectively studied. In all subjects, a blood sample was collected at admission to examine liver function, renal function, international normalized ratio and B12 levels. A total of 9 clinical chemistry and biochemical variables were analyzed for possible association with outcomes by using Cox proportional hazards and multiple regression models.
   Results: AoCLF patients had significantly higher B12 levels at admission compared with HCs (AoCLF patients vs HCs, median 1218 pg/ml, mean 17362 pg/ml, SD, 1294.6 vs 504 pg/ml, 529.8 +/- 149.8 pg/ml, P<0.001). Elevated B12 levels were associated with increased severity of liver disease and 3-month mortality rate. Multivariate analysis demonstrated that B12 levels and the model for end-stage liver disease score were independent predictors for mortality (both P<0.001).
   Conclusion: B12 levels were significantly higher in AoCLF patients than in HCs and elevated B12 were associated with increased severity of disease. Moreover, B12 levels are an independent predicting factor for the 3-month mortality rate in AoCLF patients. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.
C1 [Xu, WeiYi; Ye, Bo; Zhang, Yi; Mao, WeiLin] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Clin Lab, Hangzhou 310003, Zhejiang, Peoples R China.
   [Dou, JiuFeng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Tradit Chinese Med Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
RP Mao, WL (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Clin Lab, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM mao_wei_lin@163.com
FU Health Department of Zhejiang Province [2011KYA058]
FX The work was supported by grants from Health Department of Zhejiang
   Province (2011KYA058). WeiLin Mao proposed the study. JiuFeng Dou
   performed research and WeiYi Xu wrote the first draft. Bo Ye and Yi
   Zhang collected and analyzed the data. All authors contributed to the
   design and interpretation of the study and to further drafts. WeiLin Mao
   is the guarantor.
CR Bailey SW, 2009, P NATL ACAD SCI USA, V106, P15424, DOI 10.1073/pnas.0902072106
   BAKER H, 1987, ALCOHOL ALCOHOLISM, V22, P1
   Bertoletti A, 1997, GASTROENTEROLOGY, V112, P193, DOI 10.1016/S0016-5085(97)70235-X
   Chen LG, 2011, WORLD J EMERG MED, V4, P283
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   Cylwik Bogdan, 2010, Pol Merkur Lekarski, V28, P122
   DJALALI M, 1988, DIGESTION, V41, P215
   Ermens AAM, 2003, CLIN BIOCHEM, V36, P585, DOI 10.1016/j.clinbiochem.2003.08.004
   Fragasso A, 2010, EUR J INTERN MED, V21, P97, DOI 10.1016/j.ejim.2009.11.012
   Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927
   HAGELSKJAER L, 1992, CLIN CHEM, V38, P493
   HOLDSWOR.CD, 1964, GUT, V5, P601, DOI 10.1136/gut.5.6.601
   Jalan R, 2002, BLOOD PURIFICAT, V20, P252, DOI 10.1159/000047017
   KANAZAWA S, 1985, LAB INVEST, V53, P108
   Katoonizadeh A, 2010, GUT, V59, P1561, DOI 10.1136/gut.2009.189639
   Lildballe DL, 2011, EJSO-EUR J SURG ONC, V37, P72, DOI 10.1016/j.ejso.2010.11.001
   Lin CY, 2010, NUTR CANCER, V62, P190, DOI 10.1080/01635580903305334
   LINDEMANS J, 1984, ACTA PAEDIATR SCAND, V73, P768, DOI 10.1111/j.1651-2227.1984.tb17773.x
   LINNELL JC, 1977, CANCER RES, V37, P2975
   MAJUMDAR SK, 1982, INT J VITAM NUTR RES, V52, P266
   Mao WL, 2010, ASAIO J, V56, P475, DOI 10.1097/MAT.0b013e3181e6bf13
   Mao WL, 2011, J CLIN GASTROENTEROL, V45, P551, DOI 10.1097/MCG.0b013e3181faefa3
   Marrero J, 2003, AM J RESP CRIT CARE, V168, P1421, DOI 10.1164/rccm.200303-361UP
   AREEKUL S, 1977, Southeast Asian Journal of Tropical Medicine and Public Health, V8, P322
   Sarin SK, 2009, HEPATOL INT, V3, P269, DOI 10.1007/s12072-008-9106-x
NR 25
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2012
VL 413
IS 23-24
BP 1809
EP 1812
DI 10.1016/j.cca.2012.07.008
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 006UN
UT WOS:000308844700001
ER

PT J
AU Hou, F
   Li, Z
   Ma, DX
   Zhang, WJ
   Zhang, YZ
   Zhang, TG
   Kong, BH
   Cui, BX
AF Hou, Fei
   Li, Zhen
   Ma, Daoxin
   Zhang, Wenjing
   Zhang, Youzhong
   Zhang, Tingguo
   Kong, Beihua
   Cui, Baoxia
TI Distribution of Th17 cells and Foxp3-expressing T cells in
   tumor-infiltrating lymphocytes in patients with uterine cervical cancer
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Uterine cervical cancer; Cervical intraepithelial neoplasia; Th17 cells;
   Foxp3-expressing T cells
ID TRANSCRIPTION FACTOR FOXP3; HEPATOCELLULAR-CARCINOMA;
   PROGNOSTIC-SIGNIFICANCE; OVARIAN-CARCINOMA; GASTRIC-CANCER; SURVIVAL;
   MICROENVIRONMENT; EXPRESSION; ANGIOGENESIS; RECRUITMENT
AB Background: Recent studies suggest a potential impact of Th17 cells on tumor. In the present study, we investigated the distribution of Th17 cells in relation to Foxp3-expressing T cells in the tumor-infiltrating lymphocytes (Ills) from patients with uterine cervical cancer (UCC), cervical tissues from patients with cervical intraepithelial neoplasia (ON) and healthy cervical tissues.
   Methods: Th17 cells and Foxp3-expressing T cells were evaluated by immunohistochemical staining. IL-6, TGF-beta, IL-17 and IL-10 were detected by enzyme-linked immunosorbent assay (ELISA). Immunohistochemical staining for microvessel density (MVD) was performed in order to assess the association of IL-17 expression with angiogenesis.
   Results: Compared with controls, patients with UCC or CIN had a higher proportion of Th17 cells and Foxp3-expressing T cells, when the ratio of Th17/Foxp3-expressing T cells in TILs was decreased in individual cases, it was more markedly decreased in TILs than normal cervical tissues. Meanwhile, the cytokine(IL-6, TGF-beta and IL-10) concentrations were significantly higher in UCC patients than those in healthy controls. Interestingly, the levels of intratumoral Th17 cells were positively correlated with MVD in tumors.
   Conclusions: The imbalance of Th17/Foxp3-expressing T cells may play critical roles in the development and progression of UCC and Th17 cells may promote tumor progression by fostering angiogenesis. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hou, Fei; Zhang, Wenjing; Zhang, Youzhong; Kong, Beihua; Cui, Baoxia] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250012, Peoples R China.
   [Li, Zhen] Shandong Univ, Qilu Hosp, Ctr Oncol, Jinan 250012, Peoples R China.
   [Hou, Fei; Ma, Daoxin; Zhang, Wenjing] Shandong Univ, Qilu Hosp, Haematol Oncol Ctr, Jinan 250012, Peoples R China.
   [Zhang, Tingguo] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Peoples R China.
RP Cui, BX (reprint author), Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, 107 Wenhua Xi Rd, Jinan 250012, Peoples R China.
EM cuibaoxia@sdu.edu.cn
FU National Natural Science Foundation of China [81072122, 81172486,
   81170515]
FX This study was supported by grants from the National Natural Science
   Foundation of China (nos. 81072122, 81172486 and 81170515).
CR Bethwaite PB, 1996, PATHOLOGY, V28, P321
   Cannon MJ, 2011, EXPERT OPIN BIOL TH, V11, P441, DOI 10.1517/14712598.2011.554812
   Chao HT, 1999, EUR J GYNAECOL ONCOL, V20, P136
   Couzin J, 2006, SCIENCE, V313, P1868
   Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   Ersvaer Elisabeth, 2010, BMC Immunol, V11, P38
   Ferrandina G, 2006, CLIN CANCER RES, V12, P2055, DOI 10.1158/1078-0432.CCR-05-2530
   Gnerlich JL, 2010, J IMMUNOL, V185, P4063, DOI 10.4049/jimmunol.0902609
   Gounaris E, 2009, CANCER RES, V69, P5490, DOI 10.1158/0008-5472.CAN-09-0304
   Hohn H, 2000, J VIROL, V74, P6632, DOI 10.1128/JVI.74.14.6632-6636.2000
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249
   Kryczek I, 2007, J IMMUNOL, V178, P6730
   LAKHDAR M, 1991, INT J CANCER, V48, P57
   Lee JJ, 2011, HEAD NECK
   Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5
   Martinez GJ, 2010, J BIOL CHEM, V285, P29039, DOI 10.1074/jbc.C110.155820
   Maruyama T, 2010, CANCER SCI, V101, P1947, DOI 10.1111/j.1349-7006.2010.01624.x
   McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539
   Mizukami Y, 2008, INT J CANCER, V122, P2286, DOI 10.1002/ijc.23392
   Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998
   Musha H, 2005, INT J CANCER, V116, P949, DOI 10.1002/ijc.21135
   Nakamura T, 2007, CANCER SCI, V98, P874, DOI 10.1111/j.1349-7006.2007.00470.x
   Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461
   Peng Su-fang, 2010, Zhonghua Zhong Liu Za Zhi, V32, P185
   Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388
   Pilch H, 2002, CLIN DIAGN LAB IMMUN, V9, P267, DOI 10.1128/CDLI.9.2.267-278.2002
   Ruffini E, 2009, ANN THORAC SURG, V87, P365, DOI 10.1016/j.athoracsur.2008.10.067
   Ruffini E, 2009, ANN THORAC SURG, V2009, p[87, 371]
   Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006
   Sfanos KS, 2008, CLIN CANCER RES, V14, P3254, DOI 10.1158/1078-0432.CCR-07-5164
   Singh N, 2004, INT J GYNECOL CANCER, V14, P741, DOI 10.1111/j.1048-891X.2004.014504.x
   Tartour E, 1999, CANCER RES, V59, P3698
   Tomsova M, 2008, GYNECOL ONCOL, V108, P415, DOI 10.1016/j.ygyno.2007.10.016
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Uhlig HH, 2006, J IMMUNOL, V177, P5852
   Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244
   Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016
   Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033
   Zhang Y, 2010, CLIN CHIM ACTA, V412, P894
NR 43
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2012
VL 413
IS 23-24
BP 1848
EP 1854
DI 10.1016/j.cca.2012.07.012
PG 7
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 006UN
UT WOS:000308844700008
ER

PT J
AU Chen, WJ
   He, J
   Zhang, QJ
   Lin, QF
   Chen, YF
   Lin, XZ
   Lin, MT
   Murong, SX
   Wang, N
AF Chen, Wan-Jin
   He, Jin
   Zhang, Qi-Jie
   Lin, Qi-Fang
   Chen, Ya-Fang
   Lin, Xiao-Zhen
   Lin, Min-Ting
   Murong, Shen-Xing
   Wang, Ning
TI Modification of phenotype by SMN2 copy numbers in two Chinese families
   with SMN1 deletion in two continuous generations
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Spinal muscular atrophy; Survival motor neuron gene; Quantification;
   Genotype-phenotype analysis
ID SPINAL MUSCULAR-ATROPHY; MOTOR-NEURON GENE; MOLECULAR ANALYSIS;
   SURVIVAL; PROTEIN; PCR; IDENTIFICATION; EXPRESSION; PREDICTION;
   INCLUSION
AB Background: As a lethal autosomal recessive hereditary disorder, childhood spinal muscular atrophy (SMA) is caused by mutations of the survival motor neuron 1 (SMN1) gene. Most of the patients died at early stage or were seriously disabled, which accounts partly for the scarcity of two continuous generations with SMA Increasing evidence indicated that SMN2 copy number was a modifier of SMA, but in majority of sporadic patients, the bias of phenotype judgments may largely reduce the accuracy of genotype-phenotype analysis.
   Methods: We presented two families with SMN1-deleted individuals in two continuous generations, the father and daughter of family 1 and the mother and daughter of family 2 were determined to be hornozygous for the deletion of the SMN1 gene. Quantitative analysis of SMN1 and SMN2 was carried out by real-time fluorescence quantitative PCR and multiplex ligation-dependent probe amplification.
   Results: Quantitative analysis showed that the father of family 1 possessed three copies of SMN2, and his daughter had only two SMN2 copies: the slightly affected mother of family 2 had three copies of SMN2, but her sick daughter had only two copies of SMN2: we also performed prenatal prediction for family 1 and a healthy boy was born under our suggestion.
   Conclusion: For the phenotypes of patients from different generations within the same family are obviously different, the results of a genotype-phenotype analysis may be more convincing, which strongly support the hypothesis that SMN2 is an important modifier for SMA, and SMN2 copy number should be considered in the prenatal diagnosis situation. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Chen, Wan-Jin; He, Jin; Zhang, Qi-Jie; Lin, Qi-Fang; Chen, Ya-Fang; Lin, Xiao-Zhen; Lin, Min-Ting; Murong, Shen-Xing; Wang, Ning] Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, Fuzhou 350005, Peoples R China.
   [Chen, Wan-Jin; He, Jin; Zhang, Qi-Jie; Lin, Qi-Fang; Chen, Ya-Fang; Lin, Xiao-Zhen; Lin, Min-Ting; Murong, Shen-Xing; Wang, Ning] Fujian Med Univ, Affiliated Hosp 1, Inst Neurol, Fuzhou 350005, Peoples R China.
   [Chen, Wan-Jin; Wang, Ning] Fujian Med Univ, Ctr Neurosci, Fuzhou 350005, Peoples R China.
RP Chen, WJ (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurol, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
EM wanjinchen75@yahoo.com.cn; ningwang63@yahoo.com
FU National Natural Science Foundation of China [30900481]; Natural Science
   Foundation of Fujian Province of China [2012J06016]; Fujian Medical
   Innovating Program [2009-CXB-25]; Program for Innovative Research Team
   in Science and Technology in Fujian Province University; Program for
   clinical medical key discipline of Fujian Medical University [XK201108];
   key program of scientific research of Fujian Medical University
   [2009D064]
FX This work was supported by grant 30900481 from the National Natural
   Science Foundation of China, grant 2012J06016 from the Natural Science
   Foundation of Fujian Province of China, and grant 2009-CXB-25 from the
   Fujian Medical Innovating Program, Program for Innovative Research Team
   in Science and Technology in Fujian Province University, a Program for
   clinical medical key discipline of Fujian Medical University(XK201108),
   and a key program of scientific research of Fujian Medical University
   (2009D064). The authors sincerely thank the SMA families for their help
   and willingness to participate in this study.
CR Arkblad EL, 2006, NEUROMUSCULAR DISORD, V16, P830, DOI 10.1016/j.nmd.2006.08.011
   Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886
   [陈万金 CHEN Wanfin], 2005, [中华神经科杂志, Chinese Journal of Neurology], V38, P673
   Chen WJ, 2007, ARCH NEUROL-CHICAGO, V64, P225, DOI 10.1001/archneur.64.2.225
   Chen WJ, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-45
   Chen Wan-jin, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P291
   Chen Wani-jin, 2005, Zhonghua Yixue Yichuanxue Zazhi, V22, P599
   COBBEN JM, 1995, AM J HUM GENET, V57, P805
   Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205
   Feldkotter M, 2002, AM J HUM GENET, V70, P358, DOI 10.1086/338627
   HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927
   Hsieh-Li HM, 2000, NAT GENET, V24, P66
   Kolb SJ, 2011, ARCH NEUROL-CHICAGO, V68, P979, DOI 10.1001/archneurol.2011.74
   Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3
   Lunn JS, 2011, ANN NEUROL, V70, P353, DOI 10.1002/ana.22487
   Marquis J, 2007, MOL THER, V15, P1479, DOI 10.1038/sj.mt.6300200
   McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465
   Prior TW, 2004, AM J MED GENET A, V130A, P307, DOI 10.1002/ajmg.a.30251
   Pyatt RE, 2007, CLIN CHEM, V53, P1879, DOI 10.1373/clinchem.2007.092312
   Scardolla O, 2006, NEUROGENETICS, V7, P268
   Schmid A, 2007, J CHILD NEUROL, V22, P1004, DOI 10.1177/0883073807305667
   Schwartz M, 1997, HUM MOL GENET, V6, P99, DOI 10.1093/hmg/6.1.99
   Sheng-Yuan Zhu, 2010, Eur J Hum Genet, V18, P978
   Su YN, 2005, HUM MUTAT, V25, P460, DOI 10.1002/humu.20160
   Sutomo R, 2002, AM J MED GENET, V113, P225, DOI 10.1002/ajmg.10744
   Talbot K, 1999, J INHERIT METAB DIS, V22, P545, DOI 10.1023/A:1005516625866
   Taylor JE, 1998, EUR J HUM GENET, V6, P467, DOI 10.1038/sj.ejhg.5200210
   Thurmond J, 2008, J MED CHEM, V51, P449, DOI 10.1021/jm061475p
   VANDERSTEEGE G, 1995, LANCET, V345, P985, DOI 10.1016/S0140-6736(95)90732-7
   Vezain M, 2011, HUM MUTAT, V32, P989, DOI 10.1002/humu.21528
   Wang CH, 1996, HUM MOL GENET, V5, P359, DOI 10.1093/hmg/5.3.359
   Wang N, 1999, CHIN J NEUROIMMUNOL, V6, P124
   Wu ZY, 1998, CHIN J NEUROL, V5, P289
   Yang BQ, 2005, FORENSIC SCI INT, V151, P293, DOI 10.1016/j.forsciint.2005.02.001
   Yuo CY, 2008, ANN NEUROL, V63, P26, DOI 10.1002/ana.21241
   Zheleznyakova GY, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-96
NR 37
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2012
VL 413
IS 23-24
BP 1855
EP 1860
DI 10.1016/j.cca.2012.07.020
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 006UN
UT WOS:000308844700009
ER

PT J
AU Wei, XM
   Sun, Y
   Xie, JS
   Shi, Q
   Qu, N
   Yang, GH
   Cai, J
   Yang, Y
   Liang, Y
   Wang, W
   Yi, X
AF Wei, Xiaoming
   Sun, Yan
   Xie, Jiansheng
   Shi, Quan
   Qu, Ning
   Yang, Guanghui
   Cai, Jun
   Yang, Yi
   Liang, Yu
   Wang, Wei
   Yi, Xin
TI Next-generation sequencing identifies a novel compound heterozygous
   mutation in MYO7A in a Chinese patient with Usher Syndrome 1B
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Hereditary hearing loss; Usher Syndrome 1B; Next-generation sequencing;
   MYO7A gene; Mutations
ID NONSYNDROMIC HEARING IMPAIRMENT; GJB2 MUTATION; SPECTRUM; DEAFNESS;
   FAMILIES; GENETICS; DEFECTS; SLC26A4; GENES
AB Background: Targeted enrichment and next-generation sequencing (NGS) have been employed for detection of genetic diseases. The purpose of this study was to validate the accuracy and sensitivity of our method for comprehensive mutation detection of hereditary hearing loss, and identify inherited mutations involved in human deafness accurately and economically.
   Methods: To make genetic diagnosis of hereditary hearing loss simple and timesaving, we designed a 0.60 MB array-based chip containing 69 nuclear genes and mitochondrial genome responsible for human deafness and conducted NGS toward ten patients with five known mutations and a Chinese family with hearing loss (never genetically investigated).
   Results: Ten patients with five known mutations were sequenced using next-generation sequencing to validate the sensitivity of the method. We identified four known mutations in two nuclear deafness causing genes (GJB2 and SLC26A4), one in mitochondrial DNA. We then performed this method to analyze the variants in a Chinese family with hearing loss and identified compound heterozygosity for two novel mutations in gene MYO7A.
   Conclusions: The compound heterozygosity identified in gene MYO7A causes Usher Syndrome 1B with severe phenotypes. The results support that the combination of enrichment of targeted genes and next-generation sequencing is a valuable molecular diagnostic tool for hereditary deafness and suitable for clinical application. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wei, Xiaoming; Sun, Yan; Shi, Quan; Qu, Ning; Yang, Guanghui; Yang, Yi; Liang, Yu; Wang, Wei; Yi, Xin] BGI Shenzhen, Shenzhen 518083, Peoples R China.
   [Xie, Jiansheng; Cai, Jun] Shenzhen Matern & Child Healthcare Hosp, Prenatal Diag Ctr, Shenzhen, Guangdong, Peoples R China.
RP Yi, X (reprint author), BGI Shenzhen, Shenzhen 518083, Peoples R China.
EM yix@genomics.org.cn
CR Berg JS, 2011, GENET MED, V13, P218, DOI 10.1097/GIM.0b013e318203cff2
   Brownstein Z, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r89
   Chen KT, 2012, OTOLARYNG HEAD NECK, V146, P972, DOI 10.1177/0194599812439670
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Dai P, 2007, GENET MED, V9, P283, DOI 10.1097/GIM.0b013e31804d2371
   Dai P, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-26
   Dai P, 2006, BIOCHEM BIOPH RES CO, V340, P194, DOI 10.1016/j.bbrc.2005.11.156
   Davarnia B, 2012, INT J PEDIATR OTORHI, V76, P268, DOI 10.1016/j.ijporl.2011.11.019
   Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695
   Gorlin RJ, 1995, HEREDITARY HEARING L
   Hilgert N, 2009, MUTAT RES-REV MUTAT, V681, P189, DOI 10.1016/j.mrrev.2008.08.002
   Homoe P, 2012, INT J AUDIOL, V51, P433, DOI 10.3109/14992027.2012.660575
   Hu H, 2007, J HUM GENET, V52, P492, DOI 10.1007/s10038-007-0139-0
   Liu Xin, 2006, Zhonghua Yi Xue Za Zhi, V86, P1318
   Nance WE, 2003, MENT RETARD DEV D R, V9, P109, DOI 10.1002/mrdd.10067
   Petersen MB, 2012, INT J PEDIATR OTORHI, V76, P549, DOI 10.1016/j.ijporl.2012.01.014
   Shearer AE, 2010, P NATL ACAD SCI USA, V107, P21104, DOI 10.1073/pnas.1012989107
   Steel KP, 2000, BRIT MED J, V320, P622, DOI 10.1136/bmj.320.7235.622
   Audo I, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-8
   Wang J, 2008, NATURE, V456, P60, DOI 10.1038/nature07484
   Wei XM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029500
   Williams DS, 2011, BIOCHEM SOC T, V39, P1207, DOI 10.1042/BST0391207
   Xie SQ, 2012, GENE, V499, P139, DOI 10.1016/j.gene.2012.03.029
NR 23
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 20
PY 2012
VL 413
IS 23-24
BP 1866
EP 1871
DI 10.1016/j.cca.2012.07.022
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 006UN
UT WOS:000308844700011
ER

PT J
AU Liao, SG
   Zhang, LJ
   Wang, Z
   Sun, F
   Li, YJ
   Wang, AM
   Huang, Y
   Lan, YY
   Wang, YL
AF Liao, Shang-Gao
   Zhang, Li-Juan
   Wang, Zhen
   Sun, Fa
   Li, Yong-Jun
   Wang, Ai-Min
   Huang, Yong
   Lan, Yan-Yu
   Wang, Yong-Lin
TI Electrospray ionization and collision-induced dissociation tandem mass
   spectrometric discrimination of polyphenolic glycosides: exact acylation
   site determination of the O-acylated monosaccharide residues
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID FLAVONOL GLYCOSIDES; PHENOLIC-COMPOUNDS; IDENTIFICATION
AB RATIONALE Acylated monosaccharide residues are structural subunits of natural products or synthetic intermediates that have received much attention in past years. Determination of the acylation sites of these residues still relies heavily on the comparison of their characteristic NMR signals with those of known standards and synthesized acylated glycosides. It is important to develop a rapid analytical method for determining the acylation sites for these compounds, and this is described in this study. METHODS Six known polyphenolic glycosides were used for the electrospray ionization and collision-induced dissociation tandem mass spectrometry (ESI-CID-MS/MS) discrimination of the acylated monosaccharide residues with different acylation sites. A combination of ESI-CID-MS/MS, using a triple quadrupole mass spectrometer, with ultra-performance liquid chromatography (UPLC) and photo-diode array (PDA) detection (UPLC-PDA) has been applied to the identification or characterization of polyphenolic glycosides in Polygonum capitatum that possess an acylated monosaccharide residue. RESULTS An ESI-MS and CID-MS/MS method has been developed for the determination of the acylation sites of polyphenolic glycosides that possess an acylated monosaccharide residue. Twelve polyphenolic glycosides including four new ones have been identified or characterized in P. capitatum. Eight (including the new ones) of the twelve glycosides were reported for the first time from this plant. CONCLUSIONS The developed ESI-MS and CID-MS/MS method provided a very useful strategy for the determination of the sites of polyphenolic glycosides that possess an acylated monosaccharide residue. The acylation site could be determined by the characteristic product ion spectra of the in-source CID-generated O-acyl monosaccharide ion [B1]+. The presented work may facilitate the structural characterization of these types of compounds. Copyright (C) 2012 John Wiley & Sons, Ltd.
C1 [Liao, Shang-Gao; Zhang, Li-Juan; Wang, Zhen; Li, Yong-Jun; Wang, Ai-Min; Huang, Yong; Lan, Yan-Yu; Wang, Yong-Lin] Guiyang Med Univ, Sch Pharm, Prov Key Lab Pharmaceut Guizhou Prov, Guiyang Med Coll, Guiyang 550004, Guizhou, Peoples R China.
   [Sun, Fa] Guiyang Med Coll, Affiliated Hosp, Dept Urinary Surg, Guiyang 550004, Guizhou, Peoples R China.
RP Wang, YL (reprint author), Guiyang Med Univ, Sch Pharm, Prov Key Lab Pharmaceut Guizhou Prov, Guiyang Med Coll, 9 Beijing Rd, Guiyang 550004, Guizhou, Peoples R China.
EM lshangg@163.com; ylwang_gmc@163.com
FU National Natural Science Foundation of China [81160516]; Guizhou
   Province [2010-43]; Guiyang Municipal Science and Technology Bureau
   [2009-9-3-04]; Ministry of Education for construction of the Engineering
   Research Center for TCM and Ethnic Medicines; GSTD for Construction of
   the Technological Innovation Team for Development and Application of
   TCMs
FX This research was supported by projects supported by National Natural
   Science Foundation of China (No. 81160516), the Governor of Guizhou
   Province (No. 2010-43), Guiyang Municipal Science and Technology Bureau
   (No. 2009-9-3-04), and by the Program of the Ministry of Education for
   construction of the Engineering Research Center for TCM and Ethnic
   Medicines and Special Program of GSTD for Construction of the
   Technological Innovation Team for Development and Application of TCMs.
   Professors Huan-Xin Zhao and Yuan-Shu Wang at the Institute of Materia
   Medica, Shandong Academy of Medical Sciences, Key Laboratory for Modern
   Medicine and Technology of Shandong Province, are greatly acknowledged
   for providing the standard of compound 11.
CR Abad-Garcia B, 2009, J CHROMATOGR A, V1216, P5398, DOI 10.1016/j.chroma.2009.05.039
   Ahmad V. U., 2011, MAGN RESON CHEM, V48, P304
   Bateman KP, 1997, J MASS SPECTROM, V32, P297, DOI 10.1002/(SICI)1096-9888(199703)32:3<297::AID-JMS485>3.0.CO;2-6
   Clifford MN, 2003, J AGR FOOD CHEM, V51, P2900, DOI 10.1021/jf026187q
   De Oliveira EB, 2009, J MOL CATAL B-ENZYM, V59, P96, DOI 10.1016/j.molcatb.2009.01.011
   Diaz JG, 2008, PHYTOCHEM LETT, V1, P125, DOI 10.1016/j.phytol.2008.06.005
   Goncalves AG, 2010, J AM SOC MASS SPECTR, V21, P1404, DOI 10.1016/j.jasms.2010.03.045
   Isaza JH, 2001, PHYTOCHEMISTRY, V58, P321, DOI 10.1016/S0031-9422(01)00247-3
   Khan A, 2009, HELV CHIM ACTA, V92, P731
   Li X, 2007, FITOTERAPIA, V78, P506, DOI 10.1016/j.fitote.2007.05.003
   Liao SG, 2010, RAPID COMMUN MASS SP, V24, P2533, DOI 10.1002/rcm.4662
   Liu CJ, 2010, J ORG CHEM, V75, P4992, DOI 10.1021/jo100575a
   Matsuzaki K, 2010, J NAT MED-TOKYO, V64, P252, DOI 10.1007/s11418-010-0400-2
   Moharram FA, 2006, NAT PROD RES, V20, P927, DOI 10.1080/14786410500378494
   Ono M., 2011, J NAT PRODUCTS, V73, P1846
   Poay T. Hooi, 2010, PHYTOCHEM ANALYSIS, V22, P516
   Regos I, 2009, J AGR FOOD CHEM, V57, P5843, DOI 10.1021/jf900625r
   Simerska P, 2003, FOLIA MICROBIOL, V48, P329, DOI 10.1007/BF02931362
   Sohretoglu D, 2009, HELV CHIM ACTA, V92, P520
   Veitch NC, 2011, PHYTOCHEMISTRY, V72, P423, DOI 10.1016/j.phytochem.2011.01.001
   Zhao H.-X., 2011, TIANRAN CHANWU YANJI, P23
NR 21
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV 15
PY 2012
VL 26
IS 21
BP 2483
EP 2492
DI 10.1002/rcm.6366
PG 10
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 011RJ
UT WOS:000309182200001
ER

PT J
AU Leng, JP
   Zhu, D
   Wu, DJ
   Zhu, TY
   Zhao, NW
   Guo, YL
AF Leng, Jiapeng
   Zhu, Dong
   Wu, Duojiao
   Zhu, Tongyu
   Zhao, Ningwei
   Guo, Yinlong
TI Analysis of the differentially expressed low molecular weight peptides
   in human serum via an N-terminal isotope labeling technique combining
   nano-liquid chromatography/matrix-assisted laser desorption/ionization
   mass spectrometry
SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY
LA English
DT Article
ID RENAL-ALLOGRAFT REJECTION; URINARY METABOLOMICS; PROTEOME ANALYSIS;
   BREAST-CANCER; MALDI-TOF; IDENTIFICATION; QUANTITATION; BIOMARKERS;
   DIAGNOSIS; DISEASE
AB RATIONALE Peptidomics analysis of human serum is challenging due to the low abundance of serum peptides and interference from the complex matrix. This study analyzed the differentially expressed (DE) low molecular weight peptides in human serum integrating a DMPITC-based N-terminal isotope labeling technique with nano-liquid chromatography and matrix-assisted laser desorption/ionization mass spectrometry (nano-LC/MALDI-MS). METHODS The workflow introduced a [d6]-4,6-dimethoxypyrimidine-2-isothiocyanate (DMPITC)-labeled mixture of aliquots from test samples as the internal standard. The spiked [d0]-DMPITC-labeled samples were separated by nano-LC then spotted on the MALDI target. Both quantitative and qualitative studies for serum peptides were achieved based on the isotope-labeled peaks. RESULTS The DMPITC labeling technique combined with nano-LC/MALDI-MS not only minimized the errors in peptide quantitation, but also allowed convenient recognition of the labeled peptides due to the 6?Da mass difference. The data showed that the entire research procedure as well as the subsequent data analysis method were effective, reproducible, and sensitive for the analysis of DE serum peptides. CONCLUSIONS This study successfully established a research model for DE serum peptides using DMPITC-based N-terminal isotope labeling and nano-LC/MALDI-MS. Application of the DMPITC-based N-terminal labeling technique is expected to provide a promising tool for the investigation of peptides in vivo, especially for the analysis of DE peptides under different biological conditions. Copyright (C) 2012 John Wiley & Sons, Ltd.
C1 [Leng, Jiapeng; Guo, Yinlong] Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai Mass Spectrometry Ctr, Shanghai, Peoples R China.
   [Zhu, Tongyu] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai 200433, Peoples R China.
   [Zhao, Ningwei] Shimadzu Global COE Applicat & Tech Dev, Shanghai, Peoples R China.
RP Guo, YL (reprint author), Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai Mass Spectrometry Ctr, 345 Lingling Rd, Shanghai, Peoples R China.
EM tyzhu@fudan.edu.cn; ylguo@sioc.ac.cn
FU National Natural Science Foundation of China [20875097, 21072215];
   Ministry of Science and Technology of China [2010IM030900]; Chinese
   Academy of Sciences [YZ200938]
FX This work was supported by financial support from the National Natural
   Science Foundation of China (20875097, 21072215), the Ministry of
   Science and Technology of China (2010IM030900), and the Chinese Academy
   of Sciences (YZ200938).
CR Blagojevic V, 2010, ANALYST, V135, P1456, DOI 10.1039/c0an00003e
   Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018
   Carabetta VJ, 2010, J AM SOC MASS SPECTR, V21, P1050, DOI 10.1016/j.jasms.2010.02.004
   Choe L, 2007, PROTEOMICS, V7, P3651, DOI 10.1002/pmic.200700316
   Choi YS, 2010, ANAL BIOCHEM, V401, P15, DOI 10.1016/j.ab.2010.02.027
   Diamandis EP, 2006, J PROTEOME RES, V5, P2079, DOI 10.1021/pr060225u
   Fang F, 2009, RAPID COMMUN MASS SP, V23, P1703, DOI 10.1002/rcm.4060
   Fang F, 2009, CHINESE J CHEM, V27, P2397
   Fiedler GM, 2009, CLIN CANCER RES, V15, P3812, DOI 10.1158/1078-0432.CCR-08-2701
   Gluckmann M, 2007, PROTEOMICS, V7, P1564, DOI 10.1002/pmic.200600836
   Goodlett DR, 2001, RAPID COMMUN MASS SP, V15, P1214, DOI 10.1002/rcm.362
   Heller M, 2003, J AM SOC MASS SPECTR, V14, P704, DOI 10.1016/S1044-0305(03)00207-1
   Hofmann S, 2005, MOL CELL PROTEOMICS, V4, P1888, DOI 10.1074/mcp.M500076-MCP200
   Hu LH, 2007, J PROTEOME RES, V6, P801, DOI 10.1021/pr060469e
   Hutcheon SD, 2002, AGE AGEING, V31, P295, DOI 10.1093/ageing/31.4.295
   Ji CJ, 2005, J PROTEOME RES, V4, P2099, DOI 10.1021/pr050215d
   Ji CJ, 2005, J PROTEOME RES, V4, P1419, DOI 10.1021/pr050094h
   Jia XF, 2009, PROTEOM CLIN APPL, V3, P694, DOI 10.1002/prca.200800209
   Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829
   Kim Y, 2001, ANAL CHEM, V73, P2617, DOI 10.1021/ac001392v
   Leng JP, 2011, J AM SOC MASS SPECTR, V22, P1204, DOI 10.1007/s13361-011-0129-5
   Liotta LA, 2006, J CLIN INVEST, V116, P26, DOI 10.1172/JCI27467
   Liu CW, 2011, ANAL CHEM, V83, P6593, DOI 10.1021/ac201016c
   Liu Z, 2010, J PROTEOME RES, V9, P227, DOI 10.1021/pr900528j
   Lochnit G, 2004, BIOMED CHROMATOGR, V18, P841, DOI 10.1002/bmc.399
   Matrisian Lynn M., 2003, Cancer Research, V63, P6105
   Oe T, 2010, RAPID COMMUN MASS SP, V24, P173, DOI 10.1002/rcm.4372
   Petrotchenko EV, 2009, MOL CELL PROTEOMICS, V8, P273, DOI 10.1074/mcp.M800265-MCP200
   Quintana LF, 2009, MOL CELL PROTEOMICS, V8, P1658, DOI 10.1074/mcp.M900059-MCP200
   Ru QHC, 2006, MOL CELL PROTEOMICS, V5, P1095, DOI 10.1074/mcp.M500387-MCP200
   Schmidt A, 2005, PROTEOMICS, V5, P4, DOI 10.1002/pmic.200400873
   Schmidt F, 2007, ELECTROPHORESIS, V28, P4359, DOI 10.1002/elps.200700119
   Schouten O, 2009, J VASC SURG, V49, P435, DOI 10.1016/j.jvs.2008.08.063
   Seo J, 2011, J AM SOC MASS SPECTR, V22, P1668, DOI 10.1007/s13361-011-0189-6
   Solez K, 2008, AM J TRANSPLANT, V8, P753, DOI 10.1111/j.1600-6143.2008.02159.x
   Sui WG, 2010, CLIN EXP MED, V10, P259, DOI 10.1007/s10238-010-0094-5
   Wang J, 2011, TRANSPL P, V43, P3738, DOI 10.1016/j.transproceed.2011.08.109
   Wang JN, 2008, J PROTEOME RES, V7, P3597, DOI 10.1021/pr800092f
   Wu CJ, 2010, J AM SOC MASS SPECTR, V21, P460, DOI 10.1016/j.jasms.2009.12.001
   Zhang J, 2007, J MASS SPECTROM, V42, P1514, DOI 10.1002/jms.1260
   Zheng XY, 2006, J CHROMATOGR A, V1120, P173, DOI 10.1016/j.chroma.2006.01.098
NR 41
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-4198
J9 RAPID COMMUN MASS SP
JI Rapid Commun. Mass Spectrom.
PD NOV 15
PY 2012
VL 26
IS 21
BP 2555
EP 2562
DI 10.1002/rcm.6369
PG 8
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 011RJ
UT WOS:000309182200009
ER

PT J
AU Chang, LL
   Wun, WSA
   Wang, PS
AF Chang, Ling-Ling
   Wun, Wan-Song A.
   Wang, Paulus S.
TI In utero and neonate exposure to nonylphenol develops hyperadrenalism
   and metabolic syndrome later in life. I. First generation rats (F-1)
SO TOXICOLOGY
LA English
DT Article
DE NP; Developmental exposure; 11 beta-HSD1; Body weight; Hyperadrenalism;
   Metabolic syndrome
ID 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; OXIDATIVE
   ENERGY-METABOLISM; ZONA GLOMERULOSA CELLS; CORTICOSTERONE RELEASE;
   ENDOCRINE DISRUPTORS; OVARIECTOMIZED RATS; HEART-MITOCHONDRIA; OBESITY
   EPIDEMIC; ADIPOSE-TISSUE; BISPHENOL-A
AB Nonylphenol (NP) is an endocrine disruptor (ENDR). It is a chemical associated with the production and degradation of nonylphenol ethoxylates (NPE). NPE is widely used as nonionic surfactants. Previously, we observed that NP increased the production of corticosterone and aldosterone from zona fasciculata-reticularis, and zona glomerulosa cells, respectively. By the "fetal origins adult diseases" (Barker hypothesis), we examined the possible impact of NP exposure during developmental (in utero and neonatal) period with focus on disturbed adrenal function and related hyperadrenal syndrome, i.e. Cushings syndrome/metabolic syndrome. In this study, female rats drink NP water during pregnancy and lactation conferred F-1 generation: (1) increase the corticosterone, aldosterone concentration in plasma; (2) increase 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) activity in liver and adipose tissue; (3) increase aldosterone synthase activity in adrenal for adult offspring. Furthermore, it can increase body weight, adrenocorticotropin (ACTH) concentration in plasma, 11 beta-HSD1 protein expression in liver, steroidogenic acute regulatory (StAR) protein expression and 11 beta-hydroxylase activity in adrenal for male adult offspring. In summary, NP exposure during developmental period bestowed F-1 generation with hyperadrenalism and its consequence of metabolic syndrome. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Chang, Ling-Ling] Chinese Culture Univ, Dept Chem & Mat Engn, Taipei 11114, Taiwan.
   [Wun, Wan-Song A.] Obstetr & Gynecol Associates PA, Houston, TX 77054 USA.
   [Wang, Paulus S.] Natl Yang Ming Univ, Sch Med, Dept Physiol, Taipei 11221, Taiwan.
   [Wang, Paulus S.] China Med Univ, PhD Program Aging, Taichung 40402, Taiwan.
   [Wang, Paulus S.] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan.
RP Chang, LL (reprint author), Chinese Culture Univ, Dept Chem & Mat Engn, Taipei 11114, Taiwan.
EM llchiang@staff.pccu.edu.tw
FU National Science Council, Taiwan, ROC [NSC 97-2314-B-075-055-MY3, NSC
   97-2621-M-010-002]
FX We thank Dr. D.M. Stocco (Department of Cell Biology and Biochemistry,
   Texas Tech University Health Science Center, Lubbock, TX, USA) for
   kindly providing the anti-StAR antibody. This study was supported by
   grants from the National Science Council, Taiwan, ROC: NSC
   97-2314-B-075-055-MY3 and NSC 97-2621-M-010-002.
CR Ademollo N, 2008, ENVIRON INT, V34, P984, DOI 10.1016/j.envint.2008.03.001
   Atkinson HC, 1997, ENDOCRINOLOGY, V138, P3842, DOI 10.1210/en.138.9.3842
   Baillie-Hamilton PF, 2002, J ALTERN COMPLEM MED, V8, P185, DOI 10.1089/107555302317371479
   Baquedano E., 2011, PLOS ONE, V6
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Brown AP, 2000, CONTEMP TOP LAB ANIM, V39, P17
   Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391
   Campbell JE, 2011, AM J PHYSIOL-CELL PH, V300, pC198, DOI 10.1152/ajpcell.00045.2010
   Carson Rachel, 1962, SILENT SPRING
   Chang LL, 2012, CHEM-BIOL INTERACT, V195, P11, DOI 10.1016/j.cbi.2011.09.004
   Chang LL, 2002, CHINESE J PHYSIOL, V45, P137
   Chang LL, 2010, TOXICOL SCI, V118, P411, DOI 10.1093/toxsci/kfq274
   Chang YJ, 2011, CHINESE J PHYSIOL, V54, P324, DOI 10.4077/CJP.2011.AMM088
   Chapin RE, 1999, TOXICOL SCI, V52, P80, DOI 10.1093/toxsci/52.1.80
   Chen GW, 2010, FOOD CHEM TOXICOL, V48, P1939, DOI 10.1016/j.fct.2010.04.038
   Chen ML, 2008, CHEMOSPHERE, V73, pS239, DOI 10.1016/j.chemosphere.2007.04.091
   Colborn T., 1996, OUR STOLEN FUTURE AR
   Cooper MS, 2009, J CLIN ENDOCR METAB, V94, P4645, DOI 10.1210/jc.2009-1412
   CROFTON JT, 1986, ENDOCRINOLOGY, V118, P1777
   Cunny HC, 1997, REGUL TOXICOL PHARM, V26, P172, DOI 10.1006/rtph.1997.1154
   D'Eon TM, 2005, J BIOL CHEM, V280, P35983, DOI 10.1074/jbc.M507339200
   Dicker A, 2004, DIABETOLOGIA, V47, P420, DOI 10.1007/s00125-003-1324-0
   Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004-0212
   Feng Y, 2010, BRIT J PHARMACOL, V161, P113, DOI 10.1111/j.1476-5381.2010.00826.x
   Ferguson SA, 2000, NEUROTOXICOLOGY, V21, P947
   Ferguson SA, 2009, NEUROTOXICOL TERATOL, V31, P143, DOI 10.1016/j.ntt.2009.01.009
   Ferrara F, 2011, CHEMOSPHERE, V82, P1044, DOI 10.1016/j.chemosphere.2010.10.064
   Garcia-Caceres C, 2010, PSYCHONEUROENDOCRINO, V35, P1525, DOI 10.1016/j.psyneuen.2010.05.006
   Gathercole LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026223
   Geerling JC, 2008, EXP PHYSIOL, V93, P177, DOI 10.1113/expphysiol.2007.039891
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114
   GRUN F, 2006, ENDOCRINOLOGY, V147, pS50, DOI DOI 10.1210/EN.2005-1129
   Hatch EE, 1998, JAMA-J AM MED ASSOC, V280, P630, DOI 10.1001/jama.280.7.630
   HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604
   Holtcamp W, 2012, ENVIRON HEALTH PERSP, V120, pA62
   Hossaini A, 2001, REPROD TOXICOL, V15, P537, DOI 10.1016/S0890-6238(01)00155-1
   Jie X, 2010, BIRTH DEFECTS RES B, V89, P418, DOI 10.1002/bdrb.20268
   Jing Xiao, 2011, Biomed Environ Sci, V24, P40
   Kau MM, 1999, J INVEST MED, V47, P425
   Kearney PM, 2004, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)17741-1
   Laws SC, 2000, TOXICOL SCI, V54, P154, DOI 10.1093/toxsci/54.1.154
   Lo MJ, 1998, AM J PHYSIOL-ENDOC M, V274, pE238
   Lo MJ, 2000, J CELL BIOCHEM, V77, P560, DOI 10.1002/(SICI)1097-4644(20000615)77:4<560::AID-JCB4>3.0.CO;2-D
   Lopez-Espinosa MJ, 2009, CHEMOSPHERE, V76, P847, DOI 10.1016/j.chemosphere.2009.03.063
   Mariniello B, 2006, EUR J ENDOCRINOL, V155, P435, DOI 10.1530/eje.1.02228
   McCormick KL, 2006, J BIOL CHEM, V281, P341, DOI 10.1074/jbc.M506026200
   Miyawaki J, 2008, TOXICOL SCI, V102, P82, DOI 10.1093/toxsci/kfm296
   Nagao T, 2001, REPROD TOXICOL, V15, P293, DOI 10.1016/S0890-6238(01)00123-X
   Newbold RR, 2007, REPROD TOXICOL, V23, P290, DOI 10.1016/j.reprotox.2006.12.010
   Oki K, 2012, CLIN EXP PHARMACOL P, V39, P90, DOI 10.1111/j.1440-1681.2011.05538.x
   Padwal RS, 2010, CAN J CARDIOL, V26, p18C, DOI 10.1016/S0828-282X(10)71077-1
   Palin SL, 2003, METABOLISM, V52, P383, DOI 10.1053/meta.2003.50088
   Pereira C.D., 2012, DIABETES OBES MATAB
   Seckl JR, 2004, EUR J ENDOCRINOL, V151, pU49
   Seki Y, 2012, ENDOCRINOLOGY, V153, P1031, DOI 10.1210/en.2011-1805
   Shankar A., 2012, J ENV PUBLIC HLTH, DOI [DOI 10.1155/2012/481641, 10.1155/2012/481641]
   Shukla VH, 2000, COMP BIOCHEM PHYS C, V127, P79, DOI 10.1016/S0742-8413(00)00134-1
   Steel RGD, 1960, PRINCIPLES PROCEDURE
   Stimson R H, 2007, Minerva Endocrinol, V32, P141
   Swegert CV, 1999, MECH AGEING DEV, V112, P27, DOI 10.1016/S0047-6374(99)00051-2
   Torres-Farfan C, 2011, ENDOCRINOLOGY, V152, P1891, DOI 10.1210/en.2010-1260
   Wada K, 2007, J PHARMACOL SCI, V105, P133, DOI 10.1254/jphs.FM0070034
   Wan ZK, 2011, J ORG CHEM, V76, P7048, DOI 10.1021/jo200958a
   Wang P.S., 1983, CHINESE J PHYSL, V26, P93
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14
   Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180
   XU XF, 1990, ENDOCRINOLOGY, V126, P1229
NR 70
TC 0
Z9 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD NOV 15
PY 2012
VL 301
IS 1-3
BP 40
EP 49
DI 10.1016/j.tox.2012.06.017
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 003RN
UT WOS:000308629100005
ER

PT J
AU Yang, LQ
   Lin, CY
   Wang, L
   Guo, HJ
   Wang, XJ
AF Yang, Liuqi
   Lin, Caiyu
   Wang, Li
   Guo, Huijie
   Wang, Xiujie
TI Hypoxia and hypoxia-inducible factors in glioblastoma multiforme
   progression and therapeutic implications
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Review
DE Hypoxia; Hypoxia-inducible factors; Glioblastoma multiforme; Glioma stem
   cells; Targeting therapy
ID ENDOTHELIAL GROWTH-FACTOR; GLIOMA STEM-CELLS; UBIQUITIN-PROTEASOME
   PATHWAY; IN-VIVO; TRANSCRIPTIONAL ACTIVITY; TUMOR ANGIOGENESIS;
   MALIGNANT GLIOMAS; GENE-EXPRESSION; HIF-2-ALPHA PROMOTES; OXYGEN-TENSION
AB Glioblastoma multiforme (GBM) is the most malignant and aggressive primary brain tumor in humans, with a uniformly poor prognosis. Hypoxia is a predominant feature in GBM and its microenvironment; it is associated with the tumor growth, progression and resistance to conventional therapy of cancers. Hypoxia-inducible factors (HIFs) are the master regulators of the transcriptional response to hypoxia in tumor cells and their microenvironment Numerous studies indicated that hypoxia and HIFs played pivotal roles in the initiation, progression, therapy resistance and recurrence of GBM and maintained the phenotype of glioma stem cells (GSCs), which makes the prognosis of GBM patients worse. This review summarized the current research advance of hypoxia and HIFs in GBM progression and therapeutic implications, which will provide a better understanding of the contribution of hypoxia and HIFs to GBM initiation and progression and highlight that HIFs might be taken as the attractive molecular target approaches for GBM therapeutics. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Yang, Liuqi; Lin, Caiyu; Wang, Li; Guo, Huijie; Wang, Xiujie] Sichuan Univ, W China Med Sch, W China Hosp, State Key Lab Biotherapy,Lab Geriat, Chengdu 610041, Peoples R China.
RP Wang, XJ (reprint author), Sichuan Univ, W China Med Sch, W China Hosp, State Key Lab Biotherapy,Lab Geriat, Chengdu 610041, Peoples R China.
EM xiujiewang@scu.edu.cn
FU National Natural Science Foundation of China [31071197]
FX This work was supported by National Natural Science Foundation of China
   (Grant number 31071197).
CR Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003
   Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023
   Ao JE, 2012, BIOCHEM BIOPH RES CO, V420, P913, DOI 10.1016/j.bbrc.2012.03.101
   Argyriou AA, 2009, ONCOLOGY-BASEL, V77, P1, DOI 10.1159/000218165
   Bao Bin, 2012, Biochim Biophys Acta, V1826, P272, DOI 10.1016/j.bbcan.2012.04.008
   Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bao SD, 2008, CANCER RES, V68, P6043, DOI 10.1158/0008-5472.CAN-08-1079
   Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021
   Birner P, 2003, BRAIN PATHOL, V13, P133
   Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007
   Blum R, 2005, CANCER RES, V65, P999
   Brat DJ, 2003, ANN INTERN MED, V138, P659
   Cassavaugh J, 2011, J CELL BIOCHEM, V112, P735, DOI 10.1002/jcb.22956
   Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x
   Cheng L, 2011, BIOCHEM BIOPH RES CO, V406, P643, DOI 10.1016/j.bbrc.2011.02.123
   Chigurupati S, 2010, CANCER RES, V70, P418, DOI 10.1158/0008-5472.CAN-09-2654
   DAUMASDUPORT C, 1988, CANCER, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T
   Dreyfuss JM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-71
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Ducray F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-234
   Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x
   Fiorenzo P, 2010, INT J ONCOL, V36, P785, DOI 10.3892/ijo_00000554
   Fischer I, 2005, BRAIN PATHOL, V15, P297
   Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1
   Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Gillespie DL, 2007, CLIN CANCER RES, V13, P2441, DOI 10.1158/1078-0432.CCR-06-2692
   Gleadle JM, 1997, BLOOD, V89, P503
   Gopal U, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017649
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109
   Heddleston JM, 2009, CELL CYCLE, V8, P3274
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355
   Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059
   Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026
   Hsieh CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023945
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Hueng DY, 2011, J NEURO-ONCOL, V104, P21, DOI 10.1007/s11060-010-0467-3
   Irie Nobuyuki, 2004, Brain Tumor Pathol, V21, P1, DOI 10.1007/BF02482169
   Jensen RL, 2009, J NEURO-ONCOL, V92, P317, DOI 10.1007/s11060-009-9827-2
   Jensen RL, 2006, J NEURO-ONCOL, V78, P233, DOI 10.1007/s11060-005-9103-z
   Jensen Randy L, 2006, Neurosurg Focus, V20, pE24, DOI 10.3171/foc.2006.20.4.16
   Jiang BH, 1996, J BIOL CHEM, V271, P17771
   Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199
   Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519
   Kaluz S, 2006, MOL CELL BIOL, V26, P5895, DOI 10.1128/MCB.00552-06
   Kang SH, 2006, CANCER RES, V66, P11991, DOI 10.1158/0008-5472.CAN-06-1320
   Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115
   Kawai N, 2011, EUR J NUCL MED MOL I, V38, P441, DOI 10.1007/s00259-010-1645-4
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283
   Kirkpatrick J., 2007, J CLIN ONCOL, V25, P2065
   Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235
   Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013
   Li LM, 2005, CANCER RES, V65, P7249, DOI 10.1158/0008-5472.CAN-04-4426
   Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018
   Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701
   Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67
   Liu YB, 2012, CARCINOGENESIS, V33, P1187, DOI 10.1093/carcin/bgs142
   Lopez-Lazaro M., 2006, CANCER EPIDEM BIOMAR, V15, P2232
   Lu HM, 2009, FEBS J, V276, P7291, DOI 10.1111/j.1742-4658.2009.07441.x
   Mabjeesh NJ, 2007, HISTOL HISTOPATHOL, V22, P559
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Mao XG, 2011, LAB INVEST, V91, P1068, DOI 10.1038/labinvest.2011.56
   McCord AM, 2009, MOL CANCER RES, V7, P489, DOI 10.1158/1541-7786.MCR-08-0360
   Mendez O, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-133
   Merighi S, 2006, BIOCHEM PHARMACOL, V72, P19, DOI 10.1016/j.bcp.2006.03.020
   Michel G, 2000, J BIOMOL STRUCT DYN, V18, P169
   Oliver L, 2009, Curr Mol Pharmacol, V2, P263
   Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109
   Pistollato F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006206
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Platet N, 2007, CANCER LETT, V258, P286, DOI 10.1016/j.canlet.2007.09.012
   Ponnala S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026191
   Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001
   Said HM, 2010, CURR PHARM DESIGN, V16, P3288
   Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652
   Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2008, IUBMB LIFE, V60, P591, DOI 10.1002/iub.93
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252
   Stoeltzing O, 2004, J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10
   Xue X, 2012, CANCER RES, V72, P2285, DOI 10.1158/0008-5472.CAN-11-3836
   Yeo EJ, 2006, BLOOD, V107, P916, DOI 10.1182/blood-2005-06-2564
   Yu SP, 2011, CHINESE MED J-PEKING, V124, P2599, DOI 10.3760/cma.j.issn.0366-6999.2011.17.007
   Zagzag D, 2000, CANCER, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W
   Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482
   Zundel W, 2000, GENE DEV, V14, P391
NR 100
TC 0
Z9 0
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD NOV 15
PY 2012
VL 318
IS 19
BP 2417
EP 2426
DI 10.1016/j.yexcr.2012.07.017
PG 10
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 013KB
UT WOS:000309303200001
ER

PT J
AU Ping, JF
   Wang, YX
   Wu, J
   Ying, YB
   Ji, F
AF Ping, Jianfeng
   Wang, Yixian
   Wu, Jian
   Ying, Yibin
   Ji, Feng
TI Determination of ascorbic acid levels in food samples by using an ionic
   liquid-carbon nanotube composite electrode
SO FOOD CHEMISTRY
LA English
DT Article
DE Ascorbic acid; Ionic liquid; Single-walled carbon nanotube; Composite
   electrode; Food
ID URIC-ACID; GRAPHITE ELECTRODE; DOPAMINE; VOLTAMMETRY; NADH; FILM
AB A novel carbon composite electrode consisted of ionic liquid n-octylpyridinum hexafluorophosphate (OPFP) and single-walled carbon nanotube (SWCNT) was fabricated and investigated. This electrode combined the advantages of ionic liquid and SWCNT together with the "bulk" composite electrode. Compared with other composite electrodes using graphite or paraffin oil, the ionic liquid-SWCNT (IL-SWCNT) composite electrode exhibited remarkable increase in the electron transfer rate for electroactive compound and significant decrease in the overpotential for ascorbic acid oxidation reaction. Based on the greatly enhanced electrocatalytic activity for the oxidation of ascorbic acid, a wide linear detection range from 3.0 mu M to 4.2 mM with a low detection limit of 1.0 mu M was obtained. Furthermore, the IL-SWCNT electrode was applied to determine ascorbic acid levels in real food samples. Experimental results showed that the proposed electrode could be used as an effective and sensitive sensor for direct detection of ascorbic acid. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Ping, Jianfeng; Wang, Yixian; Wu, Jian; Ying, Yibin] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Ji, Feng] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
RP Wu, J (reprint author), Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou 310058, Zhejiang, Peoples R China.
EM wujian69@zju.edu.cn; jifeng1126@sina.com
FU Key Scientific Project of China [2009ZX08012-004B]; Key Scientific
   Project of Zhejiang Province of China [2008C14077]
FX We are grateful for the financial supports from the Key Scientific
   Project of China (No. 2009ZX08012-004B) and the Key Scientific Project
   of Zhejiang Province of China (No. 2008C14077).
CR Agui L, 2008, ANAL CHIM ACTA, V622, P11, DOI 10.1016/j.aca.2008.05,070
   Andre C, 2010, TRENDS FOOD SCI TECH, V21, P229, DOI 10.1016/j.tifs.2009.12.003
   Banks CE, 2005, ANALYST, V130, P1232, DOI 10.1039/b508702c
   Banks CE, 2006, ANGEW CHEM INT EDIT, V45, P2533, DOI 10.1002/anie.200600033
   de Quiros ARB, 2009, FOOD CHEM, V116, P509, DOI 10.1016/j.foodchem.2009.03.013
   Dursun Z, 2010, ELECTROANAL, V22, P1106, DOI 10.1002/elan.200900525
   El-Said WA, 2010, ELECTROCHEM COMMUN, V12, P1756, DOI 10.1016/j.elecom.2010.10.015
   Guerreiro JRL, 2010, FOOD CHEM, V120, P934, DOI 10.1016/j.foodchem.2009.11.015
   Guo C. X., 2010, ELECTROCHEMISTRY COM, V12, P1237
   Habibi B, 2010, ELECTROCHIM ACTA, V55, P5492, DOI 10.1016/j.electacta.2010.04.052
   Huang SH, 2010, BIOSENS BIOELECTRON, V25, P2351, DOI 10.1016/j.bios.2010.03.028
   Kachoosangi RT, 2009, ANAL CHEM, V81, P435, DOI 10.1021/ac801853r
   Kalimuthu P, 2009, BIOELECTROCHEMISTRY, V77, P13, DOI 10.1016/j.bioelechem.2009.04.010
   KNETEN KR, 1992, ANAL CHEM, V64, P2518, DOI 10.1021/ac00045a011
   Kumar SA, 2010, BIOSENS BIOELECTRON, V25, P2592, DOI 10.1016/j.bios.2010.04.024
   Lahiff E, 2010, ANAL BIOANAL CHEM, V398, P1575, DOI 10.1007/s00216-010-4054-4
   Liu Y, 2010, ELECTROCHEM COMMUN, V12, P1108, DOI 10.1016/j.elecom.2010.05.041
   Lourencao BC, 2010, ELECTROANAL, V22, P1717, DOI 10.1002/elan.200900612
   Maleki N, 2006, ANAL CHEM, V78, P3820, DOI 10.1021/ac060070+
   Manjunatha R, 2010, SENSOR ACTUAT B-CHEM, V145, P643, DOI 10.1016/j.snb.2010.01.011
   Ping JF, 2010, MICROCHIM ACTA, V171, P117, DOI 10.1007/s00604-010-0420-3
   Pournaghi-Azar MH, 2010, ELECTROANAL, V22, P229, DOI 10.1002/elan.200900213
   Safavi A, 2006, ANAL BIOCHEM, V359, P224, DOI 10.1016/j.ab.2006.09.008
   Salimi A, 2010, ELECTROANAL, V22, P1707, DOI 10.1002/elan.201000020
   Shahrokhian S, 2010, ELECTROCHIM ACTA, V55, P666, DOI 10.1016/j.electacta.2009.08.065
   Sun P, 2010, ANAL CHIM ACTA, V661, P1, DOI 10.1016/j.aca.2009.12.007
   Tashkhourian J, 2009, J ELECTROANAL CHEM, V633, P85, DOI 10.1016/j.jelechem.2009.04.028
   TEE E S, 1988, Pertanika, V11, P39
   Wu J, 2000, ELECTROCHEM COMMUN, V2, P90, DOI 10.1016/S1388-2481(99)00148-4
   Xi LL, 2010, J ELECTROANAL CHEM, V650, P127, DOI 10.1016/j.jelechem.2010.08.014
   Zheng D, 2009, J ELECTROANAL CHEM, V625, P82, DOI 10.1016/j.jelechem.2008.10.012
   Zhu SY, 2009, BIOSENS BIOELECTRON, V25, P940, DOI 10.1016/j.bios.2009.08.022
NR 32
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
J9 FOOD CHEM
JI Food Chem.
PD NOV 15
PY 2012
VL 135
IS 2
BP 362
EP 367
DI 10.1016/j.foodchem.2012.05.013
PG 6
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA 002YF
UT WOS:000308574300008
ER

PT J
AU Guan, P
   Howell-Jones, R
   Li, N
   Bruni, L
   de Sanjose, S
   Franceschi, S
   Clifford, GM
AF Guan, Peng
   Howell-Jones, Rebecca
   Li, Ni
   Bruni, Laia
   de Sanjose, Silvia
   Franceschi, Silvia
   Clifford, Gary M.
TI Human papillomavirus types in 115,789 HPV-positive women: A
   meta-analysis from cervical infection to cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE human papillomavirus; cervical cancer; precancerous cervical lesions;
   genotype; epidemiology; meta-analysis
ID FOLLOW-UP; LESIONS; RISK; NEOPLASIA; CYTOLOGY; PERFORMANCE; PERSISTENCE;
   PROGRESSION; COHORT; TESTS
AB Genotyping may improve risk stratification of high-risk (HR) human papillomavirus (HPV)-positive women in cervical screening programs; however, prospective data comparing the natural history and carcinogenic potential of individual HR types remain limited. A meta-analysis of cross-sectional HR HPV-type distribution in 115,789 HPV-positive women was performed, including 33,154 normal cytology, 6,810 atypical squamous cells of undetermined significance (ASCUS), 13,480 low-grade squamous intraepithelial lesions (LSIL) and 6,616 high-grade SIL (HSIL) diagnosed cytologically, 8,106 cervical intraepithelial neoplasia grade 1 (CIN1), 4,068 CIN2 and 10,753 CIN3 diagnosed histologically and 36,374 invasive cervical cancers (ICCs) from 423 PCR-based studies worldwide. No strong differences in HPV-type distribution were apparent between normal cytology, ASCUS, LSIL or CIN1. However, HPV16 positivity increased steeply from normal/ASCUS/LSIL/CIN1 (2028%), through CIN2/HSIL (40/47%) to CIN3/ICC (58/63%). HPV16, 18 and 45 accounted for a greater or equal proportion of HPV infections in ICC compared to normal cytology (ICC:normal ratios = 3.07, 1.87 and 1.10, respectively) and to CIN3 (ICC:CIN3 ratios = 1.08, 2.11 and 1.47, respectively). Other HR types accounted for important proportions of HPV-positive CIN2 and CIN3, but their contribution dropped in ICC, with ICC:normal ratios ranging from 0.94 for HPV33 down to 0.16 for HPV51. ICC:normal ratios were particularly high for HPV45 in Africa (1.85) and South/Central America (1.79) and for HPV58 in Eastern Asia (1.36). ASCUS and LSIL appear proxies of HPV infection rather than cancer precursors, and even CIN3 is not entirely representative of the types causing ICC. HPV16 in particular, but also HPV18 and 45, warrant special attention in HPV-based screening programs.
C1 [Guan, Peng; Howell-Jones, Rebecca; Li, Ni; Franceschi, Silvia; Clifford, Gary M.] Int Agcy Res Canc, F-69372 Lyon 08, France.
   [Guan, Peng] China Med Univ, Shenyang, Peoples R China.
   [Howell-Jones, Rebecca] Hlth Protect Agcy, London, England.
   [Li, Ni] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China.
   [Bruni, Laia; de Sanjose, Silvia] Inst Catalan Oncol, Barcelona, Spain.
RP Clifford, GM (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM clifford@iarc.fr
FU Bill and Melinda Gates Foundation [35537]; International Agency for
   Research on Cancer; Fondation Innovations en Infectiologie (FINOVI);
   Department of Health, United Kingdom
FX Grant sponsor: Bill and Melinda Gates Foundation; Grant number: 35537;
   Grant sponsors: International Agency for Research on Cancer; Fondation
   Innovations en Infectiologie (FINOVI); Department of Health, United
   Kingdom.
CR Ault KA, 2011, INT J CANCER, V128, P1344, DOI 10.1002/ijc.25723
   Bouvard V, 2009, LANCET ONCOL, V10, P321
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Bulkmans NWJ, 2007, LANCET, V370, P1764, DOI 10.1016/S0140-6736(07)61450-0
   Carozzi FM, 2011, J CLIN MICROBIOL, V49, P1446, DOI 10.1128/JCM.02311-10
   Castle PE, 2011, LANCET ONCOL, V12, P880, DOI 10.1016/S1470-2045(11)70188-7
   Chen HC, 2011, J NATL CANCER I, V103, P1387, DOI 10.1093/jnci/djr283
   Clifford G, 2008, INT J CANCER, V122, P1684, DOI 10.1002/ijc.23282
   Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024
   Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688
   Clifford GM, 2005, CANCER EPIDEM BIOMAR, V14, P1157, DOI 10.1158/1055-9965.EPI-04-0812
   Einstein MH, 2010, GYNECOL ONCOL, V118, P116, DOI 10.1016/j.ygyno.2010.04.013
   Katki HA, 2011, LANCET ONCOL, V12, P663, DOI 10.1016/S1470-2045(11)70145-0
   Kjaer SK, 2010, J NATL CANCER I, V102, P1478, DOI 10.1093/jnci/djq356
   Klug SJ, 2008, J MED VIROL, V80, P1264, DOI 10.1002/jmv.21191
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Matsumoto K, 2011, INT J CANCER, V128, P2898, DOI 10.1002/ijc.25630
   Naucler P, 2009, J NATL CANCER I, V101, P88, DOI 10.1093/jnci/djn444
   Naucler P, 2007, BRIT J CANCER, V97, P129, DOI 10.1038/sj.bjc.6603843
   Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9
   Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2
   Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516
   Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206
   Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002
   Schweizer J, 2010, J CLIN MICROBIOL, V48, P4646, DOI 10.1128/JCM.01315-10
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Soderlund-Strand A, 2011, AM J OBSTET GYNECOL, V205
   Tjalma WAA, 2012, AM J CLIN PATHOL, V137, P161, DOI 10.1309/AJCPYB6C4HIMLZIX
   Wang SS, 2009, CANCER EPIDEM BIOMAR, V18, P113, DOI 10.1158/1055-9965.EPI-08-0591
   Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x
   Wright TC, 2007, AM J OBSTET GYNECOL, V197, P346, DOI 10.1016/j.ajog.2007.07.047
NR 31
TC 3
Z9 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2012
VL 131
IS 10
BP 2349
EP 2359
DI 10.1002/ijc.27485
PG 11
WC Oncology
SC Oncology
GA 011SM
UT WOS:000309185300016
ER

PT J
AU Ling, CH
   Chen, G
   Chen, GD
   Zhang, ZB
   Cao, BY
   Han, KK
   Yin, JM
   Chu, A
   Zhao, Y
   Mao, XL
AF Ling, Chunhua
   Chen, Gang
   Chen, Guodong
   Zhang, Zubin
   Cao, Biyin
   Han, Kunkun
   Yin, Jianming
   Chu, Alex
   Zhao, Yun
   Mao, Xinliang
TI A deuterated analog of dasatinib disrupts cell cycle progression and
   displays anti-non-small cell lung cancer activity in vitro and in vivo
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE non-small cell lung cancer; dasatinib; deuterium substitution; cell
   cycle
ID SRC FAMILY KINASES; ACTIVATION; APOPTOSIS; XENOGRAFTS; PACLITAXEL;
   RESISTANCE; DOCETAXEL; EFFICACY; ARREST
AB The pan-Src family kinase inhibitor dasatinib has been approved for chronic myeloid leukemia treatment but displays limited activity in lung cancer patients. In this study, we used a deuterium substitution strategy to develop a class of novel chemicals based on dasatinib and found that these compounds maintain inhibition on c-Src activity and display anti-non-small cell lung cancer activity in vitro and in vivo. BRP800, one of these compounds, was chosen for further studies. BRP800 mainly displayed antiproliferative but not proapoptotic activity. Molecularly, BRP800 did not show significant effects on the expression of antiapoptotic genes, such as Bcl-2 and Mcl1, or on the activation of apoptotic enzymes, such as caspase-3, -8 or 9. However, BRP800 decreased expression of cell cycle promoting genes such as cyclins D1, D3, E, A and CDK4 and 6, and increased the expression of cell cycle negative regulators including p21, p27 and p53. Consistent with these findings, BRP800 arrested cells at the G0/G1 phase in a concentration-dependent manner, and the G0/G1 fraction was increased from 64% in control to 85% in BRP800-treated cells. We also evaluated the effects of BRP800 on NSCLC xenografts using H460 as a model in nude mice. Compared with the known NSCLC drug docetaxel, BRP800 displayed potent and similar antitumor activity but with less toxicity. These findings suggest that the deuterated analog of dasatinib is antiproliferative by inhibiting c-Src and disrupting cell cycle progression, and could be further developed as a novel drug for non-small lung cancer treatment.
C1 [Ling, Chunhua; Chen, Gang; Chen, Guodong; Zhang, Zubin; Cao, Biyin; Han, Kunkun; Zhao, Yun; Mao, Xinliang] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Cyrus Tang Hematol Ctr, Suzhou, Peoples R China.
   [Ling, Chunhua; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Resp Dis, Suzhou, Peoples R China.
   [Yin, Jianming; Chu, Alex] Borui Pharmaceut Inc, Dept Chem, Suzhou, Peoples R China.
   [Mao, Xinliang] Soochow Univ, Coll Pharm, Dept Pharmacol, Suzhou, Peoples R China.
RP Mao, XL (reprint author), Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Cyrus Tang Hematol Ctr, Suzhou, Peoples R China.
EM xinliangmao@suda.edu.cn
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD)
FX The authors thank Dr. Michael Moran, the Hospital for Sick Children, the
   University of Toronto, Canada, for his discussion and critical comments.
   This project was supported by the project for the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (PAPD).
CR Amaral Joana D, 2010, Discov Med, V9, P145
   Brown L, 2007, CRIT REV EUKAR GENE, V17, P73
   CALALB MB, 1995, MOL CELL BIOL, V15, P954
   Cao XM, 1996, MOL CELL BIOL, V16, P1595
   Clarke KO, 2002, J PHARM SCI, V91, P1054, DOI 10.1002/jps.10102
   Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779
   Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029
   Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912
   Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757
   Kerekes AD, 2011, J MED CHEM, V54, P201, DOI 10.1021/jm1010995
   Kushner DJ, 1999, CAN J PHYSIOL PHARM, V77, P79, DOI 10.1139/cjpp-77-2-79
   Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI 10.1038/NCHEMBIO.332
   Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Mao XL, 2011, MOL PHARMACOL, V79, P672, DOI 10.1124/mol.110.068122
   Mao XL, 2011, BLOOD, V117, P1986, DOI 10.1182/blood-2010-05-284810
   Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078
   Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108
   Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4
   Park EJ, 2009, CANCER LETT, V277, P133, DOI 10.1016/j.canlet.2008.11.029
   Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171
   Sampath D, 2003, MOL CANCER THER, V2, P873
   Shao LM, 2006, BIOORG MED CHEM LETT, V16, P691, DOI 10.1016/j.bmcl.2005.10.024
   Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Thun MJ, 2008, PLOS MED, V5, P1357, DOI 10.1371/journal.pmed.0050185
   Vanhoefer U, 1997, ANN ONCOL, V8, P1221, DOI 10.1023/A:1008290406221
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   [Anonymous], 2008, CANC FACTS FIG, P9
NR 31
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2012
VL 131
IS 10
BP 2411
EP 2419
DI 10.1002/ijc.27504
PG 9
WC Oncology
SC Oncology
GA 011SM
UT WOS:000309185300023
ER

PT J
AU Gao, F
   Fei, FX
   Deng, YF
   Qi, YB
   Balasingham, I
AF Gao Fei
   Fei Feng-xia
   Deng Yan-fang
   Qi Yi-bo
   Balasingham, Ilangko
TI A novel non-Lyapunov approach through artificial bee colony algorithm
   for detecting unstable periodic orbits with high orders
SO EXPERT SYSTEMS WITH APPLICATIONS
LA English
DT Article
DE Unstable periodic orbits; Artificial bee colony algorithm; Non-Lyapunov;
   Non-negative functions' minimization
ID PARTICLE SWARM OPTIMIZATION; CHAOTIC SYSTEMS; EFFICIENT ALGORITHM;
   DYNAMICAL-SYSTEMS; PARAMETERS; ATTRACTORS
AB In this paper, a novel non-Lyapunov way is proposed to detect the unstable periodic orbits (UPOs) with high orders by a new artificial bee colony algorithm (ABC). And UPOs with high orders of nonlinear systems, are one of the most challenging problems of nonlinear science in both numerical computations and experimental measures. The proposed method maintains an effective searching mechanism with fine equilibrium between exploitation and exploration. To improve the performance for the optimums of the multi-model functions and to avoid the coincidences among the UPOs with different orders, we add the techniques as function stretching, deflecting and repulsion to ABC. The problems of detecting the UPOs are converted into a non-negative functions' minimization through a proper translation, which finds a UPO such that the objective function is minimized. Experiments to different high orders UPOs of 5 wellknown and widely used nonlinear maps indicate that the proposed algorithm is robust, by comparison of results through the ABC and quantum-behaved particle swarm optimization (QPSO), respectively. And it is effective even in cases where the Newton-family algorithms may not be applicable. Density of the orbits are discussed. Simulation results show that ABC is superior to QPSO, and it is a successful method in detecting the UPOs, with the advantages of fast convergence, high precision and robustness. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Gao Fei; Fei Feng-xia; Deng Yan-fang; Qi Yi-bo] Wuhan Univ Technol, Sch Sci, Dept Math, Wuhan 430070, Hubei, Peoples R China.
   [Gao Fei; Balasingham, Ilangko] Norwegian Univ Sci & Technol, Dept Elect & Telecommun, Signal Proc Grp, N-7491 Trondheim, Norway.
   [Balasingham, Ilangko] Oslo Univ Hosp, Intervent Ctr, N-0424 Oslo, Norway.
   [Balasingham, Ilangko] Univ Oslo, Inst Clin Med, N-0316 Oslo, Norway.
RP Gao, F (reprint author), Wuhan Univ Technol, Sch Sci, Dept Math, Luoshi Rd 122, Wuhan 430070, Hubei, Peoples R China.
EM hgaofei@gmail.com; 1092285218@qq.com; 986627833@qq.com;
   manshengyibo@163.com; ilangko.balasingham@iet.ntnu.no
FU European Commission; Scientific Research Foundation for Returned
   Scholars from Ministry of Education of China [20111j0032]; HOME Program
   (Help Our Motherland through Elite Intellectual Resources from Overseas)
   [11044]; China Association for Science and Technology; NSFC of China
   [10647141, 60773210]; Natural Science Foundation of Hubei Province of
   China [2009CBD213]; Fundamental Research Funds for the Central
   Universities of China; WUT [2012-la-035, 2012-la-041, 2010-la-004];
   National Soft Science Research Program of China [2009GXS1D012]; National
   Science Foundation for Post-doctoral Scientists of China [20080431004]
FX The work was carried out during the tenure of the ERCIM Alain Bensoussan
   Fellowship Programme, which is supported by the Marie Curie Co-funding
   of Regional, National and International Programmes (COFUND) of the
   European Commission. The work is also supported by Scientific Research
   Foundation for Returned Scholars from Ministry of Education of China
   (No. 20111j0032), the HOME Program No. 11044 (Help Our Motherland
   through Elite Intellectual Resources from Overseas) funded by China
   Association for Science and Technology, the NSFC projects Nos. 10647141,
   60773210 of China, the Natural Science Foundation of Hubei Province of
   China No. 2009CBD213, the Fundamental Research Funds for the Central
   Universities of China, the self-determined and innovative research funds
   of WUT No. 2012-la-035, 2012-la-041, 2010-la-004, The National Soft
   Science Research Program 2009GXS1D012 of China, the National Science
   Foundation for Post-doctoral Scientists of China No. 20080431004.
CR Akay B, 2009, LECT NOTES ARTIF INT, V5883, P355, DOI 10.1007/978-3-642-10291-2_36
   Akay B, 2009, LECT NOTES ARTIF INT, V5796, P608
   Akbari R, 2010, COMMUN NONLINEAR SCI, V15, P3142, DOI 10.1016/j.cnsns.2009.11.003
   Alatas B, 2011, EXPERT SYST APPL, V38, P13170, DOI 10.1016/j.eswa.2011.04.126
   Alatas B, 2010, EXPERT SYST APPL, V37, P5682, DOI 10.1016/j.eswa.2010.02.042
   Albers DJ, 2006, PHYSICA D, V223, P194, DOI 10.1016/j.physd.2006.09.004
   Awrejcewicz J, 2004, CHAOS SOLITON FRACT, V19, P503, DOI 10.1016/S0960-0779(03)00062-6
   Baig AR, 2007, GECCO 2007: GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, VOL 1 AND 2, P169
   Bennett CH, 2000, NATURE, V404, P247, DOI 10.1038/35005001
   BIHAM O, 1989, PHYS REV LETT, V63, P819, DOI 10.1103/PhysRevLett.63.819
   Bu SL, 2004, CHAOS SOLITON FRACT, V22, P237, DOI 10.1016/j.chaos.2003.12.089
   Christini DJ, 2000, PHYS REV E, V61, P5149, DOI 10.1103/PhysRevE.61.5149
   Davidchack RL, 1999, PHYS REV E, V60, P6172, DOI 10.1103/PhysRevE.60.6172
   DEVANEY RL, 1984, PHYSICA D, V10, P387, DOI 10.1016/0167-2789(84)90187-8
   Dhamala M, 1999, PHYS REV E, V60, P6176, DOI 10.1103/PhysRevE.60.6176
   Figueiredo R. J. d., 1993, NONLINEAR FEEDBACK C
   Gao F., 2010, 2010 INT C COMP INT, P425
   Gao F, 2009, CHAOS SOLITON FRACT, V42, P2450, DOI 10.1016/j.chaos.2009.03.119
   Gao F., 2010, 5 INT C COMP SCI CON, P659, DOI 10.1109/ICCIT.2010.5711137
   Gao F., 2010, 2010 INT C PROGR INF, P317, DOI 10.1109/PIC.2010.5687439
   Gao F, 2012, APPL MECH MATER, V110-116, P5048, DOI 10.4028/www.scientific.net/AMM.110-116.5048
   Gao F, 2008, CHINESE PHYS B, V17, P1196, DOI 10.1088/1674-1056/17/4/008
   Gao F, 2006, ACTA PHYS SIN-CH ED, V55, P577
   Gao F, 2012, EXPERT SYST APPL, V39, P1779, DOI 10.1016/j.eswa.2011.08.076
   Gao F, 2009, CHAOS SOLITON FRACT, V42, P1286, DOI 10.1016/j.chaos.2009.03.074
   Gluckman BJ, 1997, PHYS REV E, V55, P4935, DOI 10.1103/PhysRevE.55.4935
   Guney K, 2010, EXPERT SYST APPL, V37, P3129, DOI 10.1016/j.eswa.2009.09.072
   HENON M, 1976, COMMUN MATH PHYS, V50, P69, DOI 10.1007/BF01608556
   Hogg T, 2000, INFORM SCIENCES, V128, P181, DOI 10.1016/S0020-0255(00)00052-9
   Karaboga D, 2007, LECT NOTES COMPUT SC, V4529, P789
   Karaboga D., 2005, TR06 ERC U ENG FAC C
   Karaboga D, 2008, APPL SOFT COMPUT, V8, P687, DOI 10.1016/j.asoc.2007.05.007
   Karaboga D, 2009, APPL MATH COMPUT, V214, P108, DOI 10.1016/j.amc.2009.03.090
   Karaboga D, 2009, ARTIF INTELL REV, V31, P61, DOI 10.1007/s10462-009-9127-4
   Katok A., 2003, DYNAMICS 1 COURSE PA
   Magoulas GD, 1997, NONLINEAR ANAL-THEOR, V30, P4545, DOI 10.1016/S0362-546X(96)00369-0
   Mocholi JA, 2010, EXPERT SYST APPL, V37, P4921, DOI 10.1016/j.eswa.2009.12.023
   Mullen RJ, 2009, EXPERT SYST APPL, V36, P9608, DOI 10.1016/j.eswa.2009.01.020
   Ott E., 1993, CHAOS DYNAMICAL SYST
   OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196
   Parsopoulos KE, 2003, PROCEEDINGS OF THE 2003 IEEE SWARM INTELLIGENCE SYMPOSIUM (SIS 03), P34, DOI 10.1109/SIS.2003.1202244
   Parsopoulos K. E., 2002, P 4 GRACM C COMP MEC
   Petalas YG, 2007, IEEE C EVOL COMPUTAT, P2040, DOI 10.1109/CEC.2007.4424724
   PIERSON D, 1995, PHYS REV LETT, V75, P2124, DOI 10.1103/PhysRevLett.75.2124
   Schmelcher P, 1997, PHYS REV LETT, V78, P4733, DOI 10.1103/PhysRevLett.78.4733
   So P, 1996, PHYS REV LETT, V76, P4705, DOI 10.1103/PhysRevLett.76.4705
   So P, 1998, BIOPHYS J, V74, P2776
   Sun J., 2004, IEEE C CYB INT SYST, P111
   Takens F., 1981, LECT NOTES MATH, V898, P366
   Tereshko V., 2005, Computing and Information Systems, V9
   Tereshko V., 2000, LECT NOTES COMPUTER, P807
   Thammano A, 2012, EXPERT SYST APPL, V39, P5576, DOI 10.1016/j.eswa.2011.11.060
   Valery T., 2002, OPEN SYSTEMS INFORM, V9, P181
   VRAHATIS MN, 1995, J COMPUT PHYS, V119, P105, DOI 10.1006/jcph.1995.1119
   Yusup N, 2012, EXPERT SYST APPL, V39, P9909, DOI 10.1016/j.eswa.2012.02.109
   Zelinka I, 2010, STUD COMPUT INTELL, V267, P1, DOI 10.1007/978-3-642-10707-8
NR 56
TC 0
Z9 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4174
J9 EXPERT SYST APPL
JI Expert Syst. Appl.
PD NOV 15
PY 2012
VL 39
IS 16
BP 12389
EP 12397
DI 10.1016/j.eswa.2012.04.083
PG 9
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Operations Research & Management Science
SC Computer Science; Engineering; Operations Research & Management Science
GA 992RB
UT WOS:000307796300011
ER

PT J
AU Weng, BH
   Li, X
AF Weng, Binghuan
   Li, Xiao
TI An external quality assessment scheme for prenatal detection of rare
   chromosomal abnormalities
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Cytogenetics; Prenatal diagnosis; Chromosomal abnormality; External
   quality assessment
ID AMNIOTIC-FLUID; ASSURANCE; RECOMMENDATIONS; PERFORMANCE; EXPERIENCE
AB Objective: To improve the accuracy of prenatal cytogenetic diagnosis by establishing an external quality assessment (EQA) scheme for rare, or subtle, structural chromosomal abnormalities.
   Method: Typical metaphase images of rare chromosomal abnormalities along with an anonymized clinical history were sent to 35 prenatal diagnosis laboratories. The laboratories were required to provide independent reports using current nomenclature. Evaluation of reports was based on established criteria for quality assessment of karyotype analysis.
   Results: Totally 6 kinds of typical rare chromosomal abnormalities were collected. 35 laboratories were enrolled with a response rate of 94.29%. The overall analytical accuracy is 82.20%. This is comparable with our former EQA scheme using established lymphocyte cell lines with rare abnormal chromosome karyotypes (chi(2) = 0.065. P = 0.799).
   Conclusion: Introduction of efficient EQA for prenatal genetic diagnosis is currently imperative, due to the limited performances of karyotype analysis of rare chromosomal abnormalities. Metaphase images could be used as a simple and effective material for EQA and to improve the quality of prenatal genetic diagnosis. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Weng, Binghuan; Li, Xiao] Zhejiang Univ, Womens Hosp, Sch Med, Womens Reprod Hlth Lab Zhejiang Prov, Hangzhou 310006, Zhejiang, Peoples R China.
RP Li, X (reprint author), Zhejiang Univ, Womens Hosp, Sch Med, Womens Reprod Hlth Lab Zhejiang Prov, 1 Xueshi Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM lixsure@yahoo.com.cn
FU Natural Scientific Foundation of Zhejiang Province [Y207054]; National
   Natural Science Foundation of China [81001164]; Fundamental Research
   Funds for the Central Universities
FX Financial support for this work was provided by the project of the
   Natural Scientific Foundation of Zhejiang Province (Grant code:
   Y207054), the National Natural Science Foundation of China (Grant code:
   81001164) and the Fundamental Research Funds for the Central
   Universities (2010).
CR Bastien P, 2007, CLIN MICROBIOL INFEC, V13, P430, DOI 10.1111/j.1469-0691.2006.01642.x
   Catalina P, 2007, CELL BIOL INT, V31, P861, DOI 10.1016/j.cellbi.2007.03.012
   Dequeker E, 2000, EUR J HUM GENET, V8, pS2, DOI 10.1038/sj.ejhg.5200487
   Hastings R, 2010, METHODS MOL BIOL, V659, P249, DOI 10.1007/978-1-60761-789-1_18
   Hastings RJ, 2008, EUR J HUM GENET, V16, P1217, DOI 10.1038/ejhg.2008.82
   LAESSIG RH, 1988, CLIN CHEM, V34, P1849
   Libeer JC, 2001, CLIN CHIM ACTA, V309, P173, DOI 10.1016/S0009-8981(01)00518-6
   Ramsden SC, 2007, PRENATAL DIAG, V27, P404, DOI 10.1002/pd.1698
   Sikkema-Raddatz B, 2006, PRENATAL DIAG, V26, P791, DOI 10.1002/pd.1505
   Taruscio D, 2004, CLIN CHEM LAB MED, V42, P915, DOI 10.1515/CCLM.2004.148
   Weng Bin-huan, 2007, Zhonghua Yixue Yichuanxue Zazhi, V24, P689
   Williams LO, 2003, ARCH PATHOL LAB MED, V127, P1353
   Ye YH, 2011, FERTIL STERIL, V96, pE71, DOI 10.1016/j.fertnstert.2011.04.080
   [Anonymous], 2007, OECD GUID QUAL ASS M
   [Anonymous], 2011, 15189 ISO
NR 15
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 12
PY 2012
VL 413
IS 21-22
BP 1721
EP 1724
DI 10.1016/j.cca.2012.07.004
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 003PB
UT WOS:000308622700001
ER

PT J
AU Wang, KY
   Yu, GF
   Zhang, ZY
   Huang, Q
   Dong, XQ
AF Wang, Ke-Yi
   Yu, Guo-Feng
   Zhang, Zu-Yong
   Huang, Qiang
   Dong, Xiao-Qiao
TI Plasma high-mobility group box 1 levels and prediction of outcome in
   patients with traumatic brain injury
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE High-mobility group box 1; Traumatic brain injury; Functional outcome;
   Mortality
ID DNA-BINDING PROTEINS; SUBARACHNOID HEMORRHAGE; CHROMATIN PROTEIN;
   HEAD-INJURY; HMGB1; ISCHEMIA; RELEASE; HMG-1; INFLAMMATION; ARTHRITIS
AB Background: High-mobility group box 1 (HMGB1), a marker of inflammation, has been associated with poor outcome of critical illness. The present study was undertaken to investigate the plasma HMGB1 concentrations in patients with traumatic brain injury (TBI) and to analyze the correlation of HMGB1 with TBI outcome.
   Methods: We performed an observational, clinical study. Plasma HMGB1 concentration of 106 healthy subjects and 106 patients with severe TBI was measured by ELISA. The correlation with 1-y mortality and unfavorable outcome (Glasgow Outcome Scale score of 1-3) was analyzed.
   Results: Thirty-one patients (29.2%) died and 48 patients (45.3%) had an unfavorable outcome at 1 y after TBI. Plasma HMGB1 level was substantially higher in patients than in healthy controls. A multivariate analysis selected plasma HMGB1 level as an independent predictor for 1-y mortality and unfavorable outcome of patients. A receiver operating characteristic curve analysis showed plasma HMGB1 level statistically significantly predicted 1-y mortality and unfavorable outcome. The prognostic value of HMGB1 was similar to that of Glasgow Coma Scale score for 1-y clinical outcomes.
   Conclusions: Plasma HMGB1 concentration emerges as a novel biomarker for predicting 1-y clinical outcomes of TBI. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Zu-Yong; Dong, Xiao-Qiao] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China.
   [Yu, Guo-Feng; Huang, Qiang] Quzhou Peoples Hosp, Dept Neurosurg, Quzhou 324100, Peoples R China.
   [Wang, Ke-Yi] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Cent Lab, Hangzhou 310006, Zhejiang, Peoples R China.
RP Dong, XQ (reprint author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM dxqhyy@163.com
FU Zhejiang Provincial Program [2012KYB148]
FX This work was financially supported by the Zhejiang Provincial Program
   (No. 2012KYB148).
CR Abraham E, 2000, J IMMUNOL, V165, P2950
   Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890
   Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x
   Bustin M, 1999, MOL CELL BIOL, V19, P5237
   Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009
   Goldstein RS, 2006, SHOCK, V25, P571, DOI 10.1097/01.shk.0000209540.99176.72
   Guazzi S, 2003, GENE EXPR PATTERNS, V3, P29, DOI 10.1016/S1567-133X(02)00093-5
   JENNETT B, 1975, LANCET, V1, P480
   Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001
   King MD, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09223
   Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune
   Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161
   Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F
   LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   MARSHALL LF, 1991, J NEUROSURG, V75, pS14
   Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128
   Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008
   Murakami K, 2011, TRANSL STROKE RES, V2, P72, DOI 10.1007/s12975-010-0052-2
   Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y
   Ombrellino M, 1999, LANCET, V354, P1446, DOI 10.1016/S0140-6736(99)02658-6
   Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582
   Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE
   Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859
   Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1
   Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614
   Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-1880C
   Van den Berghe G, 2005, NEUROLOGY, V64, P1348
   Vogelgesang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008718
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang HC, 1999, SURGERY, V126, P389, DOI 10.1016/S0039-6060(99)70182-0
   Watanabe Mitsuya, 2012, Acta Neurochir Suppl, V113, P91
   Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100
   Zhou Y, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/142458
NR 36
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 12
PY 2012
VL 413
IS 21-22
BP 1737
EP 1741
DI 10.1016/j.cca.2012.07.002
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 003PB
UT WOS:000308622700004
ER

PT J
AU Du, DN
   Zhu, XJ
   Kuno, A
   Matsuda, A
   Tsuruno, C
   Yu, DM
   Zhang, Y
   Ikehara, Y
   Tanaka, Y
   Zhang, XX
   Narimatsu, H
AF Du, Dongning
   Zhu, Xuejuan
   Kuno, Atsushi
   Matsuda, Atsushi
   Tsuruno, Chikayuki
   Yu, Demin
   Zhang, Yan
   Ikehara, Yuzuru
   Tanaka, Yasuhito
   Zhang, Xinxin
   Narimatsu, Hisashi
TI Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis
   in hepatitis B virus infected patients with different ALT levels
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Liver fibrosis; Glycomarker; Hepatitis B; Cirrhosis; Alanine
   aminotransferase
ID TRANSIENT ELASTOGRAPHY; VIRAL-HEPATITIS; STIFFNESS MEASUREMENT; SERUM
   MARKERS; C PATIENTS; DISEASE; BIOPSY; CIRRHOSIS; PROGRESSION; MANAGEMENT
AB Background: FibroScan is one of the noninvasive techniques based on the transient elastography that can assess the progression of liver fibrosis in chronic hepatitis patients in daily clinical practice. Recently, LecT-Hepa was validated as a serological glycomarker correlating well with the fibrosis stage determined by liver biopsy, and was superior to many other noninvasive biochemical markers and tests. We compared the reliability of LecT-Hepa with that of FibroScan for evaluation of liver fibrosis.
   Methods: The effects of increased alanine aminotransferase (ALT) activities on LecT-Hepa and FibroScan were investigated.
   Results: The areas under the receiver-operating characteristic curves, sensitivity and specificity for detecting cirrhosis, which is one of the outcomes of fibrosis estimation, were 0.82, 72.5% and 782% of LecT-Hepa, 0.85, 87.0% and 74.1% of FibroScan; these did not differ significantly. The count distribution of LecT-Hepa in non-cirrhosis group or cirrhosis group did not differ between the patients grouped according to their ALT levels, whereas that of FibroScan was substantially affected.
   Conclusion: LecT-Hepa was confirmed as a reliable noninvasive test for the evaluation of liver fibrosis in hepatitis B virus-infected patients with comparable performance to that of FibroScan and proved to be unaffected by inflammation. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Du, Dongning; Zhu, Xuejuan; Yu, Demin; Zhang, Xinxin] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai 200025, Peoples R China.
   [Du, Dongning; Kuno, Atsushi; Matsuda, Atsushi; Ikehara, Yuzuru; Narimatsu, Hisashi] Natl Inst Adv Ind Sci & Technol, RCMG, Tsukuba, Ibaraki 3058568, Japan.
   [Du, Dongning; Zhang, Yan; Narimatsu, Hisashi] SCSB China AIST Japan Joint Med Glyc Lab, Shanghai 200240, Peoples R China.
   [Tsuruno, Chikayuki] Sysmex Corp, Prod Dev Div 2, Kobe, Hyogo 6512271, Japan.
   [Zhang, Yan] Shanghai Jiao Tong Univ, SCSB, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China.
   [Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   [Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
RP Zhang, XX (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.
EM zxx10375@rjh.com.cn; h.narimatsu@aist.go.jp
CR Afdhal N, 2008, J HEPATOL, V48, P1000, DOI 10.1016/j.jhep.2008.03.009
   Alberti A, 2005, J HEPATOL, V42, P615, DOI 10.1016/j.jhep.2005.03.003
   Arena U, 2008, HEPATOLOGY, V47, P380, DOI 10.1002/hep.22007
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706
   Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018
   Castera L, 2009, J VIRAL HEPATITIS, V16, P300, DOI 10.1111/j.1365-2893.2009.01087.x
   Chang TT, 2010, HEPATOLOGY, V52, P886, DOI 10.1002/hep.23785
   Colletta C, 2005, HEPATOLOGY, V42, P838, DOI 10.1002/hep.20814
   Colloredo G, 2003, J HEPATOL, V39, P239, DOI 10.1016/S0168-8278(03)00191-0
   Forns X, 2002, HEPATOLOGY, V36, P986, DOI 10.1053/jhep.2002.36128
   Friedrich-Rust M, 2008, GASTROENTEROLOGY, V134, P960, DOI 10.1053/j.gastro.2008.01.034
   Ganne-Carrie N, 2006, HEPATOLOGY, V44, P1511, DOI 10.1002/hep.21420
   Hoofnagle JH, 2007, HEPATOLOGY, V45, P1056, DOI 10.1002/hep.21627
   IMBERTBISMUT F, 2001, J GERONTOL B-PSYCHOL, V357, P1069
   Ito K, 2012, HEPATOLOGY
   Kuno A, 2011, CLIN CHIM ACTA, V412, P1767, DOI 10.1016/j.cca.2011.05.028
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Leevy CM, 1994, DIS LIVER BILIARY TR
   Lu FM, 2009, CHINESE MED J-PEKING, V122, P3, DOI 10.3760/cma.j.issn.0366-6999.2009.01.001
   Patel K, 2004, J HEPATOL, V41, P935, DOI 10.1016/j.jhep.2004.08.008
   PICCININO F, 1986, J HEPATOL, V2, P165, DOI 10.1016/S0168-8278(86)80075-7
   Rosenberg WMC, 2004, GASTROENTEROLOGY, V127, P1704, DOI 10.1053/j.gastro.2004.08.052
   Sagir A, 2008, HEPATOLOGY, V47, P592, DOI 10.1002/hep.22056
   Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001
   Shaheen AAM, 2007, AM J GASTROENTEROL, V102, P2589, DOI 10.1111/j.1572-0241.2007.01466.x
   TURNER GA, 1992, CLIN CHIM ACTA, V208, P149, DOI 10.1016/0009-8981(92)90073-Y
   Wong VWS, 2010, HEPATOLOGY, V51, P454, DOI 10.1002/hep.23312
NR 28
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD NOV 12
PY 2012
VL 413
IS 21-22
BP 1796
EP 1799
DI 10.1016/j.cca.2012.07.005
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 003PB
UT WOS:000308622700014
ER

PT J
AU Li, KN
   Wang, JN
   Liu, XQ
   Xiong, XP
   Liu, HQ
AF Li, Kaina
   Wang, Jiangnan
   Liu, Xinqing
   Xiong, Xiaopeng
   Liu, Haiqing
TI Biomimetic growth of hydroxyapatite on phosphorylated electrospun
   cellulose nanofibers
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Electrospinning; Nanofiber; Hydroxyapatite; Cellulose biocomposite
ID BACTERIAL CELLULOSE; CALCIUM-PHOSPHATE; MINERALIZATION; NANOCOMPOSITE;
   SCAFFOLDS; MEMBRANES; FILMS
AB In biomimicking the formation of collagen fiber/hydroxyapatite (HAp) in natural bone, electrospun cellulose nanofiber(CelluNF)/HAp composites were synthesized in simulated body fluid (SBF). Their morphology and structure were characterized by SEM, TEM. XRD and XPS. CelluNFs showed low bioactivity in inducing the growth of HAp. In order to improve this ability. CelluNFs were slightly phosphorylated with a degree of substitution of phosphate group of 0.28. The modified CelluNFs were highly effective in guiding the HAp growth along the fibers. The HAp crystal size in the composites was ca. 24 nm, and the lattice spacing of (211) plane was 2.83 angstrom. It was found that the HAps in the composites were calcium deficient. The CelluNF/HAp composites are highly porous materials with micro-, meso-, and macro-pores. A mechanism for the HAp growth on CelluNFs was presented. Such CelluNF/HAp composites can be potentially useful in the field of bone tissue engineering. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Li, Kaina; Wang, Jiangnan; Liu, Haiqing] Fujian Normal Univ, Coll Mat Sci & Engn, Key Lab Polymer Mat Fujian Prov, Fuzhou 350007, Fujian, Peoples R China.
   [Liu, Xinqing] Peoples Hosp Jiangxi Prov, Nanchang 330006, Peoples R China.
   [Xiong, Xiaopeng] Xiamen Univ, Coll Mat, Dept Mat Sci & Engn, Xiamen 361005, Peoples R China.
RP Liu, HQ (reprint author), Fujian Normal Univ, Coll Mat Sci & Engn, Key Lab Polymer Mat Fujian Prov, Fuzhou 350007, Fujian, Peoples R China.
EM haiqing.liu@gmail.com
FU Natural Science Foundation of Fujian Province [2010J06017]; National
   Basic Research Program of China [2010CB732203]; National Natural Science
   Foundation of China [50973019]
FX This work is supported by the Natural Science Foundation of Fujian
   Province (2010J06017), the National Basic Research Program of China
   (2010CB732203), and the National Natural Science Foundation of China
   (No. 50973019).
CR Backdahl H, 2006, BIOMATERIALS, V27, P2141, DOI 10.1016/j.biomaterials.2005.10.026
   Brown W., 1965, EUR POLYM J, V1, P1, DOI 10.1016/0014-3057(65)90041-8
   Cai YL, 2011, J MATER SCI-MATER M, V22, P1633, DOI 10.1007/s10856-011-4348-x
   Collins AM, 2009, ADV MATER, V21, P75, DOI 10.1002/adma.200802239
   Dahle S, 2012, THIN SOLID FILMS, V520, P1842, DOI 10.1016/j.tsf.2011.08.112
   Entcheva E, 2004, BIOMATERIALS, V25, P5753, DOI 10.1016/j.biomaterials.2004.01.024
   Garcia A, 2011, ACTA BIOMATER, V7, P1265, DOI 10.1016/j.actbio.2010.10.006
   Greish YE, 2010, CARBOHYD POLYM, V82, P569, DOI 10.1016/j.carbpol.2010.05.012
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187
   He M, 2012, CARBOHYD POLYM, V87, P2512, DOI 10.1016/j.carbpol.2011.11.029
   Hutchens SA, 2006, BIOMATERIALS, V27, P4661, DOI 10.1016/j.biomaterials.2006.04.032
   ISOGAI A, 1989, MACROMOLECULES, V22, P3168, DOI 10.1021/ma00197a045
   Juhasz JA, 2012, J MATER SCI, V47, P610, DOI 10.1007/s10853-011-6063-x
   Kim CW, 2005, J POLYM SCI POL PHYS, V43, P1673, DOI 10.1002/polb.20475
   Klemm D, 2001, PROG POLYM SCI, V26, P1561, DOI 10.1016/S0079-6700(01)00021-1
   Knill CJ, 2003, CARBOHYD POLYM, V51, P281, DOI 10.1016/S0144-8617(02)00183-2
   Liao HQ, 2012, CELLULOSE, V19, P111, DOI 10.1007/s10570-011-9604-1
   Liu HQ, 2002, J POLYM SCI POL PHYS, V40, P2119, DOI 10.1002/polb.10261
   Liu RL, 2010, J ALLOY COMPD, V503, P103, DOI 10.1016/j.jallcom.2010.04.211
   Martson M, 1999, BIOMATERIALS, V20, P1989, DOI 10.1016/S0142-9612(99)00094-0
   MIYAMOTO T, 1989, J BIOMED MATER RES, V23, P125, DOI 10.1002/jbm.820230110
   Padilha PD, 1997, TALANTA, V45, P317
   Rodriguez K, 2011, ACS APPL MATER INTER, V3, P681, DOI 10.1021/am100972r
   Wan YZ, 2009, J NANOSCI NANOTECHNO, V9, P6494, DOI 10.1166/jnn.2009.1311
   Wan YZ, 2007, MAT SCI ENG C-BIO S, V27, P855, DOI 10.1016/j.msec.2006.10.002
   Xu FJ, 2007, LANGMUIR, V23, P8585, DOI 10.1021/la7011342
   Zimmermann KA, 2011, MAT SCI ENG C-MATER, V31, P43, DOI 10.1016/j.msec.2009.10.007
NR 27
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD NOV 6
PY 2012
VL 90
IS 4
BP 1573
EP 1581
DI 10.1016/j.carbpol.2012.07.033
PG 9
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 013UI
UT WOS:000309331000024
ER

PT J
AU Tian, J
   Che, HL
   Ha, D
   Wei, YP
   Zheng, SY
AF Tian, Jing
   Che, Huilian
   Ha, Da
   Wei, Yeping
   Zheng, Shuyun
TI Characterization and anti-allergic effect of a polysaccharide from the
   flower buds of Lonicera japonica
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Lonicera japonica; Polysaccharide; Characterization; Anti-allergic
   effect; Allergic contact dermatitis
ID DELAYED-TYPE HYPERSENSITIVITY; ALLERGIC CONTACT-DERMATITIS; MAST-CELL
   HISTAMINE; DE-GRANULATION; IN-VITRO; MICE; RELEASE; MOUSE; SENSITIVITY;
   PREVENTION
AB A water-soluble polysaccharide (LJP-1), with a molecular weight of 1.8 x 10(5) Da, was isolated from the flower buds of Lonicera japonica. Gas chromatography (GC) analysis showed that the LJP-1 was mainly composed of D-glucose and a small amount of D-arabinose. On the basis of methylation analysis, LJP-1 had the backbone chain mainly consisting of 1,6-linked Glc and 1,3,6-linked Glc, which was terminated with 1-linked Ara residues at the O-3 position of 13,6-linked Glc in a relative molar ratio of 2.9:1:0.9. The anti-allergic effect of LJP-1 was evaluated on allergic contact dermatitis (ACD) induced by picryl chloride (PC) in mouse ear. Similar to prednisolone, orally administrated LJP-1 (20,40 and 80 mg/kg) potently inhibited the PC-induced ACD, leading to substantial reductions in ear thickness, serum level of IgE and histamine, as well as tissue TNF-alpha. These results demonstrate that treatment with LJP-1 may be effective for preventing the development of PC-induced ACD. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Tian, Jing; Ha, Da; Wei, Yeping; Zheng, Shuyun] Harbin Med Univ, Affiliated Hosp 1, Dept Dermatol, Harbin 150001, Peoples R China.
   [Che, Huilian] China Agr Univ, Coll Food Sci & Nutr Engn, Beijing 100083, Peoples R China.
RP Zheng, SY (reprint author), Harbin Med Univ, Affiliated Hosp 1, Dept Dermatol, Harbin 150001, Peoples R China.
EM shuyunzhenghmu@gmail.com
CR Alam N., 1986, PLANTA MED, V52, P308, DOI DOI 10.1055/S-2007-969161
   ASHERSON GL, 1968, IMMUNOLOGY, V15, P405
   ASKENASE PW, 1995, INT ARCH ALLERGY IMM, V107, P145
   ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358
   Belsito DV, 2000, J ALLERGY CLIN IMMUN, V105, P409, DOI 10.1067/mai.2000.104937
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   DVORAK AM, 1985, LAB INVEST, V53, P45
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Guo YC, 1997, EUR J PHARMACOL, V331, P237, DOI 10.1016/S0014-2999(97)01002-9
   Hammerberg B, 2001, VET DERMATOL, V12, P339, DOI 10.1046/j.0959-4493.2001.00273.x
   Heinemann C, 2004, PLANTA MED, V70, P385, DOI 10.1055/s-2004-818963
   Holtmann MH, 2002, ARCH IMMUNOL THER EX, V50, P279
   Itoh K, 2009, J NAT MED, V63, P443, DOI 10.1007/s11418-009-0349-1
   Jin JH, 2010, BIOMOL THER, V18, P197, DOI 10.4062/biomolther.2010.18.2.197
   Kang OH, 2010, MOLECULES, V15, P385, DOI 10.3390/molecules15010385
   Kimber I, 2002, INT IMMUNOPHARMACOL, V2, P201, DOI 10.1016/S1567-5769(01)00173-4
   KIMBER I, 1993, J PHARMACOL TOXICOL, V29, P11, DOI 10.1016/1056-8719(93)90045-G
   Ko HC, 2006, J ETHNOPHARMACOL, V107, P205, DOI 10.1016/j.jep.2006.03.004
   Kwak WJ, 2003, CHEM PHARM BULL, V51, P333, DOI 10.1248/cpb.51.333
   Lee EJ, 2010, FOOD CHEM, V120, P134, DOI 10.1016/j.foodchem.2009.09.088
   Lee SJ, 2007, BIOL PHARM BULL, V30, P1468, DOI 10.1248/bpb.30.1468
   Lin LM, 2008, J ASIAN NAT PROD RES, V10, P925, DOI 10.1080/10286020802217366
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MALORNY U, 1990, INT ARCH ALLER A IMM, V92, P356
   NEEDS PW, 1993, CARBOHYD RES, V245, P1, DOI 10.1016/0008-6215(93)80055-J
   Oku H, 2011, BIOL PHARM BULL, V34, P1330, DOI 10.1248/bpb.34.1330
   PHANUPHA.P, 1974, J IMMUNOL, V112, P115
   Pinto NB, 2010, PHYTOMEDICINE, V17, P740, DOI 10.1016/j.phymed.2010.01.006
   Prieto JM, 2008, PHYTOTHER RES, V22, P297, DOI 10.1002/ptr.2309
   Rios J. L., 2005, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V4, P65, DOI 10.2174/1568014053005273
   Shang XF, 2011, J ETHNOPHARMACOL, V138, P1, DOI 10.1016/j.jep.2011.08.016
   Sun GC, 2007, J PHARM PHARMACOL, V59, P1405, DOI 10.1211/jpp.59.10.0011
   Sun YX, 2008, BIORESOURCE TECHNOL, V99, P900, DOI 10.1016/j.biortech.2007.01.029
   SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X
   THIERS BH, 1989, ALLERGY PROC, V10, P413, DOI 10.2500/108854189778935809
   THORNE PS, 1991, FUND APPL TOXICOL, V17, P790, DOI 10.1016/0272-0590(91)90186-8
   Turk J. L, 1980, ROLE DELAYED HYPERSE
   UBUKATA K, 1992, J CLIN MICROBIOL, V30, P1728
   VADAS MA, 1975, INT ARCH ALLER A IMM, V49, P670
   VANLOVEREN H, 1983, J EXP MED, V157, P1604, DOI 10.1084/jem.157.5.1604
   Wang ZJ, 2004, CARBOHYD POLYM, V57, P241, DOI 10.1016/j.carbpol.2004.04.018
   White M, 1999, J ALLERGY CLIN IMMUN, V103, pS378, DOI 10.1016/S0091-6749(99)70215-0
   Zhao GH, 2005, CARBOHYD POLYM, V61, P125, DOI 10.1016/j.carbpol.2005.04.020
NR 43
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD NOV 6
PY 2012
VL 90
IS 4
BP 1642
EP 1647
DI 10.1016/j.carbpol.2012.07.044
PG 6
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 013UI
UT WOS:000309331000034
ER

PT J
AU Liu, X
   Sun, ZL
   Zhang, MS
   Meng, XM
   Xia, XK
   Yuan, WP
   Xue, F
   Liu, CH
AF Liu, Xin
   Sun, Zhenliang
   Zhang, Miansong
   Meng, Xiumei
   Xia, Xuekui
   Yuan, Wenpeng
   Xue, Feng
   Liu, Changheng
TI Antioxidant and antihyperlipidemic activities of polysaccharides from
   sea cucumber Apostichopus japonicus
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Apostichopus japonicus; Polysaccharide; Antioxidant activity;
   Antihyperlipidemic activity
ID OXIDATIVE STRESS; DISORDERS; ALGAE; DIET; RATS
AB Polysaccharides (AJP) were prepared from Apostichopus japonicus by protease hydrolysis method. Antioxidant activity in vitro and antihyperlipidemic activity in vivo was investigated. Chemical composition analysis indicated that AJP was mainly composed of glucosamine, galactosamine, glucuronic acid, mannose, glucose, galactose and fucose, with an average molecular weight of about 36.2 kDa. The antioxidant capacities of AJP were, respectively, evaluated by the assays of scavenging DPPH, hydroxyl and superoxide radicals, and reducing power in vitro. It showed potent free radical scavenging activities and reducing power. Serum total cholesterol (TC), triglyceride (TG) and low-density lipoprotein (LDL-C) decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after treatment of hyperlipidemic Wistar rats with AJP. These results suggest that AJP may prove to be a potential candidate of the natural antioxidants as a therapeutic agent for hyperlipidemia. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Xin; Meng, Xiumei; Yuan, Wenpeng; Liu, Changheng] Shandong Acad Sci, Inst Biol, Key Lab Biosensors Shandong Prov, Jinan 250014, Peoples R China.
   [Zhang, Miansong; Xia, Xuekui] Shandong Acad Sci, Ctr Biotechnol, Key Lab Appl Microbiol Shandong Prov, Jinan 250014, Peoples R China.
   [Sun, Zhenliang; Xue, Feng] Shanghai 6 Peoples Hosp, Branch Hosp Fengxian, Shanghai 201499, Peoples R China.
RP Liu, CH (reprint author), Shandong Acad Sci, Inst Biol, Key Lab Biosensors Shandong Prov, Jinan 250014, Peoples R China.
EM skeyan@yahoo.cn; rock0515@yahoo.cn
FU National Natural Science Foundation of China [31000008]; Science and
   Technology Program of Shandong Province [BS2010HZ019, BS2009HZ004,
   2012GGA10045]; Key Laboratory of Marine Drug (Ocean University of
   China), Ministry of Education
FX This study was granted by the National Natural Science Foundation of
   China (No. 31000008) and Science and Technology Program of Shandong
   Province (Nos. BS2010HZ019, BS2009HZ004 and 2012GGA10045). The project
   was supported by Key Laboratory of Marine Drug (Ocean University of
   China), Ministry of Education.
CR Ananthi S, 2010, FOOD CHEM TOXICOL, V48, P187, DOI 10.1016/j.fct.2009.09.036
   BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   BROWN WV, 1994, MED CLIN N AM, V78, P143
   Chen Y, 2011, BIORESOURCE TECHNOL, V102, P8179, DOI 10.1016/j.biortech.2011.06.048
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Elahi MM, 2009, OXID MED CELL LONGEV, V2, P259
   Gao C. J., 1996, CHIN J HEMATOL, V17, P458
   [郭莲英 GUO Lian-ying], 2009, [中国微生态学杂志, Chinese Journal of Microecology], V21, P806
   Hu D. Y., 2005, J CAPITAL U MED SCI, V26, P99
   Iso H., 1994, CIRCULATION, V89, P25
   Kariya Y, 2004, CARBOHYD RES, V339, P1339, DOI 10.1016/j.carres.2004.02.025
   Knopp RH, 1999, NEW ENGL J MED, V341, P498
   Li HP, 2010, NUTRITION, V26, P556, DOI 10.1016/j.nut.2009.06.009
   Liu CH, 2008, INT IMMUNOPHARMACOL, V8, P1835, DOI 10.1016/j.intimp.2008.09.005
   Liu HH, 2002, J AGR FOOD CHEM, V50, P3602, DOI 10.1021/jf020070k
   Ma M, 2009, FOOD CHEM, V113, P872, DOI 10.1016/j.foodchem.2008.03.064
   Muzzarelli R.A.A., 2006, FUNCTIONAL FOOD CARB, P215
   Qi HM, 2012, CARBOHYD POLYM, V87, P1637, DOI 10.1016/j.carbpol.2011.09.073
   REN DL, 1994, FISHERIES SCI, V60, P83
   Sathivel A, 2008, FOOD CHEM TOXICOL, V46, P3262, DOI 10.1016/j.fct.2008.07.016
   [盛文静 SHENG Wenjing], 2007, [中国海洋药物, Chinese Journal of Marine Drugs], V26, P44
   Sun HH, 2009, CARBOHYD POLYM, V78, P117, DOI 10.1016/j.carbpol.2009.04.017
   Therho T. T., 1971, ANAL BIOCHEM, V41, P471
   Wang Y. M., 2003, CHINESE J MARINE DRU, V22, P33
   Wijesekara I, 2011, CARBOHYD POLYM, V84, P14, DOI 10.1016/j.carbpol.2010.10.062
   Yan B., 2004, J PHARM PRACTICE, V22, P101
   Zhang JunRui, 2009, Modern Food Science and Technology, V25, P542
   Zhang L. S., 2011, FOOD CHEM, V124, P182
   Zhang YJ, 2010, J BIOSCI BIOENG, V110, P479, DOI 10.1016/j.jbiosc.2010.05.009
   Zhang ZS, 2010, CARBOHYD POLYM, V82, P118, DOI 10.1016/j.carbpol.2010.04.031
   Zhong XK, 2010, CARBOHYD POLYM, V82, P722, DOI 10.1016/j.carbpol.2010.05.042
   Zhu BW, 2010, FOOD CHEM, V121, P712, DOI 10.1016/j.foodchem.2010.01.010
NR 33
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD NOV 6
PY 2012
VL 90
IS 4
BP 1664
EP 1670
DI 10.1016/j.carbpol.2012.07.047
PG 7
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 013UI
UT WOS:000309331000037
ER

PT J
AU Xin, T
   Zhang, FB
   Jiang, QY
   Chen, CH
   Huang, DY
   Lv, YJ
   Shen, WX
   Jin, YH
AF Xin, Tao
   Zhang, Fubin
   Jiang, Qiuying
   Chen, Chunhong
   Huang, Dayong
   Lv, Yanju
   Shen, Weixi
   Jin, Yinghua
TI Purification and antitumor activity of two acidic polysaccharides from
   the roots of Polygala tenuifolia
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Polygala tenuifolia; Polysaccharide; Antioxidative; Antitumor; Human
   lung adenocarcinoma A549
ID EXTRACT; MOUSE
AB Two acidic polysaccharide fractions (PTPa and PTPb) extracted from the roots of Polygala tenuifolia, were obtained by DEAE-Sephacel anion-exchange, and Sephadex G-100 gel-permeation chromatography. High-performance liquid chromatography (HPLC) identified that PTPa and PTPb was composed of Ara, Glc, Gal, Man and GlcUA in the proportion of 2.4:1.2:0.6:0.4:1.1 and 2.1:1.7:0.5:0.6:1.7, respectively. Their molecular weight was evaluated to be 5.9 x 10(4) (PTPa) and 2.5 x 10(4) Da (PTPb) as determined by high performance size exclusion chromatography (HPSEC). Pharmacological studies revealed PTPa and PTPb significantly inhibited the growth of A549 cells in vitro and exhibited significantly higher antitumor activity against solid tumor A549 in vivo than did a blank control. Moreover, treatment with two acidic polysaccharides caused an enhancement of superoxide dismutase (SOD) and catalase (CAT) activities in tumor-bearing mice and a reduction in thiobarbituric acid reactive substances (TBARS) level. Taken together, these results indicated that two acidic polysaccharides from the roots of P. tenuifolia may be useful as potent antitumor agents for the prevention of lung tumorigenesis. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Zhang, Fubin] Harbin Med Univ, Affiliated Tumor Hosp 3, Dept Gynecol, Harbin 150040, Peoples R China.
   [Xin, Tao; Jiang, Qiuying; Chen, Chunhong; Huang, Dayong; Lv, Yanju; Shen, Weixi; Jin, Yinghua] Harbin Med Univ, Affiliated Hosp 2, Dept Med Oncol, Harbin 150081, Peoples R China.
RP Zhang, FB (reprint author), Harbin Med Univ, Affiliated Tumor Hosp 3, Dept Gynecol, Harbin 150040, Peoples R China.
EM fubinzhang.hrbmu@hotmail.com
FU Research Fund of Health Department of Heilongjiang Province [2009-022];
   Scientific Research Foundation of The Third Affiliated Hospital of
   Harbin Medical University [JJ2009-09]
FX We wish to thank Jianping Cai at Harbin Medical University for the
   positive suggestions in the manuscript preparation. This study was
   financially supported by Research Fund of Health Department of
   Heilongjiang Province (No. 2009-022) and Scientific Research Foundation
   of The Third Affiliated Hospital of Harbin Medical University (No.
   JJ2009-09).
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Cheng MC, 2006, J NAT PROD, V69, P1305, DOI 10.1021/np060207r
   Chung I. W., 1992, J KOREAN NEUROPSYCHI, V31, P856
   Chung IW, 2002, PHARMACOL BIOCHEM BE, V71, P191, DOI 10.1016/S0091-3057(01)00648-7
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   HONDA S, 1989, ANAL BIOCHEM, V180, P351, DOI 10.1016/0003-2697(89)90444-2
   Jang KJ, 1997, ARCH PHARM RES, V20, P375, DOI 10.1007/BF02976204
   Kim HM, 1998, J ETHNOPHARMACOL, V61, P201, DOI 10.1016/S0378-8741(98)00040-3
   Lin YL, 2008, J FOOD DRUG ANAL, V16, P26
   Liu JY, 2007, J MASS SPECTROM, V42, P861, DOI 10.1002/jms.1210
   Liu Y, 2011, INT J BIOL MACROMOL, V49, P1007, DOI 10.1016/j.ijbiomac.2011.08.024
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Park CH, 2002, J NEUROSCI RES, V70, P484, DOI 10.1002/jnr.10429
   STAUB A. M., 1965, METHOD CARBOHYD CHEM, V5, P5
   Sun YX, 2011, CARBOHYD POLYM, V86, P1381, DOI 10.1016/j.carbpol.2011.06.043
   Wang B, 2011, INT J BIOL MACROMOL, V48, P386, DOI 10.1016/j.ijbiomac.2010.12.005
   Wu Q, 2010, INT J BIOL MACROMOL, V46, P284, DOI 10.1016/j.ijbiomac.2010.01.016
   Wu Y, 2012, CARBOHYD POLYM, V88, P926, DOI 10.1016/j.carbpol.2012.01.035
   Xie Y, 2010, INT J BIOL MACROMOL, V47, P528, DOI 10.1016/j.ijbiomac.2010.07.008
   Zhang H, 2008, PHYTOMEDICINE, V15, P587, DOI 10.1016/j.phymed.2007.12.004
   Zhang S, 2010, INT J BIOL MACROMOL, V46, P363, DOI 10.1016/j.ijbiomac.2010.01.008
   Zhao W, 2012, CARBOHYD POLYM, V89, P448, DOI 10.1016/j.carbpol.2012.03.027
   Zhu MY, 2010, CARBOHYD POLYM, V80, P672, DOI 10.1016/j.carbpol.2009.11.038
NR 24
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD NOV 6
PY 2012
VL 90
IS 4
BP 1671
EP 1676
DI 10.1016/j.carbpol.2012.07.048
PG 6
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 013UI
UT WOS:000309331000038
ER

PT J
AU Li, ZT
   Zhu, LB
   Zhang, H
   Yang, J
   Zhao, J
   Du, DW
   Meng, JP
   Yang, F
   Zhao, YL
   Sun, JF
AF Li, Zhanting
   Zhu, Libing
   Zhang, Han
   Yang, Jie
   Zhao, Jie
   Du, Dewei
   Meng, Junping
   Yang, Feng
   Zhao, Yanlong
   Sun, Jifeng
TI Protective effect of a polysaccharide from stem of Codonopsis pilosula
   against renal ischemia/reperfusion injury in rats
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Codonopsis pilosula; Polysaccharide; Characterization; Renal
   ischemia/reperfusion injury; Kidney
ID SALVIAE-MILTIORRHIZAE; REPERFUSION INJURY; KIDNEY; TRANSPLANTATION;
   RADIX; ACTIVATION; EXTRACT; ACIDS
AB In this study, we purified a homogeneous polysaccharide (S-CPPA1) with a molecular weight (Mw) of 133.2 kDa from the stem of Codonopsis pilosula for the first time. Gas chromatography (GC) analysis identified that S-CPPA1 contained glucose, galactose, and arabinose with a molar ratio of 10.5:3.4:1.7, along with a trace of mannose. Methylation analysis suggested S-CPPA1 was a branched polysaccharide, with five glucosidic linkage forms, namely (1 -> 4)-linked Glcp (residue A), (1 -> 6)-linked Galp (residue B). (1 -> 2,6)-linked Glcp (residue C), (1 -> 5)-linked Araf(residue D), and non-reducing terminal (1 ->)-linked Glcp (residue E). The protective effect of S-CPPA1 on kidney ischemia/reperfusion (I/R) injury was also evaluated. Blood urea nitrogen (BUN), creatinine and INF-alpha levels, as well as lactate dehydrogenase(LDH) and alanine transaminase (AST) activities were elevated in the I/R group as compared to the sham group. On the other hand, S-CPPA1 treatment reversed all these biochemical indices, as well as histopathological alterations, which were induced by I/R. The findings imply that S-CPPA1 plays a causal role in the protection against I/R-induced renal injury and its renoprotective effect is probably mediated by inhibiting the proinflammatory cytokine TNF-alpha release. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Li, Zhanting; Zhang, Han; Yang, Jie; Zhao, Jie; Du, Dewei; Meng, Junping; Yang, Feng; Zhao, Yanlong; Sun, Jifeng] Fourth Mil Med Univ, Tangdu Hosp, Div Nephrol, Xian 710038, Peoples R China.
   [Zhu, Libing] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian 710032, Peoples R China.
   [Zhu, Libing] Peoples Liberat Army Mt Lu Sanat, Jiujiang 332000, Peoples R China.
RP Sun, JF (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Div Nephrol, Xian 710038, Peoples R China.
EM jifengsun@126.com
CR BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   CHUNG HY, 1986, CHEM PHARM BULL, V34, P3818
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Guan XH, 2009, TRANSPL INT, V22, P232, DOI 10.1111/j.1432-2277.2008.00770.x
   [韩凤梅 Han Fengmei], 2005, [中国药学杂志, Chinese Pharmaceutical Journal], V40, P1381
   Han J., 2002, MICROCIRCULATION, P31
   He B, 2011, PEDIATR SURG INT, V27, P1203, DOI 10.1007/s00383-011-2935-z
   LEHRFELD J, 1985, ANAL CHEM, V57, P346, DOI 10.1021/ac00279a077
   Li G., 2001, CHEM WORLD, V8, P421
   NEEDS PW, 1993, CARBOHYD RES, V245, P1, DOI 10.1016/0008-6215(93)80055-J
   PALLER MS, 1994, J INVEST MED, V42, P632
   Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200
   Singh B, 2004, ALTERN THER HEALTH M, V10, P52
   Sivarajah A, 2003, AM J NEPHROL, V23, P267, DOI 10.1159/000072088
   STAUB A. M., 1965, METHOD CARBOHYD CHEM, V5, P5
   STOGDALE L, 1981, J S AFR VET ASSOC, V52, P155
   Sun YX, 2008, INT J BIOL MACROMOL, V43, P279, DOI 10.1016/j.ijbiomac.2008.06.009
   Tang MK, 2002, PHYTOMEDICINE, V9, P405, DOI 10.1078/09447110260571634
   Uz E, 2009, RENAL FAILURE, V31, P251, DOI 10.1080/08860220902779921
   Varley H., 1984, PRACTICAL CLIN BIOCH
   Wang Y, 2008, PHYTOMEDICINE, V15, P923, DOI 10.1016/j.phymed.2008.09.003
   Wingenfeld P, 1996, ADV EXP MED BIOL, V403, P203
   Wojcikowsi K, 2008, FOOD CHEM TOXICOL, V46, P3122, DOI 10.1016/j.fct.2008.06.090
   杨光, 2005, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V21, P39
   [张晓君 Zhang Xiaojun], 2003, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V14, P174
   Zhang YJ, 2010, FITOTERAPIA, V81, P157, DOI 10.1016/j.fitote.2009.08.011
   Zou YF, 2011, CARBOHYD POLYM, V84, P503, DOI 10.1016/j.carbpol.2010.12.013
NR 28
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0144-8617
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD NOV 6
PY 2012
VL 90
IS 4
BP 1739
EP 1743
DI 10.1016/j.carbpol.2012.07.062
PG 5
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
SC Chemistry; Polymer Science
GA 013UI
UT WOS:000309331000047
ER

PT J
AU Yan, N
   Yu, YL
   Yang, J
   Qin, Q
   Zhu, YF
   Wang, X
   Song, RH
   Zhang, JA
AF Yan, Ni
   Yu, Yong-Liang
   Yang, Jing
   Qin, Qiu
   Zhu, Yuan-Feng
   Wang, Xuan
   Song, Rong-Hua
   Zhang, Jin-An
TI Association of interleukin-17A and-17F gene single-nucleotide
   polymorphisms with autoimmune thyroid diseases
SO AUTOIMMUNITY
LA English
DT Article
DE Interleukin-17A (IL-17A); interleukin-17F (IL-17F); Graves' disease;
   Hashimoto's thyroiditis; single nucleotide polymorphism (SNP)
ID SEQUENCE VARIANT HIS161ARG; INFLAMMATORY-BOWEL-DISEASE; GRAVES-DISEASE;
   CHINESE POPULATION; BEHCETS-DISEASE; THYROGLOBULIN; SUSCEPTIBILITY;
   IL-17F; RECEPTOR; FAMILY
AB Th17 lymphocyte and its relative cytokines have been shown to play an important role in autoimmune thyroid diseases (AITD). The aim of this study was to investigate the association between IL-17A and IL-17F gene polymorphisms and two main types of AITD, Graves' disease (GD) and Hashimoto's thyroiditis (HT). Whole blood specimens and clinical data were collected from 508 AITD patients (326 with GD and 182 with HT) and 224 age-and gender-matched healthy controls, respectively. IL-17A (rs2275913, rs8193037, rs3819025) polymorphism was determined using DNA sequencing method and IL-17F/rs763780 polymorphism was assayed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The results indicated that the frequencies of IL-17F/rs763780 genotypes in patients with GD and HT differed significantly from their controls (P = 0.013 and P = 0.005, respectively); the G allele frequencies were also significantly higher in the patient groups than the control groups (P = 0.002 and 0.001, respectively). For IL-17A/rs2275913 and rs8193037 SNP, no significant difference was observed in patients with either GD or HT compared to the control groups (P > 0.05). Interestingly, for rs3819025, the frequency of A allele was lower in patients with GD than controls (P = 0.011). The frequencies of haplotype AGGG and GGGG in patients with GD and HT were significantly higher than in controls (P = 0.012, P = 0.019, P = 0.017 and P = 0.029, respectively). In conclusion, the results indicate that IL-17F/rs763780 polymorphisms may affect the susceptibility to AITD, and IL-17A/rs3819025 SNP is likely a protective factor to GD in the Chinese population.
C1 [Yan, Ni; Yang, Jing; Qin, Qiu; Zhu, Yuan-Feng; Wang, Xuan; Song, Rong-Hua; Zhang, Jin-An] Fudan Univ, Jinshan Hosp, Dept Endocrinol, Shanghai 201508, Peoples R China.
   [Yu, Yong-Liang] Xian Cent Hosp, Dept Gen Surg, Xian, Peoples R China.
   [Yan, Ni] Fifth Hosp Xian, Xian, Peoples R China.
   [Yang, Jing] Fifth Peoples Hosp Chengdu, Chengdu, Peoples R China.
RP Zhang, JA (reprint author), Fudan Univ, Jinshan Hosp, Dept Endocrinol, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
EM zhangjinan@hotmail.com
FU National Natural Science Foundation of China [30871184, 81070627]
FX This work was supported by grants from the National Natural Science
   Foundation of China (30871184, 81070627).
CR Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Arisawa T, 2008, J CLIN IMMUNOL, V28, P44, DOI 10.1007/s10875-007-9125-8
   Ban Y, 2005, AUTOIMMUNITY, V38, P151, DOI 10.1080/08916930500050319
   Ban YY, 2003, AUTOIMMUNITY, V36, P367, DOI 10.1080/08916930310001603037
   Chen B, 2009, SCAND J GASTROENTERO, V44, P720, DOI 10.1080/00365520902795430
   Collins JE, 2003, J CLIN ENDOCR METAB, V88, P5039, DOI 10.1210/jc.2003-030093
   Dechairo BM, 2005, EUR J HUM GENET, V13, P1223, DOI 10.1038/sj.ejhg.5201485
   Figueroa-Vega N, 2010, J CLIN ENDOCR METAB, V95, P953, DOI 10.1210/jc.2009-1719
   Herbon N, 2003, GENOMICS, V81, P510, DOI 10.1016/S0888-7543(03)00035-6
   Hodge SE, 2006, THYROID, V16, P351, DOI 10.1089/thy.2006.16.351
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Jacobson EM, 2007, J AUTOIMMUN, V28, P85, DOI 10.1016/j.jaut.2007.02.006
   Jang WC, 2008, RHEUMATOL INT, V29, P173, DOI 10.1007/s00296-008-0664-y
   Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346
   Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019
   Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018
   Maierhaba M, 2008, ENDOCRINE, V33, P294, DOI 10.1007/s12020-008-9082-x
   Metzger K, 2008, BIOCHEM BIOPH RES CO, V376, P231, DOI 10.1016/j.bbrc.2008.08.135
   Nordang GBN, 2009, RHEUMATOLOGY, V48, P367, DOI 10.1093/rheumatology/ken512
   Paradowska-Gorycka A, 2010, SCAND J IMMUNOL, V72, P134, DOI 10.1111/j.1365-3083.2010.02411.x
   Pearce SHS, 1999, AM J HUM GENET, V65, P1462, DOI 10.1086/302610
   Ramsey CD, 2005, GENES IMMUN, V6, P236, DOI 10.1038/sj.gene.6364170
   Rutitzky LI, 2005, J IMMUNOL, V175, P3920
   Seiderer J, 2008, INFLAMM BOWEL DIS, V14, P437, DOI 10.1002/ibd.20339
   Shibata S, 2009, J DERMATOL SCI, V53, P163, DOI 10.1016/j.jdermsci.2008.09.003
   Shibata T, 2009, HUM IMMUNOL, V70, P547, DOI 10.1016/j.humimm.2009.04.030
   Shu QM, 2010, HUM IMMUNOL, V71, P988, DOI 10.1016/j.humimm.2010.06.020
   Tomer Y, 2002, THYROID, V12, P1129, DOI 10.1089/105072502321085234
   Tomer Y, 2002, J CLIN ENDOCR METAB, V87, P404, DOI 10.1210/jc.87.1.404
   Tomer Y, 2003, ENDOCR REV, V24, P694, DOI 10.1210/er.2002-0030
   Tonacchera M, 2000, J CLIN ENDOCR METAB, V85, P2637, DOI 10.1210/jc.85.8.2637
   Vaidya B, 1999, HUM MOL GENET, V8, P1195, DOI 10.1093/hmg/8.7.1195
   Wu XAQ, 2010, INT J CANCER, V127, P86, DOI 10.1002/ijc.25027
   Zhang J, 2006, J INT MED RES, V34, P585
NR 34
TC 0
Z9 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0891-6934
J9 AUTOIMMUNITY
JI Autoimmunity
PD NOV
PY 2012
VL 45
IS 7
BP 533
EP 539
DI 10.3109/08916934.2012.702814
PG 7
WC Immunology
SC Immunology
GA 015UG
UT WOS:000309471200005
ER

PT J
AU Guo, BN
   Zhang, J
   Yu, JC
   Wu, XJ
   Shi, YG
   Tsai, CY
AF Guo, Beining
   Zhang, Jing
   Yu, Jicheng
   Wu, Xiaojie
   Shi, Yaoguo
   Tsai, Cheng-Yuan
TI A liquid chromatography-tandem mass spectrometry assay for the
   determination of nemonoxacin (TG-873870), a novel nonfluorinated
   quinolone, in human plasma and urine and its application to a
   single-dose pharmacokinetic study in healthy Chinese volunteers
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article
DE nemonoxacin; LC-MS; MS; Method validation; human plasma; human urine
ID NON-FLUORINATED QUINOLONE; IN-VITRO ACTIVITIES
AB Nemonoxacin (TG-873870) is a novel C-8-methoxy nonfluorinated quinolone with higher activity than ciprofloxacin, levofloxacin and moxifloxacin against Gram-positive pathogens including methicillin-susceptible or methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae with various resistant phenotypes. A rapid, sensitive and selective liquid chromatographytandem mass spectrometric (LC-MS/MS) method was developed and validated to determine the concentration of nemonoxacin in human plasma and urine. Protein precipitation and liquidliquid extraction were employed for plasma and urine sample preparations, respectively, and extract was then injected into the system. Separation was performed on a C18 reversed-phase column using acetonitrile0.1% formic acid as a mobile phase. Both analyte and internal standard (gatifloxacin) were determined using electrospray ionization and the MS data acquisition via the selected reaction monitoring in positive-ion mode. The lower limit of quantification was 5?ng/mL and the calibration curves were linear in the concentration range of 51000?ng/mL. The accuracy, precision, selectivity, linearity, recovery, matrix effect and stability were validated for TG-873870 in human plasma and urine. The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers administered nemonoxacin malate capsules. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Guo, Beining; Zhang, Jing; Yu, Jicheng; Wu, Xiaojie; Shi, Yaoguo] Fudan Univ, Huashan Hosp, Inst Antibiot, Shanghai 200040, Peoples R China.
   [Guo, Beining; Zhang, Jing; Yu, Jicheng; Wu, Xiaojie; Shi, Yaoguo] Minist Hlth, Key Lab Clin Pharmacol Antibiot, Shanghai 200040, Peoples R China.
   [Tsai, Cheng-Yuan] TaiGen Biopharmaceut Co Beijing Ltd, Beijing 100020, Peoples R China.
RP Zhang, J (reprint author), Fudan Univ, Huashan Hosp, Inst Antibiot, 12 Wulumuqi Zhong Rd, Shanghai 200040, Peoples R China.
EM ioa100601@yahoo.com.cn
FU Ministry of Science and Technology of China [2008ZX09312-010]
FX The work was partially supported by the Ministry of Science and
   Technology of China (2008ZX09312-010).
CR Adam HJ, 2009, ANTIMICROB AGENTS CH, V53, P4915, DOI 10.1128/AAC.00078-09
   Andersson MI, 2003, J ANTIMICROB CHEMOTH, V51, P1, DOI 10.1093/jac/dkg212
   Barry AL, 2001, ANTIMICROB AGENTS CH, V45, P1923, DOI 10.1128/AAC.45.6.1923-1927.2001
   Chen YH, 2009, J ANTIMICROB CHEMOTH, V64, P1226, DOI 10.1093/jac/dkp370
   Chung DT, 2010, ANTIMICROB AGENTS CH, V54, P411, DOI 10.1128/AAC.00683-09
   Lauderdale TL, 2010, ANTIMICROB AGENTS CH, V54, P1338, DOI 10.1128/AAC.01197-09
   Li CR, 2010, J ANTIMICROB CHEMOTH, V65, P2411, DOI 10.1093/jac/dkq341
   Lin L, 2010, ANTIMICROB AGENTS CH, V54, P405, DOI 10.1128/AAC.00682-09
   Peterson LR, 2001, CLIN INFECT DIS, V33, pS180, DOI 10.1086/321846
NR 9
TC 1
Z9 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-3879
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD NOV
PY 2012
VL 26
IS 11
BP 1333
EP 1340
DI 10.1002/bmc.2699
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 014YS
UT WOS:000309412500006
ER

PT J
AU Wang, JK
   Zhu, XX
   Peng, Y
   Zha, WB
   Feng, D
   Zhu, YC
   Wan, P
   Qi, HH
   He, JC
   Zhou, J
   Sun, JG
AF Wang, Jiankun
   Zhu, Xuanxuan
   Peng, Ying
   Zha, Weibin
   Feng, Dong
   Zhu, Yinci
   Wan, Ping
   Qi, Huanhuan
   He, Jichao
   Zhou, Jie
   Sun, Jianguo
TI Liquid chromatography/tandem mass spectrometry method for quantification
   of trans-stilbene glycoside in rat plasma and its pharmacokinetic
   application
SO BIOMEDICAL CHROMATOGRAPHY
LA English
DT Article
DE trans-stilbene glycoside; LC-MS; MS; pharmacokinetics; isomerization;
   rat plasma
ID POLYGONUM-MULTIFLORUM THUNB; IN-VIVO; ISOMERIZATION; GLUCOSIDE
AB A rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of trans-stilbene glycoside (SG) in rat plasma. As trans-SG can be rapidly isomerized under light exposure, trans-SG plasma samples were prepared in the dark and assayed immediately. Trans-SG and internal standard were extracted by protein precipitation. Chromatographic separation was achieved on a C18 column with a gradient elution program. The detection of analytes was performed by negative ion via multiple reaction monitoring mode. The precursor-to-product ions of m/z 405.1???242.9 for trans-SG and m/z 389.1???226.9 for polydatin (internal standard) were monitored. No interference of endogenous components was observed for any plasma samples that we studied.The method was linear over the concentration range of 1.01000.0?ng/mL with a good correlation coefficient. The lower limit of quantification was 1.0?ng/mL for trans-SG. The intra and inter-batch accuracy for trans-SG in stable rat plasma samples ranged from 93.3 to 102.7% and the variation was less than 8.1%. The extraction recoveries of trans-SG in rat plasma were from 102.8 to 112.4% and the matrix effects were also acceptable. This method was successfully applied to pharmacokinetic study of trans-SG in rats after intravenous administration. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Wang, Jiankun; Zhu, Xuanxuan; Zhou, Jie] Nanjing Univ Tradit Chinese Med, Coll Pharm, Nanjing 210046, Jiangsu, Peoples R China.
   [Wang, Jiankun; Peng, Ying; Zha, Weibin; Feng, Dong; Zhu, Yinci; Wan, Ping; Qi, Huanhuan; He, Jichao; Sun, Jianguo] China Pharmaceut Univ, Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhu, Xuanxuan] Jiangsu Prov Hosp Tradit Chinese Med, Clin Res Inst, Pharmacol Lab, Nanjing 210029, Jiangsu, Peoples R China.
RP Zhu, XX (reprint author), Inst Jiangsu Prov Hosp Tradit Chinese Med, Pharmacol Lab Clin Res, Nanjing 210046, Jiangsu, Peoples R China.
EM zhuxuanxuan@sina.com.cn; jgsun_cpucn@yahoo.cn
FU Nation Key New Drug Creation Special Programme [2009ZX09304-001,
   2009ZX09502-004]; Fundamental Research Funds for the Central
   Universities [JKP2009007]
FX The study was financially supported by the Nation Key New Drug Creation
   Special Programme (2009ZX09304-001, 2009ZX09502-004) and the Fundamental
   Research Funds for the Central Universities (JKP2009007).
CR Figueiras TS, 2011, J FLUORESC, V21, P1897, DOI 10.1007/s10895-011-0886-3
   Hui Y, 2011, J CHROMATOGR A, V1218, P5858, DOI 10.1016/j.chroma.2011.06.100
   Ip SP, 1997, PHYTOTHER RES, V11, P42, DOI 10.1002/(SICI)1099-1573(199702)11:1<42::AID-PTR940>3.3.CO;2-X
   Lv GY, 2011, J ETHNOPHARMACOL, V137, P449, DOI 10.1016/j.jep.2011.05.049
   Lv L, 2007, FOOD CHEM, V104, P1678, DOI 10.1016/j.foodchem.2007.03.022
   Lv LS, 2010, J AGR FOOD CHEM, V58, P2239, DOI 10.1021/jf904122q
   Park WH, 2008, ANTIMICROB AGENTS CH, V52, P3451, DOI 10.1128/AAC.00562-08
   Ren Xiaoliang, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2620
   Sun JiangHao, 2003, Acta Pharmaceutica Sinica, V38, P968
   Wang T, 2009, FREE RADICAL BIO MED, V47, P229, DOI 10.1016/j.freeradbiomed.2009.02.027
   Zhang W, 2009, PLANTA MED, V75, P1209, DOI 10.1055/s-0029-1185540
NR 11
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-3879
J9 BIOMED CHROMATOGR
JI Biomed. Chromatogr.
PD NOV
PY 2012
VL 26
IS 11
BP 1371
EP 1376
DI 10.1002/bmc.2707
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 014YS
UT WOS:000309412500012
ER

PT J
AU Charles, JF
   Coury, F
   Sulyanto, R
   Sitara, D
   Wu, J
   Brady, N
   Tsang, K
   Sigrist, K
   Tollefsen, DM
   He, L
   Storm, D
   Aliprantis, AO
AF Charles, Julia F.
   Coury, Fabienne
   Sulyanto, Rosalyn
   Sitara, Despina
   Wu, Jing
   Brady, Nicholas
   Tsang, Kelly
   Sigrist, Kirsten
   Tollefsen, Douglas M.
   He, Li
   Storm, Daniel
   Aliprantis, Antonios O.
TI The collection of NFATc1-dependent transcripts in the osteoclast
   includes numerous genes non-essential to physiologic bone resorption
SO BONE
LA English
DT Article
DE Osteoclast; Gene array; NFATc1; Bone resorption; NHEDC2
ID HEPARIN-COFACTOR-II; MICE; EXPRESSION; CYCLASE; NFATC1; OSTEOIMMUNOLOGY;
   DIFFERENTIATION; OSTEOPETROSIS; OSTEOPOROSIS; OSTEOBLASTS
AB Osteoclasts are specialized secretory cells of the myeloid lineage important for normal skeletal homeostasis as well as pathologic conditions of bone including osteoporosis, inflammatory arthritis and cancer metastasis. Differentiation of these multinucleated giant cells from precursors is controlled by the cytokine RANKL, which through its receptor RANK initiates a signaling cascade culminating in the activation of transcriptional regulators which induce the expression of the bone degradation machinery. The transcription factor nuclear factor of activated T-cells c1 (NFATc1) is the master regulator of this process and in its absence osteoclast differentiation is aborted both in vitro and in vivo. Differential mRNA expression analysis by microarray is used to identify genes of potential physiologic relevance across nearly all biologic systems. We compared the gene expression profile of murine wild-type and NFATc1-deficient osteoclast precursors stimulated with RANKL and identified that the majority of the known genes important for osteoclastic bone resorption require NFATc1 for induction. Here, five novel RANKL-induced, NFATc1-dependent transcripts in the osteoclast are described: Nhedc2, Rhoc, Serpind1, Adcy3 and Rab38. Despite reasonable hypotheses for the importance of these molecules in the bone resorption pathway and their dramatic induction during differentiation, the analysis of mice with mutations in these genes failed to reveal a function in osteoclast biology. Compared to littermate controls, none of these mutants demonstrated a skeletal phenotype in vivo or alterations in osteoclast differentiation or function in vitro. These data highlight the need for rigorous validation studies to complement expression profiling results before functional importance can be assigned to highly regulated genes in any biologic process. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Charles, Julia F.; Aliprantis, Antonios O.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
   [Charles, Julia F.; Aliprantis, Antonios O.] Harvard Univ, Sch Med, Boston, MA USA.
   [Coury, Fabienne; Sulyanto, Rosalyn; Sitara, Despina; Wu, Jing; Brady, Nicholas; Tsang, Kelly; Sigrist, Kirsten; Aliprantis, Antonios O.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Coury, Fabienne] Harvard Univ, Sch Dent, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Tollefsen, Douglas M.; He, Li] Washington Univ, Sch Med, Div Hematol, St Louis, MO USA.
   [Storm, Daniel] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA.
   [Coury, Fabienne] Ecole Normale Super Lyon, Inst Genom Fonct Lyon, F-69364 Lyon, France.
   [Sulyanto, Rosalyn] OCC Dent, Columbus, OH USA.
   [Sitara, Despina] NYU, Coll Dent, New York, NY USA.
   [Wu, Jing] China Novartis Inst BioMed Res Co, Shanghai 201203, Peoples R China.
   [Brady, Nicholas] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [Brady, Nicholas] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA.
   [Sigrist, Kirsten] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA.
RP Aliprantis, AO (reprint author), Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.
EM aaliprantis@partners.org
FU NIH [P30 AR046032, K08AR054859, R01AR060363, DC04156, HL55520]; American
   College of Rheumatology Research and Education Foundation Rheumatology
   Investigator Award; International Bone and Mineral Society; Societe
   Francaise de Rhumatologie; Association pour la Recherche sur le Cancer;
   Philippe Foundation; Howard Hughes Fellowship; Burroughs Wellcome Fund
FX The authors acknowledge Dr. Marc Lenburg, for assistance with the
   microarray analysis. Histomorphometric analysis was performed by the
   Yale Core Center for Musculoskeletal Disorders, supported by NIH P30
   AR046032. Funding for this work was provided by the American College of
   Rheumatology Research and Education Foundation Rheumatology Investigator
   Award (JFC), International Bone and Mineral Society, Societe Francaise
   de Rhumatologie, Association pour la Recherche sur le Cancer and the
   Philippe Foundation (FC), Howard Hughes Fellowship (RS) and NIH grants
   K08AR054859 (AOA) and R01AR060363 (AOA), DC04156 (DRS), and HL55520
   (DMT). A.O.A. also holds a Career Award for Medical Scientists from the
   Burroughs Wellcome Fund.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Aliprantis AO, 2012, FASEB J, V26, P1110, DOI 10.1096/fj.11-196642
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431
   Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280
   Ha BG, 2008, PROTEOMICS, V8, P2625, DOI 10.1002/pmic.200701192
   Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805
   He L, 2002, J CLIN INVEST, V109, P213, DOI 10.1172/JCI13432
   Hofstetter W, 2010, BONE, V47, P331, DOI 10.1016/j.bone.2010.04.605
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Jonsson B, 2011, OSTEOPOROSIS INT, V22, P967, DOI 10.1007/s00198-010-1424-x
   Kendler DL, 2011, CALCIFIED TISSUE INT, V25, p[72, 91]
   KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125
   Loftus SK, 2002, P NATL ACAD SCI USA, V99, P4471, DOI 10.1073/pnas.072087599
   Meyers SN, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-337
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Osanai K, 2010, AM J PHYSIOL-LUNG C, V298, pL243
   PARFITT AM, 1987, J BONE MINER RES, V2, P595
   Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253-5269.2005
   PRATT CW, 1990, J BIOL CHEM, V265, P6092
   RAISZ LG, 1979, PROSTAGLANDINS, V17, P905, DOI 10.1016/0090-6980(79)90061-3
   Rogers MJ, 2011, SMALL GTPASES, V2, P117, DOI DOI 10.4161/SGTP.2.3.16453
   Sellmeyer DE, 2010, JAMA-J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Seto S, 2011, TRAFFIC, V12, P407, DOI 10.1111/j.1600-0854.2011.01165.x
   Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Sitara D, 2010, IMMUNOL REV, V233, P286
   Smyth GK, 1995, J R STAT SOC B, V57, p[3, 289]
   Sun C, 1995, J CELL SCI 6, V23, p[260, 2285]
   Takami M, 2005, FEBS LETT, V579, P832, DOI 10.1016/j.febslet.2004.12.066
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6
   Tollefsen DM, 2007, ARTERIOSCL THROM VAS, V27, P454, DOI 10.1161/01.ATV.0000256471.22437.8
   Wang ZS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006979
   WARE CB, 1995, DEVELOPMENT, V121, P1283
   Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X
   Woo SB, 2006, ANN INTERN MED, V144, P753
   Wu J, 2008, P NATL ACAD SCI USA, V105, P16934, DOI 10.1073/pnas.0808763105
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yoon SH, 2011, J BONE MINER RES, V26, P1217, DOI 10.1002/jbmr.310
   Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200
NR 46
TC 0
Z9 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD NOV
PY 2012
VL 51
IS 5
BP 902
EP 912
DI 10.1016/j.bone.2012.08.113
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 015FX
UT WOS:000309432900010
ER

PT J
AU Chen, W
   Li, ZY
   Su, YL
   Hou, ZY
   Zhang, Q
   Zhang, YZ
AF Chen, Wei
   Li, Zhiyong
   Su, Yanling
   Hou, Zhiyong
   Zhang, Qi
   Zhang, Yingze
TI Garden type I fractures myth or reality? A prospective study comparing
   CT scans with X-ray findings in Garden type I femoral neck fractures
SO BONE
LA English
DT Article
DE Femoral neck fracture; Garden classification; Incomplete fracture;
   Computed tomography
ID INTRACAPSULAR HIP-FRACTURES; TIBIAL PLATEAU FRACTURES;
   COMPUTED-TOMOGRAPHY; OBSERVER VARIATION; CORTICAL BONE; CLASSIFICATION;
   FEMUR; DIAGNOSIS; RECONSTRUCTION; DISPLACEMENT
AB The Garden type I femoral neck fracture is defined as an incomplete fracture of the neck of the femur as seen on the antero-posterior (AP) radiograph of the injured hip. The diagnosis of incomplete femoral neck fractures has decreased in recent years with the development of improved radiographic imaging. We hypothesized that incomplete femoral neck fractures seen on radiographs are in fact complete fractures on computed tomography (CT). The study aims to test this hypothesis by comparing CT scan images to X-ray findings in patients diagnosed with Garden type I femoral neck fractures. From January 2008 to October 2010, our management of femoral neck fractures included a CT scan of the injured hip for all Garden type I fractures. CT findings were reported by a musculoskeletal radiologist. A classification of the fracture was performed by an orthopedic surgeon. Eight hundred and twenty five femoral neck fractures were admitted during the study period. Seventeen of these fractures (2.1%) were considered incomplete based on radiographic evaluation. In 17 cases (100%), the CT scan demonstrated a complete fracture extending through the medial cortex. Subsequently, all 17 fractures were fixed with standard cannulated screw technique on a fracture table. Secondary displacement occurred in one patient prior to fixation. All fractures healed well and no avascular necrosis was noted. In summary, our study shows that incomplete femoral neck fractures identified on X-rays are actually complete fractures based on CT scans. If confirmed by a larger study population, our findings can simplify the Garden classification by eliminating an inaccurate subcategory. The clinical implications are that Garden type I fractures should all likely be fixed with cannulated screws and with an effort to prevent displacement during treatment. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Chen, Wei; Li, Zhiyong; Su, Yanling; Hou, Zhiyong; Zhang, Qi; Zhang, Yingze] Hebei Med Univ, Hosp 3, Dept Orthopaed Surg, Shijiazhuang 050051, Hebei, Peoples R China.
RP Zhang, YZ (reprint author), Hebei Med Univ, Hosp 3, Dept Orthopaed Surg, 139 Ziqiang Rd, Shijiazhuang 050051, Hebei, Peoples R China.
EM drchenwei1981@gmail.com; 845247428@qq.com; drzhangyingze@yahoo.com.cn;
   dryzzhang@yahoo.com.cn; surgeonzhangqi@yahoo.com.cn;
   drzhangyingze@yahoo.com.cn
CR BARNES R, 1976, J BONE JOINT SURG BR, V58, P2
   Beimers L, 2002, CAN J SURG, V45, P411
   Blundell CM, 1998, J BONE JOINT SURG BR, V80B, P679, DOI 10.1302/0301-620X.80B4.8476
   Borrell Jr J J, 2002, J ORTHOP TRAUMA, V16, P56
   Borrelli J, 2002, J ORTHOP TRAUMA, V16, P449, DOI 10.1097/01.BOT.0000025140.46512.6C
   Bradley M, 2006, BRIT J RADIOL, V79, P216, DOI 10.1259/bjr/31965396
   CAMPION ER, 1993, J BONE JOINT SURG AM, V75A, P1879
   Chen C K, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P591
   Conn KS, 2004, CLIN ORTHOP RELAT R, P249, DOI 10.1097/01.blo.0000119459.00792.c1
   Crabtree N, 2001, J BONE MINER RES, V16, P1318, DOI 10.1359/jbmr.2001.16.7.1318
   DeLaMora SN, 2002, CLIN ORTHOP RELAT R, P9
   Dimon Tine Jochewet Ravn, 2008, Ugeskr Laeger, V170, P2949
   France John C, 2005, J Orthop Trauma, V19, P640, DOI 10.1097/01.bot.0000188036.69078.ef
   FRANDSEN PA, 1983, ACTA ORTHOP SCAND, V54, P681
   FRANDSEN PA, 1988, J BONE JOINT SURG BR, V70, P588
   GARDEN RS, 1961, J BONE JOINT SURG BR, V43, P647
   Geijer M, 2012, ACTA RADIOL, V53, P197, DOI 10.1258/ar.2011.110466
   Gruber JE, 1998, EMERGENCY MED CONCEP, P763
   Helland EB, 2000, ACTA ORTHOP SCAND, V71, P639, DOI 10.1080/000164700317362316
   Hernigou P, 1997, J BONE JOINT SURG BR, V79B, P285, DOI 10.1302/0301-620X.79B2.7109
   Hoffmann R, 2000, AO PRINCIPLES FRACTU, P445
   Johannesdottir F, 2011, BONE, V48, P1268, DOI 10.1016/j.bone.2011.03.776
   Kim JW, 2007, INT ORTHOP, V31, P61, DOI 10.1007/s00264-006-0138-3
   Kyle RF, 1993, FRACTURES DISLOCATIO, V2, P770
   Laursen J O, 1999, Acta Orthop Belg, V65, P478
   Liow RYL, 1999, ORTHOPEDICS, V22, P929
   Lubovsky O, 2005, INJURY, V36, P788, DOI 10.1016/j.injury.2005.01.024
   MATIN P, 1979, J NUCL MED, V20, P1227
   Mui LW, 2007, SKELETAL RADIOL, V36, P145, DOI 10.1007/s00256-006-0216-z
   NIEMINEN S, 1975, ACTA ORTHOP SCAND, V46, P775
   Perron AD, 2002, AM J EMERG MED, V20, P234, DOI 10.1053/ajem.2002.33007
   RAAYMAKERS ELFB, 1993, ACTA ORTHOP SCAND, V64, P233, DOI 10.3109/17453679308994579
   Shuqiang Ma, 2006, Injury, V37, P974, DOI 10.1016/j.injury.2006.04.136
   Thomsen NOB, 1996, INT ORTHOP, V20, P326, DOI 10.1007/s002640050087
   Thorngren K-G, 2002, Injury, V33 Suppl 3, pC1
   Verheyen CCPM, 2005, ARCH ORTHOP TRAUM SU, V125, P166, DOI 10.1007/s00402-004-0791-1
   Wicky S, 2000, EUR RADIOL, V10, P1227, DOI 10.1007/s003300000326
   WOLINSKY PR, 1995, CLIN ORTHOP RELAT R, P81
   Yang KH, 1998, J BONE JOINT SURG BR, V80B, P673, DOI 10.1302/0301-620X.80B4.8406
   Zhang YZ, 2009, CLIN EPIDEMIOLOGY TR, P201
   Zlowodzki M, 2005, ARCH ORTHOP TRAUM SU, V125, P503, DOI 10.1007/s00402-005-0022-4
NR 41
TC 0
Z9 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD NOV
PY 2012
VL 51
IS 5
BP 929
EP 932
DI 10.1016/j.bone.2012.07.027
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 015FX
UT WOS:000309432900013
ER

PT J
AU Liu, YS
   Liu, H
   Titus, L
   Boden, SD
AF Liu, Yunshan
   Liu, Hui
   Titus, Louisa
   Boden, Scott D.
TI Natural antisense transcripts enhance bone formation by increasing sense
   IFITM5 transcription
SO BONE
LA English
DT Article
DE Interferon induced transmembrane proteins; Natural antisense
   transcripts; Osteoblast differentiation; Bone formation
ID DIFFERENTIATION IN-VITRO; MAMMARY CELL-LINE; DOME FORMATION; EXPRESSION;
   IDENTIFICATION; DISSECTION; KINASE; MOUSE; BMP-2; MICE
AB Interferon induced transmembrane protein 5 (IFITM5) has been recognized as an osteoblast differentiation factor. Its regulation, however, is still unclear. In this report, four novel naturally occurring antisense transcripts of rat IFITM2 and IFITM5 transcribed from the opposite strand of the IFITM gene locus, were isolated and characterized. They are alternatively transcribed from rat chromosome 1 and expressed at relatively high levels during early differentiation of primary isolates of rat osteoblast cells. There are two common fragments in all of the isoform cDNA sequences that are complimentary to both IFITM2 and IFITM5 respectively. There is an additional unique region in one isoform, immediately downstream of the putative IFITM5 complimentary region, which is also complimentary to IFITM cDNA sequence. Reading frame analysis showed that these antisense transcripts are non protein coding mRNAs. We investigated the expression of these antisense transcripts and their effects on IFITM expression as well as osteoblast differentiation. All isoforms were positively correlated with IFITM5 expression and antisense specific siRNAs inhibited osteoblast differentiation significantly. In contrast, these antisense transcripts had no effect on the expression of IFITM2. We speculate that IFITM5 may be regulated by antisense transcripts. Published by Elsevier Inc.
C1 [Liu, Yunshan; Liu, Hui; Titus, Louisa; Boden, Scott D.] Emory Univ, VAMC Res Serv, Sch Med, Decatur, GA 30033 USA.
   [Liu, Yunshan; Liu, Hui; Titus, Louisa; Boden, Scott D.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.
   [Liu, Yunshan] Emory Univ, Dept Orthopaed, Sch Med, Decatur, GA 30033 USA.
   [Liu, Hui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Spine Surg, Guangzhou 510080, Guangdong, Peoples R China.
   [Boden, Scott D.] Emory Orthopaed & Spine Ctr, Atlanta, GA 30320 USA.
RP Titus, L (reprint author), Emory Univ, VAMC Res Serv, Sch Med, 1670 Clairmont Rd, Decatur, GA 30033 USA.
EM yliu5@emory.edu; hippocratez@gmail.com; ftitus@emory.edu;
   sboden@emory.edu
FU Atlanta Research and Education Foundation
FX We would like to thank Maggie Bargouti for cell culture assistance and
   helpful discussions, Mesfin Teklemariam for real-time RT-PCR assistance
   and data analysis, and Dr. Manjula Viggeswarapu and Dr. Sreedhara
   Sangadala for helpful discussions. This work was funded by the Atlanta
   Research and Education Foundation. One of the authors (SDB) receives
   royalties from Medtronic for a demineralized bone matrix product. No
   other potential conflicts of interest exist.
CR BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985
   Boden SD, 1996, ENDOCRINOLOGY, V137, P3401, DOI 10.1210/en.137.8.3401
   BRADBURY LE, 1992, J IMMUNOL, V149, P2841
   Carmichael GG, 2003, NAT BIOTECHNOL, V21, P371, DOI 10.1038/nbt0403-371
   Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230
   Chen JJ, 2004, NUCLEIC ACIDS RES, V32, P4812, DOI 10.1093/nar/gkh818
   EVANS SS, 1990, BLOOD, V76, P2583
   EVANS SS, 1993, J IMMUNOL, V150, P736
   Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738
   Hanagata N, 2011, J BONE MINER METAB, V29, P279, DOI 10.1007/s00774-010-0221-0
   KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x
   Knowling S, 2011, BIOCHIMIE, V93, P1922, DOI 10.1016/j.biochi.2011.07.031
   Lange UC, 2008, MOL CELL BIOL, V28, P4688, DOI 10.1128/MCB.00272-08
   Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1
   Lavorgna G, 2004, TRENDS BIOCHEM SCI, V29, P88, DOI 10.1016/j.tibs.2003.12.002
   Li KG, 2010, ONCOTARGET, V1, P447
   Liu H, 2011, J BONE MINER RES, V26, P1122, DOI 10.1002/jbmr.296
   Moffatt P, 2008, J BONE MINER RES, V23, P1497, DOI 10.1359/JBMR.080412
   Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927
   Tanaka SS, 2004, DEV DYNAM, V230, P651, DOI 10.1002/dvdy.20085
   Wang XJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r30
   Watanabe Y, 2010, GENOMICS, V96, P333, DOI 10.1016/j.ygeno.2010.08.007
   Zucchi I, 2001, P NATL ACAD SCI USA, V98, P5608, DOI 10.1073/pnas.091101898
   Zucchi I, 1999, P NATL ACAD SCI USA, V96, P13766, DOI 10.1073/pnas.96.24.13766
   Zucchi I, 1998, P NATL ACAD SCI USA, V95, P1079, DOI 10.1073/pnas.95.3.1079
   Zucchi I, 2004, P NATL ACAD SCI USA, V101, P1880, DOI 10.1073/pnas.0307292101
NR 26
TC 0
Z9 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD NOV
PY 2012
VL 51
IS 5
BP 933
EP 938
DI 10.1016/j.bone.2012.07.024
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 015FX
UT WOS:000309432900014
ER

PT J
AU Huang, SQ
   Liao, QJ
   Wang, XW
   Xin, DQ
   Chen, SX
   Wu, QJ
   Ye, G
AF Huang, S. Q.
   Liao, Q. J.
   Wang, X. W.
   Xin, D. Q.
   Chen, S. X.
   Wu, Q. J.
   Ye, G.
TI RNAi-mediated knockdown of pituitary tumor-transforming gene-1 (PTTG1)
   suppresses the proliferation and invasive potential of PC3 human
   prostate cancer cells
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE PTTG1; Prostate cancer; Cell proliferation; Transwell invasion assay;
   Anticancer drug resistance
ID INCREASED EXPRESSION; POOR-PROGNOSIS; ACTIVATION; IDENTIFICATION;
   ANGIOGENESIS; CARCINOMA; TARGET; DOMAIN
AB Pituitary tumor-transforming gene-1 (PTTG1) is a proto-oncogene that promotes tumorigenesis and metastasis in numerous cell types and is overexpressed in a variety of human tumors. We have demonstrated that PTTG1 expression was up-regulated in both human prostate cancer specimens and prostate cancer cell lines. For a more direct assessment of the function of PTTG1 in prostate tumorigenesis, RNAi-mediated knockdown was used to selectively decrease PTTG1 expression in PC3 human prostate tumor cells. After three weeks of selection, colonies stably transfected with PTTG1-targeted RNAi (the knockdown PC3 cell line) or empty vector (the control PC3 cell line) were selected and expanded to investigate the role of PTTG1 expression in PC3 cell growth and invasion. Cell proliferation rate was significantly slower (28%) in the PTTG1 knockdown line after 6 days of growth as indicated by an MTT cell viability assay (P < 0.05). Similarly, a soft agar colony formation assay revealed significantly fewer (66.7%) PTTG1 knockdown PC3 cell colonies than control colonies after three weeks of growth. In addition, PTTG1 knockdown resulted in cell cycle arrest at G1 as indicated by fluorescence-activated cell sorting. The PTTG1 knockdown PC3 cell line also exhibited significantly reduced migration through Matrigel in a transwell assay of invasive potential, and down-regulation of PTTG1 could lead to increased sensitivity of these prostate cancer cells to a commonly used anticancer drug, taxol. Thus, PTTG1 expression is crucial for PC3 cell proliferation and invasion, and could be a promising new target for prostate cancer therapy.
C1 [Huang, S. Q.; Liao, Q. J.; Wang, X. W.; Chen, S. X.; Wu, Q. J.; Ye, G.] Third Mil Med Univ, Xinqiao Hosp, Dept Urol, Chongqing 400037, Peoples R China.
   [Huang, S. Q.; Liao, Q. J.; Wang, X. W.; Chen, S. X.; Wu, Q. J.; Ye, G.] Third Mil Med Univ, Xinqiao Hosp, Ctr Nephrol, Chongqing 400037, Peoples R China.
   [Huang, S. Q.; Xin, D. Q.] Peking Univ, Inst Urol, Beijing 100871, Peoples R China.
   [Huang, S. Q.; Xin, D. Q.] Peking Univ, Hosp 1, Dept Urol, Beijing 100871, Peoples R China.
RP Wang, XW (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Urol, Chongqing 400037, Peoples R China.
EM doctorwangxianwei@163.com
FU National Natural Science Foundation of China [81172443]
FX Research supported by the National Natural Science Foundation of China
   (#81172443).
CR BROWN TR, 1988, P NATL ACAD SCI USA, V85, P8151, DOI 10.1073/pnas.85.21.8151
   Chesnokova V, 2007, CANCER RES, V67, P10564, DOI 10.1158/0008-5472.CAN-07-0974
   Cho-Rok Jung, 2006, Hepatology, V43, P1042
   Cinar B, 1999, CANC RES ALERT, V1, P100
   Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140
   EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249
   Fujii T, 2006, HEPATOLOGY, V43, P1267, DOI 10.1002/hep.21181
   Genkai N, 2006, ONCOL REP, V15, P1569
   Ghayad SE, 2009, J MOL ENDOCRINOL, V42, P87, DOI 10.1677/JME-08-0076
   Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3
   Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.3.CO;2-2
   Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043
   Ivanova AV, 2009, CLIN CANCER RES, V15, P2602, DOI 10.1158/1078-0432.CCR-08-2755
   Lai YQ, 2007, J BIOCHEM MOL BIOL, V40, P966
   Lee UE, 2010, FEBS LETT, V584, P1006, DOI 10.1016/j.febslet.2010.01.049
   Liao LJ, 2011, HEAD NECK-J SCI SPEC, V33, P719, DOI 10.1002/hed.21531
   Malik MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-61
   McCabe CJ, 1999, J ENDOCRINOL, V162, P163, DOI 10.1677/joe.0.1620163
   Moreno-Mateos MA, 2011, MOL BIOL CELL, V22, P4302, DOI 10.1091/mbc.E10-10-0838
   Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200
   Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433
   Scheuner MT, 2010, GENET MED, V12, P726, DOI 10.1097/GIM.0b013e3181f30e9e
   Shah PP, 2011, CANCER LETT, V311, P66, DOI 10.1016/j.canlet.2011.06.033
   Shen XL, 2010, BIOCHEM BIOPH RES CO, V398, P707, DOI 10.1016/j.bbrc.2010.07.005
   Smith VE, 2010, EXPERT REV MOL MED, V3
   Tong YG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023754
   Tong YG, 2009, J MOL ENDOCRINOL, V43, P179, DOI 10.1677/JME-08-0176
   Wen DS, 2008, ORAL ONCOL, V44, P545, DOI 10.1016/j.oraloncology.2007.06.016
   Xin Dian-qi, 2005, Beijing Da Xue Xue Bao, V37, P638
   Yong EL, 2000, ANN MED, V32, P15, DOI 10.3109/07853890008995905
   Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761
   Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156
   Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592
   Zhu XH, 2006, ANTICANCER RES, V26, P1253
   Park JJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-81
NR 35
TC 0
Z9 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2012
VL 45
IS 11
BP 995
EP 1001
DI 10.1590/S0100-879X2012007500126
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 015TZ
UT WOS:000309470400001
ER

PT J
AU Wang, GJ
   Wang, HX
   Yao, YS
   Guo, LY
   Liu, P
AF Wang, Gui-Jun
   Wang, Hong-Xin
   Yao, Yu-Sheng
   Guo, Lian-Yi
   Liu, Pei
TI The role of Ca2+/calmodulin-dependent protein kinase II and calcineurin
   in TNF-alpha-induced myocardial hypertrophy
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Myocardial hypertrophy; Tumor necrosis factor alpha; Calcium;
   Calmodulin-dependent kinase; Calcineurin
ID NECROSIS-FACTOR-ALPHA; ADRENERGIC-RECEPTOR STIMULATION; CARDIAC
   MYOCYTES; RAT CARDIOMYOCYTES; CA2+ TRANSIENTS; INHIBITION; EXPRESSION;
   FAILURE; GROWTH; HEART
AB We investigated whether Ca2+/calmodulin-dependent kinase II (CaMKII) and calcineurin (CaN) are involved in myocardial hypertrophy induced by tumor necrosis factor alpha (TNF-alpha). The cardiomyocytes of neonatal Wistar rats (1-2 days old) were cultured and stimulated by TNF-alpha (100 mu g/L), and Ca2+ signal transduction was blocked by several antagonists, including BAPTA (4 mu M), KN-93 (0.2 mu M) and cyclosporin A (CsA, 0.2 mu M). Protein content, protein synthesis, cardiomyocyte volumes, [Ca2+](i) transients, CaMKII delta(B) and CaN were evaluated by the Lowry method, [H-3]-leucine incorporation, a computerized image analysis system, a Till imaging system, and Western blot analysis, respectively. TNF-alpha induced a significant increase in protein content in a dose-dependent manner from 10 mu g/L (53.56 mu g protein/well) to 100 mu g/L (72.18 mu g protein/well), and in a time-dependent manner from 12 h (37.42 mu g protein/well) to 72 h (42.81 mu g protein/well). TNF-alpha (100 mu g/L) significantly increased the amplitude of spontaneous [Ca2+](i) transients, the total protein content, cell size, and [H-3]-leucine incorporation in cultured cardiomyocytes, which was abolished by 4 mu M BAPTA, an intracellular Ca2+ chelator. The increases in protein content, cell size and [H-3]-leucine incorporation were abolished by 0.2 mu M KN-93 or 0.2 mu M CsA. TNF-alpha increased the expression of CaMKII delta(B) by 35.21% and that of CaN by 22.22% compared to control. These effects were abolished by 4 mu M BAPTA, which itself had no effect. These results suggest that TNF-alpha induces increases in [Ca2+](i), CaMKIIdB and CaN and promotes cardiac hypertrophy. Therefore, we hypothesize that the Ca2+/CaMKII- and CaN-dependent signaling pathways are involved in myocardial hypertrophy induced by TNF-alpha.
C1 [Wang, Gui-Jun; Liu, Pei] China Med Univ, Affiliated Hosp 1, Dept Infect Dis, Shenyang 110001, Liaoning, Peoples R China.
   [Wang, Gui-Jun; Wang, Hong-Xin; Yao, Yu-Sheng; Guo, Lian-Yi] Liaoning Med Coll, Jinzhou, Peoples R China.
RP Liu, P (reprint author), China Med Univ, Affiliated Hosp 1, Dept Infect Dis, 155 Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
EM syliupei2003@yahoo.com.cn
CR Amadou A, 2002, AM J PHYSIOL-CELL PH, V282, pC1339, DOI 10.1152/ajpcell.00471.2001
   Arras M, 1996, CELL TISSUE RES, V285, P39, DOI 10.1007/s004410050618
   BELTRAMI CA, 1994, CIRCULATION, V89, P151
   Bogoyevitch MA, 1996, BIOCHEM J, V314, P115
   Bozkurt B, 1998, CIRCULATION, V97, P1382
   Defer N, 2007, J BIOL CHEM, V282, P35564, DOI 10.1074/jbc.M704003200
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   KROWN KA, 1995, FEBS LETT, V376, P24, DOI 10.1016/0014-5793(95)01238-5
   Li XQ, 2003, ACTA PHARMACOL SIN, V24, P1224
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luo JD, 2001, BRIT J PHARMACOL, V132, P159, DOI 10.1038/sj.bjp.0703792
   MacDonnell SM, 2007, AM J PHYSIOL-HEART C, V293, pH3122, DOI 10.1152/ajpheart.00687.2007
   Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466
   Nakamura K, 1998, CIRCULATION, V98, P794
   Obasanjo-Blackshire K, 2006, CARDIOVASC RES, V71, P672, DOI 10.1016/j.cardiores.2006.05.026
   Rohini Agrawal, 2010, Pharmacol Res, V61, P269
   Sekiguchi K, 2004, CARDIOVASC RES, V63, P433, DOI 10.1016/j.cardiores.2004.02.005
   Sheng JZ, 1996, EUR J PHARMACOL, V307, P323, DOI 10.1016/0014-2999(96)00280-4
   SIMPSON P, 1985, CIRC RES, V56, P884
   Yokoyama T, 1997, CIRCULATION, V95, P1247
   Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239
NR 21
TC 0
Z9 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2012
VL 45
IS 11
BP 1045
EP 1051
DI 10.1590/S0100-879X2012007500121
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 015TZ
UT WOS:000309470400008
ER

PT J
AU Li, YW
   Xu, YQ
   Lei, B
   Wang, WX
   Ge, X
   Li, JR
AF Li, Yiwen
   Xu, Yuqing
   Lei, Bo
   Wang, Wenxiu
   Ge, Xin
   Li, Jingrui
TI Rhein induces apoptosis of human gastric cancer SGC-7901 cells via an
   intrinsic mitochondrial pathway
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Rhein, SGC-7901 cells; MTT; TUNEL; Flow cytometry; Apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; NASOPHARYNGEAL CARCINOMA-CELLS;
   CYTOCHROME-C; GENE-EXPRESSION; DEATH PATHWAY; BCL-2 FAMILY; ALOE-EMODIN;
   CASCADE; GROWTH; PROLIFERATION
AB Rhein is a primary anthraquinone found in the roots of a traditional Chinese herb, rhubarb, and has been shown to have some anticancer effects. The aim of the present study was to investigate the effect of rhein on the apoptosis of the human gastric cancer line SGC-7901 and to identify the mechanism involved. SGC-7901 cells were cultured and treated with rhein (0, 50, 100, 150, and 200 mu M) for 24, 48, or 72 h. Relative cell viability assessed by the MTT assay after treatment was 100, 99, 85, 79, 63% for 24 h; 100, 98, 80, 51, 37% for 48 h, and 100, 97, 60, 36, 15% for 72 h, respectively. Cell apoptosis was detected with TUNEL staining and quantified with flow cytometry using annexin FITC-PI staining at 48 h after 100, 200 and 300 mu m rhein. The percentage of apoptotic cells was 7.3, 21.9, 43.5%, respectively. We also measured the mRNA levels of caspase-3 and -9 using real-time PCR. Treatment with 100 mu M rhein for 48 h significantly increased mRNA expression of caspase-3 and -9. The levels of apoptosis-related proteins including Bcl-2, Bax, Bcl-xL, and pro-caspase-3 were evaluated in rhein-treated cells. Rhein increased the Bax: Bcl-2 ratio but decreased the protein levels of Bcl-xL and pro-caspase-3. Moreover, rhein significantly increased the expression of cytochrome c and apoptotic protease activating factor 1, two critical components involved in mitochondrial pathway-mediated apoptosis. We conclude that rhein inhibits SGC-7901 proliferation by inducing apoptosis and this antitumor effect of rhein is mediated in part by an intrinsic mitochondrial pathway.
C1 [Li, Yiwen; Xu, Yuqing; Wang, Wenxiu] Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, Harbin 150086, Heilongjiang, Peoples R China.
   [Ge, Xin; Li, Jingrui] Heilongjiang Prov Hosp, Dept Gen Surg, Harbin, Heilongjiang, Peoples R China.
   [Lei, Bo] Harbin Med Univ, Affiliated Hosp 3, Dept Breast Surg, Harbin 150086, Heilongjiang, Peoples R China.
RP Wang, WX (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Oncol, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China.
EM wangwenxiu150086@163.com
CR Aviello G, 2010, J CELL MOL MED, V14, P2006, DOI 10.1111/j.1582-4934.2009.00815.x
   Baell JB, 2002, BIOCHEM PHARMACOL, V64, P851, DOI 10.1016/S0006-2952(02)01148-6
   CASTIGLIONE S, 1993, ANTI-CANCER DRUG, V4, P407
   Chen YY, 2010, INT J ONCOL, V36, P1113
   Chen YY, 2010, ANTICANCER RES, V30, P945
   DELPINO A, 1992, CANCER BIOCHEM BIOPH, V12, P241
   Dvorakova K, 2002, ANTI-CANCER DRUG, V13, P1031, DOI 10.1097/00001813-200211000-00007
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Goodsell DS, 2002, STEM CELLS, V20, P355, DOI 10.1634/stemcells.20-4-355
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Heo SK, 2009, J VASC RES, V46, P375, DOI 10.1159/000189798
   Hess CJ, 2007, J CLIN ONCOL, V25, P1209, DOI 10.1200/JCO.2006.08.4061
   Hsia TC, 2009, ANTICANCER RES, V29, P309
   Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094
   Ip SW, 2007, ANTICANCER RES, V27, P379
   Jemal A, 2002, CA-CANCER J CLIN, V52, P23
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kuo PL, 2004, PLANTA MED, V70, P12, DOI 10.1055/s-2004-815448
   Lai WW, 2009, IN VIVO, V23, P309
   Lee HJ, 2008, CANCER LETT, V270, P342, DOI 10.1016/j.canlet.2008.05.040
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1
   Lin ML, 2007, ANTICANCER RES, V27, P3313
   Lin ML, 2009, ORAL ONCOL, V45, P531, DOI 10.1016/j.oraloncology.2008.07.012
   Lin SG, 2003, ARCH BIOCHEM BIOPHYS, V418, P99, DOI 10.1016/j.abb.2003.08.004
   Lin SG, 2003, INT J ONCOL, V22, P829
   Lin YJ, 2009, ANTI-CANCER DRUG, V20, P65, DOI 10.1097/CAD.0b013e3283182913
   Mantena SK, 2006, CARCINOGENESIS, V27, P1682, DOI 10.1093/carcin/bgl030
   MICCADEI S, 1993, ANTICANCER RES, V13, P1507
   OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O
   SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834
   Shi P, 2008, AM J CHINESE MED, V36, P805, DOI 10.1142/S0192415X08006259
   Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263
NR 36
TC 0
Z9 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD NOV
PY 2012
VL 45
IS 11
BP 1052
EP 1059
DI 10.1590/S0100-879X2012007500125
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 015TZ
UT WOS:000309470400009
ER

PT J
AU Zhao, YC
   Xin, J
   Sun, CH
   Zhao, BX
   Zhao, J
   Su, L
AF Zhao, YanChun
   Xin, Jie
   Sun, ChunHui
   Zhao, BaoXiang
   Zhao, Jing
   Su, Le
TI Safrole oxide induced neuronal differentiation of rat bone-marrow
   mesenchymal stem cells by elevating Hsp70
SO GENE
LA English
DT Article
DE Safrole oxide; Bone marrow mesenchymal stem cell; Differentiation;
   Neuron-like cells; Hsp70
ID STROMAL CELLS; IN-VITRO; EXPRESSION; PROTEINS; APOPTOSIS; GROWTH; GENES;
   BRAIN; LEVEL
AB In a previous study, we found that at low concentrations, safrole oxide (SFO) could induce vascular endothelial cell (VEC) transdifferentiation into neuron-like cells; however, whether SFO could induce bone-marrow mesenchymal stem cell (BMSC) neural differentiation was unknown. Here, we found that SFO could effectively induce BMSC neural differentiation in the presence of serum and fibroblast growth factor 2 and did not affect cell viability at low concentrations. The levels of neuron-specific enolase and neurofilament-L were increased greatly, but that of glial fibrillary acidic protein was absent with SFO treatment for 48 h. Furthermore, SFO could increase the level of heat shock protein 70 (Hsp70), an important factor in neuronal differentiation. Knockdown of Hsp70 by its small interfering RNA blocked SFO-induced BMSC differentiation. Thus, SFO is a novel inducer of BMSC differentiation to neuron-like cells and Hsp70 is implicated in the differentiation process. We provide a new tool for obtaining neuron-like cells from BMSCs and for further investigating the new effect of Hsp70 on BMSC neuronal differentiation. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhao, YanChun; Xin, Jie; Sun, ChunHui; Zhao, BaoXiang; Zhao, Jing; Su, Le] Shandong Univ, Inst Dev Biol, Sch Life Sci, Shandong Prov Key Lab Anim Cells & Dev Biol, Jinan 250100, Peoples R China.
   [Sun, ChunHui; Zhao, Jing; Su, Le] Shandong Univ, Chinese Minist Educ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Jinan 250012, Peoples R China.
   [Sun, ChunHui; Zhao, Jing; Su, Le] Shandong Univ, Qilu Hosp, Chinese Minist Hlth, Jinan 250012, Peoples R China.
   [Zhao, BaoXiang] Shandong Univ, Sch Chem & Chem Engn, Inst Organ Chem, Jinan 250100, Peoples R China.
RP Zhao, BX (reprint author), Shandong Univ, Inst Dev Biol, Sch Life Sci, Shandong Prov Key Lab Anim Cells & Dev Biol, Shanda Nan Rd, Jinan 250100, Peoples R China.
EM bxzhao@sdu.edu.cn; sule@sdu.edu.cn
FU National Natural Science Foundation of China [31070735, 30800398,
   31000510]; National 973 Research Project [2011CB503906]; Science and
   Technology Development Project of Shandong Province [2008GG10 002034,
   Z2008D04, ZR2010CZ004, 2007BSB01062]; Shandong Province Postdoctoral
   Special Funds for Innovative Projects [200901008, 200802024];
   Independent Innovation Foundation of Shandong University [2009JC007,
   2009GN033]
FX This study was supported in part by the National Natural Science
   Foundation of China (No. 31070735, No. 30800398, No. 31000510), the
   National 973 Research Project (No. 2011CB503906), the Science and
   Technology Development Project of Shandong Province (2008GG10 002034,
   Z2008D04, ZR2010CZ004 and 2007BSB01062), Shandong Province Postdoctoral
   Special Funds for Innovative Projects (200901008, 200802024) and the
   Independent Innovation Foundation of Shandong University (2009JC007,
   2009GN033). We thank Laura Smales for English editing.
CR Aguirre N, 1999, NEUROREPORT, V10, P3675, DOI 10.1097/00001756-199911260-00039
   Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212
   Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561
   Barnabe GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005222
   Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705
   Calabrese V, 2002, DEV NEUROSCI-BASEL, V24, P1, DOI 10.1159/000064941
   Chen SY, 2006, MOL VIS, V12, P1355
   Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609
   D'Souza SM, 1998, CELL STRESS CHAPERON, V3, P188, DOI 10.1379/1466-1268(1998)003<0188:CEOHSP>2.3.CO;2
   Fan BS, 2011, GENE, V485, P167, DOI 10.1016/j.gene.2011.06.027
   Foster JA, 1996, J NEUROSCI RES, V46, P652, DOI 10.1002/(SICI)1097-4547(19961215)46:6<652::AID-JNR2>3.0.CO;2-E
   Hofman-Bang J, 1999, GENE, V238, P387, DOI 10.1016/S0378-1119(99)00343-1
   Huh YH, 2009, GENE, V448, P7, DOI 10.1016/j.gene.2009.08.015
   Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941
   Mao HT, 2011, GENE, V486, P74, DOI 10.1016/j.gene.2011.07.018
   Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100
   Miao JY, 2002, ACTA PHARMACOL SIN, V23, P323
   Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437
   Renbaum P, 2003, GENE, V318, P113, DOI 10.1016/S0378-1119(03)00766-2
   Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Scintu F, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-14
   Su L, 2006, BBA-MOL CELL RES, V1763, P247, DOI 10.1016/j.bbamcr.2006.01.002
   Tanaka Y, 2007, J CELL BIOCHEM, V102, P689, DOI 10.1002/jcb.21322
   Tao H, 2005, DEV GROWTH DIFFER, V47, P423
   Tondreau T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-166
   Wang N, 2007, J CELL BIOCHEM, V100, P1548, DOI 10.1002/jcb.21139
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C
NR 27
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD NOV 1
PY 2012
VL 509
IS 1
BP 85
EP 92
DI 10.1016/j.gene.2012.07.088
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 015GW
UT WOS:000309435400010
ER

PT J
AU Shieh, JJ
   Lu, YH
   Huang, SW
   Huang, YH
   Sun, CH
   Chiou, HJ
   Liu, CS
   Lo, MY
   Lin, CY
   Niu, DM
AF Shieh, Jeng-Jer
   Lu, Yung-Hsiu
   Huang, Shi-Wei
   Huang, Yu-Hsiu
   Sun, Chih-Hao
   Chiou, Hong-Jen
   Liu, Chinsu
   Lo, Ming-Yu
   Lin, Ching-Yuang
   Niu, Dau-Ming
TI Misdiagnosis as steatohepatitis in a family with mild glycogen storage
   disease type 1a
SO GENE
LA English
DT Article
DE Glycogen storage disease type 1a; Hyperuricemia; Hyperlipidemia;
   Hepatocellular carcinoma
ID GLUCOSE-6-PHOSPHATASE GENE; HEPATOCELLULAR-CARCINOMA; MESSENGER-RNA;
   JAPANESE PATIENTS; IA; MUTATIONS; IDENTIFICATION; EXPRESSION; HEPCIDIN;
   DIAGNOSIS
AB The manifestations of glycogen storage disease type 1a (GSD 1a) are usually so prominent in childhood that it is readily diagnosed by pediatricians. However, a mild form of the disease may only become apparent during adolescence or adulthood. We observed a brother and sister with subtle manifestations of the disease, which was discovered after the brother's son was diagnosed with typical GSD 1a. The adult siblings never suffered from hypoglycemia, had normal fasting blood glucose and liver transaminases at the time of diagnosis, and were taller than average for Chinese. Their only notable disease manifestations were recurrent gouty arthritis associated with hyperuricemia and hyperlipidemia during adolescence. When diagnosed, the brother had multiple benign and malignant hepatic tumors, and died of fulminant metastatic hepatocellular carcinoma 6 months after liver transplantation. p.M121V/p.R83H and p.M121V/p.M121V genotypic constellations of the G6PC gene were identified in this family. Both siblings were homozygous for the newly identified p.M121V mutation. The infant had compound heterozygous mutations, p.R83H and p.M121V. We recommend that mild GSD should be considered in the adolescents with unexplained hyperuricemia and hyperlipidemia, despite the presence of normal blood glucose levels. This report also reminds us that hepatocellular carcinoma could develop even in very mild GSD 1a patients. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Lu, Yung-Hsiu; Niu, Dau-Ming] Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 112, Taiwan.
   [Shieh, Jeng-Jer; Huang, Shi-Wei] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.
   [Shieh, Jeng-Jer] Taichung Vet Gen Hosp, Dept Educ & Res, Taichung, Taiwan.
   [Huang, Yu-Hsiu] Natl Yang Ming Univ, Sch Nursing, Inst Clin & Community Nursing, Taipei 112, Taiwan.
   [Lu, Yung-Hsiu; Huang, Yu-Hsiu; Lo, Ming-Yu; Niu, Dau-Ming] Vet Gen Hosp, Dept Pediat, Taipei, Taiwan.
   [Sun, Chih-Hao] Vet Gen Hosp, Dept Pathol, Taipei, Taiwan.
   [Chiou, Hong-Jen] Vet Gen Hosp, Dept Radiol, Taipei, Taiwan.
   [Liu, Chinsu] Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan.
   [Lin, Ching-Yuang] China Med Univ & Hosp, Coll Med, Clin Immunol Ctr, Taichung, Taiwan.
RP Niu, DM (reprint author), Natl Yang Ming Univ, Sch Med, Inst Clin Med, 155,Sec 2,Li Nong St, Taipei 112, Taiwan.
EM dmniu111@yahoo.com.tw
CR Akanuma J, 2000, AM J MED GENET, V91, P107, DOI 10.1002/(SICI)1096-8628(20000313)91:2<107::AID-AJMG5>3.0.CO;2-Y
   Cassiman D, 2010, J HEPATOL, V53, P213
   Chen W., 2003, MID TAIWAN J MED S2, V8, pS85
   Chen Y.T., 2001, METABOLIC MOL BASES, P1521
   Chou JY, 2008, HUM MUTAT, V29, P921, DOI 10.1002/humu.20772
   Franco LM, 2005, J INHERIT METAB DIS, V28, P153, DOI 10.1007/s10545-005-7500-2
   Hemrika W, 1997, FEBS LETT, V409, P317, DOI 10.1016/S0014-5793(97)00530-9
   HSIAO R-L, 1990, Acta Paediatrica Sinica, V31, P166
   Kamai T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-270
   Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600
   Koeberl DD, 2008, MOL THER, V16, P665, DOI 10.1038/mt.2008.15
   Lee PJ, 1996, J INHERIT METAB DIS, V19, P201, DOI 10.1007/BF01799429
   LEI KJ, 1995, J BIOL CHEM, V270, P11882
   LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187
   LIMMER J, 1988, HEPATOLOGY, V8, P531, DOI 10.1002/hep.1840080317
   Matern D, 2002, EUR J PEDIATR, V161, pS10, DOI 10.1007/s00431-002-0998-5
   Parvari R, 1997, EUR J HUM GENET, V5, P191
   Rake JP, 2000, HUM MUTAT, V15, P381, DOI 10.1002/(SICI)1098-1004(200004)15:4<381::AID-HUMU13>3.0.CO;2-K
   Shieh JJ, 2002, J BIOL CHEM, V277, P5047, DOI 10.1074/jbc.M110486200
   Stukey J, 1997, PROTEIN SCI, V6, P469
   Takahashi K, 2000, AM J MED GENET, V92, P90, DOI 10.1002/(SICI)1096-8628(20000515)92:2<90::AID-AJMG2>3.0.CO;2-H
   Ward DG, 2008, WORLD J GASTROENTERO, V14, P1339, DOI 10.3748/wjg.14.1339
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   Wong LJC, 2001, MOL GENET METAB, V72, P175, DOI 10.1006/mgme.2000.3129
NR 24
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD NOV 1
PY 2012
VL 509
IS 1
BP 154
EP 157
DI 10.1016/j.gene.2012.07.057
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 015GW
UT WOS:000309435400020
ER

PT J
AU Liu, YH
   Xie, RG
   Zhang, XY
   Wei, SD
   He, Y
   Xu, WF
   Lin, YY
   Xiong, F
AF Liu, Yan-hui
   Xie, Run-gui
   Zhang, Xiao-yan
   Wei, Shun-di
   He, Yi
   Xu, Wang-fang
   Lin, Yang-yang
   Xiong, Fu
TI A new partial trisomy 12p with artery catheter vagus, congenital
   cataracts, external auditory canal, and no turbinate
SO GENE
LA English
DT Article
DE Trisomy 12p; Karyotype analysis; Chromosomal aberration
ID PALLISTER-KILLIAN-SYNDROME; INVERTED TANDEM DUPLICATION;
   PRENATAL-DIAGNOSIS; LDH-B; HYBRIDIZATION; CHROMOSOME; PATIENT;
   IDENTIFICATION; FLUORESCENCE; SEGREGATION
AB We describe the prenatal diagnosis and fetal phenotype of partial trisomy 12 (p12-pter) transmitted from a maternal reciprocal translocation 6;12. Genetic analysis was conducted on umbilical cord blood for a fetus accompanied with tricuspid regurgitation and orbital hypertelorism from a 27-year-old gravida 4, para 1 after sonography at gestation 35 weeks. The karyotype was unusual, with 46, XY, der (6), t (6;12) (p24; p12) mat. The pregnancy was terminated at 37 gestational weeks. The aborted fetus displayed dysmorphic features of a round flat face with prominent cheeks and high forehead, hypertelorism, short nose, broad and depressed nasal bridge, anteverted nares, deformed philtrum, open mouth, thin upper vermilion and broad everted lower lip, low-set ears and aural atresia, broad hands with simian creases, and a short neck. Fetal anatomy showed right artery catheter vagus, congenital cataract, no turbinate and external auditory canals. Through karyotype-phenotype analysis of this patient and a review of other reported cases, we believe this is a first report that expands the database of partial trisomy 12p, and is beneficial for future clinical genetic counseling. This study supports that phenotypic variability depends on the type and extent of the associated partial monosomy. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Liu, Yan-hui; Xiong, Fu] So Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou 510515, Guangdong, Peoples R China.
   [Liu, Yan-hui; Xie, Run-gui; Zhang, Xiao-yan; Wei, Shun-di; He, Yi; Xu, Wang-fang; Lin, Yang-yang] Dongguan Maternal & Child Hlth Hosp, Dept Prenatal, Diag Ctr, Dongguan 523112, Guangdong, Peoples R China.
RP Xiong, F (reprint author), So Med Univ, Sch Basic Med Sci, Dept Med Genet, 1838 Guangzhou Dadao Rd, Guangzhou 510515, Guangdong, Peoples R China.
EM xf7803@yahoo.com.cn
FU National Natural Science Foundation of China [30900806]; key project of
   science and technology of Dongguan [2011105102012]
FX We would like to thank the patients for their participation in this
   project. This work was partially supported by a grant from the National
   Natural Science Foundation of China (30900806) and the key project of
   science and technology of Dongguan (2011105102012)
CR Allen TL, 1996, AM J MED GENET, V63, P250, DOI 10.1002/(SICI)1096-8628(19960503)63:1<250::AID-AJMG43>3.0.CO;2-K
   ARMENDARES S, 1975, ANN GENET-PARIS, V18, P89
   Battaglia A, 2007, AM J MED GENET A, V143A, P184, DOI 10.1002/ajmg.a.31590
   Benussi DG, 2009, GENET TEST MOL BIOMA, V13, P199, DOI 10.1089/gtmb.2008.0109
   Cetin Z, 2011, AM J MED GENET A, V155A, P349, DOI 10.1002/ajmg.a.33811
   DALLAPICCOLA B, 1980, ANN GENET-PARIS, V23, P111
   Fryns J.P., 1990, BIRTH DEFECTS ENCY, P365
   Hansteen I.L., 1978, CLIN GENET, V3, P339
   Hung CC, 2012, GENE, V495, P178, DOI 10.1016/j.gene.2011.12.050
   Inage E, 2010, EUR J MED GENET, V53, P159, DOI 10.1016/j.ejmg.2010.02.009
   LEANACOX J, 1993, AM J HUM GENET, V52, P1067
   Liang DS, 2006, AM J MED GENET A, V140A, P238, DOI 10.1002/ajmg.a.31077
   Los FJ, 1995, PRENATAL DIAG, V15, P1155, DOI 10.1002/pd.1970151212
   Lu Ying, 2009, Leuk Res, V33, pe124
   PARSLOW M, 1979, HUM GENET, V47, P253, DOI 10.1007/BF00321017
   PFEIFFER RA, 1992, ANN GENET-PARIS, V35, P41
   Plaja A, 1998, ANN GENET-PARIS, V41, P52
   QAZI QH, 1981, AM J MED GENET, V9, P195, DOI 10.1002/ajmg.1320090305
   Rauch A, 1996, AM J MED GENET, V63, P243, DOI 10.1002/(SICI)1096-8628(19960503)63:1<243::AID-AJMG42>3.0.CO;2-L
   RAY M, 1985, ANN GENET-PARIS, V28, P235
   RETHORE MO, 1975, ANN GENET-PARIS, V18, P81
   Schinzel A., 1984, CATALOGUE UNBALANCED, p[459, 690]
   SCHINZEL A, 1991, J MED GENET, V28, P122, DOI 10.1136/jmg.28.2.122
   Segel R, 2006, AM J MED GENET A, V140A, P695, DOI 10.1002/ajma.a.31143
   Smigiel R, 2008, EUR J PEDIATR, V167, P1063, DOI 10.1007/s00431-007-0608-7
   STENGELRUTKOWSKI S, 1981, EUR J PEDIATR, V136, P249, DOI 10.1007/BF00442992
   Stumm M, 2007, PRENATAL DIAG, V27, P475, DOI 10.1002/pd.1703
   SUERINCK E, 1978, ANN GENET-PARIS, V21, P243
   TAYEL S, 1989, CLIN GENET, V35, P382
   Tekin M, 2001, AM J MED GENET, V104, P42, DOI 10.1002/ajmg.10025
   TENCONI R, 1978, ANN GENET-PARIS, V21, P229
   Tsai Anne Chun-Hui, 2005, Am J Med Genet A, V134A, P229, DOI 10.1002/ajmg.a.30555
   UCHIDA IA, 1973, J PEDIATR, V82, P269, DOI 10.1016/S0022-3476(73)80165-9
   Vaglio A, 2007, EUR J MED GENET, V50, P224, DOI 10.1016/j.ejmg.2007.01.001
   ZELANTE L, 1994, CLIN GENET, V46, P368
   Zen P.R., 2010, PEDIATR INT, V52, P144
   Zumkeller W, 2004, AM J MED GENET A, V129A, P261, DOI 10.1002/ajmg.a.30125
NR 37
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD NOV 1
PY 2012
VL 509
IS 1
BP 164
EP 167
DI 10.1016/j.gene.2012.07.052
PG 4
WC Genetics & Heredity
SC Genetics & Heredity
GA 015GW
UT WOS:000309435400022
ER

PT J
AU Shen, HC
   Li, X
   Meng, L
   Ni, Y
   Wang, GH
   Dong, W
   Du, JJ
AF Shen, Hongchang
   Li, Xin
   Meng, Long
   Ni, Yang
   Wang, Guanghui
   Dong, Wei
   Du, Jiajun
TI Confirmation of histology of PET positive lymph nodes recovered by
   hand-video-assisted thoracoscopy surgery
SO GENE
LA English
DT Article
DE Esophageal cancer; Positron Emission Tomography-Computed Tomography;
   Hand- and video-assisted thoracoscopy surgery
ID MINIMALLY INVASIVE ESOPHAGECTOMY; SQUAMOUS-CELL CARCINOMA; TRANSHIATAL
   ESOPHAGECTOMY; CANCER; MEDIASTINOSCOPY; EXPERIENCE; ESOPHAGUS
AB PET/CT (Positron Emission Tomography-Computed Tomography) is an advanced diagnostic imaging device that combines both PET and an X-ray CT. This study evaluates the effects of PET/CT on detecting primary tumors and metastases, and looks at the therapeutic effect of minimally invasive surgery on esophageal cancer patients. Eighty patients with esophageal cancer were enrolled in the study between January, 2004 and December, 2007, who were randomly divided into two groups of 40, one of which was treated with hand-video-assisted thoracoscopy surgery (HVATS) esophagectomy and one of which was treated with conventional surgery. All patients underwent a PET/CT scan 2-3 weeks before their operation, and their cervical, thoracic and upper abdominal lymph nodes were biopsied. All the primary esophageal lesions showed high FDG uptake. The maximum standardized uptake value (SUV) was 3.78-25.64 (11.73 +/- 5.32), while the mean SUV was 3.65 = 16.92 (9.12 +/- 4.37). Using 2.5 as the SUV standard, all esophageal lesions were detected by PET/CT image. Of the 80 patients, 53 had lymph nodal metastases, with a total of 142 metastatic lymph nodes, which showed high FDG uptake. The maximum SUV was 2.77-14.63 (7.98 +/- 3.25), and the mean SUV was 2.31-12.84 (5.34 +/- 3.19). The visual analysis from the PET/CT scan showed a sensitivity of 86.62%, a specificity of 95.85%, a positive predictive value of 93.89%, a negative predictive value of 90.69% and an accuracy of 91.94%. The PET/CT scan showed a high sensitivity and specificity in detecting primary esophageal cancer and lymph nodal metastases. The mean post-surgery life expectancies for patients undergoing HVATS and conventional surgery are 27.93 months and 28.05 months, respectively. The two groups showed no statistically significant difference. We thus conclude that PET/CT combined with HVATS is a new choice for esophageal carcinoma patients. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Shen, Hongchang; Ni, Yang; Wang, Guanghui; Dong, Wei; Du, Jiajun] Shandong Univ, Prov Hosp, Inst Oncol, Jinan 250012, Peoples R China.
   [Li, Xin] Shandong Univ, Prov Hosp, PET CT Ctr, Jinan 250012, Peoples R China.
   [Meng, Long; Du, Jiajun] Shandong Univ, Prov Hosp, Dept Thorac Surg, Jinan 250012, Peoples R China.
RP Du, JJ (reprint author), Shandong Univ, Shandong Prov Hosp, Dept Thorac Surg, Jinan 250021, Peoples R China.
EM dujiajun@sdu.edu.cn
FU National Natural Science Foundation of China [81141100]; Provincial
   Natural Science Foundation of Shandong [ZR2010HM067, ZR2011HM077];
   Provincial Science and Technology Development Planning of Shandong
   [2011GGH21819]
FX This work was supported by the National Natural Science Foundation of
   China (81141100), the Provincial Natural Science Foundation of Shandong
   (ZR2010HM067 and ZR2011HM077) and the Provincial Science and Technology
   Development Planning of Shandong (2011GGH21819). There is no conflict of
   interests for all authors.
CR Benzoni E, 2008, SURG LAPARO ENDO PER, V18, P178, DOI 10.1097/SLE.0b013e318165f205
   Bonavina L, 2004, J LAPAROENDOSC ADV A, V14, P13, DOI 10.1089/109264204322862298
   Braghetto I, 2006, SURG ENDOSC, V20, P1681, DOI 10.1007/s00464-006-0009-4
   Chatterton B.E., 2008, EUR J NUCL MED MOL I
   Choi JY, 2000, J NUCL MED, V41, P808
   Chowdhury FU, 2008, CLIN RADIOL, V63, P1297, DOI 10.1016/j.crad.2008.05.010
   Du Jia-jun, 2005, CHINESE J SURG, V3, P351
   [杜贾军 DU Jiajun], 2007, [中华外科杂志, Chinese Journal of Surgery], V45, P822
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Fabian T, 2008, DIS ESOPHAGUS, V21, P220, DOI 10.1111/j.1442-2050.2007.00783.x
   Gallo A, 2006, WORLD J GASTROENTERO, V12, P3237
   [关庆民 GUAN Qingmiu], 2007, [中华外科杂志, Chinese Journal of Surgery], V45, P688
   Ikeda Y, 2002, ANN THORAC SURG, V73, P1329, DOI 10.1016/S0003-4975(01)03593-7
   Jamil LH, 2008, CURR OPIN GASTROEN, V24, P530, DOI 10.1097/MOG.0b013e3283025c91
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kato H, 2008, ONCOL REP, V20, P857, DOI 10.3892/or_00000083
   Korst Robert J, 2004, Thorac Surg Clin, V14, P61, DOI 10.1016/S1547-4127(04)00038-6
   Mizowaki T, 1996, INT J RADIAT ONCOL, V36, P1091, DOI 10.1016/S0360-3016(96)00425-7
   Pop D, 2007, J THORAC CARDIOV SUR, V133, P267, DOI 10.1016/j.jtcvs.2006.08.066
   Rice T W, 2000, Chest Surg Clin N Am, V10, P471
   Romagnuolo J, 2002, GASTROINTEST ENDOSC, V55, P648, DOI 10.1067/mge.2002.122650
   Sakamoto H., 2004, J GASTROENTEROL, V39, P7
   Schreurs LM, 2008, ANTICANCER RES, V28, P1867
   Shichinohe T, 2008, SURG TODAY, V38, P206, DOI 10.1007/s00595-007-3606-5
   Shinkai M, 2000, GUT, V47, P120, DOI 10.1136/gut.47.1.120
   Sunpaweravong Somkiat, 2008, Journal of the Medical Association of Thailand, V91, P1202
   Toker A, 2005, THORAC CARDIOV SURG, V53, P110, DOI 10.1055/s-2004-830424
   Westerterp M, 2008, J CANCER RES CLIN, V134, P227, DOI 10.1007/s00432-007-0275-0
NR 28
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD NOV 1
PY 2012
VL 509
IS 1
BP 173
EP 177
DI 10.1016/j.gene.2012.07.060
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 015GW
UT WOS:000309435400024
ER

PT J
AU Lei, T
   Xie, LX
   Tu, WB
   Chen, YB
   Tang, Z
   Tan, YH
AF Lei, Tao
   Xie, Liangxian
   Tu, Wenbing
   Chen, Yubin
   Tang, Zhen
   Tan, Yinghui
TI Blast injuries to the human mandible: Development of a finite element
   model and a preliminary finite element analysis
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Mandible; Blast injury; Finite element model; Dynamic simulation;
   Biomechanical analysis
ID MAXILLOFACIAL INJURIES; MANAGEMENT; PATTERNS; BONE; IRAQ
AB Objective: In an attempt to explore new tools for constructing a model of blast injuries to the human mandible, a finite element method was used. This model allowed us to perform dynamic simulations and analyse the injury processes and severity of trauma to the human mandible from an explosion striking at the middle mandibular angle.
   Methods: A 3D finite element model of the human mandible was created using digitally visualised CT scanning data of the human mandible. It was used to dynamically simulate the complete injury process of a blast event to a human mandible (at the middle mandibular angle) under the injury conditions of a 600 mg TNT explosion. The model was also used to elucidate the subsequent mandibular damage and the dynamic distribution of several biomechanical indices (e. g., stress, and strain). The resulting data were subjected to a comparative analysis.
   Results: Simulation was successfully conducted for injury events in which 600 mg of TNT exploded at 3 cm, 5 cm and 10 cm from the middle mandibular angle of a human mandible; specifically, the simulation included the dynamic injury processes and the distribution of stress and strain in various parts of the damaged mandible. A comparison of the simulation data revealed that different blast distances resulted in considerable variation in the severity and biological indices of the mandibular injury.
   Conclusion: The finite element model was able to dynamically simulate the blast-initiated trauma processes to a human mandible, which allowed for investigation of the severity of damage to the mandible under different injury conditions. This model and the simulation method are conducive for applications in basic studies and clinical investigations of blast-initiated injury mechanisms of bone tissues. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
C1 [Lei, Tao; Tu, Wenbing; Chen, Yubin; Tan, Yinghui] Third Mil Med Univ, Xinqiao Hosp, Dept Oral & Maxillofacial Surg, Chongqing 400037, Peoples R China.
   [Lei, Tao; Xie, Liangxian] 324th Hosp PLA, Dept Oral, Chongqing 400020, Peoples R China.
   [Tang, Zhen] Mil Med Coll 2, Changhai Hosp, Dept Oral & Maxillofacial Surg, Shanghai 200433, Peoples R China.
RP Tan, YH (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Oral & Maxillofacial Surg, Chongqing 400037, Peoples R China.
EM 31485761@QQ.com; xlx_324@163.com; twb_2001@163.com; ddmgc@263.net;
   tanyhoms@yahoo.cn; tanyh1962@yahoo.com.cn
CR Alia A, 2006, APPL THERM ENG, V26, P1032, DOI 10.1016/j.applthermaleng.2005.10.018
   Bochicchio GV, 2008, AM SURGEON, V74, P267
   Breeze J, 2011, BRIT J ORAL MAX SURG, V49, P464, DOI 10.1016/j.bjoms.2010.08.002
   Breeze J, 2010, BRIT J ORAL MAX SURG, V48, P613, DOI 10.1016/j.bjoms.2009.10.013
   Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z
   Chen YB, 2010, J BIOMECH, V43, P1131, DOI 10.1016/j.jbiomech.2009.12.009
   Gataa IS, 2011, INT J ORAL MAX SURG, V40, P65, DOI 10.1016/j.ijom.2010.07.005
   Lei T, 2012, J TRAUMA
   Lew TA, 2010, J ORAL MAXIL SURG, V68, P3, DOI 10.1016/j.joms.2009.06.006
   Martin AD, 1987, J SPORT SCI, V5, P155, DOI 10.1080/02640418708729773
   Maurer P, 2003, J CRANIO MAXILL SURG, V31, P284, DOI 10.1016/S1010-5182(03)00073-8
   Powers D B, 2010, J R Army Med Corps, V156, P117
   Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025
   Shuker ST, 2008, BRIT J ORAL MAX SURG, V46, P547, DOI 10.1016/j.bjoms.2008.03.014
   SHUKER ST, 1995, J CRANIO MAXILL SURG, V23, P91, DOI 10.1016/S1010-5182(05)80454-8
   Shuker ST, 2010, J ORAL MAXIL SURG, V68, P93, DOI 10.1016/j.joms.2009.07.077
   Shuker ST, 2010, J ORAL MAXIL SURG, V68, P1818, DOI 10.1016/j.joms.2010.03.003
   Tada S, 2003, INT J ORAL MAX IMPL, V18, P357
   Tang Z, 2011, INJURY
   Turegano-Fuentes F, 2008, WORLD J SURG, V32, P1168, DOI 10.1007/s00268-008-9557-1
   Wang ZL, 2003, MIL MED, V168, P330
   Zhang SX, 2004, J ANAT, V204, P165, DOI 10.1111/j.0021-8782.2004.00274.x
NR 22
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD NOV
PY 2012
VL 43
IS 11
BP 1850
EP 1855
DI 10.1016/j.injury.2012.07.187
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 014VR
UT WOS:000309404300013
ER

PT J
AU Yeh, CC
   Liao, CC
   Muo, CH
   Chang, SN
   Hsieh, CH
   Chen, FN
   Lane, HY
   Sung, FC
AF Yeh, Chun-Chieh
   Liao, Chien-Chang
   Muo, Chih-Hsin
   Chang, Shih-Ni
   Hsieh, Chi-Hsun
   Chen, Fei-Na
   Lane, Hsien-Yuan
   Sung, Fung-Chang
TI Mental disorder as a risk factor for dog bites and post-bite cellulitis
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Mental disorder; Dog bites; Cellulitis; Socio-economic status; Taiwan
ID EMERGENCY-DEPARTMENTS; ANIMAL BITES; INJURIES; CHILDREN; EPIDEMIOLOGY;
   PREVALENCE; SURGERY; CANINE; CITY
AB Objectives: Patients with mental disorders are at an increased risk for sustaining traumatic injury. No study has evaluated the association between mental disorders and the injury of dog bite. We conducted case-control studies to investigate whether people with mental disorders are at elevated risks of dog bite and post-bite cellulitis.
   Methods: Using insurance data of 2000-2007, we compared 4660 patients with dog bites and 18,640 controls without the events for the association with mental disorders and other covariates. Amongst those with dog bites, a nested case-control study was performed to compare 286 patients with post-bite cellulites and rest of 4374 patients for factors associated with the infection.
   Results: Young children, the older adults, and people with low socioeconomic status were at an elevated risk of sustaining the dog bite. In separate logistic regression models adjusting for socio-demographic variables, the results showed that patients with concomitant psychotic and non-psychotic mental disorders were associated with increased risks of dog bites (adjusted odds ratio [OR] = 1.51, 95% confidence interval [CI]: 1.32-1.74) and of post-bite cellulitis (OR = 2.13, 95% CI 1.46-3.10).
   Conclusions: Individuals with mental disorders are likely at an elevated risk for serious dog bites and post-bite cellulitis. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
C1 [Sung, Fung-Chang] China Med Univ, Coll Publ Hlth, Inst Environm Hlth, Dept Publ Hlth, Taichung 404, Taiwan.
   [Yeh, Chun-Chieh; Hsieh, Chi-Hsun] China Med Univ, China Med Univ Hosp, Trauma & Emergency Ctr, Taichung 404, Taiwan.
   [Liao, Chien-Chang; Muo, Chih-Hsin; Chang, Shih-Ni; Sung, Fung-Chang] China Med Univ Hosp, Management Off Hlth Data, Taichung 404, Taiwan.
   [Chen, Fei-Na] China Med Univ, Dept Social Med, Taichung 404, Taiwan.
   [Lane, Hsien-Yuan] China Med Univ Hosp, Dept Psychiat, Taichung 404, Taiwan.
RP Sung, FC (reprint author), China Med Univ, Coll Publ Hlth, Inst Environm Hlth, Dept Publ Hlth, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
EM b8202034@gmail.com; jacky48863027@yahoo.com.tw; b8507006@hotmail.com;
   u9665856@cmu.edu.tw; chihsun@mail.cmuh.org.tw; feina@mail.cmu.edu.tw;
   hylane@gmail.com; fcsung@mail.cmu.edu.tw
FU Executive Yuan National Science Council in Taiwan, Republic of China
   [NSC 97-2625-M-039-003]; China Medical University Hospital [1MS1];
   Taiwan Department of Health Clinical Trials and Research Centre for
   Excellence [DOH100-TD-B-111-004]; Cancer Research Centre of Excellence
   [DOH100-TD-C-111-005]
FX This study was supported partly by the Executive Yuan National Science
   Council in Taiwan, Republic of China (grant number NSC
   97-2625-M-039-003), the China Medical University Hospital (grant number
   1MS1), and the Taiwan Department of Health Clinical Trials and Research
   Centre for Excellence (grant number DOH100-TD-B-111-004) and Cancer
   Research Centre of Excellence (grant number DOH100-TD-C-111-005).
CR Abuabara Allan, 2006, Med Oral Patol Oral Cir Bucal, V11, pE348
   Agarwal N, 2004, TROP DOCT, V34, P76
   AVNER JR, 1991, PEDIATRICS, V88, P55
   BHANGANADA K, 1993, ACTA TROP, V55, P249, DOI 10.1016/0001-706X(93)90082-M
   Boenning D A, 1983, Am J Emerg Med, V1, P17, DOI 10.1016/0735-6757(83)90032-3
   Borud LJ, 2000, PLAST RECONSTR SURG, V106, P987, DOI 10.1097/00006534-200010000-00004
   BROGAN TV, 1995, PEDIATRICS, V96, P947
   Calkins CM, 2001, J PEDIATR SURG, V36, P1115, DOI 10.1053/jpsu.2001.25670
   Castrodale LJ, 2007, INT J CIRCUMPOL HEAL, V66, P320
   Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9
   De Keuster T, 2006, VET J, V172, P482, DOI 10.1016/j.tvjl.2005.04.024
   Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017
   Dwyer JP, 2007, SAMJ S AFR MED J, V97, P597
   Fang JF, 2008, INJURY, V39, P881, DOI 10.1016/j.injury.2008.03.012
   Fei CY, 2007, EPIDEMIOLOGICAL STAT
   FRANCIS DP, 1975, JAMA-J AM MED ASSOC, V233, P42, DOI 10.1001/jama.233.1.42
   GALLART RM, 2002, AN ESP PEDIATR, V56, P425
   Georges K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-85
   GERSHMAN KA, 1994, PEDIATRICS, V93, P913
   Gilchrist J, 2008, INJURY PREV, V14, P296, DOI 10.1136/ip.2007.016220
   Gracia Romero J, 1992, AN ESP PEDIATR, V37, P287
   JAFFE AC, 1983, PEDIATR CLIN N AM, V30, P405
   Kahn A, 2003, EUR J PEDIATR, V162, P254, DOI 10.1007/s00431-002-1130-6
   LAUER EA, 1982, AM J DIS CHILD, V136, P202
   Marsh Louise, 2004, N Z Med J, V117, pU1043
   Mitchell RB, 2003, LARYNGOSCOPE, V113, P492, DOI 10.1097/00005537-200303000-00018
   Ostanello F, 2005, EMERG MED J, V22, P260, DOI 10.1136/emj.2004.014886
   Peters V, 2004, J PEDIATR, V144, P121, DOI 10.1016/j.jpeds.2003.10.024
   Rosado B, 2009, VET J, V179, P383, DOI 10.1016/j.tvjl.2008.02.002
   Savino F, 2002, Minerva Pediatr, V54, P237
   Schecter WP, 2005, ARCH SURG-CHICAGO, V140, P902, DOI 10.1001/archsurg.140.9.902
   Shuler CM, 2008, JAVMA-J AM VET MED A, V232, P542, DOI 10.2460/javma.232.4.542
   Tepsumethanon Saowaluck, 2007, Travel Med Infect Dis, V5, P189, DOI 10.1016/j.tmaid.2006.07.001
   Weiss HB, 1998, JAMA-J AM MED ASSOC, V279, P51, DOI 10.1001/jama.279.1.51
   Zanini F, 2008, MEDICINA-BUENOS AIRE, V68, P1
   Zatzick DF, 2000, J TRAUMA, V49, P487, DOI 10.1097/00005373-200009000-00017
NR 36
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD NOV
PY 2012
VL 43
IS 11
BP 1903
EP 1907
DI 10.1016/j.injury.2011.03.016
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 014VR
UT WOS:000309404300022
ER

PT J
AU Lui, TH
   Chan, KB
AF Lui, T. H.
   Chan, K. B.
TI Posteromedial ankle dislocation without malleolar fracture: A report of
   six cases
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Ankle; Dislocation; Chondrolysis; Osteoarthrosis; Distraction
   arthroplasty; Osteochondral lesion
ID FOLLOW-UP; CHONDROLYSIS; JOINT
AB Posteromedial ankle dislocation without malleolar fracture is a rare injury. Six patients who suffered from this injury were reviewed. The deltoid ligament was not at risk in this particular type of dislocation. Those patients without chondral lesion have a good long-term prognosis if prompt reduction is performed. Associated chondral lesion is a significant contributing factor to late development of ankle osteoarthrosis. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lui, T. H.; Chan, K. B.] N Dist Hosp, Dept Orthopaed & Traumatol, Sheung Shui, Hong Kong, Peoples R China.
RP Lui, TH (reprint author), N Dist Hosp, Dept Orthopaed & Traumatol, 9 Po Kin Rd, Sheung Shui, Hong Kong, Peoples R China.
EM luithderek@yahoo.co.uk; billzoefamily@yahoo.com.hk
CR Bojescul JA, 2005, ARTHROSCOPY, V21, P224, DOI 10.1016/j.arthro.2004.10.006
   COLVILLE MR, 1987, J BONE JOINT SURG AM, V69A, P706
   DANCA AF, 1970, J BONE JOINT SURG AM, VA 52, P1643
   Demiralp B, 2008, J AM PODIAT MED ASSN, V98, P469
   Elise S, 1998, Acta Orthop Belg, V64, P25
   Fotiadis E, 2009, J FOOT ANKLE SURG, V48
   Georgilas I, 2008, ACTA ORTHOP BELG, V74, P266
   Gogi N, 2008, J FOOT ANKLE SURG, V14, P47
   Hatori M, 2006, UPSALA J MED SCI, V111, P263
   Larsen J, 1998, J Foot Ankle Surg, V37, P334
   Lertwanich Pisit, 2008, Journal of the Medical Association of Thailand, V91, P1137
   Lui TH, 2008, ARCH ORTHOP TRAUM SU, V128, P49, DOI 10.1007/s00402-007-0352-5
   Lui TH, 2006, ARTHROSCOPY, V22, P283, DOI 10.1016/j.arthro.2002.12.012
   MOEHRING HD, 1994, J ORTHOP TRAUMA, V8, P167, DOI 10.1097/00005131-199404000-00015
   MOONEY JF, 1991, SOUTHERN MED J, V84, P244
   Prost a la Denise J, 2009, ORTHOPAEDICS TRAUMAT, V95, P558
   Rivera F, 2001, CLIN ORTHOP RELAT R, P179
   Sabharwal S, 2007, FOOT ANKLE INT, V28, P942, DOI 10.3113/FAI.2007.0942
   Saied Alireza, 2007, J Foot Ankle Surg, V46, P307, DOI 10.1053/j.jfas.2007.02.006
   SEGAL LS, 1992, CLIN ORTHOP RELAT R, P171
   Thangarajah T, 2008, J FOOT ANKLE SURG, V47, P441, DOI 10.1053/j.jfas.2008.05.004
   TOOHEY JS, 1989, CLIN ORTHOP RELAT R, P207
   Tranovich M, 2003, PHYSICIAN SPORTSMED, V31, P42
   Uyar M, 2004, BRIT J SPORT MED, V38, P342, DOI 10.1136/bjsm.2002.003954
   Wehner J, 1990, J Orthop Trauma, V4, P362, DOI 10.1097/00005131-199004030-00022
   Yurttas Yuksel, 2009, Cases J, V2, P6550
NR 26
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD NOV
PY 2012
VL 43
IS 11
BP 1953
EP 1957
DI 10.1016/j.injury.2012.07.002
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 014VR
UT WOS:000309404300030
ER

PT J
AU Wu, QY
   Li, F
   Wang, XY
   Xu, KL
AF Wu, Qing-Yun
   Li, Feng
   Wang, Xiao-Yun
   Xu, Kai-Lin
TI Evidence that the amino acid residue Ile121 is involved in arginine
   kinase activity and structural stability
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Arginine kinase; Aggregation; Conformational change; Insecticides;
   Structural stability
ID CREATINE-KINASE; SUBUNIT INTERACTIONS; CLONING; LOCUST; PURIFICATION;
   METABOLISM; ALLERGEN; LINKERS; IMPACT; MUSCLE
AB Arginine kinase (AK) catalyzes the reversible phosphorylation of arginine by ATP, yielding the phosphoarginine. Domain-domain interactions may be very important to the structure and functions of many multidomain proteins. However, little is known about the role of amino acid residues located in the linker between the N- and C-terminal domains in the structural stability and functions of multidomain proteins. In this research. A series mutation of conserved residue Ile121 located in the linker were mutated to explore its roles in the activity and structural stability of AK. The mutations I121D and I121K led to pronounced loss of activity and structural stability. Furthermore, these mutations also led to serious aggregation during heat-and GdnHCl-induced denaturation and refolding from the GdnHCl-denatured state. More importantly, all the mutantions except I121L could not successfully recover their activities by dilution-initiated refolding, and showed significant decreased rate constant during AK refolding. While the mutation I121L almost had no effect on AK activity and structural stability. These results suggested that mutations of the residue I121 in the linker might affect the correct positioning of the domains and thus disrupt the efficient recognition and interactions between the N- and C-terminal domains. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wang, Xiao-Yun] Shandong Agr Univ, Coll Life Sci, State Key Lab Crop Biol, Tai An 271018, Shandong, Peoples R China.
   [Wu, Qing-Yun; Xu, Kai-Lin] Xuzhou Med Coll, Affiliated Hosp, Dept Hematol, Xuzhou 221002, Peoples R China.
   [Wu, Qing-Yun] Xuzhou Med Coll, Lab Transplantat & Immunol, Xuzhou 221002, Peoples R China.
   [Li, Feng] Xuzhou Med Coll, Dept Neurobiol, Xuzhou 221002, Peoples R China.
RP Wang, XY (reprint author), Shandong Agr Univ, Coll Life Sci, State Key Lab Crop Biol, Tai An 271018, Shandong, Peoples R China.
EM xyunwang@sdau.edu.cn; lihmd@163.com
FU Natural Science Foundation of China [30971281, 81070447, 81000210,
   81100349]; National Key Scientific Program of China [2007CB914504];
   Program for Changjiang Scholar and Innovative Research Team in
   University [IRT0635]
FX The present investigation was supported by grants from the Natural
   Science Foundation of China (30971281, 81070447, 81000210 and 81100349)
   and the National Key Scientific Program of China (2007CB914504). Program
   for Changjiang Scholar and Innovative Research Team in University
   (IRT0635)
CR ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223
   Binder M, 2001, J IMMUNOL, V167, P5470
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Chamberlin ME, 1997, J EXP BIOL, V200, P2789
   CHAMBERLIN ME, 1983, J COMP PHYSIOL, V151, P191
   Cleland W W, 1979, Methods Enzymol, V63, P103
   Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289
   Feng S, 2007, INT J BIOCHEM CELL B, V39, P392, DOI 10.1016/j.biocel.2006.09.004
   Garel Jean-Renaud, 1992, P405
   George RA, 2002, PROTEIN ENG, V15, P871, DOI 10.1093/protein/15.11.871
   Gokhale RS, 2000, CURR OPIN CHEM BIOL, V4, P22, DOI 10.1016/S1367-5931(99)00046-0
   Guo Q., 2007, INT J BIOL MACROMOL, V41, P521
   Li M, 2006, PROTEIN PEPTIDE LETT, V13, P405, DOI 10.2174/092986606775974375
   Pan JC, 2004, BIOCHEM BIOPH RES CO, V317, P539, DOI 10.1016/j.bbrc.2004.03.084
   Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495
   SCHNEIDER A, 1989, INSECT BIOCHEM, V19, P471, DOI 10.1016/0020-1790(89)90029-2
   Sippl MJ, 2008, BIOINFORMATICS, V24, P426, DOI 10.1093/bioinformatics/btm622
   Sookrung N, 2006, ENVIRON HEALTH PERSP, V114, P875, DOI 10.1289/ehp.8650
   Tanaka K, 2007, INSECT BIOCHEM MOLEC, V37, P338, DOI 10.1016/j.ibmb.2006.12.006
   Uda K, 2009, INT J BIOL MACROMOL, V44, P413, DOI 10.1016/j.ijbiomac.2009.03.001
   Uda K, 2004, PROTEIN J, V23, P53, DOI 10.1023/B:JOPC.0000016258.55991.8a
   Wang HC, 2009, GENE, V430, P38, DOI 10.1016/j.gene.2008.10.021
   Werr M, 2009, INSECT BIOCHEM MOLEC, V39, P634, DOI 10.1016/j.ibmb.2009.07.001
   Wu QY, 2008, INSECT BIOCHEM MOLEC, V38, P59, DOI 10.1016/j.ibmb.2007.09.004
   Wu QY, 2009, INT J BIOL MACROMOL, V45, P393, DOI 10.1016/j.ijbiomac.2009.06.016
   Wu QY, 2011, ARCH BIOCHEM BIOPHYS, V512, P61, DOI 10.1016/j.abb.2011.04.015
   Wu QY, 2011, INT J BIOL MACROMOL, V49, P822, DOI 10.1016/j.ijbiomac.2011.07.020
   Wu QY, 2007, COMP BIOCHEM PHYS B, V148, P355, DOI 10.1016/j.cbpb.2007.07.002
   WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0005-2728(92)90096-K
   Yousef MS, 2003, PROTEIN SCI, V12, P103, DOI 10.1110/ps.0226303
   Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449
   Zhu WJ, 2007, INT J BIOL MACROMOL, V41, P564, DOI 10.1016/j.ijbiomac.2007.07.007
NR 32
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2012
VL 51
IS 4
BP 369
EP 377
DI 10.1016/j.ijbiomac.2012.05.022
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 013MW
UT WOS:000309310500004
ER

PT J
AU Cai, ZB
   Li, W
   Wang, HT
   Yan, WQ
   Zhou, YL
   Wang, GJ
   Cui, JW
   Wang, F
AF Cai, Zibin
   Li, Wei
   Wang, Haotian
   Yan, Weiqun
   Zhou, Yulai
   Wang, Guanjun
   Cui, Jiuwei
   Wang, Fang
TI Anti-tumor and immunomodulating activities of a polysaccharide from the
   root of Sanguisorba officinalis L.
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Sanguisorba officinalis; Polysaccharide; Extraction; Antitumor;
   Immunopotentiation
ID ALTERNATIVE MEDICINE; SURGICAL-MANAGEMENT; CANCER-PATIENTS; ANTICANCER;
   COMPLEMENTARY; SUGARS; PLANT; MICE
AB A water-soluble polysaccharide, named as SOWP, was extracted and fractioned from the roots of Sanguisorba officinalis L. by DEAE-Sepharose anion exchange and Sepharose 6 Fast Flow column chromatography. The monosaccharide composition of SOWP determined by gas chromatography (GC) identified it was composed of glucose (68.5%), arabinose (13.2%), rhamnose (8.9), xylose (6.2) and galactose (3.0%). At the dose of 50, 100, and 200 mg/kg, SOWP not only significantly inhibited the growth of mouse transplantable tumor, but also remarkably increased the spleen index and promoted splenocytes proliferation, macrophage phagocytosis and the production of serum cytokines IL-2, TNF-alpha and IFN-gamma in Sarcoma 180-bearing mice. However, no direct cytotoxic activity against Sarcoma 180 cells was observed. The anti-tumor activity of the polysaccharide from S. officinalis maybe achieved by not directly cytotoxicity but rather immunopotentiation. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wang, Haotian; Yan, Weiqun; Zhou, Yulai; Wang, Fang] Jilin Univ, Sch Pharmaceut Sci, Dept Regenerat Med, Changchun 130021, Peoples R China.
   [Cai, Zibin; Li, Wei; Wang, Guanjun; Cui, Jiuwei] Jilin Univ, Hosp 1, Tumor Ctr, Changchun 130021, Peoples R China.
RP Wang, F (reprint author), Jilin Univ, Sch Pharmaceut Sci, Dept Regenerat Med, Changchun 130021, Peoples R China.
EM wangfang_jlu@sina.cn
FU Jilin Provincial Science & Technology Department [20090931]
FX The authors gratefully acknowledge financial support from the program of
   Jilin Provincial Science & Technology Department (No. 20090931).
CR BASTOW KF, 1993, PLANTA MED, V59, P240, DOI 10.1055/s-2006-959659
   Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635
   BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7
   Blankenstein T, 2003, ADV CANCER RES, V90, P179, DOI 10.1016/S0065-230X(03)90006-6
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Chay Christopher H, 2002, Clin Prostate Cancer, V1, P14, DOI 10.3816/CGC.2002.n.002
   Downey RJ, 1999, J THORAC IMAG, V14, P266, DOI 10.1097/00005382-199910000-00006
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Goun EA, 2002, J ETHNOPHARMACOL, V81, P337, DOI 10.1016/S0378-8741(02)00116-2
   Han SB, 1998, IMMUNOPHARMACOLOGY, V40, P39, DOI 10.1016/S0162-3109(98)00026-5
   Hudis Clifford A, 2003, Clin Breast Cancer, V4 Suppl 2, pS70, DOI 10.3816/CBC.2003.s.018
   Jahan S, 2009, INTEGR CANCER THER, V8, P273, DOI 10.1177/1534735409343590
   [姜丽 Jiang Li], 2010, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V16, P1079
   JONES TM, 1972, PLANT PHYSIOL, V49, P926, DOI 10.1104/pp.49.6.926
   Kim HY, 2007, J MED FOOD, V10, P25, DOI 10.1089/jmf.2006.116
   KINNE DW, 1991, CA-CANCER J CLIN, V41, P71, DOI 10.3322/canjclin.41.2.71
   Lejeune Ferdy J, 2006, Cancer Immun, V6, P6
   LIN PY, 1995, ACTA PHARM SINIC, V16, P441
   Liu X, 2005, PHYTOCHEMISTRY, V66, P1671, DOI 10.1016/j.phytochem.2005.05.011
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   OADES JM, 1967, J CHROMATOGR, V28, P246, DOI 10.1016/S0021-9673(01)85963-X
   Parikh A, 2006, BIORESOURCE TECHNOL, V97, P1822, DOI 10.1016/j.biortech.2005.09.008
   Qian J, 2003, WORLD J GASTROENTERO, V9, P1885
   Sun YX, 2009, CARBOHYD POLYM, V75, P575, DOI 10.1016/j.carbpol.2008.08.023
   Tu J, 2008, J ETHNOPHARMACOL, V119, P266, DOI 10.1016/j.jep.2008.07.007
   Yates JS, 2005, SUPPORT CARE CANCER, V13, P806, DOI 10.1007/s00520-004-0770-7
NR 28
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2012
VL 51
IS 4
BP 484
EP 488
DI 10.1016/j.ijbiomac.2012.05.029
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 013MW
UT WOS:000309310500020
ER

PT J
AU Zhang, YX
   Wang, QS
   Wang, T
   Zhang, HK
   Tian, Y
   Luo, H
   Yang, S
   Wang, Y
   Huang, X
AF Zhang, Yunxin
   Wang, Qiusheng
   Wang, Tie
   Zhang, Haikui
   Tian, Ying
   Luo, Hong
   Yang, Shen
   Wang, Yuan
   Huang, Xun
TI Inhibition of human gastric carcinoma cell growth in vitro by a
   polysaccharide from Aster tataricus
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Aster tataricus; Polysaccharide; Purification; Apoptosis; Human gastric
   cancer
ID TRITERPENOID SAPONINS; CYTO-TOXICITY; CANCER; QUANTITATION; LINGULATUS;
   APOPTOSIS; SUGARS
AB A water-soluble polysaccharide (WATP), with a molecular weight of 6.3 x 10(4) Da, was isolated from Aster tataricus. According to gas chromatography (GC) analysis, WATP was composed of galactose, glucose, fucose, rhamnose, arabinose and mannose with molar ratios of 2.1:1.3:0.9:0.5:0.3:0.6. The effects of WATP on cell proliferation and apoptosis in human gastric cancer SGC-7901 cells were examined. MTT assay showed that WATP had a perfectly tumor growth inhibitory activity on SGC-7901 cells, but no cytotoxicity on SGC-7901 and primary human polymorphonuclear (PMN) cells analyzed using LDH assay. Flow cytometry analysis indicated that WATP could significantly induce apoptosis of SGC-7901 cells. Furthermore using Rh123 and Fluo-3 as fluorescent probes, respectively, it was found that mitochondrial transmembrane potential (Delta Psi(m)) of treatment groups was significantly lower than that in un-treatment group and the concentration of calcium in cells exposed to WATP for 24 h was increased in a dose dependent manner compared with unexposed group. These results suggest that WATP induces apoptosis of SGC-7901 cells through calcium- and Delta Psi(m)-dependent pathways, indicating that it is potentially useful as a natural anti-cancer agent. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Zhang, Yunxin; Wang, Qiusheng; Yang, Shen; Wang, Yuan; Huang, Xun] Peking Univ, Peoples Hosp, Dept Gen Surg, Beijing 100044, Peoples R China.
   [Wang, Tie] Cangzhou Hosp Integrated Tradit Chinese & Western, Dept Surg, Cangzhou 061000, Peoples R China.
   [Zhang, Haikui] Xingtai Peoples Hosp, Dept Anesthesiol, Xingtai 054031, Peoples R China.
   [Tian, Ying] Beijing Anorectal Hosp, Dept Surg, Beijing 100032, Peoples R China.
   [Luo, Hong] Capital Med Univ, Dept Neurobiol, Beijing 100069, Peoples R China.
   [Luo, Hong] Capital Med Univ, Beijing Inst Neurosci, Beijing 100069, Peoples R China.
RP Wang, QS (reprint author), Peking Univ, Peoples Hosp, Dept Gen Surg, Beijing 100044, Peoples R China.
EM qiushengwang_pku@yahoo.com.cn
CR BASAK RK, 1981, CARBOHYD RES, V97, P315, DOI 10.1016/S0008-6215(00)80677-1
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Gotoda T, 2006, J GASTROENTEROL, V41, P929, DOI 10.1007/s00535-006-1954-3
   Grivell AR, 1996, BBA-GEN SUBJECTS, V1291, P83, DOI 10.1016/0304-4165(96)00049-9
   Lacikova L, 2009, MOLECULES, V14, P3259, DOI 10.3390/molecules14093259
   Ma J, 2001, PLANTA MED, V67, P754
   McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775
   Morita H, 1996, CHEM PHARM BULL, V44, P1026
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   OADES JM, 1967, J CHROMATOGR, V28, P246, DOI 10.1016/S0021-9673(01)85963-X
   Shao Y, 1997, PHYTOCHEMISTRY, V44, P337, DOI 10.1016/S0031-9422(96)00551-1
   Shao Y, 1997, J NAT PROD, V60, P743, DOI 10.1021/np970080t
   Shirota Osamu, 1997, Natural Medicines, V51, P170
   STAUB A. M., 1965, METHOD CARBOHYD CHEM, V5, P5
   Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245
   Wang CZ, 1998, PLANTA MED, V64, P50, DOI 10.1055/s-2006-957365
   Zhou WB, 2010, Z NATURFORSCH B, V65, P1393
NR 21
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2012
VL 51
IS 4
BP 509
EP 513
DI 10.1016/j.ijbiomac.2012.06.019
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 013MW
UT WOS:000309310500024
ER

PT J
AU Han, XQ
   Chan, BCL
   Yu, H
   Yang, YH
   Hu, SQ
   Ko, CH
   Dong, CX
   Wong, CK
   Shaw, PC
   Fung, KP
   Leung, PC
   Hsiao, WL
   Tu, PF
   Han, QB
AF Han, Xiao-Qiang
   Chan, Ben Chung Lap
   Yu, Hua
   Yang, Yin-Hua
   Hu, Shui-Qing
   Ko, Chun-Hay
   Dong, Cai-Xia
   Wong, Chun-Kwok
   Shaw, Pang-Chui
   Fung, Kwok-Pui
   Leung, Ping-Chung
   Hsiao, Wen-Luan
   Tu, Peng-Fei
   Han, Quan-Bin
TI Structural characterization and immuno-modulating activities of a
   polysaccharide from Ganoderma sinense
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Ganoderma sinense; Polysaccharide; Immunological activities; Human
   peripheral blood mononuclear cells; Macrophages
ID EDIBLE MUSHROOM; FUNGAL; FOODS
AB A protein-bound polysaccharide (GSP-4) with a molecular weight of 8.3 x 10(5) Da, was isolated from the water extract of the fruiting bodies of Ganoderma sinense. Chemical study revealed that this fraction was composed of mannose, glucose and galactose in the molar ratio of 4.7:27.1:1.0, with the sugar residues of t-, 1,3-, 1,4-, 1,6-, 1,3,4- and 1,3.6-linked Glcp, t-linked Galp, and 1,6-linked Manp. The immnomodulatory effects of GSP-4 were assessed using human peripheral blood mononuclear cells (PBMCs) and murine monocyte/macrophage cell line RAW 264.7. We found that GSP-4 could significantly stimulate the production of the immunomodulatory markers tumor necrosis factor alpha (INF-alpha), interleukin (IL)-1 beta, IL-12, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in PBMCs. This observation was further substantiated in RAW 264.7 cells, as indicated by the increase of nitric oxide (NO), TNF-alpha and IL-6 production. GSP-4 also enhanced the expression of inducible NO synthase mRNA in dose-dependent manner. Our current finding gives the first piece of evidence to support that GSP-4 possesses some promising immunomodulating effects and it could be a potential candidate to be further used in related cancer immunotherapy. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Han, Xiao-Qiang; Yang, Yin-Hua; Tu, Peng-Fei] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Han, Xiao-Qiang; Chan, Ben Chung Lap; Yu, Hua; Hu, Shui-Qing; Ko, Chun-Hay; Wong, Chun-Kwok; Shaw, Pang-Chui; Fung, Kwok-Pui; Leung, Ping-Chung; Han, Quan-Bin] Chinese Univ Hong Kong, Inst Chinese Med, State Key Lab Phytochem & Plant Resources W China, Shatin, Hong Kong, Peoples R China.
   [Yu, Hua; Dong, Cai-Xia; Hsiao, Wen-Luan; Han, Quan-Bin] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Shaw, Pang-Chui] Chinese Univ Hong Kong, Sch Life Sci, Shatin, Hong Kong, Peoples R China.
   [Shaw, Pang-Chui] Chinese Univ Hong Kong, Ctr Prot Sci & Crystallog, Shatin, Hong Kong, Peoples R China.
   [Wong, Chun-Kwok] Chinese Univ Hong Kong, Dept Chem Pathol, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
RP Tu, PF (reprint author), Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Hlth Sci Ctr, Beijing 100191, Peoples R China.
EM pengfeitu@bjmu.edu.cn; simonhan@hkbu.edu.hk
FU Innovation and Technology Fund of the Government of the Hong Kong
   Special Administrative Region [ITS/311/09, InP/108/10]; Hong Kong
   Baptist University [FRG2/11-12/048]; One-Off Special Equipment Grant of
   the University Grants Council of Hong Kong SAR [SEG CUHK08, CUHK09]
FX This research is funded by the Innovation and Technology Fund
   (ITS/311/09 and InP/108/10) of the Government of the Hong Kong Special
   Administrative Region and Hong Kong Baptist University (FRG2/11-12/048).
   The purchase of the 700 MHz nuclear magnetic spectrometer was by a
   One-Off Special Equipment Grant (SEG CUHK08 and CUHK09) of the
   University Grants Council of Hong Kong SAR.
CR Bhunia SK, 2010, CARBOHYD RES, V345, P2542, DOI 10.1016/j.carres.2010.09.015
   Chan C. F. G., 2009, J HEMATOL ONCOL, V25, P1
   Chen JZ, 2007, MYCOL RES, V111, P635, DOI 10.1016/j.mycres.2007.02.011
   Chen L, 2011, AM J CHINESE MED, V39, P5
   Chen XP, 2009, CARBOHYD POLYM, V77, P389, DOI 10.1016/j.carbpol.2009.01.009
   Cunningham-Rundles S., 2009, NUTR REV, V67, P152
   Demirbas A., 2005, FOOD CHEM, V90, P273
   Kobayashi H, 2005, J CANCER RES CLIN, V131, P527, DOI 10.1007/s00432-005-0672-1
   Kogan G, 2005, CARBOHYD POLYM, V61, P18, DOI 10.1016/j.carbpol.2005.02.010
   Kruppa MD, 2009, CARBOHYD RES, V344, P2474, DOI 10.1016/j.carres.2009.09.029
   LAWRENCE JF, 1985, J CHROMATOGR, V350, P237, DOI 10.1016/S0021-9673(01)93522-8
   Liao CH, 2011, FOOD CHEM, V125, P930, DOI 10.1016/j.foodchem.2010.09.082
   Lin KI, 2006, J BIOL CHEM, V281, P24111, DOI 10.1074/jbc.M601106200
   Maity K., 2010, CARBOHYD RES, V345, P2157
   MCINTOSH GH, 1991, AM J CLIN NUTR, V53, P1205
   Mondal S, 2006, CARBOHYD RES, V341, P878, DOI 10.1016/j.carres.2006.02.004
   NEEDS PW, 1993, CARBOHYD RES, V245, P1, DOI 10.1016/0008-6215(93)80055-J
   Rout D, 2008, CARBOHYD RES, V343, P982, DOI 10.1016/j.carres.2007.12.022
   Russell R, 2006, PHYTOCHEMISTRY, V67, P1985, DOI 10.1016/j.phytochem.2006.07.004
   Schmid F, 2006, CARBOHYD RES, V341, P365, DOI 10.1016/j.carres.2005.10.013
   Suarez ER, 2008, CARBOHYD RES, V343, P2623, DOI 10.1016/j.carres.2008.07.009
   SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X
   Thakur BR, 1997, CRIT REV FOOD SCI, V37, P47
   Veena CK, 2007, FOOD CHEM, V100, P1552, DOI 10.1016/j.foodchem.2005.12.040
   Wang CC, 2009, FOOD CHEM, V116, P595, DOI 10.1016/j.foodchem.2009.03.015
   Zhang M, 2004, CARBOHYD RES, V339, P2297, DOI 10.1016/j.carres.2004.07.003
   Zhu BW, 2010, FOOD CHEM, V121, P712, DOI 10.1016/j.foodchem.2010.01.010
NR 27
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2012
VL 51
IS 4
BP 597
EP 603
DI 10.1016/j.ijbiomac.2012.06.029
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 013MW
UT WOS:000309310500036
ER

PT J
AU Wu, J
   Zhou, JX
   Lang, YG
   Yao, L
   Xu, H
   Shi, HB
   Xu, SD
AF Wu, Jun
   Zhou, Jinxu
   Lang, Yaoguo
   Yao, Lei
   Xu, Hai
   Shi, Hubo
   Xu, Shidong
TI A polysaccharide from Armillaria mellea exhibits strong in vitro
   anticancer activity via apoptosis-involved mechanisms
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Armillaria mellea; Polysaccharide; Apoptosis; Caspase; Mitochondrial
   membrane potential
ID CANCER CELLS; SUBSTANCES; MUSHROOMS
AB Armillaria mellea is a famous traditional Chinese medicinal and edible fungus. In this study, we purified a water-soluble polysaccharide (AMP) from the fruiting bodies of this fungus. AMP contained 94.8% carbohydrate, 2.3% uronic acid and 0.5% protein. Its molecular weight was determined as 4.6 x 10(5) Da, as determined by high-performance gel-permeation chromatography (HPGPC). Gas chromatography (GC) analysis indicated that AMP was mainly composed of o-glucose. In vitro assay. AMP exhibited a potent tumor growth inhibitory effect on A549 cells, and induced cell cycle disruption in the GO/G1 phase, accompanied by an increment of apoptotic cells. Furthermore, AMP induced the disruption of mitochondrial membrane potential, thus leading to cytochrome c release from mitochondria and activation of caspase-3 and -9. Taken together, our results demonstrate that AMP possesses strong antitumor activities through the mitochondria dependent pathway and activation of caspase cascade through cytochrome c release. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wu, Jun; Lang, Yaoguo; Yao, Lei; Xu, Hai; Shi, Hubo; Xu, Shidong] Harbin Med Univ, Affiliated Tumor Hosp 3, Dept Thorac Surg, Harbin 150040, Peoples R China.
   [Zhou, Jinxu] Harbin Inst Technol, Dept Foreign Languages, Harbin 150001, Peoples R China.
RP Xu, SD (reprint author), Harbin Med Univ, Affiliated Tumor Hosp 3, Dept Thorac Surg, Harbin 150040, Peoples R China.
EM shidongxuharbinmu@tom.com
FU Heilongjiang Province Science and Technology Agency [Gc04c305101]
FX This study was supported by Project of Heilongjiang Province Science and
   Technology Agency (Gc04c305101).
CR Adrie C, 2001, AM J RESP CRIT CARE, V164, P389
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   BREENE WM, 1990, J FOOD PROTECT, V53, P883
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Grabarek J, 2002, EXP CELL RES, V278, P61, DOI 10.1006/excr.2002.5568
   Lemasters JJ, 1997, BIOSCIENCE REP, V17, P281, DOI 10.1023/A:1027332611839
   Li QQ, 2010, J PHARM PHARMACOL, V62, P1018, DOI 10.1111/j.2042-7158.2010.01135.x
   Li ZB, 2007, PHYTOMEDICINE, V14, P846, DOI 10.1016/j.phymed.2007.09.004
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Mizuno M, 2000, IMMUNOPHARMACOLOGY, V46, P113, DOI 10.1016/S0162-3109(99)00163-0
   Ooi VEC, 2000, CURR MED CHEM, V7, P715
   Oosterveld A, 1996, CARBOHYD RES, V288, P143, DOI 10.1016/0008-6215(96)00092-4
   Salah-Abbes Jalila Ben, 2010, J Pharm Pharmacol, V62, P231
   Selegean M, 2009, INT J MOL SCI, V10, P3616, DOI 10.3390/ijms10083616
   Sheu F, 2004, FOOD CHEM, V87, P593, DOI 10.1016/j.foochem.2004.01.015
   STAUB A. M., 1965, METHOD CARBOHYD CHEM, V5, P5
   Sun YX, 2008, BIORESOURCE TECHNOL, V99, P900, DOI 10.1016/j.biortech.2007.01.029
   Wasser SP, 1999, CRIT REV IMMUNOL, V19, P65
   Xu Q.M., 2012, PHYTOMEDICINE, V15, P293
   YANG J S, 1989, Planta Medica, V55, P564, DOI 10.1055/s-2006-962096
   Yang Lihong, 2007, Food Science, China, V28, P309
   Yu Lei, 2006, Chinese Journal of Information on Traditional Chinese Medicine, V13, P29
   Zhang Ying, 2001, Edible Fungi of China, V20, P38
NR 24
TC 0
Z9 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2012
VL 51
IS 4
BP 663
EP 667
DI 10.1016/j.ijbiomac.2012.06.040
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 013MW
UT WOS:000309310500046
ER

PT J
AU Zhang, XM
   Xu, L
   Huang, X
   Wei, SC
   Zhai, ML
AF Zhang, Xiangmei
   Xu, Ling
   Huang, Xin
   Wei, Shicheng
   Zhai, Maolin
TI Structural study and preliminary biological evaluation on the collagen
   hydrogel crosslinked by ?-irradiation
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE collagen; hydrogel; radiation crosslinking; radiation effect;
   biodegradation
ID GAMMA-RAY IRRADIATION; MECHANICAL-PROPERTIES; UV-IRRADIATION; I
   COLLAGEN; RADIATION; LINKING; GELATIN; FILMS; GLUTARALDEHYDE; MODEL
AB Under ?-irradiation, concentrated collagen solutions yielded collagen hydrogels and liquid products. The molecular structure of collagen hydrogels and the source of the liquid products were studied. Furthermore, preliminary biological properties of the hydrogels were investigated. The results revealed that crosslinking occurred to form collagen hydrogel and the crosslinking density increased with the increasing of the absorbed dose, and the collagen hydrogels showed enhanced mechanical properties. Meanwhile, collagen underwent radiation degradation and water was squeezed out from hydrogel by contraction of hydrogel, yielding liquid products. Collagen hydrogels induced by ?-irradiation maintained the backbone structure of collagen, and tyrosine partially involved in crosslinking. The irradiated collagen hydrogels have higher denatured temperature, can promote fibroblasts proliferation, and their degradation rate in vivo depended on the absorbed dose. The comprehensive results suggested that the collagen hydrogels prepared by radiation crosslinking preserved the triple helical conformation, possessed improved thermal stability and mechanical properties, excellent biocompatibility, which is expected to favor its application as biomaterials. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A:29602969, 2012.
C1 [Zhang, Xiangmei; Xu, Ling; Huang, Xin] Peking Univ, Coll Engn, Beijing Key Lab Solid Waste Utilizat & Management, Beijing 100871, Peoples R China.
   [Zhang, Xiangmei; Xu, Ling; Huang, Xin; Wei, Shicheng] Peking Univ, Acad Adv Interdisciplinary Studies, Ctr Biomed Mat & Tissue Engn, Beijing 100871, Peoples R China.
   [Xu, Ling] PKU HKUST ShenZhen HongKong Inst, Shenzhen Key Lab Polymer Sci, Shenzhen 518057, Peoples R China.
   [Huang, Xin] Beijing Jishuitan Hosp, Dept Burns, Beijing 100035, Peoples R China.
   [Wei, Shicheng] Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Beijing 100081, Peoples R China.
   [Zhai, Maolin] Peking Univ, Coll Chem & Mol Engn, Dept Appl Chem, Beijing Natl Lab Mol Sci, Beijing 100871, Peoples R China.
RP Xu, L (reprint author), Peking Univ, Coll Engn, Beijing Key Lab Solid Waste Utilizat & Management, Beijing 100871, Peoples R China.
EM lingxu@pku.edu.cn; sc-wei@pku.edu.cn
FU National Natural Science Foundation of China [21103004]; National Key
   Technology RD Program [2011BAB02B05]
FX Contract grant sponsor: National Natural Science Foundation of China;
   contract grant number: 21103004Contract grant sponsor: National Key
   Technology R&D Program; contract grant number: 2011BAB02B05
CR Bessho M, 2005, J BIOMAT SCI-POLYM E, V16, P715, DOI 10.1163/1568562053992478
   BOWES JH, 1962, RADIAT RES, V16, P211, DOI 10.2307/3571153
   Brinkman WT, 2003, BIOMACROMOLECULES, V4, P890, DOI 10.1021/bm0257412
   Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5
   Cataldo F, 2008, J RADIOANAL NUCL CH, V275, P125, DOI 10.1007/s10967-007-7003-8
   Chang MC, 2002, BIOMATERIALS, V23, P4811, DOI 10.1016/S0142-9612(02)00232-6
   Chen RN, 2006, BIOMACROMOLECULES, V7, P1058, DOI 10.1021/bm050754b
   Chevallay B, 2000, MED BIOL ENG COMPUT, V38, P211, DOI 10.1007/BF02344779
   Diridollou S, 2000, SKIN RES TECHNOL, V6, P214, DOI 10.1034/j.1600-0846.2000.006004214.x
   Fathima NN, 2008, COLLOID SURFACE B, V62, P11, DOI 10.1016/j.colsurfb.2007.09.006
   Fathima NN, 2007, J APPL POLYM SCI, V104, P3642, DOI 10.1002/app.26129
   Figueiro SD, 2004, CARBOHYD POLYM, V56, P313, DOI 10.1016/j.carbpol.2004.01.011
   Hara M, 2006, J ORAL TISSUE ENG, V3, P118
   HardinYoung J, 1996, BIOTECHNOL BIOENG, V49, P675, DOI 10.1002/(SICI)1097-0290(19960320)49:6<675::AID-BIT9>3.0.CO;2-L
   Hawkins CL, 2001, BBA-BIOENERGETICS, V1504, P196, DOI 10.1016/S0005-2728(00)00252-8
   He LR, 2011, INT J BIOL MACROMOL, V48, P354, DOI 10.1016/j.ijbiomac.2010.12.012
   Inoue N, 2006, J BIOMAT SCI-POLYM E, V17, P837, DOI 10.1163/156856206777996835
   Itoh S, 2002, BIOMATERIALS, V23, P4475, DOI 10.1016/S0142-9612(02)00166-7
   Jiang B, 2006, BIOMATERIALS, V27, P15, DOI 10.1016/j.biomaterials.2005.05.091
   Jiang B, 2005, J APPL POLYM SCI, V98, P2094, DOI 10.1002/app.21992
   Jorge-Herrero E, 1999, BIOMATERIALS, V20, P539, DOI 10.1016/S0142-9612(98)90205-8
   Kaminska A, 1996, POLYM DEGRAD STABIL, V51, P19, DOI 10.1016/0141-3910(95)00159-X
   KATO Y, 1994, PHOTOCHEM PHOTOBIOL, V59, P343, DOI 10.1111/j.1751-1097.1994.tb05045.x
   Khatyr F, 2004, SKIN RES TECHNOL, V10, P96, DOI 10.1111/j.1600-0846.2004.00057.x
   Lee CR, 2001, BIOMATERIALS, V22, P3145, DOI 10.1016/S0142-9612(01)00067-9
   Lee JE, 2001, YONSEI MED J, V42, P172
   Lin YK, 2006, FOOD CHEM, V99, P244, DOI 10.1016/j.foodchem.2005.06.053
   Mu CD, 2010, MACROMOL MATER ENG, V295, P100, DOI 10.1002/mame.200900292
   Muyonga JH, 2004, FOOD CHEM, V86, P325, DOI 10.1016/j.foodchem.2003.09.038
   Nguyen TD, 2005, RADIAT PHYS CHEM, V72, P381, DOI 10.1016/j.radphyschem.2004.01.011
   OBRIEN TK, 1984, T AM SOC ART INT ORG, V30, P440
   Ohan MP, 2003, J BIOMED MATER RES A, V67A, P1188, DOI 10.1002/jbm.a.20018
   PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105
   Pekel N, 2004, CARBOHYD POLYM, V55, P139, DOI 10.1016/j.carbpol.2003.08.015
   Pietrucha K, 2005, INT J BIOL MACROMOL, V36, P299, DOI 10.1016/j.ijbiomac.2005.07.004
   Rabotyagova O.S., 2008, Materials Science & Engineering: C (Materials for Biological Applications), V28, DOI 10.1016/j.msec.2008.03.012
   Rauf MA, 2009, J HAZARD MATER, V166, P6, DOI 10.1016/j.jhazmat.2008.11.043
   Sai KP, 2000, BURNS, V26, P54
   Sionkowska A, 1999, J PHOTOCH PHOTOBIO A, V120, P207, DOI 10.1016/S1010-6030(98)00427-4
   Sionkowska A, 2000, POLYM DEGRAD STABIL, V68, P147, DOI 10.1016/S0141-3910(99)00176-7
   Sionkowska A, 2006, POLYM DEGRAD STABIL, V91, P3026, DOI 10.1016/j.polymdegradstab.2006.08.009
   Sionkowska A, 1999, J PHOTOCH PHOTOBIO A, V124, P91, DOI 10.1016/S1010-6030(99)00061-1
   Tsuboi Y, 2001, J PHOTOCH PHOTOBIO A, V145, P209, DOI 10.1016/S1010-6030(01)00584-6
   Tzaphlidou M, 2002, MICRON, V33, P117, DOI 10.1016/S0968-4328(01)00009-9
   Wisniewski M, 2007, J PHOTOCH PHOTOBIO A, V188, P192, DOI 10.1016/j.jphotochem.2006.12.012
NR 45
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2012
VL 100A
IS 11
BP 2960
EP 2969
DI 10.1002/jbm.a.34243
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 009ZF
UT WOS:000309063400012
ER

PT J
AU Yin, H
   Li, YG
   Si, M
   Li, JM
AF Yin, Han
   Li, Yong-Gang
   Si, Meng
   Li, Jian-Min
TI Simvastatin-loaded macroporous calcium phosphate cement: Preparation, in
   vitro characterization, and evaluation of in vivo performance
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE calcium phosphate bone cements; sodium dodecyl sulfate; simvastatin;
   drug delivery systems
ID ALPHA-TRICALCIUM PHOSPHATE; COA REDUCTASE INHIBITORS; BONE MORPHOGENETIC
   PROTEIN-2; RAT CALVARIAL DEFECT; POSTMENOPAUSAL WOMEN; MINERAL DENSITY;
   STATINS; SURFACTANT; IMPLANTS; DELIVERY
AB The aim of our study was to construct macroporous calcium phosphate bone cements (CPCs) with enhanced osteogenic potential. For this purpose, 300 mM sodium dodecyl sulfate (SDS) as an air-entraining agent was added to the liquid phase and 1, 5, and 10% simvastatin (SIM) was homogenized with the solid phase. The physical and mechanical characteristics of the test samples were investigated. Biological properties of the new CPCs were examined after intramuscular and endosteal implantation in rabbits. The introduction of SDS produced interconnected macropores and did not significantly affect initial setting time, transformation of solid phase to hydroxyapatite, and biocompatibility of CPCs. Large amounts (10 wt %) of SIM could decrease the compressive strength and induce severe muscular necrosis and inflammatory reaction. Small amounts (1 wt %) of SIM were compatible with the CPCs did not affect the physico-chemical properties or biocompatibility and were sufficient to enhance the osteogenic potential of macroporous CPCs. (c) 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A:29913000, 2012.
C1 [Yin, Han; Li, Yong-Gang; Si, Meng; Li, Jian-Min] Shandong Univ, Qilu Hosp, Dept Orthoped, Jinan 250100, Shandong, Peoples R China.
   [Yin, Han] Taishan Med Univ, Liaocheng Peoples Hosp, Dept Orthopaed, Liaocheng, Shandong, Peoples R China.
   [Yin, Han] Taishan Med Univ, Liaocheng Clin Sch, Liaocheng, Shandong, Peoples R China.
RP Li, JM (reprint author), Shandong Univ, Qilu Hosp, Dept Orthoped, Jinan 250100, Shandong, Peoples R China.
EM gklijianmin@sina.com
CR Adah F, 2006, BIOMED SCI INSTRUM, V42, P126
   Ambard Alberto J, 2006, J Prosthodont, V15, P321, DOI 10.1111/j.1532-849X.2006.00129.x
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Blumenthal NM, 2002, J PERIODONTOL, V73, P1494, DOI 10.1902/jop.2002.73.12.1494
   Bodde EWH, 2008, J BIOMED MATER RES A, V87A, P780, DOI 10.1002/jbm.a.31830
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Chow LC, 2009, DENT MATER J, V28, P1
   Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jc.85.3.1137
   del Real RP, 2002, BIOMATERIALS, V23, P3673, DOI 10.1016/S0142-9612(02)00101-1
   Dhiman MK, 2009, AAPS PHARMSCITECH, V10, P258, DOI 10.1208/s12249-009-9203-8
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140-6736(00)02408-9
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Ginebra MP, 2010, ACTA BIOMATER, V6, P2863, DOI 10.1016/j.actbio.2010.01.036
   Habraken WJEM, 2010, ACTA BIOMATER, V6, P2200, DOI 10.1016/j.actbio.2009.12.028
   HIRSCH D, 1993, J BIOMED MATER RES, V27, P1477, DOI 10.1002/jbm.820271203
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365-2362.2009.02092.x
   Hunninghake Donald B., 1998, American Journal of Medicine, V104, p9S, DOI 10.1016/S0002-9343(98)00040-0
   Kroese-Deutman HC, 2006, J BIOMED MATER RES A, V79A, P503, DOI 10.1002/jbm.a.30805
   Sarda S, 1999, CHEM MATER, V11, P2722, DOI 10.1021/cm991022r
   Li M, 2009, J MATER SCI-MATER M, V20, P925, DOI 10.1007/s10856-008-3654-4
   Li M, 2010, CLIN ORTHOP RELAT R, V468, P1978, DOI 10.1007/s11999-010-1321-9
   Link DP, 2008, BIOMATERIALS, V29, P675, DOI 10.1016/j.biomaterials.2007.10.029
   Link DP, 2008, J BIOMED MATER RES A, V87A, P760, DOI 10.1002/jbm.a.31831
   Margulis-Goshen K, 2009, NANOMED-NANOTECHNOL, V5, P274, DOI 10.1016/j.nano.2008.11.004
   Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756-3282(03)00034-6
   Montufar EB, 2010, J MATER SCI-MATER M, V21, P863, DOI 10.1007/s10856-009-3918-7
   Mullen PJ, 2010, BIOCHEM PHARMACOL, V79, P1200, DOI 10.1016/j.bcp.2009.12.007
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nyan M, 2009, CLIN ORAL IMPLAN RES, V20, P280, DOI 10.1111/j.1600-0501.2008.01639.x
   Nyan M, 2010, J BIOMED MATER RES B, V93B, P65, DOI 10.1002/jbm.b.31559
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Ohura K, 1999, J BIOMED MATER RES, V44, P168, DOI 10.1002/(SICI)1097-4636(199902)44:2<168::AID-JBM7>3.0.CO;2-4
   Rojbani H, 2011, J BIOMED MATER RES A, V98A, P488, DOI 10.1002/jbm.a.33117
   Ruddy SB, 1999, INT J PHARM, V182, P173, DOI 10.1016/S0378-5173(99)00056-3
   Ruhe PQ, 2004, BIOMATERIALS, V25, P2123, DOI 10.1016/j.biomaterials.2003.09.007
   Rutledge J, 2011, J PERIODONTOL, V82, P597, DOI 10.1902/jop.2010.100214
   Sarda S, 2003, J BIOMED MATER RES A, V65A, P215, DOI 10.1002/jbm.a.10458
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Takagi S, 2001, J MATER SCI-MATER M, V12, P135, DOI 10.1023/A:1008917910468
   Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681
   Wang PS, 2000, JAMA-J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Wong RWK, 2003, BRIT J ORAL MAX SURG, V41, P244, DOI 10.1016/S0266-4356(03)00081-0
NR 44
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2012
VL 100A
IS 11
BP 2991
EP 3000
DI 10.1002/jbm.a.34228
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 009ZF
UT WOS:000309063400015
ER

PT J
AU Li, TM
   Wu, CM
   Huang, HC
   Chou, PC
   Fong, YC
   Tang, CH
AF Li, Te-Mao
   Wu, Chi-Ming
   Huang, Hsin-Chih
   Chou, Pei-Chi
   Fong, Yi-Chin
   Tang, Chih-Hsin
TI Interleukin-11 Increases Cell Motility and Up-Regulates Intercellular
   Adhesion Molecule-1 Expression in Human Chondrosarcoma Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE IL-11; CHONDROSARCOMA; ICAM-1; MIGRATION
ID NF-KAPPA-B; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY;
   CARCINOMA CELLS; IL-11 RECEPTOR; CANCER CELLS; ACTIVATION; INVASION;
   ALPHA
AB Interleukin-11 (IL-11) was originally identified as the cytokine that could induce the proliferation of human cells. Recent studies have shown that IL-11 plays a critical role in tumor growth, angiogenesis, and metastasis. Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. However, the effects of IL-11 on human chondrosarcoma cells are largely unknown. Here, we found that IL-11 increased the migration and expression of intercellular adhesion molecule-1 (ICAM)-1 in human chondrosarcoma cells. We also found that human chondrosarcoma tissues had significant expression of the IL-11 which was higher than that in primary chondrocytes. The phosphatidylinositol 3-kinase (PI3K), Akt, and NF-?B pathways were activated by IL-11 treatment, and the IL-11-induced expression of ICAM-1 and migration activity were inhibited by the specific inhibitors and mutant forms of PI3K, Akt, and NF-?B cascades. Taken together, our results indicate that IL-11 enhanced the migration of the chondrosarcoma cells by increasing ICAM-1 expression through the IL-11Ra receptor, PI3K, Akt, and NF-?B signal transduction pathway. J. Cell. Biochem. 113: 33533362, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Tang, Chih-Hsin] China Med Univ, Dept Pharmacol, Sch Med, Taichung, Taiwan.
   [Li, Te-Mao; Wu, Chi-Ming; Chou, Pei-Chi; Fong, Yi-Chin] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Huang, Hsin-Chih] Chi Mei Med Ctr, Tainan, Taiwan.
   [Chou, Pei-Chi] China Med Univ Hosp, Taipei Branch, Dept Chinese Med, Taipei, Taiwan.
   [Fong, Yi-Chin] China Med Univ Hosp, Dept Orthopaed, Taichung, Taiwan.
   [Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
RP Tang, CH (reprint author), China Med Univ, Dept Pharmacol, Sch Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
FU National Science Council of Taiwan [NSC99-2320-B-039-003-MY3,
   100-2320-B-039-028-MY3]; China Medical University [CMU100-NSC-07]
FX Grant sponsor: National Science Council of Taiwan; Grant numbers:
   NSC99-2320-B-039-003-MY3, 100-2320-B-039-028-MY3; Grant sponsor: China
   Medical University; Grant number: CMU100-NSC-07.
CR Bibollet-Bahena O, 2009, J NEUROCHEM, V109, P1440, DOI 10.1111/j.1471-4159.2009.06071.x
   Chen JH, 2011, J CELL BIOCHEM, V112, P2931, DOI 10.1002/jcb.23209
   Chuang JY, 2009, J CELL PHYSIOL, V220, P418, DOI 10.1002/jcp.21783
   Dahmen H, 1998, BIOCHEM J, V331, P695
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Duperray A, 1997, J BIOL CHEM, V272, P435
   Fischer P, 2007, BASIC RES CARDIOL, V102, P279, DOI 10.1007/s00395-007-0658-z
   Fong YC, 2007, J ORTHOP RES, V25, P1106, DOI 10.1002/jor.20364
   Fong YC, 2012, J CELL PHYSIOL, V227, P223, DOI 10.1002/jcp.22720
   GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Ha KH, 2009, BIOCHEMISTRY-US, V48, P7271, DOI 10.1021/bi900660f
   Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3
   Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200
   Hsieh MT, 2003, LIFE SCI, V73, P1007, DOI 10.1016/S0024-3205(03)00372-2
   Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200
   Huang WC, 2004, CARCINOGENESIS, V25, P1925, DOI 10.1093/carcin/bgh211
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005
   Inoue T, 2011, J BIOL CHEM, V286, P32045, DOI 10.1074/jbc.M111.285650
   Lawson C, 2009, PHARMACOL REP, V61, P22
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749
   Matadeen R, 2007, STRUCTURE, V15, P441, DOI 10.1016/j.str.2007.02.006
   Nakayama T, 2007, INT J ONCOL, V30, P825
   PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512
   Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784
   Qureshi HY, 2007, CELL SIGNAL, V19, P1643, DOI 10.1016/j.cellsig.2007.02.007
   Rosette C, 2005, CARCINOGENESIS, V26, P943, DOI 10.1093/carcin/bgi070
   Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961
   Su CM, 2009, J CELL PHYSIOL, V220, P499, DOI 10.1002/jcp.21802
   Suman P, 2009, J REPROD IMMUNOL, V82, P1, DOI 10.1016/j.jri.2009.07.002
   Terek RM, 1998, J ORTHOPAED RES, V16, P585, DOI 10.1002/jor.1100160510
   Tseng CP, 2003, FEBS LETT, V541, P21, DOI 10.1016/S0014-5793(03)00281-3
   Wang YC, 2003, ANAL BIOCHEM, V319, P206, DOI 10.1016/S0003-2697(03)00330-0
   Yoshizaki A, 2006, INT J ONCOL, V29, P869
   Yuan J, 2005, J ORTHOP RES, V23, P1467, DOI 10.1016/j.orthres.2005.04.004
   Zimmerman T, 2008, CURR PHARM DESIGN, V14, P2128, DOI 10.2174/138161208785740225
NR 37
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3353
EP 3362
DI 10.1002/jcb.24211
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200005
ER

PT J
AU Guo, N
   Cheng, D
   Li, ZH
   Zhou, QB
   Zhou, JJ
   Lin, Q
   Zeng, B
   Liao, QF
   Chen, RF
AF Guo, Ning
   Cheng, Di
   Li, Zhi Hua
   Zhou, Quan Bo
   Zhou, Jia Jia
   Lin, Qing
   Zeng, Bing
   Liao, Qiaofang
   Chen, Ru Fu
TI Transfection of HCVc improves hTERT expression through STAT3 pathway by
   epigenetic regulation in Huh7 cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE HEPATIC CARCINOMA; HCV; DNA METHYLTRANSFERASE; TELOMERASE; STAT3
ID TELOMERASE ACTIVITY; DNA METHYLATION; HEPATOMA-CELLS; CORE PROTEIN;
   PROMOTER; HEPATOCARCINOGENESIS; CHOLANGIOCARCINOMA; METHYLTRANSFERASES;
   ACTIVATION; CARCINOMA
AB Previous studies showed that transient transfection of HCVc improved hTERT expression in hepatoma cell lines and it was noteworthy that phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and DNA methyltransferases (DNMTs) were up regulated simultaneously. This study was designed to investigate the role of epigenetic regulation in the process of hTERT up regulation after HCVc transfection. Q-PCR and Western blot were used to analyze the expression of pSTAT3, DNMT1, and hTERT after the transfection of HCVc in hepatoma cell line Huh7. Proliferation and hTERT activity of Huh7 after HCVc transfection were examined by CCK8 and ELISA, respectively. Then, we blocked the JAK/STAT3 pathway or inhibited DNMT1 expression to investigate the regulation of pSTAT3, DNMT1, and hTERT. Methylation status of the promoter of hTERT gene was monitored by MS-PCR. Cell proliferation, hTERT expression level and activity of hTERT were promoted after HCVc transfection. The expression of pSTAT3 and DNMT1 were up-regulated simultaneously. DNMT1 and hTERT were down-regulated after blocking JAK/STAT3 pathway and the expression of hTERT weakened with DNMT1 inhibition. MS-PCR showed HCVc transfection increased the methylation level of hTERT promoter, and this effect was weakened after blocking the JAK/STAT3 pathway or with the treatment with DNMT1 inhibitor. HCVc transfection improved hTERT expression via epigenetic regulation. JAK/STAT3 pathway could be one of the essential factors in regulating DNMT1 expression during this process. J. Cell. Biochem. 113: 34193426, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Zhou, Quan Bo; Zhou, Jia Jia; Lin, Qing; Zeng, Bing; Chen, Ru Fu] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
   [Guo, Ning] Shan Dong Univ, Dept Organ Transplant, Qi Lu Hosp, Jinan 250012, Peoples R China.
   [Cheng, Di; Li, Zhi Hua; Liao, Qiaofang] Sun Yat Sen Univ, Dept Oncol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
RP Chen, RF (reprint author), Sun Yat Sen Univ, Dept Hepatobiliary Surg, Sun Yat Sen Mem Hosp, 107 Yan Jiangxi Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM gnn2000@yahoo.cn
FU Chinese National Natural Science Foundation [30872485]
FX Grant sponsor: Chinese National Natural Science Foundation; Grant
   number: 30872485.
CR Chen RF, 2007, ONCOL REP, V17, P105
   Choi JH, 2010, BIOCHEM BIOPH RES CO, V391, P449, DOI 10.1016/j.bbrc.2009.11.078
   Choi JH, 2007, BIOCHEM BIOPH RES CO, V361, P615, DOI 10.1016/j.bbrc.2007.07.051
   Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Guilleret I, 2004, BIOCHEM BIOPH RES CO, V325, P1037, DOI 10.1016/j.bbrc.2004.10.137
   Heathcote EJ, 2004, GASTROENTEROLOGY, V127, pS294, DOI 10.1053/j.gastro.2004.09.044
   Hytiroglou P, 2006, AM J GASTROENTEROL, V101, P839, DOI 10.1111/j.1572-0241.2006.00521.x
   Kasprzak A, 2008, HEPATOL RES, V38, P1, DOI 10.1111/j.1872-034X.2007.00261.x
   Liu SX, 2004, WORLD J GASTROENTERO, V10, P366
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Ripoli M, 2011, VIRUS RES, V160, P74, DOI 10.1016/j.virusres.2011.05.014
   Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308
   Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2
   TAHARA H, 1995, CANCER RES, V55, P2734
   Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x
   Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287
   Zhang Q, 2002, J IMMUNOL, V168, P466
   Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102
   Zhang RG, 2002, INT J CANCER, V97, P173, DOI 10.1002/ijc.1597
   Zhaowen Z, 2010, J MED VIROL, V82, P239
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
NR 22
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3419
EP 3426
DI 10.1002/jcb.24218
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200012
ER

PT J
AU Tsou, HK
   Chen, HT
   Chang, CH
   Yang, WY
   Tang, CH
AF Tsou, Hsi-Kai
   Chen, Hsien-Te
   Chang, Chia-Hao
   Yang, Wan-Yu
   Tang, Chih-Hsin
TI Apoptosis signal-regulating kinase 1 is mediated in TNF-alpha-induced
   CCL2 expression in human synovial fibroblasts
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE TNF-a; CCL2; ASK1; OA
ID TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ENHANCES IL-6
   PRODUCTION; RHEUMATOID-ARTHRITIS; CHEMOKINE RECEPTORS; OSTEOBLASTIC
   CELLS; KAPPA-B; PATHWAY; ACTIVATION; OSTEOARTHRITIS
AB Tumor necrosis factor-a (TNF-a), a pro-inflammatory cytokine with a critical role in osteoarthritis (OA), was primarily produced by monocytes/macrophages and plays a crucial role in the inflammatory response. Here, we investigated the intracellular signaling pathways involved in TNF-a-induced monocyte chemoattractant protein 1 (MCP-1)/CCL2 expression in human synovial fibroblast cells. Stimulation of synovial fibroblasts (OASF) with TNF-a induced concentration- and time-dependent increases in CCL2 expression. TNF-a-mediated CCL2 production was attenuated by TNFR1 monoclonal antibody (Ab). Pretreatment with an apoptosis signal-regulating kinase 1 (ASK1) inhibitor (thioredoxin), JNK inhibitor (SP600125), p38 inhibitor (SB203580), or AP-1 inhibitor (curcumin or tanshinone IIA) also blocked the potentiating action of TNF-a. Stimulation of cells with TNF-a enhanced ASK1, JNK, and p38 activation. Treatment of OASF with TNF-a also increased the accumulation of phosphorylated c-Jun in the nucleus, AP-1-luciferase activity, and c-Jun binding to the AP-1 element on the CCL2 promoter. TNF-a-mediated AP-1-luciferase activity and c-Jun binding to the AP-1 element were inhibited by TNFR1 Ab, thioredoxin, SP600125, and SB203580. Our results suggest that the interaction between TNF-a and TNFR1 increases CCL2 expression in human synovial fibroblasts via the ASK1, JNK/p38, c-Jun, and AP-1 signaling pathway. J. Cell. Biochem. 113: 35093519, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Yang, Wan-Yu; Tang, Chih-Hsin] China Med Univ, Dept Pharmacol, Sch Med, Taichung, Taiwan.
   [Tsou, Hsi-Kai] Taichung Vet Gen Hosp, Dept Neurosurg, Taichung, Taiwan.
   [Tsou, Hsi-Kai] Jen Teh Jr Coll Med Nursing & Management, Ctr Gen Educ, Miaoli Cty, Taiwan.
   [Tsou, Hsi-Kai; Chen, Hsien-Te] Feng Chia Univ, Dept Mat Sci & Engn, Taichung 40724, Taiwan.
   [Chen, Hsien-Te] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Chen, Hsien-Te] China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan.
   [Chang, Chia-Hao] Chang Hwa Hosp, Dept Hlth Execut Yuan, Dept Orthoped Surg, Chang Hwa Cty, Taiwan.
   [Tang, Chih-Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
RP Tang, CH (reprint author), China Med Univ, Dept Pharmacol, Sch Med, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
FU National Science Council of Taiwan NSC [100-2320-B-039-028-MY3]; China
   Medical University [CMU100-NSC-07]
FX Grant sponsor: National Science Council of Taiwan NSC; Grant number:
   100-2320-B-039-028-MY3; Grant sponsor: China Medical University; Grant
   number: CMU100-NSC-07.
CR AKAHOSHI T, 1993, ARTHRITIS RHEUM, V36, P762, DOI 10.1002/art.1780360605
   Bianchi K, 2009, MOL CELL, V36, P736, DOI 10.1016/j.molcel.2009.11.029
   Chiu YC, 2009, J IMMUNOL, V183, P2785, DOI 10.4049/jimmunol.0802826
   Choy EHS, 2001, NEW ENGL J MED, V344, P907
   Coelho FM, 2008, ARTHRITIS RHEUM, V58, P2329, DOI 10.1002/art.23622
   Cross SS, 2006, J CLIN PATHOL, V59, P716, DOI 10.1136/jcp.2005.030031
   DIGIOVINE FS, 1988, ANN RHEUM DIS, V47, P768, DOI 10.1136/ard.47.9.768
   Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200
   Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131
   Hsieh MT, 2003, LIFE SCI, V73, P1007, DOI 10.1016/S0024-3205(03)00372-2
   Hsu MJ, 2007, J NEUROSCI, V27, P5719, DOI 10.1523/JNEUROSCI.1874-06.2007
   Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200
   Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1
   Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90
   KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950
   Kok SH, 2009, ARTHRITIS RHEUM, V60, P1451, DOI 10.1002/art.24452
   Kunisch E, 2007, ANN RHEUM DIS, V66, P1043, DOI 10.1136/ard.20006.062521
   Levinger I, 2011, ARTHRITIS RHEUM-US, V63, P1343, DOI 10.1002/art.30287
   Liang CJ, 2011, FREE RADICAL BIO MED, V51, P1337, DOI 10.1016/j.freeradbiomed.2011.06.023
   Lin SK, 2008, ARTHRITIS RHEUM, V58, P3145, DOI 10.1002/art.23937
   Lin SK, 2004, ARTHRITIS RHEUM, V50, P785, DOI 10.1002/art.20058
   MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969
   Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011
   Mor A, 2005, CLIN IMMUNOL, V115, P118, DOI 10.1016/j.clin.2004.12.009
   Pelletier JP, 2001, ARTHRITIS RHEUM, V44, P1237, DOI 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F
   Sakkas LI, 2007, ARTHRITIS RHEUM, V56, P409, DOI 10.1002/art.22369
   SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816
   Shen PC, 2011, OSTEOARTHR CARTILAGE, V19, P728, DOI 10.1016/j.joca.2011.02.014
   Szekanecz Z, 2003, SEMIN IMMUNOL, V15, P15, DOI 10.1016/S1044-5323(02)00124-0
   Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606
   Tang CH, 2007, J IMMUNOL, V179, P5483
   TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533
   Tseng CP, 2003, FEBS LETT, V541, P21, DOI 10.1016/S0014-5793(03)00281-3
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Wang YC, 2003, ANAL BIOCHEM, V319, P206, DOI 10.1016/S0003-2697(03)00330-0
   Yang TC, 2010, MICROBES INFECT, V12, P643, DOI 10.1016/j.micinf.2010.04.007
   Yang WH, 2011, J CELL BIOCHEM, V112, P1601, DOI 10.1002/jcb.23072
   Yu CC, 2009, J IMMUNOL, V182, P7916, DOI 10.4049/jimmunol.0801582
   Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511
   Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790
NR 41
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3509
EP 3519
DI 10.1002/jcb.24227
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200021
ER

PT J
AU Chen, XM
   Kan, QC
   Wang, F
   Kong, HJ
   Zhang, YY
   Yu, WZ
   Sun, YP
AF Chen, Xue-Mei
   Kan, Quan-Cheng
   Wang, Fang
   Kong, Hui-Juan
   Zhang, Yong-Yong
   Yu, Wen-Zhu
   Sun, Ying-Pu
TI Chromosome dynamic changes in two cultured chinese human embryonic stem
   cell lines: Single nucleotide polymorphism, copy number variation and
   loss of heterozygosity
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE HUMAN EMBRYONIC STEM CELLS; COPY NUMBER VARIATION; SINGLE NUCLEOTIDE
   POLYMORPHISM; LOSS OF HETEROZYGOSITY; KARYOTYPE
ID IN-VITRO CULTURE; TUMORS; AMPLIFICATION; HYBRIDIZATION; INTEGRITY;
   REVEALS; GENES
AB The quality and safety of human embryonic stem cells (hESCs) in clinical application depend on gene stability. Two Chinese hESC lines, Zh1 and Zh21, were incubated over a long period. We observed and compared the gene stability in the passage numbers 20, 17 for Zh1 cell line and passage numbers 27, 60, 68 for Zh21 cell line. Single nucleotide polymorphisis analysis indicated that hESCs in early passages had relative gene stability; and with the increase in passage number, gene instability became strong. We also found that there were copy number variations (CNVs) in both Zh21 and Zh1. We analyzed the CNVs of Chinese Han Beijing man (CHB; normal Chinese people) and found that the all CNV forms were the loss in Zh21, Zh1, and CHB. We also analyzed and compared the related pathways of the mutant genes. We propose three steps to ensure hESC safety. Firstly, besides the conventional methods such as pluripotent genes, chromosome G-banding and teratoma, high-resolution DNA chip analysis should also be adopted; secondly, chromosomal properties are monitored every 10 passages in less than passage 50 and every 5 passages in more than passage 50; thirdly, the related pathways of mutant genes should be observed because only the mutant genes with variations of their related pathways may affected cell functions. J. Cell. Biochem. 113: 35203527, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Chen, Xue-Mei; Wang, Fang; Kong, Hui-Juan; Zhang, Yong-Yong; Yu, Wen-Zhu; Sun, Ying-Pu] Zhengzhou Univ, Reprod Med Ctr, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China.
   [Chen, Xue-Mei] Zhengzhou Univ, Dept Human Anat, Coll Basic Med Sci, Zhengzhou 450001, Peoples R China.
RP Sun, YP (reprint author), 1 Construct E Rd, Zhengzhou 450052, Peoples R China.
EM syp2008@vip.sina.com
FU National Natural Science Foundation of China [30771105]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   number: 30771105.
CR Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Azuhata T, 2001, J PEDIATR SURG, V36, P1785, DOI 10.1053/jpsu.2001.28839
   Baker DEC, 2007, NAT BIOTECHNOL, V25, P207, DOI 10.1038/nbt1285
   Caisander G, 2006, CHROMOSOME RES, V14, P131, DOI 10.1007/s10577-006-1019-8
   Castle JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020660
   Darnfors C, 2005, STEM CELLS, V23, P483, DOI 10.1634/stemcells.2004-0254
   Diskin SJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn556
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345
   Imreh MP, 2006, J CELL BIOCHEM, V99, P508, DOI 10.1002/jcb.20897
   Inzunza J, 2004, MOL HUM REPROD, V10, P461, DOI 10.1093/molehr/gah051
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003
   Li PF, 2012, GYNECOL ENDOCRINOL, V28, P25, DOI 10.3109/09513590.2011.588748
   Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631
   Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017
   Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105-19
   Moralli D, 2011, STEM CELL REV REP, V7, P471, DOI 10.1007/s12015-010-9224-4
   Narva E, 2010, NAT BIOTECHNOL, V28, P371, DOI 10.1038/nbt.1615
   Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7
   Slovak ML, 2010, MOL CYTOGENET, V3, DOI 10.1186/1755-8166-3-23
   Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100
   Staaf J, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r136
   Stephenson E, 2010, J R SOC INTERFACE, V7, pS677, DOI 10.1098/rsif.2010.0343.focus
   TRASK BJ, 1991, AM J HUM GENET, V48, P1
   van Dartel M, 2004, CANCER GENET CYTOGEN, V153, P77, DOI 10.1016/j.cancergencyto.2004.03.007
   Wang K, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn641
   Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907
   Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X
   Zafarana G, 2003, ONCOGENE, V22, P7695, DOI 10.1038/sj.onc.1207011
NR 30
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3520
EP 3527
DI 10.1002/jcb.24229
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200022
ER

PT J
AU Zhang, XY
   Jia, SZ
   Yang, SM
   Yang, Y
   Yang, TY
   Yang, YM
AF Zhang, Xinyu
   Jia, Shuzhao
   Yang, Shumeng
   Yang, Yue
   Yang, Tuoyun
   Yang, Yanmei
TI Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells
   by increasing the tumor suppressor PTEN expression
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ARSENIC TRIOXIDE; G2; M ARREST; AKT; PTEN; cdc2
ID PROSTATE-CANCER CELLS; INDUCED APOPTOSIS; GROWTH-INHIBITION; SIGNALING
   PATHWAY; PROTEIN-KINASE; MODULATING AKT; PHASE ARREST; CYCLE ARREST;
   PHOSPHORYLATION; ACTIVATION
AB Arsenic trioxide (As2O3), an effective agent against acute promyelocytic leukemia, has been reported to inhibit the viability of solid tumors cell lines recently. The detailed molecular mechanism underlying the As2O3-induced inactivation of the cdc2 and possible functional role of PTEN in the observed G2/M arrest has yet to be elucidated. Here, we assessed the role of PTEN in regulation of As2O3-mediated G2/M cell cycle arrest in Hepatocellular carcinoma cell lines (HepG2 and SMMC7721). After 24?h following treatment, As2O3 induced a concentration-dependent accumulation of cells in the G2/M phase of the cell cycle. The sustained G2/M arrest by As2O3 is associated with decreased cdc2 protein and increased phospho-cdc2(Tyr15). As2O3 treatment increased Wee1 levels and decreased phospho-Wee1(642). Moreover, As2O3 substantially decreased the Ser473 and Thr308 phosphorylation of Akt and upregulated PTEN expression. Downregulation of PTEN by siRNA in As2O3-treated cells increased phospho-Wee1(Ser642) while decreased phospho-cdc2(Tyr15), resulting in decreased the G2/M cell cycle arrest. Therefore, induction of G2/M cell cycle arrest by As2O3 involved upregulation of PTEN. J. Cell. Biochem. 113: 35283535, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Yang, Yue; Yang, Yanmei] Harbin Med Univ, Canc Res Inst, Harbin 150081, Heilongjiang, Peoples R China.
   [Zhang, Xinyu; Jia, Shuzhao; Yang, Shumeng; Yang, Tuoyun] Harbin Med Univ, Dept Surg, Affiliated Hosp 2, Harbin 150081, Heilongjiang, Peoples R China.
RP Yang, YM (reprint author), Harbin Med Univ, Canc Res Inst, 6 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.
EM yangym0916@163.com
FU Natural Science Foundation of Heilongjiang Province, China [D2007-79];
   NSFC [30972561]; Heilongjiang Postdoctoral Science-Research Foundation
FX Grant sponsor: Natural Science Foundation of Heilongjiang Province,
   China; Grant number: D2007-79; Grant sponsor: NSFC; Grant number:
   30972561; Grant sponsor: Heilongjiang Postdoctoral Science-Research
   Foundation.
CR Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016/j.mrfmmm.2010.10.007
   Baig RM, 2011, ASIAN PAC J CANCER P, V12, P2773
   Berenson JR, 2006, CLIN LYMPHOMA MYELOM, V7, P192, DOI 10.3816/CLM.2006.n.058
   Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3
   Cao F, 2006, BIOMED ENVIRON SCI, V19, P35
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chen Z, 2002, SEMIN HEMATOL, V39, P22, DOI 10.1053/shem.2002.33611
   DESAI D, 1995, MOL CELL BIOL, V15, P345
   De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M20274220
   Dilda PJ, 2007, CANCER TREAT REV, V33, P542, DOI 10.1016/j.ctrv.2007.05.001
   El-Serag HB, 2006, J HEPATOL, V44, P158, DOI 10.1016/j.jhep.2005.10.002
   Fei M, 2009, MED ONCOL, V26, P178, DOI 10.1007/s12032-008-9105-8
   GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K
   Han YH, 2008, J CELL BIOCHEM, V104, P862, DOI 10.1002/jcb.21673
   Han YH, 2008, CANCER LETT, V270, P40, DOI 10.1016/j.canlet.2008.04.041
   Hang Y, 2005, WORLD J GASTROENTERO, V11, P2224
   Huang SM, 2011, INT J ONCOL, V38, P1357, DOI 10.3892/ijo.2011.952
   Kandasamy K, 2002, CANCER RES, V62, P4929
   Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002
   Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005
   Li YC, 2009, CANCER LETT, V284, P208, DOI 10.1016/j.canlet.2009.04.035
   Liu B, 2006, CANCER SCI, V97, P675, DOI 10.1111/j.1349-7006.2006.00230.x
   Liu ZM, 2011, BIOCHEM J, V438, P349, DOI 10.1042/BJ20101653
   Maeda H, 2001, CANCER RES, V61, P5432
   MCGOWAN CH, 1993, EMBO J, V12, P75
   Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096
   NORBURY C, 1991, EMBO J, V10, P3321
   Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741
   Park WH, 2000, CANCER RES, V60, P3065
   Peyrou M, 2010, WORLD J GASTROENTERO, V16, P4627, DOI 10.3748/wjg.v16.i37.4627
   Redondo-Munoz J, 2010, CLIN CANCER RES, V16, P4382, DOI 10.1158/1078-0432.CCR-10-0072
   Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56
   Selvendiran K, 2007, J BIOL CHEM, V282, P28609, DOI 10.1074/jbc.M703796200
   van Duijn PW, 2010, PROSTATE, V70, P135, DOI 10.1002/pros.21045
   Wang Y, 2009, UROL INT, V82, P214, DOI 10.1159/000200803
   Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798
   Weir NM, 2007, CANCER BIOL THER, V6, P178
   Wells NJ, 1999, J CELL SCI, V112, P3361
   Weng JR, 2012, CHEM-BIOL INTERACT, V195, P224, DOI 10.1016/j.cbi.2012.01.003
   Xiong X, 2011, PATHOL ONCOL RES, V17, P931, DOI 10.1007/s12253-011-9406-7
   Zhang Y, 2010, INT J RADIAT BIOL, V86, P964, DOI 10.3109/09553002.2010.496032
   Zheng YH, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-31
NR 43
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3528
EP 3535
DI 10.1002/jcb.24230
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200023
ER

PT J
AU Chen, G
   Nan, C
   Tian, J
   Jean-Charles, P
   Li, Y
   Weissbach, H
   Huang, XP
AF Chen, G.
   Nan, C.
   Tian, Jie
   Jean-Charles, P.
   Li, Y.
   Weissbach, H.
   Huang, X. P.
TI Protective effects of taurine against oxidative stress in the heart of
   MsrA knockout mice
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE TAURINE; DIET SUPPLEMENT; HEART; MITOCHONDRIA; ANTI-OXIDANT
ID METHIONINE SULFOXIDE REDUCTASE; DIASTOLIC DYSFUNCTION; RESTRICTIVE
   CARDIOMYOPATHY; MITOCHONDRIAL-FUNCTION; ANTIOXIDANT DEFENSE; CARDIAC
   MYOCYTES; TRANSGENIC MICE; PROTEINS; DAMAGE; HYPOXIA/REOXYGENATION
AB Taurine has been shown to have potent anti-oxidant properties under various pathophysiological conditions. We reported previously a cellular dysfunction and mitochondrial damage in cardiac myocytes of methionine sulfoxide reductase A (MsrA) gene knockout mice (MsrA-/-). In the present study, we have explored the protective effects of taurine against oxidative stress in the heart of MsrA-/- mice with or without taurine treatment. Cardiac cell contractility and Ca2+ dynamics were measured using cell-based assays and in vivo cardiac function was monitored using high-resolution echocardiography in the tested animals. Our data have shown that MsrA-/- mice exhibited a progressive cardiac dysfunction with a significant decrease of ejection fraction (EF) and fraction shortening (FS) at age of 8 months compared to the wild type controls at the same age. However, the dysfunction was corrected in MsrA-/- mice treated with taurine supplement in the diet for 5 months. We further investigated the cellular mechanism underlying the protective effect of taurine in the heart. Our data indicated that cardiac myocytes from MsrA-/- mice treated with taurine exhibited an improved cell contraction and could tolerate oxidative stress better. Furthermore, taurine treatment reduced significantly the protein oxidation levels in mitochondria of MsrA-/- hearts, suggesting an anti-oxidant effect of taurine in cardiac mitochondria. Our study demonstrates that long-term treatment of taurine as a diet supplement is beneficial to a heart that is vulnerable to environmental oxidative stresses. J. Cell. Biochem. 113: 35593566, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Chen, G.; Nan, C.; Jean-Charles, P.; Li, Y.; Huang, X. P.] Florida Atlantic Univ, Dept Biomed Sci, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
   [Chen, G.; Tian, Jie] Chongqing Med Univ, Div Cardiol, Childrens Hosp, Chongqing 400014, Peoples R China.
   [Weissbach, H.; Huang, X. P.] Florida Atlantic Univ, Ctr Mol Biol & Biotechnol, Jupiter, FL 33458 USA.
RP Huang, XP (reprint author), Florida Atlantic Univ, Dept Biomed Sci, Coll Med, 777 Glades Rd, Boca Raton, FL 33431 USA.
EM xhuang@fau.edu
FU National Institutes of Health [HL112130-01]; American Heart Association
   [11GRNT7860030]; American Physiological Society
FX Grant sponsor: National Institutes of Health; Grant number: HL112130-01;
   Grant sponsor: American Heart Association; Grant number:
   11GRNT7860030.The authors would like to thank Dr. Rodney Levine at NIH
   for providing the MsrA<SUP>-/-</SUP> mice. Jean-Charles is a recipient
   of Porter Fellowship from the American Physiological Society.
CR AZUMA J, 1985, CLIN CARDIOL, V8, P276
   AZUMA J, 1992, JPN CIRC J, V56, P95
   Bouckenooghe T, 2006, CURR OPIN CLIN NUTR, V9, P728, DOI 10.1097/01.mco.0000247469.26414.55
   Chang L, 2004, AMINO ACIDS, V27, P37, DOI 10.1007/s00726-004-0096-2
   Du J, 2006, ARCH BIOCHEM BIOPHYS, V456, P143, DOI 10.1016/j.abb.2006.08.018
   Du JF, 2008, AM J PHYSIOL-HEART C, V294, pH2604, DOI 10.1152/ajpheart.91506.2007
   Feigenbaum H, 2005, FEIGENBAUMS ECHOCARD
   Ghesquiere B, 2011, MOL CELLULAR PROTOMI, V10, P1074
   Hanna J, 2004, EXP TOXICOL PATHOL, V56, P189, DOI 10.1016/j.etp.2004.08.004
   Hansen SH, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-S1-S23
   Hansen SH, 2006, ADV EXP MED BIOL, V583, P129
   Ito T, 2008, J MOL CELL CARDIOL, V44, P927, DOI 10.1016/j.yjmcc.2008.03.001
   Jeejeebhoy F, 2002, AM HEART J, V143, P1092, DOI 10.1067/mhj.2002.121927
   Jia YY, 2004, J BIOMED SCI, V11, P450, DOI 10.1159/000077894
   Keith ME, 2001, CAN J CARDIOL, V17, P449
   Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056
   Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036
   Li YJ, 2010, J MOL CELL CARDIOL, V49, P402, DOI 10.1016/j.yjmcc.2010.04.017
   Marin-Garcia J, 2002, J CARD FAIL, V8, P347, DOI 10.1054/jcaf.2002.127774
   Martinez-Gonzalez MA, 2009, NUTR REV, V67, pS111, DOI 10.1111/j.1753-4887.2009.00172.x
   Militante JD, 2002, AMINO ACIDS, V23, P381, DOI 10.1007/s00726-002-0212-0
   Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998
   Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071
   Nan CL, 2010, BIOCHEM BIOPH RES CO, V402, P608, DOI 10.1016/j.bbrc.2010.10.064
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   Oudit GY, 2004, CIRCULATION, V109, P1877, DOI 10.1161/01.CIR.0000124229.40424.80
   Picot CR, 2006, EXP GERONTOL, V41, P663, DOI 10.1016/j.exger.2006.03.011
   Prentice HM, 2008, BIOCHEM BIOPH RES CO, V366, P775, DOI 10.1016/j.bbrc.2007.12.043
   Quinones MA, 2002, J AM SOC ECHOCARDIOG, V15, P167, DOI 10.1067/mje.2002.120202
   Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199
   Sadek HA, 2003, ARCH BIOCHEM BIOPHYS, V420, P201, DOI 10.1016/j.abb.2003.09.029
   SAHN DJ, 1978, CIRCULATION, V58, P1072
   Salmon AB, 2009, FASEB J, V23, P3601, DOI 10.1096/fj.08-127415
   Sofi F, 2009, CURR OPIN CARDIOL, V24, P442, DOI 10.1097/HCO.0b013e32832f056e
   Warskulat U, 2007, METHOD ENZYMOL, V428, P439, DOI 10.1016/S0076-6879(07)28025-5
   Weissbach H, 2005, BBA-PROTEINS PROTEOM, V1703, P203, DOI 10.1016/j.bbapap.2004.10.004
   Wojcik OP, 2010, ATHEROSCLEROSIS, V208, P19, DOI 10.1016/j.atherosclerosis.2009.06.002
   Wojcik OP, 2012, EUR J NUTR
   Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P1159, DOI 10.1073/pnas.0308215100
   Zeybek A, 2007, ACTA HISTOCHEM, V109, P208, DOI 10.1016/j.acthis.2006.12.001
   Zeybek A, 2006, DIGEST DIS SCI, V51, P1853, DOI 10.1007/s10620-006-9425-5
   Zhao H, 2011, AM J PHYSIOL-HEART C, V301, pH1513, DOI 10.1152/ajpheart.00441.2011
NR 42
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2012
VL 113
IS 11
BP 3559
EP 3566
DI 10.1002/jcb.24233
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 007ZP
UT WOS:000308927200026
ER

PT J
AU Tang, XH
   Tan, ZQ
   Nakamura, T
   Yatani, H
AF Tang, Xuehua
   Tan, Zhenquan
   Nakamura, Takashi
   Yatani, Hirofumi
TI Effects of ageing on surface textures of veneering ceramics for zirconia
   frameworks
SO JOURNAL OF DENTISTRY
LA English
DT Article
DE Zirconia; Veneering ceramics; Accelerated ageing; Surface texture
ID ACIDULATED PHOSPHATE FLUORIDE; LOW-TEMPERATURE DEGRADATION; FIXED DENTAL
   PROSTHESES; IN-VITRO; GLASS-CERAMICS; CORROSION MECHANISMS; FAILURE
   MODES; ROUGHNESS; CROWNS; QUANTIFICATION
AB Objectives: To evaluate the effects of ageing on surface textures of veneering ceramics for zirconia frameworks.
   Methods: Five different veneering ceramics for zirconia frameworks, Vintage ZR (ZR), Cerabien ZR (CZR), VitaVM9 (VM9), Cercon ceram KISS (KISS), and IPS e.max ceram (e.max), and one veneering ceramic with metal frameworks, Vintage MP (MP), were evaluated. Twenty specimens were fabricated from each veneering ceramic. All specimens were divided into two groups, one of which was subjected to accelerated ageing. The other was used as the control. Accelerated ageing was performed on the distilled water for 5 h at 200 degrees C and 2 atm. Surface textures were examined using laser profilometry, X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS).
   Results: Compared to unaged specimens, surface roughness parameters (Ra, Rp, Rv) of all aged specimens except e.max were significantly greater (P = 0.000). Compared to the unaged specimens, sodium and potassium on the surfaces of all the aged specimens significantly decreased (P < 0.05). However, oxygen levels increased significantly (P < 0.05). Silicon showed a tendency to decrease in all aged specimens, and that of ZR, KISS and e.max have a significant decrease (P < 0.01). Numerous ruffled cracks were observed on the surfaces of all aged specimens, as shown by SEM. The peaks of all crystalline phases on the surfaces of all specimens changed after accelerated ageing.
   Conclusion: Surface textures of all examined veneering ceramics were changed by the accelerated ageing test. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Tang, Xuehua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China.
   [Tang, Xuehua; Nakamura, Takashi; Yatani, Hirofumi] Osaka Univ, Grad Sch Dent, Dept Fixed Prosthodont, Suita, Osaka 5650871, Japan.
   [Tan, Zhenquan] Osaka Univ, Joining & Welding Res Inst, Osaka 5670047, Japan.
RP Tang, XH (reprint author), 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM t-xuehua2008@hotmail.com
FU Japanese Ministry of Education, Culture, Sports, Science and Technology
   [205922620]
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research (No. 205922620) from the Japanese Ministry of Education,
   Culture, Sports, Science and Technology, for which we express our
   thanks. The authors also would like to thank Mr. Yoshimoto, Mr.
   Takahashi and Mr. Watanabe of Shofu Inc., and Mr. Ishida of Dental
   Studio Laboratory for their technical assistance in this study.
CR Abou Tara M, 2011, J DENT, V39, P208, DOI 10.1016/j.jdent.2010.12.005
   Al-Radha ASD, 2012, J DENT, V40, P146, DOI 10.1016/j.jdent.2011.12.006
   Al-Shammerya HAO, 2007, DENT MATER, V23, P736, DOI 10.1016/j.dental.2006.06.012
   Anusavice KJ, 1998, J DENT RES, V77, P1553
   Anusavice K J, 1992, Adv Dent Res, V6, P82
   Baldassarri M, 2011, J DENT, V39, P489, DOI 10.1016/j.jdent.2011.04.006
   Bonfante EA, 2010, J DENT, V38, P707, DOI 10.1016/j.jdent.2010.04.001
   Bouyer F, 2010, J SOLID STATE CHEM, V183, P2786, DOI 10.1016/j.jssc.2010.08.031
   BUNKER BC, 1994, J NON-CRYST SOLIDS, V179, P300, DOI 10.1016/0022-3093(94)90708-0
   Cailleteau C, 2008, J NON-CRYST SOLIDS, V354, P117, DOI 10.1016/j.jnoncrysol.2007.07.063
   Casucci A, 2009, J DENT, V37, P891, DOI 10.1016/j.jdent.2009.06.013
   Ccahuana VZS, 2010, J APPL ORAL SCI, V18, P155, DOI 10.1590/S1678-77572010000200010
   Chen X, 2010, J DENT RES, V89, P1510, DOI 10.1177/0022034510377795
   Craig RG, 2004, MAT DENT RESTORATION, P704
   Ersu B, 2009, J DENT, V37, P848, DOI 10.1016/j.jdent.2009.06.017
   Field J, 2010, J DENT, V38, P182, DOI 10.1016/j.jdent.2010.01.002
   Geisler T, 2010, J NON-CRYST SOLIDS, V356, P1458, DOI 10.1016/j.jnoncrysol.2010.04.033
   Greaves GN, 1989, PHILOS MAG B, V60, P181
   Harder S, 2010, J DENT, V38, P875, DOI 10.1016/j.jdent.2010.07.012
   Heintze SD, 2006, DENT MATER, V22, P146, DOI 10.1016/j.dental.2005.04.013
   Jakovac M, 2006, J EUR CERAM SOC, V26, P1695, DOI 10.1016/j.jeurceramsoc.2005.03.242
   Kim JW, 2010, J DENT RES, V89, P91, DOI 10.1177/0022034509354193
   Kim MJ, 2011, J DENT, V39, P795, DOI 10.1016/j.jdent.2011.08.012
   Kohorst P, 2012, ACTA BIOMATER, V8, P1213, DOI 10.1016/j.actbio.2011.11.016
   Kukiattrakoon B, 2010, J PROSTHET DENT, V103, P148
   Kukiattrakoon B, 2010, DENT MATER J, V29, P501
   Lughi V, 2010, DENT MATER, V26, P807, DOI 10.1016/j.dental.2010.04.006
   Lynch ME, 2007, J NON-CRYST SOLIDS, V353, P2667, DOI 10.1016/j.jnoncrysol.2007.05.012
   Milleding P, 2003, J MATER SCI-MATER M, V14, P557, DOI 10.1023/A:1023416232222
   Milleding P, 1999, BIOMATERIALS, V20, P733, DOI 10.1016/S0142-9612(98)00223-3
   Milleding P, 2002, J BIOMED MATER RES, V61, P541, DOI 10.1002/jbm.10109
   Milleding P, 2001, BIOMATERIALS, V22, P2545, DOI 10.1016/S0142-9612(00)00445-2
   Nakamura T, 2012, DENT MATER J, V31, P106, DOI 10.4012/dmj.2011-048
   Oh WS, 2002, J PROSTHET DENT, V87, P451, DOI 10.1067/mpr.2002.123851
   Ohara N, 2009, ACTA ODONTOL SCAND, V67, P313, DOI 10.1080/00016350903070911
   Ong JL, 2000, DENT MATER, V16, P20, DOI 10.1016/S0109-5641(99)00079-2
   Palmer DC, 1997, AM MINERAL, V82, P16
   Pinto MM, 2008, DENT MATER, V24, P814, DOI 10.1016/j.denta1.2007.10.001
   Raptis NV, 2006, INT J PERIODONT REST, V26, P31
   Rodriguez JM, 2009, DENT MATER, V25, P500, DOI 10.1016/j.dental.2008.10.003
   Rues S, 2010, J DENT, V38, P987, DOI 10.1016/j.jdent.2010.08.014
   Rungruanganunt P, 2010, J DENT, V38, P995, DOI 10.1016/j.jdent.2010.08.015
   Tadjiev DR, 2010, J NON-CRYST SOLIDS, V356, P102, DOI 10.1016/j.jnoncrysol.2009.10.005
   Tang XH, 2012, J DENT, V40, P372, DOI 10.1016/j.jdent.2012.01.014
   Tournie A, 2008, SOLID STATE IONICS, V179, P2142, DOI 10.1016/j.ssi.2008.07.019
   [Anonymous], 2008, 13356 INT STAND ORG
   [Anonymous], 1997, 4287 ISO
NR 47
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0300-5712
J9 J DENT
JI J. Dent.
PD NOV
PY 2012
VL 40
IS 11
BP 913
EP 920
DI 10.1016/j.jdent.2012.07.009
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 013FL
UT WOS:000309291200005
ER

PT J
AU Zhi, QH
   Lo, ECM
   Lin, HC
AF Zhi, Qing Hui
   Lo, Edward Chin Man
   Lin, Huan Cai
TI Randomized clinical trial on effectiveness of silver diamine fluoride
   and glass ionomer in arresting dentine caries in preschool children
SO JOURNAL OF DENTISTRY
LA English
DT Article
DE Dental caries; Primary dentition; Preventive dentistry; Fluoride; Glass
   ionomer cement; Child
ID RESTORATIVE TREATMENT ART; ORAL-HEALTH; PREVENTION; MANAGEMENT;
   EFFICACY; VARNISH; MOLARS
AB Objective: To compare the effectiveness of annual topical application of silver diamine fluoride (SDF) solution, semi-annual topical application of SDF solution, and annual application of a flowable high fluoride-releasing glass ionomer in arresting active dentine caries in primary teeth.
   Methods: A total of 212 children, aged 3-4 years, were randomly allocated to one of three groups for treatment of carious dentine cavities in their primary teeth: Gp1-annual application of SDF, Gp2-semi-annual application of SDF, and Gp3-annual application of glass ionomer. Follow-up examinations were carried out every six months to assess whether the treated caries lesions had become arrested.
   Results: After 24 months, 181 (85%) children remained in the study. The caries arrest rates were 79%, 91% and 82% for Gp1, Gp2 and Gp3, respectively (p = 0.007). In the logistic regression model using GEE to adjust for clustering effect, higher caries arrest rates were found in lesions treated in Gp2 (OR = 2.98, p = 0.007), those in anterior teeth (OR = 5.55, p < 0.001), and those in buccal/lingual smooth surfaces (OR = 15.6, p = 0.004).
   Conclusion: Annual application of either SDF solution or high fluoride-releasing glass ionomer can arrest active dentine caries. Increasing the frequency of application to every 6 months can increase the caries arrest rate of SDF application.
   Clinical significance: Arrest of active dentine caries in primary teeth by topical application of SDF solution can be enhanced by increasing the frequency of application from annually to every 6 months, whereas annual paint-on of a flowable glass ionomer can also arrest active dentine caries and may provide a more aesthetic outcome. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Lo, Edward Chin Man] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
   [Zhi, Qing Hui; Lin, Huan Cai] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhi, Qing Hui; Lin, Huan Cai] Sun Yat Sen Univ, Sch Stomatol, Guangzhou 510275, Guangdong, Peoples R China.
RP Lo, ECM (reprint author), Prince Philip Dent Hosp, 3-F,34 Hosp Rd, Hong Kong, Hong Kong, Peoples R China.
EM edward-lo@hku.hk
FU University of Hong Kong
FX This study was funded by the University of Hong Kong.
CR Azarpazhooh A, 2008, J CAN DENT ASSOC, V74, P73
   Bayrak Sule, 2010, Eur J Dent, V4, P245
   Beirne P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004346.pub3
   Chu CH, 2002, J DENT RES, V81, P767
   Chu CH, 2004, THESIS U HONG KONG H
   Chu CH, 2008, ORAL HLTH PREV DENT, V6, P315
   Evans RW, 2008, AUST DENT J, V53, P83, DOI 10.1111/j.1834-7819.2007.00004.x
   Frencken JE, 2008, BASIC PACKAGE ORAL C
   Gotjamanos T, 1997, AUST DENT J, V42, P166, DOI 10.1111/j.1834-7819.1997.tb00115.x
   Hardin WJ, 2003, GEN ESTIMATING EQUAT
   HatibovicKofman S, 1997, SWED DENT J, V21, P11
   Kagihara LE, 2009, J AM ACAD NURSE PRAC, V21, P1, DOI 10.1111/j.1745-7599.2008.00367.x
   Llodra JC, 2005, J DENT RES, V84, P721
   Lo ECM, 2001, CARIES RES, V35, P458, DOI 10.1159/000047490
   Murdoch-Kinch CA, 2003, J AM DENT ASSOC, V134, P87
   Petersen PE, 2003, COMMUNITY DENT ORAL, V31, P3, DOI 10.1046/j..2003.com122.x
   Qi XQ, 2008, REPORT 3 NATL ORAL H
   Rosenblatt A, 2009, J DENT RES, V88, P116, DOI 10.1177/0022034508329406
   van't Hof MA, 2006, INT DENT J, V56, P345
   WHITFORD GM, 1987, J DENT RES, V66, P1056, DOI 10.1177/00220345870660051501
   Wong MCM, 2005, J DENT RES, V84, P817
   Wong MCM, 2001, J DENT RES, V80, P1459
   Yee R, 2009, J DENT RES, V88, P644, DOI 10.1177/0022034509338671
   Yu C, 2004, INT DENT J, V54, P42
   [Anonymous], 2006, J AM DENT ASS, V137, P1151
NR 25
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0300-5712
J9 J DENT
JI J. Dent.
PD NOV
PY 2012
VL 40
IS 11
BP 962
EP 967
DI 10.1016/j.jdent.2012.08.002
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 013FL
UT WOS:000309291200012
ER

PT J
AU Cheng, T
   Sun, GF
   Huo, JY
   He, XJ
   Wang, YN
   Ren, YF
AF Cheng, Tao
   Sun, Guifeng
   Huo, Jingyu
   He, Xiaoji
   Wang, Yining
   Ren, Yan-Fang
TI Patient satisfaction and masticatory efficiency of single
   implant-retained mandibular overdentures using the stud and magnetic
   attachments
SO JOURNAL OF DENTISTRY
LA English
DT Article
DE Dental implant; Overdenture; Patient satisfaction; Clinical trial;
   Crossover design
ID SUPPORTED OVERDENTURES; EDENTULOUS PATIENTS; CLINICAL-TRIAL; IN-VITRO;
   BALL; SYSTEMS; DENTURES; STRESS
AB Objectives: To study patient satisfaction and masticatory efficiency of single implant-retained mandibular overdentures using the stud and magnetic attachments in a randomized clinical trial with a crossover design.
   Methods: Patients received a single implant placed in the midline of the mandible and either a stud (Locator) or a magnetic (Magfit) attachment, assigned at random. Patient satisfaction, including patient comfort, speech, chewing ability and retention, and masticatory efficiency measured by chewing peanuts, were assessed before and 3 months after attachment insertion. Patient satisfaction and masticatory efficiency were evaluated again 3 months after insertion of the alternate attachment bodies. The outcomes were compared before and after insertion of the attachments and between the two types of attachments using Wilcoxon signed rank tests.
   Results: Patient overall satisfaction, comfort, speech, chewing ability, and retention improved significantly after insertion of both types of attachment bodies (p < 0.05). Masticatory efficiencies also increased in both the Locator and the Magfit groups (p < 0.05). There were no statistically significant differences in patient overall satisfaction, comfort, speech, and retention between the two types of attachments (p > 0.05). The Locator attachments performed better in perceived chewing ability than the Magfit (p < 0.05), but there was no statistically significant difference in masticatory efficiency between the two attachment types (p > 0.05).
   Conclusions: Clinical outcomes were significantly improved in single implant-retained mandibular overdentures using either the Locator or the Magfit magnetic attachments. There was no difference in masticatory efficiency between the two attachment types. (c) 2012 Ltd. All rights reserved.
C1 [Cheng, Tao; Wang, Yining] Wuhan Univ, Sch Stomatol, Wuhan 430079, Hubei, Peoples R China.
   [Cheng, Tao; Sun, Guifeng; Huo, Jingyu; He, Xiaoji] Zhengzhou Hosp Stomatol, Zhengzhou, Henan, Peoples R China.
   [Cheng, Tao; Ren, Yan-Fang] Zhengzhou Univ, Sch Stomatol, Zhengzhou, Henan, Peoples R China.
   [Ren, Yan-Fang] Univ Rochester, Eastman Inst Oral Hlth, Rochester, NY USA.
RP Wang, YN (reprint author), Wuhan Univ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Hubei, Peoples R China.
EM wang.yn@whu.edu.cn; yanfang_ren@urmc.rochester.edu
FU Science and Technology Innovation; Zhengzhou municipal government
FX This study was supported in part by a Science and Technology Innovation
   grant from Zhengzhou municipal government and completed for partial
   fulfillment of a Ph.D. degree for Dr. Tao Cheng.
CR Akin H, 2011, J PROSTHET DENT, V105, P203, DOI 10.1016/S0022-3913(11)60031-0
   Alsabeeha N, 2009, CLIN ORAL IMPLAN RES, V20, P356, DOI 10.1111/j.1600-0501.2008.01666.x
   Alsabeeha NHM, 2011, CLIN ORAL IMPLAN RES, V22, P330, DOI 10.1111/j.1600-0501.2010.02004.x
   Alsabeeha NHM, 2011, INT J PROSTHODONT, V24, P247
   Assad AS, 2004, IMPLANT DENT, V13
   Branchi R, 2010, J PROSTHODONT, V19, P31, DOI 10.1111/j.1532-849X.2010.00613.x
   Cehreli MC, 2010, INT J ORAL MAX IMPL, V25, P163
   Cheng T, J DENT SCI
   Chung Kwok-Hung, 2004, J Prosthodont, V13, P221
   Cordioli G, 1997, J Prosthet Dent, V78, P159, DOI 10.1016/S0022-3913(97)70120-3
   De Kok IJ, 2011, INT J ORAL MAX IMPL, V26, P415
   [杜莉 Du Li], 2003, [华西口腔医学杂志, West China Journal of Stomatology], V21, P366
   Ellis JS, 2009, CLIN ORAL IMPLAN RES, V20, P1293, DOI 10.1111/j.1600-0501.2009.01810.x
   Gonda T, 2004, J ORAL REHABIL, V31, P1001, DOI 10.1111/j.1365-2842.2004.01324.x
   Katsuhiko K, 2004, PROSTHODONTIC RES PR, V3, P33
   Kenney R, 1998, J PROSTHET DENT, V80, P559, DOI 10.1016/S0022-3913(98)70032-0
   Klemetti E, 2008, J ORAL REHABIL, V35, P80, DOI 10.1111/j.1365-2842.2007.01825.x
   Krennmair G, 2006, INT J PROSTHODONT, V19, P164
   Liddelow GJ, 2007, J PROSTHET DENT, V97, pS126, DOI 10.1016/S0022-3913(07)60016-X
   Liddelow GJ, 2008, J PROSTHET DENT, V99, P167
   MacEntee MI, 2005, J PROSTHET DENT, V93, P28, DOI 10.1016/j.prosdent.2004.10.013
   Maeda Y, 2008, CLIN ORAL IMPLAN RES, V19, P271, DOI 10.1111/j.1600-0501.2007.01425.x
   Rashid F, 2011, J ORAL REHABIL, V38, P176, DOI 10.1111/j.1365-2842.2010.02143.x
   Sadig W, 2009, QUINTESSENCE INT, V40, P313
   Thomason JM, 2009, BRIT DENT J, V207, P185, DOI 10.1038/sj.bdj.2009.728
   Turkyilmaz I, 2010, GERODONTOLOGY, V27, P3, DOI 10.1111/j.1741-2358.2009.00294.x
   van Kampen FMC, 2004, J DENT RES, V83, P708
   Walton JN, 2009, INT J PROSTHODONT, V22, P331
NR 28
TC 0
Z9 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0300-5712
J9 J DENT
JI J. Dent.
PD NOV
PY 2012
VL 40
IS 11
BP 1018
EP 1023
DI 10.1016/j.jdent.2012.08.011
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 013FL
UT WOS:000309291200018
ER

PT J
AU Wu, Y
   Ma, Q
   Song, XR
   Zheng, Y
   Ren, W
   Zhang, JK
   Ouyang, L
   Wu, FB
   He, G
AF Wu, Yang
   Ma, Qing
   Song, Xiangrong
   Zheng, Yu
   Ren, Wen
   Zhang, Jinkun
   Ouyang, Liang
   Wu, Fengbo
   He, Gu
TI Biocompatible poly(ethylene glycol)-poly(?-cholesterol-L-glutamate)
   copolymers: Synthesis, characterization, and in vitro studies
SO JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY
LA English
DT Article
DE cholesterol; glutamic acid; nanoparticles; peptides; poly(ethylene
   glycol); polypeptide hybrid copolymers
ID DRUG-DELIVERY; BLOCK-COPOLYMERS; STEARATE L-ASPARTAMIDE); NANOPARTICLES;
   MICELLES; POLYMERIZATION; POLYPEPTIDES; PROTEINS; NANOGELS; RELEASE
AB A novel amphiphilic poly(ethylene glycol)-block-poly(gamma-cholesterol-L-glutamate) (mPEGPCHLG) diblock copolymer has been synthesized. The mPEGPCHLG copolymer has good biocompatibility and low toxicity. The mPEGPCHLG copolymers could aggregate into nanoparticles with PCHLG blocks as the hydrophobic core and PEG blocks as the hydrophilic shell through emulsion solvent evaporation method. The copolymers were characterized by nuclear magnetic resonance spectroscopy, mass spectrum, Fourier transform infrared spectroscopy, and gel permeation chromatography. The particle sizes, size distributions, and zeta potentials of nanoparticles can also be determined by dynamic light scattering and transmission electron microscopy. This work provides a new and facile approach to prepare amphiphilic block copolymer nanoparticles with controllable performances. This novel copolymer may have potential applications in drug delivery and bioimaging applications.(c) 2012 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2012
C1 [Wu, Yang; Ma, Qing; Song, Xiangrong; Zheng, Yu; Ren, Wen; Zhang, Jinkun; Ouyang, Liang; Wu, Fengbo; He, Gu] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
RP Song, XR (reprint author), Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Sichuan, Peoples R China.
EM xiangrong_11@126.com; hegu@scu.edu.cn
FU National Natural Science Foundation of China [81001357, 30901868];
   Doctoral Program of Higher Education of China [20090181120114]; Health
   Office of Sichuan Province, China [090342]
FX This research has received financial support from the National Natural
   Science Foundation of China (No. 81001357 and 30901868), the Doctoral
   Program of Higher Education of China (No. 20090181120114) and the
   Science Program of the Health Office of Sichuan Province, China (No.
   090342).
CR Ayame H, 2008, BIOCONJUGATE CHEM, V19, P882, DOI 10.1021/bc700422s
   BIJSTERBOSCH M K, 1990, Advanced Drug Delivery Reviews, V5, P231, DOI 10.1016/0169-409X(90)90018-N
   Cai CH, 2009, J POLYM SCI POL CHEM, V47, P5967, DOI 10.1002/pola.23640
   DALY WH, 1988, TETRAHEDRON LETT, V29, P5859, DOI 10.1016/S0040-4039(00)82209-1
   DHAR MM, 1964, STEROIDS, V3, P139, DOI 10.1016/0039-128X(64)90070-4
   Diezi TA, 2010, MOL PHARMACEUT, V7, P1355, DOI 10.1021/mp100069p
   Du Z, 2010, COLLOID SURFACE A, V353, P140, DOI 10.1016/j.colsurfa.2009.11.005
   Feng SS, 2004, EXPERT REV MED DEVIC, V1, P115, DOI 10.1586/17434440.1.1.115
   GOODMAN M, 1966, J AM CHEM SOC, V88, P3627, DOI 10.1021/ja00967a028
   Habraken GJM, 2009, J POLYM SCI POL CHEM, V47, P6883, DOI 10.1002/pola.23728
   Hua SH, 2010, MACROMOL RAPID COMM, V31, P81, DOI 10.1002/marc.200900473
   Kobayashi H, 2009, J BIOMED MATER RES B, V91B, P55, DOI 10.1002/jbm.b.31373
   Lavasanifar A, 2000, J BIOMED MATER RES, V52, P831, DOI 10.1002/1097-4636(20001215)52:4<831::AID-JBM29>3.3.CO;2-B
   Lin YC, 2011, J POLYM SCI POL CHEM, V49, P2127, DOI 10.1002/pola.24640
   Liu J, 2009, BIOMATERIALS, V30, P5707, DOI 10.1016/j.biomaterials.2009.06.061
   Liu W, 2011, J POLYM SCI POL CHEM, V49, P3491, DOI 10.1002/pola.24784
   Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010
   Nah JW, 1998, J POLYM SCI POL PHYS, V36, P415, DOI 10.1002/(SICI)1099-0488(199802)36:3<415::AID-POLB3>3.0.CO;2-Q
   Oh I, 1999, INT J PHARM, V181, P107, DOI 10.1016/S0378-5173(99)00012-5
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Rosler A, 2001, ADV DRUG DELIVER REV, V53, P95, DOI 10.1016/S0169-409X(01)00222-8
   Sawada S, 2010, MACROMOL BIOSCI, V10, P353, DOI 10.1002/mabi.200900304
   Segura-Sanchez F, 2010, INT J PHARMACEUT, V387, P244, DOI 10.1016/j.ijpharm.2009.12.016
   Takahashi H, 2011, ACS NANO, V5, P337, DOI 10.1021/nn101447m
   Toita S, 2009, CHEM LETT, V38, P1114, DOI 10.1246/cl.2009.1114
   Wang A, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-46
   Zentner GM, 2001, J CONTROL RELEASE, V72, P203, DOI 10.1016/S0168-3659(01)00276-0
   Zhang Z, 2011, J POLYM SCI POL CHEM, V49, P2941, DOI 10.1002/pola.24730
NR 28
TC 0
Z9 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0887-624X
J9 J POLYM SCI POL CHEM
JI J. Polym. Sci. Pol. Chem.
PD NOV 1
PY 2012
VL 50
IS 21
BP 4532
EP 4537
DI 10.1002/pola.26265
PG 6
WC Polymer Science
SC Polymer Science
GA 014TX
UT WOS:000309399700017
ER

PT J
AU Liu, SX
   Yang, CJ
   Yang, S
AF Liu, Shengxiu
   Yang, Chunjun
   Yang, Sen
TI Long-pulsed 1,064-nm high-energy dye laser improves resistant port wine
   stains: 20 report cases
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
ID BIRTHMARKS; 595-NM
C1 [Liu, Shengxiu; Yang, Chunjun; Yang, Sen] Anhui Med Univ, Inst Dermatol, Hefei 230032, Anhui, Peoples R China.
   [Liu, Shengxiu; Yang, Chunjun; Yang, Sen] Anhui Med Univ, Dept Dermatol, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China.
RP Yang, S (reprint author), Anhui Med Univ, Inst Dermatol, Hefei 230032, Anhui, Peoples R China.
EM yangsen@medmail.com.cn
CR Anderson RR, 1983, SCIENCE, V22, P524
   Bevin AA, 2006, DERMATOL SURG, V32, P7, DOI 10.1111/j1524-4725.2006.32001
   da Costa JB, 2009, PHOTOMED LASER SURG, V27, P599
   Jasim ZF, 2007, J AM ACAD DERMATOL, V57, P677, DOI 10.1016/j.jaad.2007.01.019
   Kono T, 2007, DERMATOL SURG, V33, P951, DOI 10.1111/j.1524-4725.2007.33197.x
   Kono T, 2009, J COSMET LASER THER, V11, P11, DOI 10.1080/14764170802307940
   Kono T, 2006, ANN PLAS SURG, V56, P460, DOI 10.1097/01.sap.0000201554.44010.44
   Lanigan SW, 2004, BRIT J DERMATOL, V151, P527, DOI 10.1111/j.1365-2133.2004.06163.x
   Laube S, 2003, LASER SURG MED, V33, P282, DOI 10.1002/lsm.10234
   Liu H, 2007, CLIN EXP DERMATOL, V32, P646, DOI 10.1111/j.1365-2230.2007.02517.x
   Tanghetti Emil, 2003, J Cosmet Laser Ther, V5, P71, DOI 10.1080/14769170310001249
   Tomson N, 2006, BRIT J DERMATOL, V154, P676, DOI 10.1111/j.1365-2133.2005.07113.x
   Willenberg T, 2008, VASA-J VASCULAR DIS, V37, P5, DOI 10.1024/0301-1526.37.1.5
   Yung A, 2005, BRIT J DERMATOL, V153, P601, DOI 10.1111/j.1365-2133.2005.06707.x
NR 14
TC 0
Z9 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-8921
J9 LASER MED SCI
JI Lasers Med. Sci.
PD NOV
PY 2012
VL 27
IS 6
BP 1225
EP 1227
DI 10.1007/s10103-012-1098-z
PG 3
WC Engineering, Biomedical; Surgery
SC Engineering; Surgery
GA 014AE
UT WOS:000309346600013
ER

PT J
AU Che, YF
   Zhang, DY
   Ye, F
   Wu, BY
   Jiang, B
AF Che, Yufang
   Zhang, David Y.
   Ye, Fei
   Wu, Benyan
   Jiang, Bo
TI Combination of flavopiridol and embelin effectively inhibit cell growth
   in hepatocellular carcinoma depending on regulatory relationship between
   CDK6 and XIAP
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Flavopiridol; CDK6; XIAP; Embelin; Hepatocellular carcinoma
ID TUMOR-NECROSIS-FACTOR; PRIMARY LIVER-CANCER; X-LINKED-INHIBITOR;
   SEQUENTIAL COMBINATION; INDUCED APOPTOSIS; S-PHASE; PROTEINS; LINES;
   THERAPY; TRENDS
AB Flavopiridol, as a cyclin-dependent kinase (CDK) inhibitor, has entered into phase II study of clinical trial in chronic lymphocytic leukemia. In our study, flavopiridol decreased cell viability, significantly arrested cell cycle in G1 phase and induced cell apoptosis in HepG2/2.2.1 cells. Flavopiridol also inhibited protein expression of cyclin D1, cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6), and downregulated X-linked IAP (XIAP) expression in a dose-dependent manner. Further studies using HepG2/2.2.1 cells transfected with CDK6 siRNA or expression vector demonstrated that CDK6 modulates expression of XIAP. Finally, treatment of HepG2/2.2.1 cells with combination of flavopiridol and embelin, as a XIAP specific inhibitor, could inhibit cell proliferation more effectively than each drug alone. Taking together, CDK6 regulates XIAP expression in hepatocellular carcinoma (HCC) cells. Combination of flavopiridol and embelin could be potentially used for HCC treatment subsequently.
C1 [Che, Yufang; Wu, Benyan] Peoples Liberat Army Gen Hosp, Dept Geriatr Gastroenterol, Beijing 100853, Peoples R China.
   [Zhang, David Y.; Ye, Fei] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA.
   [Jiang, Bo] So Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.
RP Wu, BY (reprint author), Peoples Liberat Army Gen Hosp, Dept Geriatr Gastroenterol, Southern Bldg, Beijing 100853, Peoples R China.
EM benyanwu@vip.sina.com; drjiang@163.com
FU National Science Foundation, China
FX The authors are grateful for support from the National Science
   Foundation, China. B Wu, B Jiang conceived the hypothesis and overall
   study design. Y Che, B Wu, B Jiang, D Zhang, and F Ye participated in
   the experimental design and Y Che performed all experiments. Y Che and D
   Zhang summarized the final data. Y Che, B Wu, B Jiang, D Zhang, and F Ye
   prepared the manuscript.
CR Alonso M, 2003, MOL CANCER THER, V2, P139
   Amir TF, 2010, CANC TREAT REV, V36, P142
   Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411
   Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011
   Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117
   Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Gomez LA, 2006, MOL CANCER THER, V5, P1216, DOI 10.1158/1535-7163.MCT-05-0467
   Grazi GL, 2001, ANN SURG, V234, P71, DOI 10.1097/00000658-200107000-00011
   Hagymasi Krisztina, 2010, Orvosi Hetilap, V151, P1763, DOI 10.1556/OH.2010.28984
   Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472
   Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255
   Jiang J, 2003, CANCER RES, V63, P7410
   Kim DM, 2003, CANCER RES, V63, P621
   Klasa R J, 2001, Hematology Am Soc Hematol Educ Program, P443
   LIN TY, 1987, BRIT J SURG, V74, P839, DOI 10.1002/bjs.1800740931
   Litz J, 2003, CLIN CANCER RES, V9, P4586
   Melanie BT, 2010, J CLIN ONCOL, V28, P3994
   OKUDA K, 1984, HEPATOLOGY, V4, pS3, DOI 10.1002/hep.1840040703
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Rizzolio F, 2010, CURR DRUG TARGETS, V11, P279
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Sato S, 2004, DIS ESOPHAGUS, V17, P338, DOI 10.1111/j.1442-2050.2004.00437.x
   Schwartz GK, 2005, J CLIN ONCOL, V23, P4499, DOI 10.1200/JCO.2005.18.341
   Shah MA, 2005, CLIN CANCER RES, V11, P3836, DOI 10.1158/1078-0432.CCR-04-2651
   Shi YH, 2008, HEPATOLOGY, V48, P497, DOI 10.1002/hep.22393
   Simonetti RG, 1997, ANN ONCOL, V8, P117, DOI 10.1023/A:1008285123736
   Thomas SL, 2010, CURR HEMATOL MALIG R, V5, P29
   Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236
   Wittmann S, 2003, CANCER RES, V63, P93
   Wu KM, 2005, INVEST NEW DRUG, V23, P299, DOI 10.1007/s10637-005-1438-y
   Zhai SP, 2002, ANN PHARMACOTHER, V36, P905, DOI 10.1345/1542-6270(2002)036<0905:FANCDK>2.0.CO;2
   Zhu AX, 2006, ONCOLOGIST, V11, P790, DOI 10.1634/theoncologist.11-7-790
NR 33
TC 0
Z9 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1054-2523
J9 MED CHEM RES
JI Med. Chem. Res.
PD NOV
PY 2012
VL 21
IS 11
BP 3369
EP 3375
DI 10.1007/s00044-011-9867-y
PG 7
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 014AY
UT WOS:000309348600005
ER

PT J
AU Yu, L
   Jiang, YF
   Sun, L
   Zhong, BH
   Niu, JQ
AF Yu, Lei
   Jiang, Yan-Fang
   Sun, Lei
   Zhong, Bo-Hua
   Niu, Jun-Qi
TI EBHU18, a novel derivative of fatty acid bile acid conjugates, prevents
   cholesterol gallstone formation in experimental mice
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Gallstone; Bile acids and salts; Mice
ID OBSTRUCTIVE CHOLESTASIS; LIPID-COMPOSITION; DISEASE; FABACS; LIVER;
   ACYLTRANSFERASE; INHIBITION; PROTECTS; PATHWAY; BINDING
AB In this study, we tested whether the oral administration of EBHU18, one of the newly synthesized fatty acid bile acid conjugates (FABACs), was able to prevent the development of cholesterol gallstones. In the first study, gallstone-susceptible C57BL/6 mice were fed a lithogenic diet for 8 weeks, and then treated with ursodeoxycholic acid (UDCA, 10 mg kg(-1) day(-1), i.g.), EBHU18-L (0.5 mg kg(-1) day(-1) i.g.), or EBHU18-H (3 mg kg(-1) day(-1) i.g.). In the second study, C57BL/6 mice were fed the lithogenic diet for 8 weeks and then treated with EBHU18 at a daily dose of 3 mg (EBHU18-H) or 0.5 mg (EBHU18-L) or with 10 mg of UDCA for another 8 weeks. Pre-treatment or post-treatment with EBHU18 at 3 mg kg(-1) day(-1) significantly decreased gallstone formation and the fatty liver score. In the first study, EBHU18-H significantly decreased gallstone formation compared with the control animals. The fatty liver score decreased from a mean of 1.6 +/- A 1.02 in the controls to 0.5 +/- A 0.67 in the EBHU18-L group (P < 0.05) and 0.3 +/- A 0.64 in the EBHU18-H group (P < 0.01). In the second study, the drug significantly lowered the gallstone formation rate in the EBHU18-H group. The fatty liver score decreased from a mean of 1.6 +/- A 0.98 in the controls to 0.67 +/- A 0.90 in the EBHU18-L group (P < 0.05) and 0.4 +/- A 0.74 in the EBHU18-H group (P < 0.01). EBHU18 can prevent and reduce gallstone formation and/or fatty liver and can be developed as a potential therapeutic candidate for anti-gallstone therapy.
C1 [Yu, Lei; Jiang, Yan-Fang; Niu, Jun-Qi] Jilin Univ, Dept Hepatol, Hosp 1, Changchun 130021, Peoples R China.
   [Yu, Lei] Harbin Med Univ, Hosp 4, Dept Infect Dis, Harbin 150001, Peoples R China.
   [Sun, Lei] Harbin Med Univ, Hosp 4, Dept Ophthalmol, Harbin 150001, Peoples R China.
   [Zhong, Bo-Hua] Acad Mil Med Sci, Dept Pharmacol & Toxicol, Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Niu, Jun-Qi] Jilin Univ, Dept Hepatobiliary & Pancreat, Hosp 1, Changchun 130021, Peoples R China.
RP Niu, JQ (reprint author), Jilin Univ, Dept Hepatol, Hosp 1, Changchun 130021, Peoples R China.
EM bohuazhong@yahoo.com; junqiniu@yahoo.com.cn
FU National High Technology Research and Development Program of China (863
   Program) [06AA02Z4C6]; project of the Jilin Provincial Division of
   Science and Technology for International Collaboration [20070729-10];
   project of the HeiLongJiang Provincial Health Department [2009-201];
   Administration of Traditional Chinese Medicine of Jilin Province
FX This study was supported by a grant from the National High Technology
   Research and Development Program of China (863 Program; No. 06AA02Z4C6),
   a project of the Jilin Provincial Division of Science and Technology for
   International Collaboration (No. 20070729-10), a project of the
   HeiLongJiang Provincial Health Department (No. 2009-201), and a grant
   from the Administration of Traditional Chinese Medicine of Jilin
   Province.
CR Acalovschi M, 2009, J VIRAL HEPATITIS, V16, P860, DOI 10.1111/j.1365-2893.2009.01141.x
   Bertolotti M, 2001, HEPATOLOGY, V34, P234, DOI 10.1053/jhep.2001.25958
   Boiadjiev SE, 2004, BIOCHEMISTRY-US, V43, P15617, DOI 10.1021/bi0481491
   CHANG TW, 1980, J INFECT DIS, V142, P113
   Coldham NG, 1998, ANALYST, V123, P2589, DOI 10.1039/a805109g
   Doggrell SA, 2006, CURR OPIN INVESTIG D, V7, P344
   Fancellu A, 2009, J GASTROINTEST SURG, V14, P753
   Fisher B, 2009, Ann R Coll Surg Engl, V91, pW1
   Gilat T, 2002, HEPATOLOGY, V35, P597, DOI 10.1053/jhep.2002.31868
   Gilat T, 2003, HEPATOLOGY, V38, P436, DOI 10.1053/jhep.2003.50348
   Gilat T, 2001, GUT, V48, P75, DOI 10.1136/gut.48.1.75
   Gilat T, 2001, LIPIDS, V36, P1135, DOI 10.1007/s11745-001-0824-3
   Goldiner I, 2006, BIOCHEM J, V396, P529, DOI 10.1042/BJ20051694
   Goldiner I, 2003, J CHROMATOGR B, V795, P35, DOI 10.1016/S1570-0232(03)00494-X
   Gonen A, 2002, PATHOBIOLOGY, V70, P215, DOI 10.1159/000069332
   Gujral JS, 2003, HEPATOLOGY, V38, P355, DOI 10.1053/jhep.2003.50341
   Hobby K, 2009, RAPID COMMUN MASS SP, V23, P219, DOI 10.1002/rcm.3863
   JACKSON EM, 1993, J NUTR, V123, P1471
   Kang YJ, 2010, ANN NEUROL, V68, P342, DOI 10.1002/ana.22070
   Konikoff FM, 2003, EUR J GASTROEN HEPAT, V15, P649, DOI 10.1097/01.meg.0000059128.68845.b3
   Konikoff Fred M., 2005, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V5, P171, DOI 10.2174/1568008054064904
   Leikin-Frenkel A, 2008, ARCH BIOCHEM BIOPHYS, V471, P63, DOI 10.1016/j.abb.2007.12.005
   Leikin-Frenkel A, 2008, EUR J GASTROEN HEPAT, V20, P1205, DOI 10.1097/MEG.0b013e3282fc9743
   Magliozzi R, 2010, ANN NEUROL, V68, P477, DOI 10.1002/ana.22230
   O'Byrne J, 2003, J BIOL CHEM, V278, P34237, DOI 10.1074/jbc.M300987200
   Panpimanmas S, 2009, J EPIDEMIOL, V19, P116, DOI 10.2188/jea.JE20080019
   Reilly SJ, 2007, FASEB J, V21, P99, DOI 10.1096/fj.06-6919com
   Saso L, 1999, JPN J PHARMACOL, V79, P89, DOI 10.1254/jjp.79.89
   SHORT CR, 1989, TOXICOLOGY, V57, P45, DOI 10.1016/0300-483X(89)90033-4
   TAKIKAWA H, 1987, BIOCHIM BIOPHYS ACTA, V926, P145, DOI 10.1016/0304-4165(87)90231-5
   Wang P, 2012, AUTOPHAGY, V69, P360
   Wang P, 2011, MOL MED, V17, P523, DOI [10.2119/molmed.2010.00134, 10.2119/molmed.2010.000134]
   Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236
   Yago MD, 2005, NUTRITION, V21, P339, DOI 10.1016/j.nut.2004.06.028
NR 34
TC 0
Z9 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1054-2523
J9 MED CHEM RES
JI Med. Chem. Res.
PD NOV
PY 2012
VL 21
IS 11
BP 3382
EP 3389
DI 10.1007/s00044-011-9828-5
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 014AY
UT WOS:000309348600007
ER

PT J
AU Zhang, WT
   Jiang, FC
   Liu, D
   Du, G
AF Zhang, Wen-Ting
   Jiang, Feng-Chao
   Liu, Dong
   Du, Guang
TI Pharmacopore hypothesis generation of BACE-1 inhibitors and
   pharmacophore-driven identification of potent multi-target
   neuroprotective agents
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Pharmacophore; BACE-1; PARP-1; Multi-target neuroprotective;
   2-Aminothiazole
ID BETA-SECRETASE INHIBITORS; ACYLGUANIDINE INHIBITORS; DESIGN; DISCOVERY;
   CONSTRUCTION; SUBSTRATE; MODEL; OPTIMIZATION; LIBRARY; BRAIN
AB A three dimensional (3D) pharmacophore model of Beta-site APP cleaving enzymes 1 (BACE-1) inhibitors with strong capability of activity prediction was generated for pharmacophore-driven identification of potent multi-target neuroprotective agents. It was developed by HypoGen process in Catalyst system from a training set of 74 BACE-1 inhibitors, represented by four features: two hydrogen bond acceptors, one hydrophobic feature, and one positive ionizable feature. And the ion-dipole interactions between P-4-site of OM99-2 and residues of BACE-1 was illustrated by using Ligand Fit in Cerius 2. Subsequently, based on the similarity of 3D pharmacophore models of the BACE-1 inhibitors and the poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors, 2-aminothiazole analogues (111-115) with potent PARP-1 inhibition were predicted to be potent molecules against BACE-1. Then, the inhibitory effect on BACE-1 activity and the cytoprotective action against A beta-induced cell death of them were tested and evaluated. Among them, compound 111 proved to be a potent multi-target neuroprotective agent for the treatment of Alzheimer's disease.
C1 [Zhang, Wen-Ting; Liu, Dong; Du, Guang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
   [Jiang, Feng-Chao] Huazhong Univ Sci & Technol, Sch Pharm, Tongji Med Coll, Wuhan 430030, Peoples R China.
RP Zhang, WT (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM cecilia_zwt@yahoo.com.cn; tjyxb@sina.com
CR Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064
   Cole DC, 2006, J MED CHEM, V49, P6158, DOI 10.1021/jm0607451
   Cole DC, 2008, BIOORG MED CHEM LETT, V18, P1063, DOI 10.1016/j.bmcl.2007.12.010
   Congreve M, 2007, J MED CHEM, V50, P1124, DOI 10.1021/jm061197u
   Debnath AK, 2002, J MED CHEM, V45, P41, DOI 10.1021/jm010360c
   Edwards PD, 2007, J MED CHEM, V50, P5912, DOI 10.1021/jm070829p
   Freskos JN, 2007, BIOORG MED CHEM LETT, V17, P78, DOI 10.1016/j.bmcl.2006.09.091
   Garino C, 2006, J MED CHEM, V49, P4275, DOI 10.1021/jm0602864
   Ghosh AK, 2001, J MED CHEM, V44, P2865, DOI 10.1021/jm0101803
   Ghosh AK, 2006, J AM CHEM SOC, V128, P5310, DOI 10.1021/ja058636j
   Gorfe AA, 2005, STRUCTURE, V13, P1487, DOI 10.1016/j.str.2005.06.015
   Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200
   Hamada Y, 2006, BIOORG MED CHEM LETT, V16, P4354, DOI 10.1016/j.bmcl.2006.05.046
   Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150
   Hu B, 2006, ACTA PHARMACOL SIN, V27, P1586, DOI 10.1111/j.1745-7254.2006.00432.x
   Huang DZ, 2006, J AM CHEM SOC, V128, P5436, DOI 10.1021/ja0573108
   Jennings LD, 2008, BIOORG MED CHEM LETT, V18, P767, DOI 10.1016/j.bmcl.2007.11.043
   John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h
   Kaminski JJ, 1997, J MED CHEM, V40, P4103, DOI 10.1021/jm970291v
   Kimura T, 2005, BIOORG MED CHEM LETT, V15, P211, DOI 10.1016/j.bmcl.2004.09.090
   Kimura T, 2006, BIOORG MED CHEM LETT, V16, P2380, DOI 10.1016/j.bmcl.2006.01.108
   Kurogi Y, 2001, J MED CHEM, V44, P2304, DOI 10.1021/jm010060v
   Kurogi Y, 2001, CURR MED CHEM, V8, P1035
   Liu L, 2007, CHINESE J CHEM, V25, P892, DOI 10.1002/cjoc.200790173
   Maillard MC, 2007, J MED CHEM, V50, P776, DOI 10.1021/jm061242y
   Pietrancosta N, 2005, LETT DRUG DES DISCOV, V2, P595, DOI 10.2174/157018005774717352
   Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317
   Stanton MG, 2007, J MED CHEM, V50, P3431, DOI 10.1021/jm070272d
   Stauffer SR, 2007, BIOORG MED CHEM LETT, V17, P1788, DOI 10.1016/j.bmcl.2006.12.051
   Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012
   Yan H, 2006, ACTA PHYS-CHIM SIN, V22, P359
   Zhang WT, 2009, J MED CHEM, V52, P718, DOI 10.1021/jm800902t
   Zhang Wen-ting, 2007, Yaoxue Xuebao, V42, P279
   Zhu Yong, 2008, Yao Xue Xue Bao, V43, P267
NR 34
TC 0
Z9 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1054-2523
J9 MED CHEM RES
JI Med. Chem. Res.
PD NOV
PY 2012
VL 21
IS 11
BP 3656
EP 3668
DI 10.1007/s00044-011-9885-9
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 014AY
UT WOS:000309348600037
ER

PT J
AU Shen, W
   Long, SB
   Yu, SA
   Chen, WW
   Zhu, Q
AF Shen, Wei
   Long, Shaobo
   Yu, Shian
   Chen, Weiwei
   Zhu, Qing
TI Design, synthesis, and evaluation of an activity-based probe for
   cellular imaging of monoamine oxidases
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Monoamine oxidase; Activity-based fluorescent probe; Cell imaging;
   Inhibitor
ID MAJOR DEPRESSIVE DISORDER; A GENE PROMOTER; MAO-A; POLYMORPHISM;
   ASSOCIATION; INHIBITORS; MALES
AB Monoamine oxidase, a FAD-containing enzyme, is responsible for the degradation of various neurotransmitters and xenobiotic amines to aldehydes. The selective targeting of monoamine oxidases (MAOs) may also help to visualize the development of related diseases. A new activity-based fluorescent probe containing acetamide group has been synthesized. To minimize the interactions with the dye, a hexyl linker was inserted between MAO tracer 2-(alkylamino)-acetamide and fluorescein. Enzyme inhibitory activities of probe 1, compounds 2 and 3 were assayed to confirm a high binding affinity of the probe to MAOs (IC50 value: 35.1 mu M for MAO-A and 150.8 mu M for MAO-B). Cell imaging was investigated in breast cancer cell MCF-7 with confocal laser scanning microscopy, and the results showed that this new acetamide-based MAO probe has a high affinity and specificity toward MAO, and thus it is a promising candidate for sensitive MAO detection in living system.
C1 [Long, Shaobo; Chen, Weiwei; Zhu, Qing] Zhejiang Univ Technol, Inst Bioengn, Hangzhou 310014, Zhejiang, Peoples R China.
   [Shen, Wei; Yu, Shian] Jinhua Cent Hosp, Dept Gen Surg, Jinhua 321000, Peoples R China.
RP Zhu, Q (reprint author), Zhejiang Univ Technol, Inst Bioengn, Chaohui Campus, Hangzhou 310014, Zhejiang, Peoples R China.
EM chmzhuq@hotmail.com
FU Qianjiang Outstanding Researcher Program [2006R10016]; Zhejiang Natural
   Science Fund [Y2080303]
FX This work was supported by Qianjiang Outstanding Researcher Program (No.
   2006R10016) and Zhejiang Natural Science Fund (No. Y2080303).
CR Albers AE, 2007, CHEM COMMUN, P4647, DOI 10.1039/b713190a
   Amit SK, 2001, CHEM RES TOXICOL, V14, P1139
   Chen G, 2005, J AM CHEM SOC, V127, P4544, DOI 10.1021/ja0428457
   Du LS, 2004, NEUROREPORT, V15, P2097, DOI 10.1097/00001756-200409150-00020
   Du LS, 2002, NEUROREPORT, V13, P1195, DOI 10.1097/00001756-200207020-00025
   Flaherty P, 1996, J MED CHEM, V39, P4756, DOI 10.1021/jm960477e
   Jessani N, 2004, CURR OPIN CHEM BIOL, V8, P54, DOI 10.1016/j.cbpa.2003.11.004
   Jia Z, 2010, BIOL PHARM BULL, V33, P725
   Jia Z, 2010, BIOORG MED CHEM LETT, V20, P6222, DOI 10.1016/j.bmcl.2010.08.104
   Joseph JPZ, 1997, J MED CHEM, V40, P1165
   KIM JM, 1995, J AM CHEM SOC, V117, P100, DOI 10.1021/ja00106a012
   Lu YY, 2008, CHINESE CHEM LETT, V19, P947, DOI 10.1016/j.cclet.2008.05.032
   Schulze TG, 2000, AM J MED GENET, V96, P801, DOI 10.1002/1096-8628(20001204)96:6<801::AID-AJMG21>3.0.CO;2-4
   Yu YWY, 2005, NEUROPSYCHOPHARMACOL, V30, P1719, DOI 10.1038/sj.npp.1300785
NR 14
TC 0
Z9 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1054-2523
J9 MED CHEM RES
JI Med. Chem. Res.
PD NOV
PY 2012
VL 21
IS 11
BP 3858
EP 3862
DI 10.1007/s00044-011-9923-7
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 014AY
UT WOS:000309348600058
ER

PT J
AU Jie, BZ
   Zhang, XX
   Wu, XS
   Xin, Y
   Liu, Y
   Guo, YF
AF Jie, Bingzhang
   Zhang, Xiaoxia
   Wu, Xuesi
   Xin, Yi
   Liu, Yong
   Guo, Yongfang
TI Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt
   and inhibiting mitochondrial permeability transition pore
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Neuregulin; Apoptosis; Mitochondria; Cardiac myocyte
ID CHRONIC HEART-FAILURE; RECOMBINANT HUMAN NEUREGULIN-1;
   ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; PATHWAY; HYPERTROPHY; EXPRESSION;
   RESPONSES; PROTECTS; GROWTH
AB Neuregulin-1 (NRG-1) has been shown to attenuate cardiomyocyte apoptosis but the underlying signaling mechanism remains elusive. In this study, we focused on mitochondrial permeability transition pore (mPTP) opening and PI3K/Akt pathway to investigate the effects of NRG-1 on oxidative stress-induced apoptosis of cardiomyocyte. Human cardiac myocytes and neonatal rat cardiac myocytes were exposed to hydrogen peroxide with or without pre-treatment with recombinant human neuregulin-1 (rhNRG-1). Cell apoptosis and mPTP opening were assayed by flow cytometry and confocal microscopy. The activation of Akt was detected by western blot analysis. The results showed that H2O2 induced cardiomyocyte apoptosis and activated mPTP. rhNRG-1 inhibited mPTP and activated Akt in the presence of H2O2, and further protected the cells from H2O2-induced apoptosis. However, rhNRG-1 failed to inhibit mPTP opening and cell apoptosis in the presence of PI3K inhibitor LY294002. Taken together, these findings suggest that NRG-1 activates PI3K/Akt signaling and inhibits mPTP opening, and downstream apoptotic events in cardiac myocytes subjected to oxidative stress.
C1 [Wu, Xuesi; Xin, Yi] Capital Med Univ, Beijing Anzhen Hosp, Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China.
   [Liu, Yong] Chinese Acad Sci, Joint Lab Apoptosis & Canc Biol, State Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing 100101, Peoples R China.
   [Guo, Yongfang] Qingdao Univ, Dept Cardiol, Affiliated Hosp, Coll Med, Qingdao 266000, Peoples R China.
RP Wu, XS (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China.
EM wuxuesi@263.net
FU Beijing Natural Science Foundation [7102043]
FX This study was supported by Beijing Natural Science Foundation (No.
   7102043). We thank Zensun Sci & Tech Ltd. (Shanghai, China) for
   providing neuregulin-1.
CR Baregamian N, 2006, J SURG RES, V136, P31, DOI 10.1016/j.jss.2006.04.028
   Bopassa JC, 2006, CARDIOVASC RES, V69, P178, DOI 10.1016/j.cardiores.2005.07.014
   Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148
   Eto K, 2010, MOL CELL BIOCHEM, V339, P119
   Gao RL, 2010, J AM COLL CARDIOL, V55, P1907, DOI 10.1016/j.jacc.2009.12.044
   Garratt AN, 2006, J MOL CELL CARDIOL, V41, P215, DOI 10.1016/j.yjmcc.2006.05.020
   Goto K, 2009, MED MOL MORPHOL, V42, P92, DOI 10.1007/s00795-009-0439-x
   Hedhli N, 2011, CIRCULATION, V123, P2254, DOI 10.1161/CIRCULATIONAHA.110.991125
   Hein S, 2003, CIRCULATION, V107, P984, DOI 10.1161/01.CIR.0000051865.66123.B7
   Horie T, 2010, CARDIOVASC RES, V87, P656, DOI 10.1093/cvr/cvq148
   Jabbour A, 2011, EUR J HEART FAIL, V13, P83, DOI 10.1093/eurjhf/hfq152
   Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2
   Kim JS, 2012, MOL CELL BIOCHEM, V365, P181, DOI 10.1007/s11010-012-1258-2
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kuramochi Y, 2004, J BIOL CHEM, V279, P51141, DOI 10.1074/jbc.M408662200
   Ky B, 2009, CIRCULATION, V120, P310, DOI 10.1161/CIRCULATIONAHA.109.856310
   Lee Y, 2009, APOPTOSIS, V14, P536, DOI 10.1007/s10495-008-0302-x
   Moore XL, 2007, ENDOCRINOLOGY, V148, P1582, DOI 10.1210/en.2006-1324
   Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5
   Predescu SA, 2007, J BIOL CHEM, V282, P17166, DOI 10.1074/jbc.M608996200
   Rahman S, 2011, ANESTHESIOLOGY, V115, P242
   Remondino A, 2003, CIRC RES, V92, P136, DOI 10.1161/01.RES.0000054624.03539.B4
   Vessey DA, 2011, MOL CELL BIOCHEM, V351, P77, DOI 10.1007/s11010-011-0713-9
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261
   Zhuo CJ, 2011, MOL CELL BIOCHEM, V346, P39, DOI 10.1007/s11010-010-0589-0
NR 26
TC 0
Z9 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD NOV
PY 2012
VL 370
IS 1-2
BP 35
EP 43
DI 10.1007/s11010-012-1395-7
PG 9
WC Cell Biology
SC Cell Biology
GA 015XB
UT WOS:000309478600005
ER

PT J
AU Lou, YL
   Guo, F
   Liu, F
   Gao, FL
   Zhang, PQ
   Niu, X
   Guo, SC
   Yin, JH
   Wang, Y
   Deng, ZF
AF Lou, Yuan-Lei
   Guo, Fei
   Liu, Fen
   Gao, Fa-Liang
   Zhang, Peng-Qi
   Niu, Xin
   Guo, Shang-Chun
   Yin, Jun-Hui
   Wang, Yang
   Deng, Zhi-Feng
TI miR-210 activates notch signaling pathway in angiogenesis induced by
   cerebral ischemia
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE miR-210; Angiogenesis; Notch1; Cerebral ischemia
ID RECEPTOR; HYPOXIA; BRAIN; MICRORNA-210; EXPRESSION; VEGF
AB The compensatory angiogenesis that occurs after cerebral ischemia increases blood flow to the injured area and limits extension of the ischemic penumbra. In this way, it improves the local blood supply. Fostering compensatory angiogenesis is an effective treatment for ischemic cerebrovascular disease. However, angiogenesis in the adult organism is a complex, multi-step process, and the mechanisms underlying the regulation of angiogenesis are not well understood. Although Notch signaling reportedly regulates the vascularization process that occurs in ischemic tissues, little is known about the role of Notch signaling in the regulation of ischemia-induced angiogenesis after ischemic stroke. Recent research has indicated that miR-210, a hypoxia-induced microRNA, plays a crucial role in regulating the biological processes that occur in blood vessel endothelial cells under hypoxic conditions. This study was undertaken to investigate the role of miR-210 in regulating angiogenesis in response to brain ischemia injury and the role of the Notch pathway in the body's response. We found miR-210 to be significantly up-regulated in adult rat ischemic brain cortexes in which the expression of Notch1 signaling molecules was also increased. Hypoxic models of human umbilical vein endothelial cells (HUVE-12) were used to assess changes in miR-210 and Notch1 expression in endothelial cells. Results were consistent with in vivo findings. To determine the molecular mechanisms behind these phenomena, we transfected HUVE-12 cells with miR-210 recombinant lentiviral vectors. We found that miR-210 overexpression caused up-regulation of Notch1 signaling molecules and induced endothelial cells to migrate and form capillary-like structures on Matrigel. These data suggest that miR-210 is involved in the regulation of angiogenesis in response to ischemic injury to the brain. Up-regulation of miR-210 can activate the Notch signaling pathway, which may contribute to angiogenesis after cerebral ischemia.
C1 [Zhang, Peng-Qi; Deng, Zhi-Feng] Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
   [Lou, Yuan-Lei; Guo, Fei; Liu, Fen; Wang, Yang] Nanchang Univ, Inst Urol, Nanchang 330006, Peoples R China.
   [Gao, Fa-Liang; Deng, Zhi-Feng] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang 330006, Peoples R China.
   [Niu, Xin; Guo, Shang-Chun; Yin, Jun-Hui; Wang, Yang] Shanghai Jiao Tong Univ, Inst Orthopaed Surg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
RP Deng, ZF (reprint author), Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Shanghai 200233, Peoples R China.
EM wangy63cn@126.com; dengzf63@126.com
FU National Natural Science Foundation of China [30960396, 81060324];
   National S&T Major Special Project on Major New Drug Innovation
   [2011ZX09102-010-01]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 30960396), (Grant No. 81060324) and the National S&T
   Major Special Project on Major New Drug Innovation (2011ZX09102-010-01).
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Chan SY, 2010, CELL CYCLE, V9, P1072
   Corn PG, 2008, CANCER BIOL THER, V7, P265, DOI 10.4161/cbt.7.2.5745
   Ehebauer M, 2006, SCIENCE, V314, P1414, DOI 10.1126/science.1134042
   Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200
   Gridley T, 2007, NATURE, V445, P722, DOI 10.1038/445722a
   Hamada Y, 2011, BLOOD, V118, pE93, DOI 10.1182/blood-2010-12-322842
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hedhli N, 2012, CARDIOVASC RES, V93, P516, DOI 10.1093/cvr/cvr352
   Hofmann JJ, 2007, GENE EXPR PATTERNS, V7, P461, DOI 10.1016/j.modgep.2006.11.002
   Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736
   Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4
   Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242-10
   KRUPINSKI J, 1994, STROKE, V25, P1794
   Liu R, 2012, BIOCHEM BIOPH RES CO, V418, P173, DOI 10.1016/j.bbrc.2012.01.002
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
NR 19
TC 0
Z9 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD NOV
PY 2012
VL 370
IS 1-2
BP 45
EP 51
DI 10.1007/s11010-012-1396-6
PG 7
WC Cell Biology
SC Cell Biology
GA 015XB
UT WOS:000309478600006
ER

EF